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From their discovery in biological systems, reactive oxygen species (ROS) have been considered
key players in tissue injury for their capacity to oxidize biological macromolecules. Aerobic organisms
possess a system of biochemical defenses to neutralize the oxidative effects of ROS, but the balance
between ROS generation and the antioxidant system is slightly in favor of the ROS so that a
continuous low level of oxidative damage exists [1]. When the imbalance toward the ROS increases,
as happens under several conditions, oxidative stress arises. This has been related to the onset
of many pathological conditions including cardiovascular disease, diabetes, rheumatoid arthritis,
cancer, and neurodegenerative disorders [2]. It has been proposed that if ROS are involved in many
pathological conditions, the use of exogenous antioxidants can help their management. However,
starting from the end of the 1970s, increasing experimental evidence has led to an opposing view
about the ROS’ role in biological systems. This suggests that living systems not only adapted to the
coexistence with free radicals but developed methods to use them in critical physiological processes [2].
It has also been shown that, when the generation of ROS induces adaptive responses that are beneficial
to the organism, the use of antioxidants can be detrimental [2].
The papers reported in this Special Issue deal with different aspects of reactive oxygen species
(ROS) actions in living organisms.
Some papers consider the role of ROS in inducing cellular dysfunction.
Thus, Hua et al. [3] treated human umbilical vein endothelial cells (HUVECs) with H2O2 to obtain
a cell model of oxidative stress to study the role of sphingomyelin synthase 2 (SMS2) in endothelial
disease (ED). They found that SMS2 induces the stress of the endoplasmic reticulum (ER) that leads to
ED both activating the Wnt/β-catenin pathway and promoting intracellular cholesterol accumulation,
both of which contribute to the induction of ER stress and finally lead to ED.
Querio et al. [4] used adult rat cardiomyocytes stressed with H2O2 or doxorubicin to verify if
trimethylamine N-oxide (TMAO), an organic compound derived from dietary choline and L-carnitine,
is a factor involved in the progression of atherosclerosis and other cardiovascular diseases. They show
that TMAO does not affect the treatment’s effect on cell viability, sarcomere length, intracellular ROS,
and mitochondrial membrane potential. Therefore, they conclude that TMAO cannot be considered a
direct cause or an exacerbating risk factor of cardiac damage at the cellular level in acute conditions.
Another work evaluates the role of ROS as agents able to induce cellular protection.
Lin et al. [5] demonstrated that ROS are involved in the mechanism underlying the protective
action of carbon monoxide-releasing molecule 2 (CORM-2) against lipopolysaccharide (LPS)-induced
inflammation in mice lung. CORM-2 induces the expression of heme oxygenase 1 (HO-1), a member of
the heme oxygenase (HO) family, able to directly protect various organs from oxidative damages. This is
due to the activation of protein kinase C (PKC)α and proline-rich tyrosine kinase (Pyk2), which, in turn,
activate NOX-derived ROS generation. The ROS signal activates the extracellular signal-regulated
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kinase 1/2 (ERK1/2) that upregulates c-Fos and c-Jun, activator protein 1 (AP-1) subunits, which turn
on the transcription of the HO-1 gene by regulating the HO-1 promoter.
ROS can also be involved in the therapeutic action of some antitumoral drugs.
Soltan et al. [6] evaluated the antitumoral action of a derivative of the plant extract indirubin,
DKP-071, on cutaneous T-cell lymphoma (CTCL). DKP-071 activated the extrinsic apoptosis cascade
via caspase-8 and caspase-3 through downregulation of the caspase antagonistic proteins c-FLIP and
XIAP. In response to DPK-071 treatment, a strong increase of ROS levels was observed as an early effect.
ROS turned out upstream of all other proapoptotic effects monitored. Thus, ROS appear as a highly
active proapoptotic pathway in CTCL.
The antioxidant capacity to protect against oxidative stress-linked disease has been evaluated by
Zhao et al. [7], who studied the protective effects of the treatment with artemisinin, an anti-malarial
Chinese medicine, on SH-SY5Y and hippocampal neuronal cells treated with hydrogen peroxide (H2O2).
Artemisinin prevents cell death at clinically relevant doses in a concentration-dependent manner.
Artemisinin restored the nuclear morphology, prevented the increased intracellular ROS, and attenuated
apoptosis. These data suggested that artemisinin protected neuronal cells. Similar results were obtained
in primary cultured hippocampal neurons. Cumulatively, these results indicated that artemisinin
protected neuronal cells from oxidative damage, at least in part through the activation of AMPK. These
findings support the role of artemisinin as a potential therapeutic agent for neurodegenerative diseases.
Moreover, some reviews are presented in this Special Issue.
Lévy et al. [8] reviewed the current literature concerning the link between oxidative stress and
protein aggregation processes, which are involved in the development of proteinopathies, such as
Alzheimer’s disease, Parkinson’s disease, and prion disease.
Damiano et al. [9] examined the data concerning antioxidant supplementation associated with
exercise in normal and sarcopenic subjects. In older people, malnutrition and physical inactivity can
lead to sarcopenia, a process in which oxidative stress seems to be involved. The effects of exercise and
antioxidant dietary supplements in limiting age-related muscle mass loss and performance reduction
have been evaluated in many studies but the results are conflicting. This can be due to the dual effects
of ROS in skeletal muscle, which at low levels increase muscle force and induce adaptations to exercise,
but at higher levels lead to a muscle performance decline. Therefore, the controversial results obtained
with antioxidant supplementation in older persons could, in part, reflect the lack of univocal effects of
ROS on muscle mass and function.
Xiao and Meierhofer [10] reviewed the current knowledge about the three main renal cell carcinoma
(RCC) subtypes—clear cell RCC (ccRCC), papillary RCC (pRCC), and chromophobe RCC (chRCC)—and
highlight their mutual influence on GSH metabolism. Altered GSH metabolism contributes to the
development and progression of the three renal carcinomas. All RCCs have a reduced oxidative
phosphorylation capacity, and the respiratory chain is the main source of ROS. Raised oxidative stress levels
in RCCs are counteracted by increased GSH levels that foster the survival of the malignancy. New studies
have shown that combinatory therapy targeting two independent pathways of GSH synthesis and one
involved in ROS metabolism is the key to improving the survival rate and eventually curing RCC.
Siauciunaite et al. [11] summarized the actual knowledge about the role of ROS as signaling molecules
and key regulators of gene expression from an evolutionary point of view. They described recent work that
has revealed significant species-specific differences in the gene expression response to ROS by exploring
diverse organisms. This evidence supports the notion that during evolution, rather than being highly
conserved, there is inherent plasticity in the molecular mechanisms responding to oxidative stress.
The review of Di Meo et al. [12] analyzed the literature dealing with sources of ROS production
and the most important redox signaling pathways, including MAPKs that are involved in the
responses to acute and chronic exercise in the muscle, particularly those involved in the induction of
antioxidant enzymes.
Ismail et al. [13] collected and discussed studies analyzing the involvement of mitochondrial
peroxiredoxins (Prdxs) in human cancers. They focused on signaling involving ROS and mitochondrial
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Prdxs that is associated with cancer development and progression. An upregulated expression of
Prdx3 and Prdx5 has been reported in different cancer types, such as breast, ovarian, endometrial, and
lung cancers, as well as in Hodgkin’s lymphoma and hepatocellular carcinoma. It is depicted that
mitochondrial Prdxs are upregulated in a variety of cancer types and directly or indirectly regulated
by transcription factors, microRNAs, and oncogenes.
It is our opinion that the articles included in this Special Issue, despite dealing with such different
topics, represent an important contribution to the knowledge of the physiological and pathological
role of ROS, and give some information on the benefits and limitations of antioxidant treatment.
Conflicts of Interest: The authors declare no conflicts of interest.
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Abstract: Endothelial dysfunction (ED) is an important contributor to atherosclerotic cardiovascular
disease. Our previous study demonstrated that sphingomyelin synthase 2 (SMS2) promotes ED.
Moreover, endoplasmic reticulum (ER) stress can lead to ED. However, whether there is a correlation
between SMS2 and ER stress is unclear. To examine their correlation and determine the detailed
mechanism of this process, we constructed a human umbilical vein endothelial cell (HUVEC)
model with SMS2 overexpression. These cells were treated with 4-PBA or simvastatin and with
LiCl and salinomycin alone. The results showed that SMS2 can promote the phosphorylation of
lipoprotein receptor-related protein 6 (LRP6) and activate the Wnt/β-catenin pathway and that
activation or inhibition of the Wnt/β-catenin pathway can induce or block ER stress, respectively.
However, inhibition of ER stress by 4-PBA can decrease ER stress and ED. Furthermore, when the
biosynthesis of cholesterol is inhibited by simvastatin, the reduction in intracellular cholesterol
coincides with a decrease in ER stress and ED. Collectively, our results demonstrate that SMS2 can
activate the Wnt/β-catenin pathway and promote intracellular cholesterol accumulation, both of
which can contribute to the induction of ER stress and finally lead to ED.
Keywords: atherosclerosis; sphingomyelin synthase 2; endothelial dysfunction; endoplasmic
reticulum stress; β-catenin
1. Introduction
Angiocardiopathy is a significant cause of death in many countries. Atherosclerosis (AS), which is
a major cause of angiocardiopathy, is an inflammatory disease that leads to clogged arteries [1].
Additionally, endothelial dysfunction (ED) plays a crucial role in the pathogenesis of atherosclerotic
cardiovascular disease [2]. Various harmful stimuli, such as oxidative stress and inflammation, can lead
to ED, and reactive oxygen species (ROS) can induce oxidative stress, which plays an essential role in
ED [3,4]. Since H2O2 is a key ROS, in this research, human umbilical vein endothelial cells (HUVECs)
were treated with H2O2 to establish a cell model of oxidative stress [5].
Sphingomyelin (SM) is a type of sphingolipid that is important for the composition of biological
membranes and plasma lipoproteins [6,7]. The production of SM requires many enzymatic reactions,
and sphingomyelin synthase (SMS), which has two isoforms (sphingomyelin synthase 1 (SMS1) and
sphingomyelin synthase 2 (SMS2)), is a critical enzyme in the final step of the production of SMS [8].
Int. J. Mol. Sci. 2019, 20, 2861; doi:10.3390/ijms20122861 www.mdpi.com/journal/ijms5
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Studies have shown that SM participates in AS [9–11]. The level of SM in normal arterial tissue
is significantly lower than that in atherosclerotic lesions [10]. Chemical inhibition of sphingolipid
biosynthesis can markedly reduce the size of AS lesions in ApoE KO (apolipoprotein E knock out)
mice [11]. These studies have mainly concentrated on the impact of SMS on reverse cholesterol transport
and foam cell production in the process of AS development. However, our recent study indicated that
SMS2 can also promote ED by activating the Wnt/β-catenin pathway under conditions of oxidative
stress [12]. The typical Wnt/β-catenin pathway plays a critical role in many physiological processes, such
as tissue patterning, the specification of cell fate, and cell proliferation [13,14]. During the process of
transmembrane signal transduction, Wnt combines with the transmembrane receptor frizzled (FZD) and
the coreceptor low-density lipoprotein receptor-related protein 6 (LRP6) to induce the phosphorylation
of LRP6, which is necessary for activating the downstream Wnt/β-catenin pathway [13,14]. Since ED
plays a crucial role in the initiation of AS [2], the Wnt/β-catenin pathway also participates in AS and its
development [15–20]. For example, Bhatt et al. found that Wnt5a expression in serum from atherosclerotic
patients is associated with the severity of atherosclerotic lesions [17,18]. However, the detailed mechanism
of SMS2 related with the Wnt/β-catenin pathway and ED (AS) is not clear.
The endoplasmic reticulum (ER) is an organelle that participates in protein folding,
calcium homeostasis, and lipid biosynthesis. Many factors, including hyperlipidemia and oxidative
stress, can disrupt homeostasis in the ER and the unfolded protein response (UPR) to induce ER
stress [21,22]. During the process of ER stress, the chaperone GRP78 dissociates from PERK, IRE1,
and ATF6, activating their downstream signaling pathways and influencing homeostasis in cells [23,24].
ER stress is strongly linked to the development of AS, and expression of GRP78, p-PERK, p-IRE1,
ATF6, and CHOP is increased in ApoE knockout mice [25,26]. In addition, many atherogenic risk
factors can activate ER stress during the initial stages of AS, strengthening ED and AS [27,28].
Undoubtedly, ER stress is involved in not only AS but also ED.
Importantly, SMS2, ER stress, and the Wnt/β-catenin pathway are all related to ED. Although our
previous study revealed that SMS2 can lead to ED by inducing the Wnt/β-catenin pathway, the relationship
between SMS2 and ER stress and the specific mechanism by which SMS2 regulates the Wnt/β-catenin
pathway needs further research. Therefore, we aimed to identify the mechanism using HUVECs.
2. Results
2.1. SMS2 Can Activate ER Stress
Both ER stress and SMS2 are associated with ED; however, the mechanism involved needs further
study. First, we established SMS2 overexpression in HUVECs. These results (Figure 1A) showed
that the amounts of SMS2 and the ER stress marker protein GRP78 in the S group were upregulated
compared with those in the C group (C, transfected with empty plasmids; S, cells overexpressing
SMS2; p < 0.001; n = 3). Furthermore, an ER stress cell model was established by treating cells with
tunicamycin (10 μg/mL) for 24 h. The results (Figure 1B) verified that expression of SMS2 and GRP78
was upregulated by 46.3% and 44.8% in the tunicamycin group compared with that in the C group,
respectively (p < 0.001; n = 3). To rule out the possibility that endoplasmic reticulum stress was not
caused by protein overload but the overexpression of SMS2, we treated the HUVECs with 20 μmol/L
Dy105 (an inhibitor of SMS2). We then measured the activity of SMS2 and expression of GRP78.
Based on the data presented in Figure 1C, we identified that the SMS enzyme activity was markedly
decreased compared with that in the C group; this activity was decreased by 60.09% compared with
that in the C group (p <0.001; n = 3). In addition, the expression of GRP78 was decreased by 40.5%
(Figure 1D; p < 0.001; n = 3). These findings demonstrate that ER stress is significantly induced by SMS2.
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Figure 1. Sphingomyelin synthase 2 (SMS2) overexpression activates endoplasmic reticulum (ER)
stress. Either a SMS2 overexpressed plasmid was used to transfect human umbilical vein endothelial
cells (HUVECs) or the cells were treated with tunicamycin (10 μg/mL). (A) The protein levels of SMS2
and GRP78 were measured by a western blot analysis. (B) The protein levels of SMS2 and GRP78 were
measured by a western blot analysis. (C) SMS activity was measured by thin-layer chromatography.
(D) The expression of GRP78 was measured by a western blot analysis. n = 3, * p < 0.05, and **
p < 0.001 vs. the C group. (A) C, transfected with empty plasmids; S, cells overexpressing SMS2.
(C,D) C, control group; Dy105, cells treated with Dy105. (C) NBD-CER, Norbornadiene -ceramide,
NBD-SM, Norbornadiene-sphingomyelin.
2.2. SMS2 Can Trigger ER Stress by Provoking the Wnt/β-Catenin Pathway
To further explore the specific mechanism of SMS2-induced ER stress, LiCl (40 μmol/L) and
salinomycin (5 μmol/L) were used to activate and inhibit the Wnt/β-catenin pathway, respectively.
The results showed that, compared with the C group, the levels of the ER stress-related proteins GRP78,
CHOP, and β-catenin were upregulated by 45.94%, 59.51%, and 94.55% in the Li group and decreased
by 45.5%, 41.36%, and 28.4% in the Sal group, respectively (Figure 2A: C, control cells; Sal, salinomycin;
Li, LiCl group; p < 0.001; n = 3). However, relative expression of phosphorylated β-catenin was
decreased by 24.9% in the Li group compared with that in the C group and increased by 67.7% in the Sal
group compared with that in the C group (Figure 2A: p < 0.05; n = 3). Additionally, we found that the
expression of the total ATF6 and cleaved ATF6 (P50) were significantly increased by 96.5% and 126.3%
compared with the C group, by activating the Wnt/β-catenin pathway. On the contrary, in the Sal group
the expression of the total ATF6 and cleaved ATF6 were significantly decreased by 50.6% and 60.2%
7
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compared with the C group. (Figure 2B: p < 0.05; n = 3). These results suggest that the provocation of
Wnt/β-catenin can induce ER stress and that the suppression of Wnt/β-catenin can inhibit ER stress.
Previous papers published by the authors have shown that SMS2 can cause dysfunction in endothelial
cells by inducing the Wnt/β-catenin pathway. As shown in Figure 2C, compared with the C group,
relative expression of β-catenin, phosphorylated LRP6, and LRP6 was upregulated by 101.9%, 132.9%,
and 104.6% in the SMS2 group, respectively (p < 0.001; n = 3). In contrast, relative expression of
phosphorylated β-catenin was reduced by 45.7%. These results suggest that SMS2 is able to trigger ER
stress by inducing Wnt/β-catenin signaling.
Figure 2. SMS2 can trigger ER stress by inducing the Wnt/β-catenin pathway. (A) Western blot
analysis detected the protein expression of β-catenin, phosphorylated β-catenin, GRP78, and CHOP.
(B) Western blotting analysis detected the protein expression of the total ATF6 and cleaved ATF6.
(C) Western blotting analysis detected the protein expression of SMS2, β-catenin, phosphorylated
β-catenin, lipoprotein receptor-related protein 6 (LRP6), and phosphorylated LRP6. n = 3, * p < 0.05 and
** p < 0.001 vs. the C group; ## p < 0.001 vs. the Li group. C, control cells; S, cells overexpressing SMS2;
Li, LiCl group, control cells treated with LiCl (40 μmol/L) for 24 h; Sal, salinomycin group, control cells
treated with salinomycin (5 μmol/L) for 24 h.
2.3. Inhibition of ER Stress Can Decrease SMS2-Induced ED
To prove the correlation between SMS2 and ER stress, cells were transfected with an empty plasmid
or an SMS2 overexpression plasmid, treated with the ER stress inhibitor 4-PBA for 24 h, and treated with
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H2O2 for 24 h to establish an oxidative stress model. The results indicated that the GRP78 and CHOP
protein expression levels in the S group were increased by 42.8% and 32.3%, respectively, compared with
those in the C group. In the PBA group, the GRP78 and CHOP protein expression levels were significantly
decreased (by 21.6% and 57.4%, respectively) compared with those in the C group. Furthermore, the total
ATF6 and cleaved ATF6 protein expression levels in the S group were upregulated by 210.7% and 163.3%
and downregulated by 32.1% and 40.2% in the PBA group, respectively, compared with those in the C
group. In particular, in the S+PBA group, the levels of GRP78, CHOP, total ATF6, and cleaved ATF6 were
markedly increased compared with those in the PBA group and down-regulated compared with those in
the S group (Figure 3A,B: C, cells transfected with empty plasmids; S, cells overexpressing SMS2; PBA,
empty plasmids treated with 4-PBA (10 mmol/L) for 24 h; S+PBA, cells overexpressing SMS2 treated with
4-PBA (10 mmol/L) for 24 h; and all cells were treated with H2O2 (450 μmol/L) for 24 h. p < 0.001, n = 3).
These data suggest that SMS2 can induce but that PBA inhibits ER stress.
 
Figure 3. SMS2 can induce ER stress and endothelial dysfunction (ED) by inducing the Wnt/β-catenin
pathway. (A) The protein levels of GRP78 and CHOP were determined by a western blot analysis.
(B) The protein levels of the total ATF6 and cleaved ATF6 were determined by a western blot analysis.
(C) The protein levels of VCAM-1, ICAM-1, and MCP-1 were determined by a western blot analysis.
(D) The adhesion ratio of THP-1 cells to HUVECs (magnification 40×). n = 3, * p < 0.05, and
** p < 0.001 vs. the C group; ## p < 0.001 vs. the S group. & p < 0.05 and && p < 0.001 vs. the PBA
group. C, cells transfected with empty plasmids treated with H2O2 (450 μmol/L) for 24 h; S, cells
overexpressing SMS2 treated with H2O2 (450 μmol/L) for 24 h; PBA, empty plasmids treated with 4-PBA
(10 mmol/L) for 24 h and then treated with H2O2 (450 μmol/L) for 24 h; S+PBA, cells overexpressing
SMS2 treated with 4-PBA (10 mmol/L) for 24 h and then treated with H2O2 (450 μmol/L) for 24 h.
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We then investigated the relationship among SMS2, ER stress, and ED. The results (Figure 3C)
suggest that, compared with the transfection with the empty plasmid in the C group, the transfection
with the SMS2 overexpression plasmid activated ER stress and increased the expression of the
adhesion-related molecules ICAM-1, VCAM-1, and MCP-1 by 58.1%, 12.6%, and 103.2%, respectively.
In contrast, the levels of these adhesion-related molecules were decreased by 42.8%, 29.3%, and
36.6% after the inhibition of ER stress by 4-PBA, compared with those in the C group without
treatment. In addition, in the S+PBA group, the levels of ICAM-1, VCAM-1, and MCP-1 were markedly
increased compared with those in the PBA group and down-regulated compared with those in the
S group (p < 0.001, n = 3). Monocyte adhesion reflects the degree of cell damage that can lead to ED.
As illustrated in Figure 3D, the adhesion ability in the S group was observably increased (by 100.96%)
compared with that in the C group (Figure 3D: p < 0.05; n = 3), though the adhesion ability in the PBA
group was significantly reduced (by 33.66%) compared with that in the C group (Figure 3D: p < 0.05;
n = 3). These results demonstrate that the repression of ER stress can repress ED and that SMS2 can
induce ED via ER stress.
2.4. Simvastatin Can Attenuate the ER Stress Induced by SMS2
To determine whether the intracellular accumulation of cholesterol is affected by SMS2,
the following experiments were performed. HUVECs were treated with different doses of
simvastatin to reduce intracellular cholesterol synthesis. The results showed that the activity of
LDH (lactic dehydrogenase) and a degree of cell injury were the lowest at the 0.1 μmol/L dose; therefore,
the final dose of simvastatin used was 0.1 μmol/L (Figure 4A: p < 0.001, n = 3). Subsequently, the
cells were stained with filipin. The results shown in Figure 4B reveal that the intracellular cholesterol
accumulation in the S group was increased by 28.8% compared with that in the C group and decreased
by 20.5% in the Sim group compared with that in the C group. In addition, the cholesterol accumulation
in the S+Sim group was increased by 20.2% compared with that in the Sim group and decreased
by 23.1% compared with that in the S group (C, cells transfected with empty plasmids; S, cells
overexpressing SMS2; Sim, empty plasmids treated with simvastatin (0.1 μmol/L) for 24 h; S+Sim, cells
overexpressing SMS2 treated with simvastatin (0.1 μmol/L) for 24 h; all the cells were treated with
H2O2 (450 μmol/L) for 24 h, p < 0.001; n = 3). These findings suggest that overexpression of SMS2 may
contribute to intracellular cholesterol accumulation. Furthermore, we detected the proteins related to
ER stress, and the results (Figure 4C,D) showed that the protein expression of GRP78, CHOP, SMS2,
total ATF6, and cleaved ATF6, in the S group was increased by 93.6%, 160.9%, 117.6%, 235.4%, and
180.5%, respectively, compared with that in the C group. Expression levels of the GRP78, CHOP, SMS2,
total ATF6, and cleaved ATF6 proteins in the Sim group were inhibited compared with those in the
C group, indicating that simvastatin can inhibit ER stress. In the S+Sim group, the levels of GRP78,
CHOP, total ATF6, and cleaved ATF6 were markedly increased compared with those in the Sim group
but reduced compared with those in the S group (p < 0.001, n = 3). These findings demonstrate that
overexpression of SMS2 can cause cholesterol accumulation, which may contribute to ER stress.
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Figure 4. Overexpression of SMS2 can lead to ER stress by increasing the deposition of intracellular
cholesterol. (A) HUVECs were treated with simvastatin at different doses (0, 0.05, 0.1, 0.2, 0.4, and 0.6
μmol/L) for 24 h, and the level of LDH in the cellular medium was detected. (B) The accumulation of
ER cholesterol after filipin staining was visualized under a fluorescence microscope (magnification
40×). (C) The protein levels of GRP78 and CHOP were determined by a western blot analysis. (D) The
protein levels of the total ATF6 and cleaved ATF6 were determined by a western blot analysis. n = 3, * p
< 0.05, and ** p < 0.001 vs. the C group; ## p < 0.001 vs. the S group. && p < 0.001 vs. the Sim group. C,
cells transfected with empty plasmids treated with H2O2 (450 μmol/L) for 24 h; S, cells overexpressing
SMS2 treated with H2O2 (450 μmol/L) for 24 h; Sim, empty plasmids treated with simvastatin (0.1
μmol/L) for 24 h and then treated with H2O2 (450 μmol/L) for 24 h; S+Sim, cells overexpressing SMS2
treated with simvastatin (0.1 μmol/L) for 24 h and then treated with H2O2 (450 μmol/L) for 24 h.
2.5. Simvastatin Can Attenuate the Injury Induced by SMS2
To further elucidate the effects of cholesterol accumulation on cell injury, we measured the LDH,
SOD (superoxide dismutase), and NOS (nitric oxide synthase) content. The results showed that SOD
and NOS production in the HUVECs in the S group was significantly reduced compared with that
in the C group; however, treatment with simvastatin increased SOD and NOS production in the Sim
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group compared with that in the C group. Additionally, SOD and NOS production in the S+Sim group
was upregulated compared with that in the S group but decreased compared with that in the Sim
group (Figure 5C,D: p < 0.001, n = 3). Conversely, LDH activity showed the opposite trend (Figure 5A:
p < 0.001, n = 3). These findings indicate that SMS2 overexpression can induce HUVEC injury due to
intracellular cholesterol accumulation and that simvastatin has a protective effect on cells. Furthermore,
compared with the C group, the results showed that, in the S group, the level of the pro-apoptotic
gene Bax was increased by 76.5%, while the level of the anti-apoptotic gene Bcl-2 was reduced by
35.9%. This finding contrasts the results observed after the simvastatin treatment. In the Sim group,
the level of the pro-apoptotic gene Bax was decreased by 51.3% compared with that in the C group,
while the level of the anti-apoptotic gene Bcl-2 was increased by 57.2% compared with that in the C
group (Figure 5B: p < 0.001, n = 3). These data indicate that overexpression of SMS2 can lead to ER
stress and ED, due to cholesterol accumulation.
 
Figure 5. Overexpression of SMS2 can promote endothelial cell injury by increasing the deposition
of intracellular cholesterol. (A) LDH, (C) NOS, and (D) SOD levels were measured with assay kits.
(B) Western blot analysis detected the protein levels of SMS2, Bax, and Bcl-2. n = 3, * p < 0.05, and
** p < 0.001 vs. the C group; ## p < 0.001 vs. the S group. && p < 0.001 vs. the Sim group. C, cells
transfected with empty plasmids treated with H2O2 (450 μmol/L) for 24 h; S, cells overexpressing SMS2
treated with H2O2 (450 μmol/L) for 24 h; Sim, empty plasmids treated with simvastatin (0.1 μmol/L) for
24 h and then treated with H2O2 (450 μmol/L) for 24 h; S+Sim, cells overexpressing SMS2 treated with
simvastatin (0.1 μmol/L) for 24 h and then treated with H2O2 (450 μmol/L) for 24 h.
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2.6. Simvastatin Can Attenuate the Adhesion Capacity Induced by SMS2
We next analyzed the adhesion capacity of HUVECs and THP-1 cells to demonstrate the effects
of simvastatin. Figure 6A shows that adhesion capacity in the S group was markedly increased
(by 100.5%) compared with that in the C group (Figure 6A: p < 0.05; n = 3), adhesion capacity in the Sim
group was evidently reduced (by 32.9%) compared with that in the C group (Figure 6A: p < 0.05; n = 3),
and adhesion capacity in the S+Sim group was higher than that in the Sim group and lower than that in
the S group. These findings suggest that simvastatin reduces cholesterol deposition, thus decreasing the
cell adhesion capacity. Moreover, the results showed that, compared with transfection with the empty
plasmid in the C group, transfection with the SMS2 overexpression plasmid increased cholesterol
accumulation and expression of the adhesion molecules VCAM-1, ICAM-1, and MCP-1 by 88.1%, 83.2%,
and 44.2%, respectively. Meanwhile, compared with the C group without treatment, the level of these
adhesion-related molecules was decreased by 39.6%, 28.6%, and 41.8% after treatment with simvastatin
(Figure 6B: p < 0.05; n = 3). Furthermore, S+Sim decreased expression of the adhesion-related molecules
compared with simvastatin treatment in the S group (Figure 6B: p < 0.001; n = 3). These data suggest
that simvastatin can attenuate the adhesion capacity induced by SMS2.
 
Figure 6. Overexpressed SMS2 increases the adhesion activity of HUVECs and THP-1 cells by increasing
the deposition of intracellular cholesterol. (A) The adhesion ratio of THP-1 cells to HUVECs (magnification
40×). (B) Western blot analysis detected the protein level of VCAM-1, ICAM-1, and MCP-1. n= 3, * p < 0.05
and ** p < 0.001 vs. the C group; ## p < 0.001 vs. the S group. && p < 0.001 vs. the Sim group. C,
cells treated with empty plasmids treated with H2O2 (450 μmol/L) for 24 h; S, cells overexpressing SMS2
treated with H2O2 (450 μmol/L) for 24 h; Sim, empty plasmids treated with simvastatin (0.1 μmol/L) for
24 h and then treated with H2O2 (450 μmol/L) for 24 h; S+Sim, cells overexpressing SMS2 treated with
simvastatin (0.1 μmol/L) for 24 h and then treated with H2O2 (450 μmol/L) for 24 h.
3. Discussion
Our previous study demonstrated that SMS2 can activate the Wnt/β-catenin pathway [12], but the
detailed mechanism has remained unclear. Both SM and cholesterol are the main components of lipid
rafts [29]. Therefore, changing the expression of SMS may affect the SM content in lipid rafts and, thus,
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influence transmembrane signal transduction. For example, Ding et al. found that overexpression
of SMS can lead to the deposition of SM in cells and lipid rafts [30]. Lipid rafts play an essential
role in physiological and biochemical processes as signaling “platforms”, such as the LPS receptor
(lipopolysaccharides), TLR4, which must be recruited to lipid rafts to transduce extracellular signals
to intracellular downstream signaling molecules [31]. During the process of Wnt/β-catenin signal
transduction, the coreceptor LRP6 needs to be phosphorylated to disinhibit DKK1 (Dickkopf related
protein 1) and form the FZD transmembrane protein receptor complex to promote signal transduction,
and the binding between the LRP6 and FZD is affected by lipid rafts [32,33]. In this study, overexpressing
SMS2 and both expressions of LRP6 and the phosphorylation of LRP6 were increased in HUVECs
(Figure 2C). These results indicate that SMS2 may increase the phosphorylation of LRP6 in lipid rafts
and decrease the degradation of LRP6 outside lipid rafts by promoting LRP6 endocytosis to lipid
rafts [34,35]. Thereafter, the increase in expression and phosphorylation of LRP6 can lead to the
provocation of the Wnt/β-catenin pathway, which contributes to ED (Figures 2 and 6).
Previously, many studies have suggested that SMS2 is involved in AS by affecting reverse cholesterol
transport [9–11]. However, we recently demonstrated that SMS2 also participates in ED by stimulating the
Wnt/β-catenin signal pathway [19]. Meanwhile, some reports believe that ER stress can lead to ED [36,37],
but the detailed correlation between these factors remains unexplored. Therefore, we transfected HUVECs
with SMS2 overexpression plasmids. The results revealed that overexpression of SMS2 can increase
expression of the ER stress marker protein, GRP78 (Figure 1). Interestingly, when ER stress was induced
by tunicamycin, expression of SMS2 was also significantly increased (Figure 1). These results suggest that
SMS2 can promote ER stress and that ER stress may regulate SMS2 expression.
Since SMS2 can stimulate the Wnt/β-catenin pathway, we investigated whether SMS2 can induce
ER stress, and subsequently ED, by activating the Wnt/β-catenin pathway in HUVECs. In this study,
the Wnt/β-catenin pathway was activated or blocked by LiCl or salinomycin, respectively. The results
revealed that activating Wnt/β-catenin signaling could decrease ER stress in the HUVECs and vice
versa (Figure 2A,B). Mechanically, Zhang et al. suggested that the Wnt/β-catenin pathway blockage and
β-catenin degradation result in the inhibition of the effect of LEF1 on ATF6 and activate ATF6-related
ER stress [38]. These findings confirm that the activation of the Wnt/β-catenin pathway can promote ER
stress. In fact, other studies have also shown that the Wnt/β-catenin pathway is negative with the ER
stress in cancer cells, but our studies contradict these results [39,40]. These conflicting results suggest
that the Wnt/β-catenin pathway has diverse functions in different types of cells. Previously, we proved
that SMS2 can activate Wnt/β-catenin signaling; therefore, after the treatment with 4-PBA, compared
with the simvastatin treatment in the S group, expression of ER stress-related proteins (GRP78, ATF6,
and CHOP) and adhesion molecules (ICAM-1, VCAM-1, and MCP-1) and the adhesion activity
were significantly decreased (Figure 3), suggesting that 4-PBA reverses the effects of SMS2 on ER
stress and ED. These results further indicate that SMS2 can activate ER stress and promote oxidative
stress-induced ED (Figures 3 and 7).
The ER is not only involved in protein folding and modification but is also inextricably linked
to the metabolism of lipids, such as cholesterol; therefore, lipid metabolism disorders can also
trigger ER stress [41,42]. For example, recent animal and human studies have identified cholesterol
deposition and ER stress activation as key players in the progression of many metabolic diseases [43].
Nonetheless, cholesterol deposition causes dysfunction inβ-cells and promotes autophagy by activating
ER stress [44,45]. In fact, SM and cholesterol can affect each other in cells and serum. For example,
patients suffering from the Niemann–Pick disease (NPD-B) cannot synthesize SM due to defective SMase
(sphingomyelinase), leading to the accumulation of SM and cholesterol in the liver [46]. Furthermore,
we previously confirmed that overexpression of SMS in Huh7 cells markedly enhances the levels of
intracellular sphingomyelin and cholesterol [47]. To investigate whether SMS2 expression can lead to
the deposition of cholesterol in HUVECs, we measured intracellular cholesterol by filipin staining.
The results suggested that in HUVECs, SMS2 overexpression can increase the intracellular cholesterol
levels (Figure 4). The inhibition of cholesterol synthesis by simvastatin can reverse the deposition
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of cholesterol induced by SMS2, and expression of the ER stress-associated proteins, GRP78, CHOP,
and ATF6, in the S+Sim group was also noticeably down-regulated compared with that in the S group
(Figure 4). Finally, ED was found to be significantly attenuated (Figures 4 and 5). SMS2 was shown to
induce ER stress and ED by promoting intracellular cholesterol accumulation (Figures 6 and 7).
Figure 7. The possible mechanism by which endoplasmic reticulum stress is induced by SMS2. ER
stress, endoplasmic reticulum stress; ED, endothelial dysfunction.
In conclusion, our results show that SMS2 (1) triggers the Wnt/β-catenin pathway and (2) promotes
intracellular cholesterol accumulation, both of which contribute to the induction of ER stress and
finally lead to ED. Although the mechanism of ED is very complex, we hope that our studies help to
further elucidate the related mechanism.
4. Materials and Methods
4.1. Cell Culture and Reagents
HUVECs were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy
of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium (DMEM; cat. no.
12100-500; Beijing Solarbio Bioscience & Technology co., Ltd., Beijing, China) containing penicillin
and streptomycin (100 U/mL and 0.1 mg/mL, respectively) and 10% certified fetal bovine serum
(FBS; Biological Industries Israel Beit Haemek, KibbutzBeit Haemek, Israel) at 37 ◦C containing 5% CO2.
In addition, the THP-1 cells (Cell Bank of Type Culture Collection of the Chinese Academy of Sciences,
Shanghai, China) were grown in RPMI-1640 (cat. no. 31800; Beijing Solarbio Bioscience & Technology
co., Ltd.) containing 10% FBS and incubated at 37 ◦C in a humidified atmosphere containing 5% CO2.
Simvastin (cat. no. MB1222-S; Meilunbiotech Co., Ltd., Dalian, China), sodium 4-phenylbutyrate (4-PBA;
cat. no. C1029659; Macklinbio co., Ltd., Shanghai, China), tunicamycin (cat. no. B7417; APExBIO co.,
Ltd., Shanghai, China), filipin (cat. no. B6034; APExBIO co., Ltd., Shanghai, China), and salinomycin
(cat. no. HY-15597; Medchem Express co., Ltd., New Jersey, USA) were dissolved in DMSO (dimethyl
sulfoxide; cat. no. 302A036; Beijing Solarbio Bioscience & Technology co., Ltd.).
4.2. Transfection with an SMS2 Overexpression Plasmid
The SMS2-overexpression plasmid was provided by Dr. Tingbo Ding (School of Pharmacy,
Fudan University, Shanghai, China) and used to transfect the HUVECs. In brief, the cells were seeded in
culture flasks (Haote Technologies co., Ltd., Guangzhou, China), and at the time of transfection, the cells
were grown to 90–95% confluency; the medium was replaced with the antibiotic-free DMEM medium
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(Biological Industries Israel Beit Haemek Ltd.). The SMS2 plasmid (4 μg; S group) or an empty control
plasmid (4 μg; C group) was diluted with 400 μL DMEM (FBS-free and antibiotic-free medium), and 24 μL
of Hieff Trans™ Liposomal Transfection Reagent was also diluted with 400 μL DMEM. After 5 min,
the dilutions were gently mixed together and incubated at 37 ◦C for 20 min, and the mixture was added
to each culture flask. Before adding the drugs, the medium was replaced with fresh DMEM (containing
10% FBS and antibiotics). The control and SMS2 groups were divided into two groups after 24 h, resulting
in four small groups as follows: C (empty plasmid), S (SMS2), Sim (control + simvastatin), and S+Sim
(SMS2 + simvastatin). Both the Sim and S+Sim groups were treated with simvastatin (0.1 μmol/L).
The following set of groups were established: C (empty plasmid), S (SMS2), PBA (control + 4-PBA), and
S+PBA (SMS2 + 4-PBA); both the PBA and S+PBA groups were treated with PBA (10 mmol/L). After 24
h, all groups were treated with H2O2 (500 μmol/L). Finally, after 24 h, the HUVECs were centrifuged at
1520× g for 5 min (at room temperature) as appropriate to collect all cells.
4.3. Measurement of the Degree of Oxidative Stress
HUVECs were cultured at a density of 1x105/well in 6-well plates and incubated overnight at 37 ◦C.
After the transfection, the cells were treated with simvastatin (0.1 μmol/L) for 24 h, and then the cells
were treated with H2O2 (500 μmol/L) for 24 h. To collect the supernatant, the HUVECs were centrifuged
(1520× g, 5 min, room temperature) and harvested, followed by digestion with trypsin, according to the
protocol of the manufacturer. The levels of LDH (cat. no. A020-1; Nanjing Jiancheng Bioengineering
Institute, Nanjing, China) and the levels of NOS (cat. no. A014-2-1; Nanjing Jiancheng Bioengineering
Institute) and SOD (cat. no. A001-1-1; Nanjing Jiancheng Bioengineering Institute) activity were measured
using a microplate reader (Thermo Fisher Scientific, Inc., Waltham, MA, USA). LDH was measured at a
wavelength of 450 nm, and SOD and NOS were measured at a wavelength of 560 nm.
4.4. Filipin Staining
Cells were seeded in 24-well plates (Beaver Nano-Technologies co., Ltd., Suzhou, China) at
a density of 2 × 104 cells/well. Following the above transfection steps described in the HUVECs,
the cells were treated with simvastatin (0.1 μmol/L) for 24 h. Subsequently, all cells were treated
with H2O2 (500 μmol/L) for 24 h and washed with PBS (phosphate buffer saline) three times.
Then, 10% paraformaldehyde was used to fix the cells at room temperature for 10 min; subsequently,
the cells were washed with PBS three times again. To eliminate the paraformaldehyde, the cells were
washed with PBS containing glycine (1.5 mg/mL), and then filipin was added in a dark room for 1 h.
The cells were washed with PBS three times. Finally, we used UV excitation at 405 nm and confocal
microscopy to observe the cholesterol aggregation.
4.5. Cell Adhesion Assay
Cells were seeded in 24-well plates in three replicates per group to obtain the average number of
adhesive monocytes/well. Following the above transfection steps described in the HUVECs, THP-1
cells at a density of 5 × 103/well were added and incubated for 2 h at 37 ◦C. The medium was discarded,
and the non-adherent THP-1 cells were removed by washing with PBS three times. The adherent
THP-1 cells were counted in a single field under a phase contrast inverted microscope (Magnification,
20×; Olympus IX71; Olympus corporation, Tokyo, Japan).
4.6. Western Blot Analysis
The total proteins were extracted from all groups by a radioimmunoprecipitation assay buffer
(cat. no. ROO20; Beijing Solarbio Bioscience & Technology co., Ltd.), and the protein content was
measured using a BCA assay kit (Bradford Protein Assay kit; cat. no. cW0014; Beijing Kangwei
century Biotechnology co., Ltd., Beijing, China). Equal amounts of protein (~50 μg) were separated
by 8–10% SDS-PAGE and transferred onto polyvinylidene fluoride membranes (Immobilon-P; EMd
Millipore, Billerica, MA, USA). An equal transfer was examined by staining with Ponceau red (cat. no.
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CW0057S; Beijing Kangwei century Biotechnology co., Ltd.). The membranes were blocked with
5% skimmed milk or 5% BSA (bovine serum albumin) in TBS (phosphate buffer saline + Tween)
for 1 h at room temperature and incubated with primary antibodies overnight at 4 ◦C in TBST
containing 0.05% Tween 20 and 2% bovine serum albumin (cat. no. A8020; Beijing Solarbio Science
& Technology co., Ltd.). Subsequently, the membranes were incubated with a 1:8,000-dilution of a
horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The peroxidase
activity was visualized using an ECL kit (Bio-Rad Laboratories Inc., USA). GAPDH was used as a
loading control. Anti-SMS2 (cat. no SA100531AA; 1:1,000) antibody was purchased from Abgent
Biotech. (Suzhou co., Ltd., Suzhou, China). Anti-apoptosis-associated proteins B-cell lymphoma 2
(Bcl-2; cat. no. 60178-1-Ig; 1:1000), anti-Bcl-2-associated X protein (Bax; cat. no. 505992-2-Ig; 1:2000),
anti-adhesion-associated proteins intracellular adhesion molecule-1 (ICAM-1; cat. no. 10831-1-AP;
1:1000), anti-Wnt/β-catenin signal pathway-associated proteins (β-catenin cat. no. 51067-2-AP;
1:2000), anti-glucose-regulated protein 78 (GRP78; cat. no. 66574-1-Ig; 1:5000), and anti-GAPDH
(cat. no. HRP-60004; 1:8000) antibodies were pauchased from ProteinTech Group, Inc. (chicago,
IL, USA). Anti-phosphorylated β-catenin (cat. no. DF2989; 1:1,000) antibody was pauchased from
Affnity Biosciences. (Cincinnati, OH, USA). Anti-vascular cell adhesion molecule-1 (VCAM-1; cat.
no. WL02474; 1:500), anti-monocyte chemoattractant protein-1 (MCP-1; cat. no. WL01755; 1:1000)
anti-activating transcription factor 6 (ATF6; cat. no. Wl02407; 1:800), and anti-C/EBP homologus
protein (CHOP; cat. no. WL00880; 1:800) antibody was pauchased from Wanleibio. (Shenyang co.,
Ltd., China). Anti-low density lipoprotein receptor-related protein 6 (LRP6: cat. no. A13325; 1:1000)
antibody was pauchased from ABclonal. (Wuhan co., Ltd., Wuhan, China). Anti-phosphorylated
LRP6 (cat. no. abs140173) antibody was pauchased from Absin. (Shanghai co., Ltd., shanghai, China).
Anti-mouse (cat. no. SA00001-1; 1:8000) secondary antibody was pauchased from ProteinTech Group,
Inc. Horseradish peroxidase-conjugated anti-rabbit (cat. no. BA1054; 1:8000) was pauchased from
Boster Biological Technology, Inc. (Wuhan, China).
4.7. LiCl or Salinomycin Treatment of HUVECs
HUVECs were plated in culture flasks. After reaching 70–80% confluency, the cells were treated
with lithium chloride (LiCl, 40 μmol/L) or salinomycin (5 μmol/L) for 24 h and harvested. The following
three experimental groups were established: C (untreated control cells), Sal (salinomycin-treated cells),
and Li (LiCl-treated cells).
4.8. Sphingomyelin Synthase Enzyme Activity Assay
The HUVECs were treated with H2O2 for 24 h as previously described. The HUVECs were
treated with 20 μmol/L Dy105 (provided by Dr. Deyong Ye, School of Pharmacy, Fudan University)
for 24 h. The treated cells were incubated with NBD-ceramide (0.1 μg/μL, cat. no. 62527; Cayman
chemical company, Ann Arbor, MI, USA) at 37 ◦C to synthesize sphingomyelin in vitro. After 3 h of
incubation, the cells were harvested by 1520× g for 5 min, and the medium was collected at room
temperature. According to the protein content in each group, the protein levels were adjusted to the
volume of the reaction system (700 μL) to ensure consistency in the amount of total protein and medium
added. The lipids were extracted in chloroform: Methanol (2:1) dried under N2 gas and separated
by thin layer chromatography using chloroform:MeOH:NH4OH (14:6:1) at room temperature for
10 min [12]. The chromatography film was scanned after 10 min with an autoradiography system
(Chemiluminescence Imaging System, Clinx Science Instruments Co., Ltd., Shanghai, China), and the
intensity of each band was measured using Image-Pro Plus version 6.0 software (Media Cybernetics,
Inc., Rockville, MD, USA) [12].
4.9. Statistical Analysis
The data were analyzed by GraphPad Prism 6.0 (San Diego, CA, USA). t-Tests were used for
comparisons between two groups, and a one-way analysis of variance (ANOVA) was used for
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comparisons among multiple groups. All results were reduplicated at least thrice. p <0.05 was
considered statistically significant.
5. Conclusions
SMS2 1) triggers the Wnt/β-catenin pathway by increasing the phosphorylation of LRP6 and 2)
promotes intracellular cholesterol accumulation, which contributes to the induction of ER stress and
causes ED.
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Abstract: Trimethylamine N-oxide (TMAO) is an organic compound derived from dietary choline
and L-carnitine. It behaves as an osmolyte, a protein stabilizer, and an electron acceptor, showing
different biological functions in different animals. Recent works point out that, in humans, high
circulating levels of TMAO are related to the progression of atherosclerosis and other cardiovascular
diseases. However, studies on a direct role of TMAO in cardiomyocyte parameters are still limited.
The purpose of this work is to study the effects of TMAO on isolated adult rat cardiomyocytes.
TMAO in both 100 μM and 10 mM concentrations, from 1 to 24 h of treatment, does not affect cell
viability, sarcomere length, intracellular ROS, and mitochondrial membrane potential. Furthermore,
the simultaneous treatment with TMAO and known cardiac insults, such as H2O2 or doxorubicin,
does not affect the treatment’s effect. In conclusion, TMAO cannot be considered a direct cause or an
exacerbating risk factor of cardiac damage at the cellular level in acute conditions.
Keywords: trimethylamine N-oxide; cardiomyocytes; cardiotoxicity; ROS; mitochondrial membrane
potential
1. Introduction
Trimethylamine N-oxide (TMAO) is an amine oxide directly introduced through diet or synthetized
from its precursors, primarily L-carnitine and choline, that are transformed into trimethylamine (TMA)
by the gut microbiota. Once absorbed, TMA in most mammals is oxidized by hepatic FMOs to form
TMAO which enters the systemic circulation. Several studies illustrate different biological functions
of TMAO in other animals. In elasmobranchs and deep-sea fishes, it acts as an osmolyte able to
counteract either osmotic or hydrostatic pressure. It is a protein stabilizer preserving protein folding
and it also acts as an electron acceptor balancing oxidative stress [1,2]. TMAO is also reduced to TMA
in the anaerobic metabolism of a number of bacteria. Although TMAO is involved in several reactions
within cells, recent studies highlight its detrimental role when present in high plasmatic concentrations
in some mammals. In fact, TMAO seems to be involved in accelerating endothelial cell senescence,
enhancing vascular inflammation and oxidative stress [3,4]; it also could be involved in the stimulation
of platelet hyperreactivity and in the onset of thrombosis, exacerbating atherosclerotic lesions [5].
Several studies also underline the role of TMAO in the pathogenesis of type 2 diabetes mellitus [6].
There are limited data on its function in mediating direct cardiac injuries, and those studies are mainly
focused on its role in the impairment of mitochondrial metabolism [7] and calcium handling [8]. On the
contrary, recent papers are re-evaluating the role of TMAO, underlining the emerging debate on its
direct effect in causing or exacerbating cardiovascular diseases (CVD) [9,10]. First criticisms point out
that populations having diets with high concentrations of TMAO, like those rich in fish products, when
compared to Western diets rich in its precursors, have reduced risks of CVD or diseases assumed to be
Int. J. Mol. Sci. 2019, 20, 3045; doi:10.3390/ijms20123045 www.mdpi.com/journal/ijms21
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related to high TMAO plasma levels [11]. Another study demonstrates that TMAO does not affect
macrophage foam cell formation and lesion progression in ApoE−/− mice expressing human cholesteryl
ester transfer protein, suggesting that the molecule does not worsen atherosclerosis [12]. Furthermore,
administration of TMAO seems to improve symptoms related to streptozotocin-induced diabetes in
rats and mice, highlighting no direct contribution of the molecule in exacerbating this condition [13].
Finally, data about TMAO plasma concentrations in healthy and pathological subjects are not clear:
the lack of plasma concentration ranges of the molecule highlights the difficulties in referring to
TMAO as a protective or a damaging factor in CVD. Starting from these conflicting considerations,
the aim of this work was to evaluate for the first time the effect of TMAO in an in vitro model of
adult rat cardiomyocytes exposed to different concentrations of the compound from 1 h to 24 h of
treatment. To show whether TMAO exacerbates or reduces induced cell stress, cardiomyocytes were
simultaneously treated with TMAO and H2O2 or doxorubicin (DOX). Investigations were focused
on cell viability after TMAO or TMAO and stressors co-treatment, assessing cell morphology and
functionality with α-actinin staining and specific probes that measure oxidative stress status and
mitochondrial membrane potential.
2. Results
2.1. TMAO and Cell Viability
In order to investigate the effect of TMAO on cell viability, cardiomyocytes were treated with
TMAO 100 μM, TMAO 10 mM, H2O2 50 μM, and H2O2 50 μM + TMAO 100 μM. After 1 h or 24 h of
treatment, cardiomyocytes were labeled with propidium iodide (PI) and marked nuclei of suffering
cells were detected by confocal microscopy at 568 nm. Concentrations used were taken from the
literature: TMAO 100 μM is recognized as a marker of cardiovascular risk, TMAO 10 mM is over
the physiological range and was tested here to detect any effect induced by high concentrations of
the compound [14]. As shown in Figure 1a, there is no effect of TMAO 100 μM or TMAO 10 mM at
either time of treatment, whereas H2O2, used here as a positive control, had effects only after 24 h.
Simultaneous treatment with H2O2 and TMAO did not improve or worsen the effect of the stressor
on cell viability (1 h—CTRL: 83.95 ± 6.59, n = 3, 52 cells; TMAO 100 μM: 85.52 ± 7.01, n = 5, 81 cells;
TMAO 10 mM: 84.08 ± 5.84, n = 5, 92 cells; H2O2: 52.92 ± 16.46, n = 3, 56 cells; H2O2 + TMAO:
50.93 ± 18.50, n = 3, 58 cells. 24 h—CTRL: 83.42 ± 2.29, n = 3, 101 cells; TMAO 100 μM: 85.66 ±
6.48, n = 3, 91 cells; TMAO 10 mM: 62.22 ± 10.47, n = 3, 119 cells; H2O2: 2.38 ± 2.38, n = 3, 82 cells
(*** p < 0.001); H2O2 + TMAO: 1.33 ± 1.33, n = 3, 41 cells (*** p < 0.001)). Figure 1b displays confocal
images of cardiomyocytes from a representative experiment of PI staining after 24 h of treatment.
White arrows point out PI-stained, damaged cardiomyocytes.
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Figure 1. Cell viability after trimethylamine N-oxide (TMAO) exposure. (a) Bar graph of cell viability
after 1 h and 24 h of treatment. Cell viability results reduced only after H2O2 treatment for 24 h,
condition not improved or worsened by the simultaneous treatment with TMAO (refer to the main text
for numerical values). (b) Merged images in bright field and fluorescence of cells treated for 24 h with
TMAO 100 μM and TMAO 10 mM, H2O2, and H2O2+TMAO and labeled with propidium iodide (PI)
(20×magnification). White arrows point out PI-stained, damaged cardiomyocytes.
2.2. TMAO and Sarcomere Length
To evaluate if TMAO was able to alter sarcomere structures after 24 h of treatment, sarcomere
length was measured in α-actinin-stained cardiomyocytes. As shown in Figure 2, no changes in
sarcomere length were observed in cells treated with TMAO, while H2O2 50 μM used as a positive
control caused cardiomyocyte shrinkage, a condition that was not improved or worsened by the
simultaneous treatment with TMAO. In cardiomyocytes treated with DOX 1 μM for 24 h, no sarcomere
length variations were observed, because the DOX treatment in our model was designed to induce
mild damage preceding cell shortening. Even so, TMAO 100 μM did not modify DOX-treated
cardiomyocytes (sarcomere length in μm—CTRL: 1.69 ± 0.01, n = 7, 42 cells; TMAO 100 μM: 1.69 ± 0.01,
n = 6, 34 cells; TMAO 10 mM: 1.67 ± 0.02, n = 3, 19 cells; H2O2: 1.22 ± 0.04, n = 5, 33 cells (*** p < 0.001);
H2O2 + TMAO: 1.28 ± 0.03, n = 3, 24 cells (*** p < 0.001); DOX: 1.62 ± 0.02, n = 3, 16 cells; DOX +
TMAO: 1.65 ± 0.01, n = 3, 15 cells).
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Figure 2. Sarcomere length after TMAO treatment. (a) Confocal microscopy images of fixed cells
labeled for α-actinin protein (40×magnification). (b) Bar graph showing sarcomere length after 24 h of
treatment with TMAO and other stressors: no cell shrinkage is measured when cells are exposed to
different TMAO concentrations (refer to the main text for numerical values).
2.3. TMAO and Intracellular Reactive Oxygen Species (ROS)
In order to determine a variation in total ROS produced after treatment with TMAO for 1 h, 3 h,
or 24 h, cells were labeled with the DCF-DA probe and its fluorescence was quantified and related
to the control. As shown in Figure 3 (1 h, 3 h) and 4 (24 h), no fluorescence variations after TMAO
treatment were detected at any concentration and time used. As a positive control, we employed
DOX 1 μM for 24 h [15]; this drug caused a significant variation in ROS production with respect to the
control condition. TMAO 100 μM did not modify ROS production in the DOX-treated cardiomyocytes
(Figure 4) (1 h—TMAO 100 μM: 1.30 ± 0.21, n = 3, 34 cells; TMAO 10 mM: 1.32 ± 0.23, n = 3, 40 cells,
vs. CTRL; 3 h—TMAO 100 μM: 0.96 ± 0.05, n = 3, 45 cells; TMAO 10 mM: 1.15 ± 0.09, n = 3, 52 cells,
vs. CTRL; 24 h—TMAO 100 μM: 1.18 ± 0.04, n = 5, 40 cells; TMAO 10 mM: 1.24 ± 0.16, n = 3, 52 cells;
DOX: 1.33 ± 0.11, n = 4, 21 cells (** p < 0.01); DOX+TMAO: 1.27 ± 0.01, n = 6, 31 cells (*** p < 0.001),
vs. CTRL).
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Figure 3. ROS production after 1 h and 3 h of treatment. (a) Confocal microscopy images of cells
treated with TMAO 100 μM and TMAO 10 mM for 1 h and 3 h and labeled with the DCF-DA
probe (60×magnification). (b) Bar graph showing mean fluorescence after 1 h and 3 h of treatment,
no variations or ROS produced are detectable (refer to the main text for numerical values).
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Figure 4. ROS production after 24 h of treatment. (a) Confocal microscopy images of cells treated with
TMAO 100 μM and TMAO 10 mM for 24 h and labeled with the DCF-DA probe. In these experiments,
doxorubicin (DOX) is used as a positive control (60× magnification). (b) Bar graph showing mean
fluorescence after 24 h of treatment. No variations of ROS produced are detectable after TMAO
treatment, and a small but significant increase is visible after DOX treatment (used here as a positive
control); this increase is not changed by a simultaneous treatment with TMAO (refer to the main text
for numerical values).
2.4. TMAO and Mitochondrial Membrane Potential
To investigate the potential metabolic damage induced by TMAO, cardiomyocytes treated with
TMAO 100 μM and 10 mM for 1 h, 3 h, or 24 h were labeled with the JC-1 probe. Figure 5 (1 h, 3 h) and
6 (24 h) show variations in mitochondrial membrane potential (red/green fluorescence ratio) detected
by confocal microscopy in living cells. TMAO treatment from 1 to 24 h did not cause any difference
with respect to the control, indicating no mitochondrial effect of the molecule, whereas, as expected,
DOX caused a depolarization of mitochondrial membrane potential after 24 h of treatment. TMAO
100 μM did not modify mitochondrial membrane potential in DOX-treated cardiomyocytes (Figure 6)
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(1 h—TMAO 100 μM: 1.09 ± 0.08, n = 5, 65 cells; TMAO 10 mM: 1.11 ± 0.11, n = 3, 49 cells, vs. CTRL.
3 h—TMAO 100 μM: 1.02 ± 0.06, n = 3, 26 cells; TMAO 10 mM: 0.88 ± 0.05, n = 4, 39 cells, vs. CTRL;
24 h—TMAO 100 μM: 1.08 ± 0.11, n = 3, 21 cells; TMAO 10 mM: 0.95 ± 0.15, n = 3, 54 cells; DOX:
0.73 ± 0.02, n = 3, 24 cells (** p < 0.01); DOX + TMAO: 0.69 ± 0.05, n = 3, 22 cells (** p < 0.01), vs. CTRL).
Figure 5. Mitochondrial membrane potential variation following 1 h and 3 h of treatment. (a) Confocal
microscopy images of cells treated with TMAO 100 μM and TMAO 10 mM for 1 h and 3 h and labeled
with the JC-1 probe (60×magnification). (b) Bar graph showing red/green fluorescence after 1 h and
3 h of treatment, no variations of mitochondrial membrane potential are detected (refer to the main text
for numerical values).
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Figure 6. Mitochondrial membrane potential variation following 24 h treatment. (a) Confocal
microscopy images of cells treated with TMAO 100 μM and TMAO 10 mM for 24 h and labeled with the
JC-1 probe. In these experiments, doxorubicin (DOX) is used as a positive control (60×magnification).
(b) Bar graph showing red/green fluorescence after 24 h of treatment, no variations of mitochondrial
membrane potential are detected, a little but significant reduction of the ratio is visible after DOX
treatment used here as a positive control, condition not changed in a simultaneous treatment with
TMAO (refer to the main text for numerical values).
3. Discussion
This study provides novel insights into the physiological role of TMAO in isolated adult rat
cardiomyocytes. Our findings do not show effects of TMAO on cell viability, sarcomere length, ROS
production, and mitochondrial membrane potential within the range of concentration used. Moreover,
we demonstrate that TMAO does not exacerbate or counteract the effect of known insults, such as
H2O2 or doxorubicin, tested for up to 24 h of treatment. Taken together, these results suggest that
28
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TMAO should not be considered a primary cause of acute cardiac damage and that the molecule could
not revert or worsen existing risk factors of cardiac damage.
In the last few years, many studies suggest a strong relationship between diet, gut microbiota, and
cardiovascular diseases [16]. In particular, some attention has been pointed to either TMAO directly
coming from diet (fish), or produced from L-carnitine and choline conversion by gut microbiota into
TMA and oxidized in the liver by FMO3 enzymes [14,17].
Experiments have mainly now focused on the role of TMAO in damaging endothelial cells. It has
been described as upregulating cellular senescence, thereby reducing cell proliferation, increasing the
expression of senescence markers, such as p53 and p21, and impairing cell migration [3]. TMAO also
increases the oxidative stress of endothelial cells through a down-regulation of SIRT-1 and impairs
NO production that causes endothelial dysfunction [4]. Hypertensive effects of TMAO have been
evaluated by Ufnal and colleagues who demonstrated that TMAO has a role in stabilizing the action of
Ang II and in prolonging its hypertensive effect, underlining the role of TMAO in stabilizing protein
conformation and no direct role of the molecule in mediating hypertension [18]. Koeth and colleagues
underlined the strong relationship between the high consumption of TMAO precursors, high TMAO
plasma concentrations, and the development of atherosclerosis [19], while another study underlined the
effect of the metabolite in enhancing platelet hyperreactivity and thrombosis risk in subjects with high
TMAO plasma concentrations [5]. With respect to the cardiovascular effects of TMAO, Dambrova and
collaborators showed that high plasma concentrations of the molecule are linked with increased body
weight and insulin resistance and that it directly correlates with an augmented risk of diabetes [20].
Only a few studies are centered on the direct effect of the molecule on cardiac cells; in particular,
they focus on the impairment of mitochondrial metabolism in the heart and underline TMAO as
an agent that increases the severity of cardiovascular events or that enhances the progression of
cardiovascular diseases [7]. Savi and colleagues showed a damaging effect of TMAO in cardiomyocytes
because it worsens intracellular calcium handling with a reduced efficiency in the intracellular calcium
removal and consequent loss in functionality of cardiac cells; furthermore, TMAO seems to alter
energetic metabolism and to facilitate protein oxidative damage [8].
This scenario presents TMAO as either a marker or a direct agent involved in vascular and
cardiac outcomes, but recent papers seem to oppose this point of view, highlighting uncertainty about
the causative relation between TMAO and CVD [9]. The function of TMAO is still being debated,
for example, the controversy surrounding fish-rich diets, because of the higher bioavailability of the
compound in seafood products and their well-known role in lowering risk of CVD. Additionally,
TMAO does not enhance atherosclerosis development because it seems not to be involved in foam cell
formation even at higher concentrations than physiological ones [12], and there is no direct correlation
between high plasma TMAO concentrations and coronary heart diseases [21,22]. Finally, findings
by Huc et al. have also underlined a protective role of TMAO in reducing diastolic dysfunction and
fibrosis in the pressure-overloaded heart [23].
The present study fits into this debate and the results presented agree with other works supporting
TMAO as a non-damaging factor. In fact, it is well known that the loss of vital cardiac cells is a
damaging condition that hampers primarily the functionality of the heart and has several aggravating
responses also in peripheral tissues. Our first investigations underline no toxic effect in cardiomyocytes
exposed to high concentrations of TMAO, highlighting the result that the molecule is not involved in
inducing cardiac tissue cell loss, and no alterations of cardiac structure emerge from the evaluation
of sarcomere length and cytoskeletal organization. Oxidative stress could be considered one of the
causative factors of senescence in cells and one of the promoters of cardiometabolic reorganization in
response to injury. With respect to TMAO as a possible inducer of ROS rising, both in a cytoplasmic and
a mitochondrial environment, we show no variation in ROS production even after 24 h of treatment
and we detect no depolarization of mitochondrial membrane potential, underlining the result of no
direct influence by the molecule in inducing cardiac cell senescence.
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4. Materials and Methods
4.1. Animal Care and Sacrifice
Experiments were performed on female adult rats which were allowed ad libitum access to tap
water and standard rodent diet. The animals received human care in compliance with the Guide for
the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996), and in accordance with Italian law (DL-116, Jan. 27, 1992).
The scientific project was supervised and approved by the Italian Ministry of Health, Rome, and by
the ethical committee of the University of Torino (approval code 116/2017-PR, 3/2/2017). Rats were
anaesthetized by i.p. injection of tiletamine (Zoletil 100, Virbac, Carros, France) and sacrificed by
stunning and cervical dislocation.
4.2. Solutions and Drugs
Tyrode standard solution containing (in mM): 154 NaCl, 4 KCl, 1 MgCl2, 5.5 D-glucose,
5 HEPES, 2 CaCl2, pH adjusted to 7.34 with NaOH. Ca2+ free Tyrode solution containing (in mM):
154 NaCl, 4 KCl, 1 MgCl2, 5.5 D-glucose, 5 HEPES, 10 2,3-Butanedione monoxime, 5 taurine, pH 7.34.
All drug-containing solutions were prepared fresh before the experiments and the Tyrode solutions
were oxygenated (O2 100%) before each experiment. Unless otherwise specified, all reagents for cell
isolation and experiments were purchased from Sigma-Aldrich (St. Louis, MO, USA).
4.3. Adult Rat Ventricular Cell Isolation
Isolated cardiomyocytes were obtained from the hearts of adult rats (200–300 g body weight)
according to the previously described method [24]. Briefly, after sacrifice, rat heart was explanted,
washed in Ca2+ free Tyrode solution, and cannulated via the aorta. All the following operations were
carried on under a laminar flow hood. The heart was perfused at a constant flow rate of 10 mL/min
with Ca2+ free Tyrode solution (37 ◦C) with a peristaltic pump for approximately 5 min to wash
away the blood and then with 10 mL of Ca2+ free Tyrode supplemented with collagenase (0.3 mg/mL)
and protease (0.02 mg/mL). Hearts were then perfused and enzymatically dissociated with 20 mL
of Ca2+ free Tyrode containing 50 μM CaCl2 and the same enzymatic concentration as before. Atria
and ventricles were then separated and the ventricles were cut in small pieces and shaken for 10 min
in 20 mL of Ca2+ free Tyrode solution in the presence of 50 μM CaCl2, collagenase, and protease.
Calcium ion concentration was slowly increased to 0.8 mM. Cardiomyocytes were then plated on glass
cover slips or glass bottom dishes (Ibidi, Martinsried, Germany), both treated with laminin to allow
cell adhesion.
4.4. Cell Viability
Cell viability was evaluated by propidium iodide (PI) staining on glass bottom dishes for adherent
cells. At the end of the treatments, cells were incubated with PI (10 μg/mL, Invitrogen, Carlsbad,
CA, USA) for 5 min in the dark. Nuclei of suffering cells were detected with confocal microscopy
using an Olympus Fluoview 200 microscope (Shinjuku, Tokyo, Japan) at 568 nm (magnification
20×). Merged images were created with ImageJ (U.S. National Institutes of Health, Bethesda, MD,
USA, https://imagej.nih.gov/ij/) and cell viability was calculated as percentage of (total cells-labeled
cells)/total cells.
4.5. Evaluation of Sarcomere Length
Cardiomyocytes on glass coverslips were stimulated with TMAO and with H2O2 as a positive
control. Cells were treated for 24 h with TMAO, at 100 μM and 10 mM, then the sarcomere protein
α-actinin, localized in the Z lines, was detected using confocal microscopy. Subsequently, cells were
fixed in 4% PFA for 40 min. After two washes with PBS, cells were incubated for 20 min with 0.3% Triton
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and 1% bovine serum albumin (BSA) in PBS and stained for 24 h at +4 ◦C with a mouse monoclonal
anti-α-actinin primary antibody (Sigma-Aldrich, 1:800). Cover slides were washed twice with PBS and
incubated 1 h at room temperature with the secondary antibody (1:2000, anti-mouse Alexa Fluor 568,
Thermo Fisher Scientific, Waltham, MA, USA). After two washes in PBS, coverslips were mounted
on standard slides with DABCO and observed after 24 h under a confocal microscope. Confocal
fluorimetric measurements were acquired using a Leica SP2 laser scanning confocal system (Wetzlar,
Germany), equipped with a 40× water-immersion objective. Image processing and analysis were
performed with ImageJ software. Sarcomere length was evaluated measuring the distance between
Z lanes in n = 10 sarcomeres/cell.
4.6. Intracellular Reactive Oxygen Species (ROS) Measurement
Production of ROS was evaluated by fluorescence microscopy using a 2′-7′-dichlorofluorescein
diacetate probe (DCF-DA). After adhesion on glass bottom dishes, DCF-DA solution (5 μg/mL) was
added to each dish 30 min prior to the end of the treatment, then the cells were washed with standard
Tyrode solution. Fluorescence images at 488 nm were acquired using an Olympus Fluoview 200
microscope (magnification 60×). Fluorescence variations were calculated with the definition and
measurement of regions of interest (ROIs) using ImageJ software and expressed as relative Medium
Fluorescence Index (MFI) compared to control, fixed at 1.
4.7. Mitochondrial Membrane Potential Measurement
Mitochondrial membrane potential was evaluated by staining cardiomyocytes with the dye
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide (JC-1). JC-1 solution (10 μM) was
added to each dish 30 min prior to the end of the treatment, then the cells were washed with standard
Tyrode solution. Fluorescence images at 488 nm and 568 nm were acquired using an Olympus Fluoview
200 microscope (magnification 60×). Amounts of the monomeric form of the dye were quantified using
the red/green fluorescence ratio in the ROIs using ImageJ software and expressed as folds towards
control, fixed at 1.
4.8. Statistical Analysis
All data are expressed as mean ± standard error of the mean. For differences between mean
values, Bonferroni’s multiple comparisons test was performed. Differences with p < 0.05 were regarded
as statistically significant.
5. Conclusions
In summary, this study demonstrates that TMAO is not directly involved in causing or exacerbating
cardiac damage in an acute stress model (Figure 7). However, this study has some limitations: a very
wide range of plasmatic TMAO concentrations have been presented in literature, within different
mammals, and also between different sexes of the same species; so, several orders of magnitude can be
considered physiological [25,26]. Therefore, to test the direct effect of the molecule, high concentrations
were used, even higher than human physiological ones. Another weakness of the study could be
linked to the time of treatment, because the evaluations were no longer than 24 h and they only
represented an acute exposure to TMAO. Moreover, in order to better evaluate the mechanism involved
in TMAO-mediated responses, it may be necessary to treat cells for a longer period to assess a chronic
stress compatible with the development of CVD. Furthermore, we only studied the TMAO effect
on female ventricular cardiomyocytes and it may be interesting to extend the analysis also to male
cardiomyocytes as gender differences have been observed in cardioprotective mechanisms [27] and
TMAO-induced intracellular calcium imbalance has been described in male cardiomyocytes [8]. Finally,
our findings provide new insights into the cardiac effect of TMAO, exploring the direct treatment of
isolated cardiomyocytes.
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Figure 7. No effects of TMAO are detectable on isolated adult rat cardiomyocyte viability, sarcomere
length, ROS production, and mitochondrial membrane potential.
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Abstract: The up-regulation of heme oxygenase-1 (HO-1) is mediated through nicotinamaide adenine
dinucleotide phosphate (NADPH) oxidases (Nox) and reactive oxygen species (ROS) generation, which
could provide cytoprotection against inflammation. However, the molecular mechanisms of carbon
monoxide-releasing molecule (CORM)-2-induced HO-1 expression in human tracheal smooth muscle
cells (HTSMCs) remain unknown. Here, we found that pretreatment with CORM-2 attenuated the
lipopolysaccharide (LPS)-induced intercellular adhesion molecule (ICAM-1) expression and leukocyte
count through the up-regulation of HO-1 in mice, which was revealed by immunohistochemistrical
staining, Western blot, real-time PCR, and cell count. The inhibitory effects of HO-1 by CORM-2
were reversed by transfection with HO-1 siRNA. Next, Western blot, real-time PCR, and promoter
activity assay were performed to examine the HO-1 induction in HTSMCs. We found that CORM-2
induced HO-1 expression via the activation of protein kinase C (PKC)α and proline-rich tyrosine
kinase (Pyk2), which was mediated through Nox-derived ROS generation using pharmacological
inhibitors or small interfering ribonucleic acids (siRNAs). CORM-2-induced HO-1 expression was
mediated through Nox-(1, 2, 4) or p47phox, which was confirmed by transfection with their own
siRNAs. The Nox-derived ROS signals promoted the activities of extracellular signal-regulated
kinase 1/2 (ERK1/2). Subsequently, c-Fos and c-Jun—activator protein-1 (AP-1) subunits—were
up-regulated by activated ERK1/2, which turned on transcription of the HO-1 gene by regulating the
HO-1 promoter. These results suggested that in HTSMCs, CORM-2 activates PKCα/Pyk2-dependent
Nox/ROS/ERK1/2/AP-1, leading to HO-1 up-regulation, which suppresses the lipopolysaccharide
(LPS)-induced airway inflammation.
Keywords: CORM-2; NADPH oxidase; ROS; AP-1; HO-1
1. Introduction
Heme oxygenase (HO), a rate-limiting enzyme, metabolizes heme to biliverdin-IXα, ferrous iron,
and carbon monoxide (CO). These secondary products are involved in the regulation of different
physiological processes. HO-1, a member of the HO family [1,2], is inducible and directly protects
various organs from oxidative damages [1,3]. Biliverdin-IXα is converted to the endogenous radical
scavenger bilirubin-IXα and has anti-inflammatory properties [4,5]. The ferrous iron is rapidly
sequestered with ferritin to function additional antioxidant and anti-apoptotic effects [5,6]. Moreover,
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CO has been shown to exert anti-apoptotic and anti-inflammatory effects that are mediated via HO-1
up-regulation [4,7,8]. However, several pro-inflammatory cytokines and oxidative stresses can also
trigger HO-1 expression [9–11]. For example, HO-1 is also induced by various factors in the airway cells
of asthmatic patients [12]. Accumulating evidence concerning HO-1/CO-dependent cytoprotection
elicits the mechanisms involved in the modulation of the inflammatory responses, including the
down-regulation of pro-inflammatory mediators, atherosclerosis, ischemia-reperfusion systems, and
airway disorders [8,13,14]
Nicotinamaide adenine dinucleotide phosphate (NADPH) oxidase (Nox)-derived reactive oxygen
species (ROS) generation has been approved to regulate either the expression of inflammatory or
anti-inflammatory mediators in the airway and pulmonary diseases [15]. Excessive ROS production
can regulate the expression of various inflammatory genes during airway disorders [15,16]. In contrast,
low levels of ROS contribute to maintain cellular redox homeostasis under physiological conditions [15].
Several studies indicate that the exogenous application of CO and HO-1 can protect against oxidative
stress and hyperoxic injury in the various organs [17,18]. It has also been reported that the
up-regulation of HO-1 via the Nox/ROS formation is induced by lipopolysaccharide (LPS) or
cytokines [8,19]. In addition, our previous reports have indicated that the Nox/ROS system is a
key player for HO-1 expression induced by lipotechoic acid (LTA) and cigarette smoke particle
extract (CSPE) in human tracheal smooth muscle cells (HTSMCs) [5,20]. Our previous studies and
others have demonstrated that the carbon monoxide-releasing molecule (CORM)-2 mediates the
Nox-dependent ROS generation in astrocytes [21,22] and human bronchial smooth muscle cells [23].
CORMs have been confirmed to provide the exogenous CO source and induce HO-1 expression
in several cell types [8,9,24]. However, the roles of Nox/ROS involved in CORM-2-induced HO-1
expression were still unknown. HO-1 expression is regulated by various intracellular signaling
pathways, such as ROS, growth factor receptors, non-receptor tyrosine kinases such as Pyk2, or
mitogen-activated protein kinases (MAPKs) [25,26]. In our previous study, CORM-2 has been shown
to induce HO-1 expression via c-Src/epidermal growth factor receptor (EGFR)/phosphoinositide
3-kinase (PI3K)/Akt/c-Jun N-terminal kinase 1/2 (JNK1/2) and p38 MAPK pathways in HTSMCs [27].
We also noticed that many stress-activated response elements on the upstream region of the HO-1
promoter, such as nuclear factor erythroid 2-related factor 2 (Nrf2) and activator protein 1 (AP-1), are
involved in the expression of HO-1 in response to oxidative stresses [28,29]. Therefore, whether an
alternative Nox/ROS-mediated pathway involved in HO-1 expression induced by CORM-2 has yet to
be investigated in HTSMCs.
Besides, several reports have shown that administration with low concentrations of CO or
pharmacological application of CORMs can also confer protective effects in the models of inflammatory
responses and tissue injury [26,30,31]. Accumulating evidence has indicated that CORM-2-liberated
CO reduces inflammatory responses in sepsis by interfering with nuclear factor (NF)-κB activation [32].
Moreover, the overexpression of HO-1 by cobalt protoporphyrin (CoPPIX) can reduce tumor necrosis
factor (TNF) α-induced oxidative stress and airway inflammation [7]. Therefore, CORM-2-induced
HO-1 gene expression could prevent inflammatory responses. However, the detailed mechanisms by
which CORM-2 induced HO-1 expression in HTSMCs are still unclear. Our results demonstrated that
CORM-2-induced HO-1 expression is mediated via protein kinase C (PKC)α/proline-rich tyrosine kinase
2 (Pyk2)-dependent Nox/ROS generation linking to the ERK1/2-mediated activation of AP-1 in HTSMCs,
which could protect against the lipopolysaccharide (LPS)-induced airway inflammatory diseases.
2. Results
2.1. CORM-2 Inhibits LPS-Induced Lung Inflammation in Mice
CORM-2 has been shown to protect against inflammatory responses induced by various
insults [4,7,8]. First, we investigated the anti-inflammatory effects of CORM-2 on LPS-induced
lung inflammation. We observed that LPS markedly induced intercellular adhesion molecule-1
36
Int. J. Mol. Sci. 2019, 20, 3157
(ICAM-1) expression, which was attenuated by CORM-2 via HO-1 expression, as determined by
immunohistochemistry staining (Figure 1A). Bronchoalveolar lavage (BAL) fluid was collected to
determine the number of leukocytes, and airway tissues were harvested to study the levels of protein
and mRNA expression. As shown in Figure 1B,D, LPS significantly enhanced ICAM-1 protein
expression and leukocytes count in BAL fluid. LPS also significantly induced ICAM-1 messenger
ribonucleic acid (mRNA) expression (Figure 1C). In addition, pretreatment with CORM-2 also inhibited
the LPS-induced ICAM-1 protein expression in HTSMCs (Figure 1E). Further, we confirmed the
inhibitory effects of HO-1 induction by CORM-2 on the LPS-up-regulated ICAM-1 expression by
transfection with HO-1 siRNA. We found that CORM-2 attenuated the LPS-induced ICAM-1 expression,
which was partially reversed by transfection with HO-1 siRNA (Figure 1F). All of these LPS-mediated
responses were attenuated by CORM-2 via the up-regulation of HO-1 in the airway tissues of mice
(Figure 1). These results suggested that the up-regulation of HO-1 by CORM-2 protects airway tissues
against the LPS-mediated inflammatory responses.
Figure 1. Cont.
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Figure 1. Induction of heme oxygenase (HO-1) by carbon monoxide-releasing molecule (CORM-2)
suppresses intercellular adhesion molecule-1 (ICAM-1) expression and leukocyte infiltration in HTSMCs
and mice. Institute of Cancer Research (ICR) mice were pretreated with CORM-2 (8 mg/kg of
body weight) for 24 h, and then treated with lipopolysaccharide (LPS) (3 mg/kg of body weight).
(A) H (hematoxylin) & E (Eosin) and immunohistochemical staining for α-smooth muscle actin
(α-SMA), ICAM-1, and HO-1 in serial section of the airway tissues from sham [0.1 mL of DMSO–PBS
(phosphate-buffered saline) (1:100) with 0.1% (w/v) BSA (bovine serum albumin) treated mice], LPS
(LPS-injected mice) and CORM-2 + LPS mice. The arrows indicate tracheal smooth muscle cells
displayed with ICAM-1 and HO-1 expression. (B,C) Airway tissues were homogenized to extract
proteins and mRNAs (messenger ribonucleic acids), and analyzed by (B) Western blot and (C) real-time
PCR to determine the levels of HO-1, ICAM-1, and β-actin (served as an internal control) protein
and mRNA expression, respectively. (D) BAL fluid was collected to count the number of leukocytes
infiltration. (E) Human tracheal smooth muscle cells (HTSMCs) were pretreated without or with
various concentrations of CORM-2 for 1 h and then incubated with LPS (50 μg/mL) for the indicated
time periods. The levels of ICAM-1 and β-actin were determined by Western blot. (F) Cells were
transfected with scrambled (Scrb) or HO-1 siRNA (small interfering ribonucleic acid), incubated with
CORM-2 (50 μM) for 1 or 6 h, and then stimulated with LPS (50 μg/mL) for 16 h. The levels of ICAM-1,
HO-1, and β-actin protein were determined by western blot. Data are expressed as mean ± SEM of
five independent experiments (n = 5). # p < 0.05, as compared with the mice exposed to the indicated
reagents. Data analysis and processing are described in the section “Statistical Analysis of Data”.
2.2. ROS Participate in CORM-2-Induced HO-1 Expression
Low levels of ROS have been shown to contribute to maintain cellular redox homeostasis and
protect cells against oxidative stress through the up-regulation of HO-1 [8,19]. To examine whether
ROS participate in HO-1 induction in HTSMCs, a ROS scavenger N-acetyl cysteine (NAC) was used
for this purpose. We found that pretreatment with NAC concentration-dependently attenuated the
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CORM-2-induced both of HO-1 protein (Figure 2A) and mRNA expression (Figure 2B), suggesting the
involvement of ROS in the CORM-2-induced HO-1 expression. Next, we evaluated whether CORM-2
stimulated ROS generation and the scavenging efficacy of NAC. Our results indicated that CORM-2
stimulated ROS generation in a time-dependent manner with a maximal response within 4 h (Figure 2C),
which was markedly attenuated by pretreatment with 10 mM of NAC (Figure 2D), indicating that
NAC can efficiently scavenge ROS in HTSMCs. These results were further supported by the data of
2′,7′-chloromethyl 2’,7’-dichloro fluorescein diacetate (CMH2DCF-DA; for H2O2) and dihydroethidium
(DHE; for O2−) fluorescence images observed under a fluorescent microscope (Figure 2E). Pretreatment
of HTSMCs with NAC (10 mM) significantly reduced CORM-2-stimulated H2O2 and O2− generation.
In addition, treatment with an inactive form of CORM-2 [iCORM-2, ruthenium (III) chloride, RuCl3] [33]
failed to induce HO-1 expression (Figure 2F). These results concluded that ROS generation stimulated
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Figure 2. Reactive oxygen species (ROS) are required for CORM-2-induced HO-1 expression in HTSMCs.
(A) Cells were pretreated with N-acetyl cysteine (NAC) for 1 h and then incubated with CORM-2
for 24 h. The protein levels of HO-1 and β-actin (served as an internal control) were determined by
Western blot. (B) Cells were pretreated with NAC (10 mM) for 1 h, and then incubated with CORM-2
for 6 h. The mRNA expression of HO-1 was determined by real-time PCR. (C) Cells were incubated
with the 2',7'-dichlorofluorescin diacetate (DCF-DA) (5 μM) for 45 min, followed by stimulation with
50 μM of CORM-2 for the indicated time intervals. (D) Cells were pretreated without or with NAC
(10 mM) for 1 h before exposure to CORM-2 for 6 h. (C,D) The fluorescence intensity of cells was
determined. (E) DCF-DA, and dihydroethidium (DHE) staining, cells were treated with CORM-2 for 6 h
in the absence or presence of NAC (10 mM). The fluorescence images were observed by a fluorescence
microscope. Image of fluorescence microscope, 400×. (F) Cells were treated with 50 μM of CORM-2 or
iCORM-2 for the indicated time intervals. The protein levels of HO-1 were determined by Western blot.
Data are expressed as mean ± SEM of five independent experiments (n = 5). # p < 0.05, as compared
with the cells exposed to vehicle (C,F) or CORM-2 (A,B,D) alone. Data analysis and processing are
described in the section “Statistical Analysis of Data”.
2.3. Nox-Derived ROS Generation Contributes to CORM-2-Induced HO-1 Expression
CORM-2 mediates the Nox-dependent ROS generation, leading to HO-1 expression [8,9,24]. Thus,
the roles of Noxs in the ROS-dependent HO-1 expression were investigated. The inhibitors of Nox
(diphenyleneiodonium, DPI) and p47phox (apocynin, APO) were used to investigate whether Noxs
mediated ROS-dependent HO-1 expression in CORM-2-treated HTSMCs. As shown in Figure 3A,B,
pretreatment with either DPI or APO significantly attenuated CORM-2-induced both HO-1 protein
and mRNA expression. To further investigate whether CORM-2 stimulates Nox activity, as shown in
Figure 3C, CORM-2 time-dependently stimulated Nox activity, significantly increased within 30 min
and sustained up to 24 h, which was blocked by pretreatment with either DPI (10 μM) or APO
(100 μM) (Figure 3D, grey bars), accompanied with inhibiting the ROS generation induced by CORM-2
(Figure 3D, open bars). These results were further supported by the data of DCF (dichlorofluorescein)
(for H2O2) and DHE (for O2−) fluorescence images observed under a fluorescent microscope (Figure 3F),
suggesting that CORM-2-stimulated Nox-derived ROS generation contributes to HO-1 expression.
Moreover, we found that Nox/ROS generation stimulated by CORM-2 was mediated via Nox(1,2,4) or
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Figure 3. Nicotinamaide adenine dinucleotide phosphate (NADPH) oxidase-dependent ROS generation
contributes to CORM-2-induced HO-1 expression in HTSMCs. (A) Cells were pretreated without or
with diphenyleneiodonium (DPI) or apocynin (APO) for 1 h before exposure to CORM-2 for 24 h.
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The protein levels of HO-1 and β-actin (served as an internal control) were determined by Western blot.
(B) Cells were pretreated with DPI (10 μM) or APO (100 μM) for 1 h, and then incubated with CORM-2
for 6 h. The mRNA expression of HO-1 was determined by real-time PCR. (C) Cells were incubated
with CORM-2 (50 μM) for the indicated time intervals. The Nox activity was analyzed. (D,E) Cells
were pretreated without or with (D) DPI (10 μM) or APO (100 μM), and (E) Ro31-8220 (10 μM), Gö6976
(10 μM), or PF431396 (10 μM) for 1 h, and then incubated with CORM-2 for 6 h. The Nox activity
and ROS generation were analyzed. (F) CMH2, DCF-DA, and DHE staining, cells were treated with
CORM-2 for 6 h in the absence or presence of DPI (10 μM), APO (100 μM), Gö6976 (10 μM), or PF431396
(10 μM). The fluorescence images were detected by a fluorescence microscope. Image of fluorescence
microscope, 400×. (G) Cells were transfected with either scrambled (Scrb), Nox-(1,2,4), or p47phox
siRNA, and then incubated with CORM-2 for 24 h. The levels of Nox-(1,2,4), p47phox, HO-1, and β-actin
(served as an internal control) protein were determined by Western blot. Data are expressed as mean ±
SEM of five independent experiments (n = 5). # p < 0.05, as compared with the cells exposed to vehicle
(C,G) or CORM-2 alone (A,B,D,E). Data analysis and processing are described in the section “Statistical
Analysis of Data”.
2.4. CORM-2 Induces HO-1 Expression via PKCα
Our previous report and the others also indicate that PKCs are involved in HO-1 expression in brain
astrocytes [25]. Thus, we investigated whether PKC members are involved in the CORM-2-induced
HO-1 expression. We found that pretreatment of HTSMCs with Ro31-8220 (a pan-PKC inhibitor)
concentration-dependently attenuated the HO-1 induction by CORM-2 (Figure 4A). Next, to determine
which PKC isoforms, PKCα especially, mediate CORM-2-induced HO-1 expression, two selective PKCα
inhibitors (Gö6976 and Gö6983) were used for these purposes. The usage of Gő6983, an ATP-competitive
bisindolylmaleimide PKC inhibitor, blocks the PKC phosphorylation [34]. Our previous report also
indicates that Gő6983 inhibits PKCα/βII phosphorylation stimulated by thrombin in SK–N–SH
(human neuroblastoma) cells [35]. We found that pretreatment with either Gö6976 or Gö6983
concentration-dependently blocked CORM-2-induced HO-1 expression in HTSMCs (Figure 4A),
indicating that PKCα was involved in CORM-2-induced HO-1 expression. Moreover, pretreatment
with Ro31-8220 (10 μM), Gö6976 (10 μM), or Gö6983 (10 μM) significantly inhibited CORM-2-induced
HO-1 mRNA expression (Figure 4B). The role of PKCα in CORM-2-induced HO-1 expression was
further confirmed by transfection with PKCα siRNA, which significantly knocked down PKCα protein
and blocked the CORM-2-induced HO-1 expression (Figure 4C). In addition, the activation of PKCα/βII
in CORM-2-induced responses was confirmed by determining their phosphorylation. As shown in
Figure 4D, CORM-2 time-dependently stimulated PKCα/βII phosphorylation with a maximal response
within 2–4 h, which was attenuated by pretreatment with Gö6983 (10 μM), but not by pretreatment
with APO, DPI, or NAC, indicating that PKCα/βII are the upstream components of Nox/ROS in HO-1
expression. This note was also supported by the results that pretreatment with either Ro31-8220
or Gö6976 inhibited the CORM-2-stimulated Nox activity and ROS generation (Figure 3E,F). These
results suggested that HO-1 expression induced by CORM-2 is mediated via PKCα/βII-dependent
Nox activation and ROS generation in HTSMCs.
2.5. Involvement of Pyk2 in CORM-2-Induced HO-1 Expression
Previous reports have indicated that PF431396 treatment attenuates proline-rich tyrosine kinase
2 (Pyk2) phosphorylation at Tyr (tyrosine)402 in various types of cells [36,37]. To investigate the role
of Pyk2 in HO-1 expression, PF431396 (a Pyk2 inhibitor) was used. In this study, we found that
pretreatment with PF431396 concentration-dependently attenuated CORM-2-induced both of HO-1
protein (Figure 5A) and mRNA (Figure 5B) expression. To confirm the role of Pyk2 in CORM-2-induced
HO-1 expression, Pyk2 siRNA transfection significantly knocked down the Pyk2 protein level and
inhibited CORM-2-induced HO-1 expression (Figure 5C). We further determined whether CORM-2
stimulated activation of Pyk2; the phosphorylation of Pyk2 was detected by Western blot. As shown in
Figure 5D, CORM-2 time-dependently stimulated Pyk2 phosphorylation, which was attenuated by
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pretreatment of PF431396 (10 μM), but not by APO, DPI, or NAC, indicating that Pyk2 is an upstream
component of Nox/ROS in HO-1 expression. This note was also supported by the results that PF431396
attenuated the CORM-2-triggered Nox activity and ROS generation (Figure 3E,F). These findings
indicated that HO-1 expression by CORM-2 is mediated via a Pyk2-dependent Nox/ROS activity
in HTSMCs.
 
Figure 4. CORM-2 induces HO-1 expression via a PKCα-dependent pathway in HTSMCs. (A) Cells
were pretreated with Ro31-8220, Gö6983, or Gö6976 for 1 h, and then incubated with CORM-2 (50 μM)
for 24 h. The protein levels of HO-1 and β-actin (served as an internal control) were determined by
Western blot. (B) Cells were pretreated with Ro31-8220 (10 μM), Gö6983 (10 μM), or Gö6976 (10 μM)
for 1 h, and then incubated with CORM-2 for 6 h. The mRNA expression of HO-1 was determined
by real-time PCR. (C) Cells were transfected with either scrambled (Scrb) or protein kinase C (PKCα)
siRNA, and then incubated with CORM-2 for 24 h. The levels of PKCα, HO-1, and β-actin (served as
an internal control) protein were determined by Western blot. (D) Cells were pretreated without or
with Gö6983 (10 μM), APO (100 μM), DPI (10 μM), or NAC (10 mM) for 1 h, and then incubated with
CORM-2 for the indicated time intervals. The levels of phospho-PKCα and PKCα were determined by
Western blot. Data are expressed as mean ± SEM of five independent experiments (n = 5). # p < 0.05,
as compared with the cells exposed to CORM-2 alone. Data analysis and processing are described in
the section “Statistical Analysis of Data”.
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Figure 5. Proline-rich tyrosine kinase 2 (Pyk2) is involved in CORM-2-induced HO-1 expression in
HTSMCs. (A) Cells were pretreated with PF431396 for 1 h, and then incubated with CORM-2 for 24 h.
The protein levels of HO-1 and β-actin (served as an internal control) were determined by western blot.
(B) Cells were pretreated with PF431396 (10 μM) for 1 h, and then incubated with CORM-2 for 6 h. The
mRNA expression of HO-1 was determined by real-time PCR. (C) Cells were transfected with either
scrambled (Scrb) or Pyk2 siRNA, and then incubated with CORM-2 for 24 h. The levels of Pyk2, HO-1,
and β-actin (served as an internal control) protein were determined by Western blot. (D) Cells were
pretreated without or with PF431396 (10 μM), APO (100 μM), DPI (10 μM), or NAC (10 mM) for 1 h,
and then incubated with CORM-2 for the indicated time intervals. The levels of phospho-Pyk2 and
Pyk2 (served as an internal control) were determined by Western blot. Data are expressed as mean
± SEM of five independent experiments (n = 5). # p < 0.05, as compared with the cells exposed to
CORM-2 alone. Data analysis and processing are described in the section “Statistical Analysis of Data”.
2.6. Involvement of ERK1/2 in CORM-2-Induced HO-1 Expression
We have previously demonstrated that MAPKs participate in the HO-1 induction by LTA and CSPE
in HTSMCs [20]. Therefore, we further approached the roles of p42/p44 MAPK in CORM-2-induced
HO-1 expression in these cells. We found that pretreatment with a MEK1/2 inhibitor (U0126) significantly
blocked HO-1 protein and mRNA expressions (Figure 6A,B), which were both CORM-2-induced.
To further ensure the role of p42/p44 MAPK in CORM-2-induced HO-1 expression, transfection
with p44 siRNA markedly knocked down the p44 protein level and blocked the CORM-2-induced
HO-1 expression (Figure 6C). To confirm whether p42/p44 MAPK phosphorylation is necessary for
CORM-2-induced HO-1 expression, activation of the kinases was assayed by Western blot using an
antibody specific for the phosphorylated form of p42/p44 MAPK. As shown in Figure 6D, CORM-2
stimulated a time-dependent phosphorylation of p42/p44 MAPK, which was inhibited by pretreatment
with U0126 (10 μM) during the period of observation. Further, pretreatment with Gö6983, PF431396,
NAC, DPI, or APO significantly attenuated CORM-2-stimulated p42/p44 MAPK phosphorylation
(Figure 5D), indicating that p42/p44 MAPK was a downstream component of PKCα, which is a
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Pyk2-mediated Nox/ROS generation pathway. Our findings demonstrated that CORM-2-induced
HO-1 expression is mediated through the activation of the PKCα, Pyk2/Nox/ROS/p42/p44 MAPK
pathway in HTSMCs.
Figure 6. CORM-2-induced HO-1 expression is mediated through extracellular signal-regulated kinase
1/2 (ERK1/2) in HTSMCs. (A) Cells were pretreated with U0126 for 1 h, and then incubated with
CORM-2 for 24 h. The protein levels of HO-1 andβ-actin (served as an internal control) were determined
by Western blot. (B) Cells were pretreated with U0126 (10 μM) for 1 h, and then incubated with CORM-2
for 6 h. The mRNA expression of HO-1 was determined by real-time PCR. (C) Cells were transfected
with either scrambled (Scrb) or p44 siRNA, and then incubated with CORM-2 for 24 h. The levels of p44
and HO-1 protein were determined by Western blot. (D) Cells were pretreated with or without U0126
(10 μM), Gö6983 (10 μM), PF431396 (10 μM), NAC (10 mM), DPI (10 μM), or APO (100 μM), and then
incubated with CORM-2 for the indicated time intervals. The levels of phospho-p42/p44 MAPK and
p42/p44 MAPK (served as an internal control) were determined by Western blot. Data are expressed as
mean ± SEM of five independent experiments (n = 5). # p < 0.05, as compared with the cells exposed to
CORM-2 alone. Data analysis and processing are described in the section “Statistical Analysis of Data”.
2.7. Induction of c-Fos and c-Jun/AP-1 is Required for CORM-2-Induced HO-1 Expression
Moreover, AP-1 has been shown to regulate HO-1 expression through binding to respective
elements in the promoter region in response to oxidative stress [38,39]. Hence, we determined
whether CORM-2-induced HO-1 expression was mediated via AP-1 using its inhibitor tanshinone
IIA (TSIIA). As shown in Figure 7A,B, pretreatment with TSIIA attenuated CORM-2-induced HO-1
protein and mRNA expression, suggesting that in HTSMCs, activated AP-1 is an important event for
CORM-2-induced HO-1 expression. To further approach the roles of c-Fos and c-Jun in CORM-2-induced
HO-1 expression, transfection with either c-Fos or c-Jun siRNA significantly knocked down the c-Fos
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or c-Jun protein expression, respectively, and attenuated HO-1 induction in CORM-2-treated HTSMCs
(Figure 7C). To study whether CORM-2 accelerated AP-1 transcription activity, a reporter plasmid
construct containing the AP-1 response element was used to evaluate AP-1 activity in HTSMCs. We
found that CORM-2 stimulated a time-dependent AP-1 promoter activity (Figure 7D), which was
inhibited by pretreatment with Gö6983, PF431396, NAC, DPI, APO, U0126, or TSIIA (Figure 7E). These
results suggested that HO-1 induction is mediated via PKCα, Pyk2/Nox/ROS/p42/p44 MAPK-dependent
activation of AP-1(c-Fos/c-Jun) in CORM-2-treated HTSMCs.
 
Figure 7. Involvement of c-Fos and c-Jun/activator protein 1 (AP-1) in CORM-2-mediated HO-1
expression. (A) Cells were pretreated with tanshinone IIA (TSIIA) for 1 h, and then incubated with
CORM-2 for 24 h. The protein levels of HO-1 andβ-actin (served as an internal control) were determined
by Western blot. (B) Cells were pretreated with TSIIA (1 μM) for 1 h, and then incubated with CORM-2
for 6 h. The mRNA expression of HO-1 was determined by real-time PCR. (C) Cells were transfected
with either scrambled (Scrb), c-Fos, or c-Jun siRNA, and then incubated with CORM-2 for 24 h.
The levels of c-Fos, c-Jun, HO-1, and β-actin (served as an internal control) protein were determined by
Western blot. (D) Cells were transiently cotransfected with pAP1-Luc (activator protein-1 luciferase
reporter plasmid) and pGal (plasmid contains the reporter gene β-galactosidase) for 24 h, and then
incubated with CORM-2 for the indicated time intervals. (E) Cells were pretreated with Gö6983 (10 μM),
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PF431396 (10 μM), N-acetyl-cysteine (NAC, 10 mM), DPI (10 μM), APO (100 μM), U0126 (10 μM), or
TSIIA (1 μM) for 1 h and then incubated with CORM-2 for 4 h. The AP-1 promoter activity in the cell
lysates was determined as described in the Methods section. Data are expressed as mean ± SEM of
five independent experiments (n = 5). # p < 0.05, as compared with the cells exposed to vehicle (D) or
CORM-2 (A–C,E) alone. Data analysis and processing are described in the section “Statistical Analysis
of Data”.
2.8. CORM-2 Induces HO-1 Expression via Its Promoter Transcriptional Activity
CORM-2 has been shown to induce HO-1 gene regulation and activate the AP-1 activity. Thus,
human HO-1 promoter was constructed in a luciferase reporter plasmid to evaluate the CORM-2
induced HO-1 transcription in HTSMCs. The HO-1 promoter contains several putative recognition
elements for a variety of transcriptional factors, including the AP-1 site. As expected, CORM-2
stimulated the HO-1 promoter activity in a time-dependent manner with a maximal response within 6
h (Figure 8A), which was inhibited by pretreatment with Gö6983, PF431396, NAC, DPI, APO, U0126,
or TSIIA (Figure 8B). These results confirmed that CORM-2 stimulates HO-1 promoter activity via AP-1
activation, which was mediated through PKCα or Pyk2-regulated Nox/ROS/p42/p44 MAPK-dependent
c-Fos-c-Jun/AP-1 pathway in HTSMCs.
Figure 8. CORM-2 induces AP-1-dependent HO-1 expression via PKCα/Pyk2/Nox/ROS/ERK pathway
in HTSMCs. (A) Cells were transiently cotransfected with pHO1-Luc and pGal for 24 h, and then
incubated with CORM-2 (50 μM) for the indicated time intervals. (B) Cells were pretreated with Gö6983
(10 μM), PF431396 (10 μM), NAC (10 mM), DPI (10 μM), APO (100 μM), U0126 (10 μM), or TSIIA
(10 μM) for 1 h and then incubated with CORM-2 for 6 h. The HO-1 promoter activity in the cell lysates
was determined. Data are expressed as mean ± SEM of five independent experiments (n = 5). # p < 0.05,
as compared with the cells exposed to vehicle (A) or CORM-2 alone. Data analysis and processing are
described in the section “Statistical Analysis of Data”.
3. Discussion
CORMs exert anti-inflammatory effects through the up-regulation of anti-oxidant enzymes such
as HO-1 [26]. However, the roles of Nox/ROS involved in CORM-2-induced HO-1 expression were
still unknown. Here, we observed that pretreatment with CORM-2 inhibited the LPS-induced airway
inflammation via HO-1 induction in mice. Further, our results demonstrated that the levels of
HO-1 protein, mRNA, and promoter activity were increased in HTSMCs challenged with CORM-2.
CORM-2-induced HO-1 expression was mediated through PKCα and Pyk2/Nox/ROS/ERK1/2 linking
to the AP-1 pathway in HTSMCs (Figure 9). These results suggested that HO-1 expression induced
by CORM-2 is mediated via a PKCα and Pyk2/Nox/ROS/p42/p44 MAPK-dependent AP-1 pathway
in HTSMCs.
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Figure 9. Schematic signaling pathways are involved in CORM-2-induced HO-1 expression in HTSMCs.
CORM-2-induced HO-1 expression is mediated via a PKCα or Pyk2/Nox/ROS/ERK1/2 cascade linking
to activation of c-Fos and c-Jun/AP-1. The up-regulation of HO-1 could protect against the LPS-induced
airway inflammation.
ROS exert as a messenger in the normal physiological functions and the inflammatory responses
dependent on their cellular concentrations [40]. The up-regulation of HO-1 due to Nox activity and
ROS formation is induced by LPS and cytokines [8,19]. Others and our previous studies indicated that
the CORMs mediate Nox-dependent ROS generation in astrocytes [21,22]. Therefore, Nox-dependent
ROS generation is involved in HO-1 expression by CORM-2 in HTSMCs. We further clarified the role
of ROS in HO-1 expression; a thiol-containing compound (NAC) was used to scavenge ROS. NAC
has been shown to reduce the injurious effects of hydrogen peroxide in human alveolar and bronchial
epithelial cells [41]. We also found that CORM-2-induced HO-1 expression was inhibited by NAC, and
strongly supported the role of ROS in the CORM-2-induced HO-1 expression.
Moreover, two Nox-related inhibitors, DPI (a Nox inhibitor) and APO (a p47phox inhibitor),
have been shown to prevent p47phox (a Nox subunit) translocation to the membrane and inhibit Nox
activation [42]. Our results showed that pretreatment with either DPI or APO attenuated CORM-2-
induced ROS generation and HO-1 expression. These data are consistent with previous reports showing
that Nox-derived ROS generation is involved in HO-1 induction by LTA or CSPE in HTSMCs [5,20].
Indeed, low levels of ROS could regulate proliferation, gene expression, immunity, and wound
healing [43]. Conversely, higher levels of ROS can exert antibacterial effect, and cause cell damage and
death [23,44]. In addition, ROS generation could initiate HO-1 expression through the degradation of
Keap1 and translocation of Nrf2 into the nucleus. In our previous study, CORM-2 has been shown to
activate Nox and produce ROS in brain astrocytes [22]. Previous reports also indicate that CO release
in mammal cells acts as a secondary messenger to mediate metabolism and gene expression, including
HO-1 [45,46]. The members of Nox family such as Nox-(1,2,4) and p47phox were shown to be involved
in CORM-2-induced HO-1 expression, which were confirmed by using their own siRNAs. In this
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study, we also demonstrated that PKCα and Pyk2 are the upstream components of ROS generation
by their inhibitors. Our results showed that PKCα/Pyk2-mediated Nox/ROS signal contributes to
CORM-2-induced HO-1 expression in HTSMCs. However, how CORM-2 activated PKCα/Pyk2 and
led to Nox/ROS generation is an important issue preserved for further investigation.
Abnormal MAPK activations are implicated in a variety of inflammatory responses and tissue
injury, and the induction of several inflammatory mediators in different cell types [25,47]. Here,
we demonstrated that ERK1/2 was required for the CORM-2-induced HO-1 expression, which was
attenuated by a selective MEK1/2 inhibitor U0126 or transfection with p44 siRNA. These kinases
involved in CORM-2-stimulated pathways were further confirmed by CORM-2-mediated ERK1/2
phosphorylation. These results are consistent with the HO-1 expression mediated by ERK1/2 to
activate the antioxidant response element (ARE) region, which is the Nrf2 binding site in HepG2
(liver hepatocellular carcinoma) Cells [48] and heme-mediated neuronal injury [49]. Moreover,
pretreatment with the inhibitor of PKCα, Pyk2, Nox, or ROS scavenger significantly attenuated
ERK1/2 phosphorylation, suggesting that PKCα/Pyk2-dependent Nox/ROS are required for ERK1/2
phosphorylation. These results are consistent with reports that ROS-dependent MAPK pathways
are involved in the regulation of cellular functions [38,50,51]. Indeed, our previous study found
that the inhibition of JNK1/2 or p38 MAPK attenuates CORM-2-induced HO-1 expression via
a c-Src/EGFR/PI3K/Akt pathway [27]. In contrast, CORM-2-stimulated JNK1/2 and p38 MAPK
phosphorylation was not mediated via the PKCα/Pyk2-mediated Nox/ROS signal, although these two
kinases also regulate CORM-2-induced HO-1 expression in HTSMCs.
The activated transcription factors interact with response elements on the HO-1 promoter to
regulate gene transcription [44]. Here, we focused on the role of transcription factor AP-1, which is
modulated during oxidative stress associated with inflammatory diseases [52]. The involvement of
AP-1 in these responses was further supported by the results that CORM-2 induced c-Fos and c-Jun,
AP-1 subunits, and activation via PKCα/Pyk2-mediated Nox/ROS linking to the ERK1/2 pathway.
Moreover, the roles of c-Fos-c-Jun/AP-1 in CORM-2-induced HO-1 expression were confirmed by
transfection with c-Fos or c-Jun siRNA to attenuate CORM-2-induced HO-1 expression. Several reports
have shown that many regulatory elements of transcription factors, including AP-1, were analyzed on
the 5′ region of the HO-1 promoter in several animal species [28,53]. Thus, we also demonstrated that
CORM-2-stimulated HO-1 promoter activity was reduced by pretreatment with Gö6976, PF431396,
NAC, DPI, APO, U0126, or TSIIA, indicating that CORM-2 induces HO-1 promoter activity via a
PKCα/Pyk2-mediated Nox/ROS/ERK1/2/AP-1 pathway. These results are consistent with the reports
that alpha-lipoic acid induced HO-1 expression in vascular smooth muscle cells [54], and BK induced
HO-1 expression in brain astrocytes [38].
Previous reports indicated that the CORMs up-regulate the HO-1 activity and attenuate the
LPS-induced inflammatory responses in macrophages [9] and animal study [8,31]. Moreover, the
overexpression of HO-1 in ovalbumin (OVA)-sensitized guinea pigs effectively decreases inflammatory
reaction, mucus secretion, and responsiveness to histamine in airways [55], suggesting that HO-1
exhibits protecting ability in the host during airway inflammation. In this study, the induction of
HO-1 by CORM-2 protected against LPS-induced ICAM-1 expression and leukocytes infiltration in
both in vitro and in vivo studies. Importantly, previous reports also indicated that CORM-2-derived
CO release can attenuate the cell sequestration, NF-κB activity, and ICAM-1 expression of leukocyte
after lung injury [36,56] and regulate the expressions of adhesion molecules on human umbilical
vein endothelia cells to affect leukocyte attachment [54]. Our previous report also indicated that the
induction of HO-1 by CoPPIX inhibits the TNF-α-induced ICAM-1 and VCAM-1 expression which is
revered by zinc protoporphyrin IX (ZnPPIX, an inhibitor of HO-1 activity) in HTSMCs [14].
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4. Materials and Methods
4.1. Reagents and Chemicals
DMEM/F-12 (Dbecco’s Modified Eagle Medium/Nutrient Mixture F-12) medium, fetal bovine
serum (FBS), TRIzol reagent, and PLUS-Lipofectamine were from Invitrogen (Carlsbad, CA,
USA). Human siRNAs for PKCα (L-003523-00-0020) was from Dharmacon (Lafayette, CO, USA)
and Pyk2 (SASI_Hs01_00032249), ERK1 (SASI_Hs01_00190617), HO-1 (SASI_Hs01_00035065),
Nox-1 (SASI_Hs01_00342845), Nox-2 (SASI_Hs01_00086110), Nox-4 (SASI_Hs02_00349918), p47phox
(SASI_Hs02_00302212), and c-Fos (SASI_Hs01_00184572) were from Sigma (St. Louis, MO, USA).
Hybond C membrane, enhanced chemiluminescence (ECL), and Western blotting detection system
were from GE Healthcare Biosciences (Buckinghamshire, UK). PhosphoPlus PKCα (#9375), Pyk2
(#3291), and ERK1/2 (#9101) antibodies were from Cell Signaling (Danvers, MA, USA). The HO-1
(ADI-SPA-895) antibody was from Enzo (Farmingdale, NY, USA). PKCα (sc-208), Pyk2 (sc-9019),
ERK1 (sc-94), c-Fos (sc-7202), and β-actin (sc-47778) antibodies were from Santa Cruz (Santa Cruz,
CA, USA). Ro31-8220, Gö6983, Gö6976, PF431396, diphenyleneiodonium chloride (DPI), apocynin
(APO), U0126, and tanshinone IIA (TSIIA) were from Biomol (Plymouth Meeting, PA, USA). The
bicinchoninic acid (BCA) protein assay kit was from Pierce (Rockford, IL, USA). SDS-PAGE (sodium
dodecyl sulfate polyacrylamide gel electrophoresis) reagents were from MDBio Inc (Taipei, Taiwan).
Tricarbonyldichlororuthenium (II) dimer (CORM-2), ruthenium (III) chloride, RuCl3 [inactive form
of CORM-2, (iCORM-2)], N-acetyl-cysteine (NAC), lipopolysaccharide (LPS), enzymes, and other
chemicals were from Sigma (St. Louis, MO, USA).
4.2. Animal Care and Experimental Procedures
Male ICR mice aged 6–8 weeks were purchased from the National Laboratory Animal Centre
(Taipei, Taiwan) and handled according to the guidelines of Animal Care Committee of Chang Gung
University (Approval Document No. Chang Gung University 16-046, 4 October 2016) and National
Institute of Health (NIH) Guides for the Care and Use of Laboratory Animals. All the studies involving
animals are reported in accordance with the ARRIVE guidelines [57,58]. Mice were assigned randomly
into three groups: sham [0.1 mL of dimethyl sulfoxide (DMSO)-phosphate-buffered saline (PBS) (1:100)
with 0.1% (w/v) bovine serum albumin (BSA) treated mice], LPS (LPS-treated mice), and CORM-2 +
LPS; 5 mice in each group/cage and kept in standard individually ventilated cages in an animal facility
under standardized conditions (12 h light/dark cycle, 21–24 ◦C, humidity of 50–60%) with food and
water ad libitum. Mice were intraperitoneally (i.p.) injected with CORM-2 (8 mg/kg of body weight)
for 24 h, and then anesthetized by i.p. injection of pentothal (50 mg/kg) placed individually on a
board in a near-vertical position and the tongues withdrawn with a lined forceps. LPS (3 mg/kg) was
placed posterior in the throat and aspirated into lungs for 16 h of development of a lung inflammation
model [59]. At the end of the experimental period, mice were killed by a high dose of pentothal
(100 mg/kg i.p.) for the collection of lung tissues extracted for protein (right superior lobe + post caval
lobe) and mRNA (right middle lobe + right inferior lobe) expression of ICAM-1, HO-1, or β-actin
analyses. BAL fluid was performed through a tracheal cannula using 1-mL aliquots of ice-cold PBS
solution. BAL fluid was centrifuged at 500× g at 4 ◦C, and cell pellets were washed and re-suspended
in PBS. Leukocyte count was determined by a hemocytometer, as previously described [7]. Data
collection and evaluation of all the in vivo and in vitro experiments were performed blindly of the
group identity.
4.3. Cell Culture and Treatment
HTSMCs were purchased from ScienCell Research Laboratories (San Diego, CA, USA). The
cultured conditions and treatments were conducted as previously described [60]. Cells were plated
onto 12-well culture plates and made quiescent at confluence by incubation in serum-free DMEM/F-12
for 24 h. Growth-arrested cells were incubated with or without CORM-2 at 37 ◦C for the indicated time
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intervals. Our previous report indicates that CORM-2 induces HO-1 expression in time-dependent and
concentration-dependent manners. The HO-1 expression is up-regulated to a maximal response within
16–24 h treatment with 50 μM of CORM-2 [27]. Therefore, the concentration of CORM-2 at 50 μM was
used throughout this study. When the inhibitors were used, cells were pretreated with the inhibitor for
1 h before exposure to CORM-2. Experiments were performed using cells from passages four to seven.
4.4. Preparation of Cell Extracts and Western Blot Analysis
After treatment, the cells were washed with ice-cold PBS, scraped, and collected by centrifugation at
16,000× g for 10 min at 4 ◦C to yield the whole cell extract, as previously described [7]. The supernatants
were harvested and mixed with SDS-PAGE loading buffer (final concentration: 100 mM Tris-HCl
pH 6.8, 1% SDS, 2.5% glycerol, 100 mM β-mercaptoethanol, 0.01% bromophenol blue). Samples
were denatured, separated with 10% SDS-PAGE, and transferred to the nitrocellulose membrane.
Membranes were probed overnight with an anti-phospho-PKCα, phospho-Pyk2, phospho-ERK1/2,
HO-1, PKCα, Pyk2, ERK1, c-Fos, or β-actin antibody. Membranes were washed with Tween-Tris
buffered solution (TTBS) four times for 5 min each, incubated with anti-rabbit or anti-mouse horseradish
peroxidase antibody (1:2000) for 1 h. The immunoreactive bands were detected by ECL (enhanced
chemiluminescence) reagents and captured by a UVP BioSpectrum 500 Imaging System (Upland,
CA, USA). The image densitometry analysis was conducted using UN-SCAN-IT gel software (Orem,
UT, USA).
4.5. Total RNA Extraction and Real Time-Quantitative PCR Analysis
Total RNA was isolated from HTSMCs treated with CORM-2 for the indicated time intervals
in 10-cm culture dishes with TRIzol according to the protocol of the manufacturer. The mRNA was
reverse-transcribed into cDNA and analyzed by real time-quantitative (q)PCR. Real time-qPCR was
performed with the TaqMan gene expression assay system, using primers and probe mixes for HO-1,
c-Fos, and endogenous GAPDH control genes. PCRs were performed using a 7500 Real Time-PCR
System (Applied Biosystems, Foster City, CA, USA). Relative gene expression was determined by the
ΔΔCt method, where Ct meant threshold cycle. All the experiments were performed in triplicate.
4.6. Plasmid Construction, Transfection, and Luciferase Reporter Gene Assays
For construction of the HO-1 luciferase (Luc) plasmid, human HO-1 promoter, a region spanning
–3106 to +186 bp provided by Dr. Y. C. Liang (Graduate Institute of Biomedical Technology, Taipei
Medical University, Taipei, Taiwan) was inserted into a pGL3-basic vector (Promega, Madison, WI,
USA). Plasmid pAP1-Luc, the fragment of the AP-1-responding element was inserted into the pGL3
(plasmid contains the reporter gene β-galactosidase) promoter. The plasmid DNA was extracted by
using QIAGEN plasmid DNA preparation kits and transfected into HTSMCs with Lipofectamine
reagent according to the standard protocol of the manufacturer. The plasmid pCMV-β-gal was
cotransfected to be the internal control. The HO-1 promoter-driven-Luc activity was analyzed by a
luciferase assay system (Promega, Madison, WI, USA). Firefly luciferase activities were standardized
with β-galactosidase activity.
4.7. Transient Transfection with siRNAs
HTSMCs (3 × 105 cells) were plated in 12-well culture plates for 24 h to about 80% confluence.
Cells were washed once with PBS, and 0.4 mL of serum-free DMEM/F-12 medium was added to each
well. The transient transfection of siRNAs (scrambled, PKCα, Pyk2, ERK1, and c-Fos, 100 nM) was
performed by using LipofectamineTM RNAiMAX reagent (from Sigma, St. Louis, MO, USA) according
to the manufacturer’s instructions.
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4.8. Measurement of Intracellular ROS Generation
The peroxide-sensitive fluorescent probe CMH2DCF-DA and DHE were used to assess the
intracellular ROS generation [61] with minor modifications. Briefly, HTSMCs were incubated with
10 μM of CMH2DCF-DA (in warm PBS) for 45 min at 37 ◦C. The medium was removed and replaced
with fresh DMEM/F-12 media for CORM-2 treatments. CMH2 DCF-DA interacted with cells, and then
generated a non-fluorescent product: H2DCF. CORM-2 induced the generation of a ROS oxidized
product: DCF. Relative fluorescence intensity was recorded (0.5 to 24 h) by a fluorescent plate reader
(Thermo, Appliskan; Waltham, MA, USA) at an excitation wavelength of 485 nm, and emission was
measured at a wavelength of 530 nm. For DHE staining, cells were treated with CORM-2 for the
indicated time intervals and then incubated with 10 μM of DHE (in DMEM/F12 medium) for 10 min.
For immunofluorescence staining, the stained cells were washed three times with cold PBS, and then
the fluorescence for DCF and DHE staining was detected at 495/529 and 518/605 nm, respectively, using
a fluorescence microscope (Zeiss, Axiovert 200M; Oberkochen, Baden-Württemberg, Germany).
4.9. Determination of NADPH Oxidase Activity by Chemiluminescence Assay
The Nox activity in intact cells was assayed by lucigenin chemiluminescence [38]. After incubation,
the cells were gently scraped and centrifuged at 400× g for 10 min at 4 ◦C. The cell pellet was re-suspended
in a known volume (35 μL/well) of ice-cold RPMI 1640 medium, and the cell suspension was kept
on ice. To a final 200 μL of pre-warmed (37 ◦C) PBS containing either NADPH (1 μM) or lucigenin
(20 μM), 5 μL of cell suspension (2 × 104 cells) was added to initiate the reaction followed by the
immediate measurement of chemiluminescence using an Appliskan luminometer (Thermo®; Waltham,
MA, USA) in an out-of-coincidence mode. Neither NADPH nor NADH enhanced the background
chemiluminescence of lucigenin alone (30–40 counts/min). Chemiluminescence was continuously
measured for 12 min, and the activity of Nox was expressed as counts per million cells. The calculated
numbers of Nox activity were calibrated with protein concentration. The equal amount of warmed
PBS medium (containing NADPH and lucigenin) was used as the blank, and the untreated cells were
the basal group.
4.10. Statistical Analysis of Data
All the data were expressed as the mean ± SEM in at least five individual experiments (n = 5).
Statistical analysis was performed by using GraphPad Prizm Program 6.0 software (GraphPad,
San Diego, CA). We used one-way ANOVA followed by Dunnett’s post hoc test when comparing
more than two groups of data and a one-way ANOVA, non-parametric Kruskal–Wallis test, followed
by Dunnett’s post hoc test when comparing multiple independent groups. p values of 0.05 were
considered to be statistically significant. Post tests were run only if F achieved p < 0.05 and there was
no significant variance in homogeneity. Error bars were omitted when they fell within the dimensions
of the symbols.
5. Conclusions
These results suggested that CORM-2-induced HO-1 expression is mediated through PKCα/Pyk2
and Nox/ROS-dependent activation of ERK1/2, linking to the up-regulation of AP-1 (c-Fos and c-Jun),
which promotes HO-1 expression and enzymatic activity in HTSMCs. Based on the observations
from literatures and our findings, we depict a model for the molecular mechanisms underlying
CORM-2-induced HO-1 expression and activity in HTSMCs. The results obtained with cellular and
animal experiments indicated that better understanding the mechanisms underlying CORM-2-induced
HO-1 expression promotes the development of therapeutic strategies for airway inflammatory disorders.
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Abbreviations
AP-1 activator protein 1
APO apocynin
ARE antioxidant response element
BAL bronchoalveolar lavage
BCA bicinchoninic acid
BSA Bovine serum albumin
CO carbon monoxide
CORM-2 carbon monoxide releasing molecule-2
CoPPIX cobalt protoporphyrin








EGFR epidermal growth factor receptor
ERK1/2 extracellular signal-regulated kinase 1/2
FBS fetal bovine serum
MCH2DCF-DA chloromethyl 2’,7’-dichloro fluorescein diacetate
H & E hematoxylin & eosin
HO-1 heme oxygenase-1
HTSMCs human tracheal smooth muscle cells
ICAM-1 intercellular adhesion molecule




MAPKs mitogen-activated protein kinases
mRNA messenger ribonucleic acid
NAC N-acetyl-cysteine
NADPH nicotinamaide adenine dinucleotide phosphate
NF-κB nuclear factor-κB
Nox NADPH oxidase
Nrf2 nuclear factor erythroid 2-related factor 2
PBS phosphate-buffered saline
PI3K phosphoinositide 3-kinase
PKC protein kinase C
Pyk2 proline-rich tyrosine kinase 2
ROS reactive oxygen species
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SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
siRNA small interfering ribonucleic acid
TNF tumor necrosis factor
TSIIA tanshinone IIA
TTBS Tween-Tris buffered solution
VCAM-1 vascular cell adhesion molecule
XTT 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide
ZnPP IX zinc protoporphyrin IX
References
1. Maines, M.D. The heme oxygenase system: A regulator of second messenger gases. Annu. Rev. Pharmacol.
Toxicol. 1997, 37, 517–554. [CrossRef]
2. Ryter, S.W.; Alam, J.; Choi, A.M. Heme oxygenase-1/carbon monoxide: From basic science to therapeutic
applications. Physiol. Rev. 2006, 86, 583–650. [CrossRef] [PubMed]
3. Tenhunen, R.; Marver, H.S.; Schmid, R. The enzymatic conversion of heme to bilirubin by microsomal heme
oxygenase. Proc. Natl. Acad. Sci. USA 1968, 61, 748–755. [CrossRef] [PubMed]
4. Otterbein, L.E.; Soares, M.P.; Yamashita, K.; Bach, F.H. Heme oxygenase-1: Unleashing the protective
properties of heme. Trends Immunol. 2003, 24, 449–455. [CrossRef]
5. Lee, I.T.; Wang, S.W.; Lee, C.W.; Chang, C.C.; Lin, C.C.; Luo, S.F.; Yang, C.M. Lipoteichoic acid induces HO-1
expression via the TLR2/MyD88/c-Src/NADPH oxidase pathway and Nrf2 in human tracheal smooth muscle
cells. J. Immunol. 2008, 181, 5098–5110. [CrossRef] [PubMed]
6. Balla, G.; Jacob, H.S.; Balla, J.; Rosenberg, M.; Nath, K.; Apple, F.; Eaton, J.W.; Vercellotti, G.M. Ferritin:
A cytoprotective antioxidant strategem of endothelium. J. Biol. Chem. 1992, 267, 18148–18153. [PubMed]
7. Matsumoto, H.; Ishikawa, K.; Itabe, H.; Maruyama, Y. Carbon monoxide and bilirubin from heme oxygenase-1
suppresses reactive oxygen species generation and plasminogen activator inhibitor-1 induction. Mol. Cell.
Biochem. 2006, 291, 21–28. [CrossRef]
8. Jamal Uddin, M.; Joe, Y.; Kim, S.K.; Oh Jeong, S.; Ryter, S.W.; Pae, H.O.; Chung, H.T. IRG1 induced by heme
oxygenase-1/carbon monoxide inhibits LPS-mediated sepsis and pro-inflammatory cytokine production.
Cell. Mol. Immunol. 2016, 13, 170–179. [CrossRef]
9. Sawle, P.; Foresti, R.; Mann, B.E.; Johnson, T.R.; Green, C.J.; Motterlini, R. Carbon monoxide-releasing
molecules (CO-RMs) attenuate the inflammatory response elicited by lipopolysaccharide in RAW264.7
murine macrophages. Br. J. Pharmacol. 2005, 145, 8008–8010. [CrossRef]
10. Rushworth, S.A.; Chen, X.L.; Mackman, N.; Ogborne, R.M.; O’Connell, M.A. Lipopolysaccharide-induced
heme oxygenase-1 expression in human monocytic cells is mediated via Nrf2 and protein kinase C. J. Immunol.
2005, 175, 4408–4415. [CrossRef]
11. Aggeli, I.K.; Gaitanaki, C.; Beis, I. Involvement of JNKs and p38-MAPK/MSK1 pathways in H2O2-induced
upregulation of heme oxygenase-1 mRNA in H9c2 cells. Cell Signal. 2006, 18, 1801–1812. [CrossRef]
[PubMed]
12. Fredenburgh, L.E.; Perrella, M.A.; Mitsialis, S.A. The role of heme oxygenase-1 in pulmonary disease. Am. J.
Respir. Cell. Mol. Biol. 2007, 36, 158–165. [CrossRef]
13. Ferrandiz, M.L.; Devesa, I. Inducers of heme oxygenase-1. Curr. Pharm. Des. 2008, 14, 473–486. [CrossRef]
[PubMed]
14. Lee, I.T.; Luo, S.F.; Lee, C.W.; Wang, S.W.; Lin, C.C.; Chang, C.C.; Chen, Y.L.; Chau, L.Y.; Yang, C.M.
Overexpression of HO-1 protects against TNF-alpha-mediated airway inflammation by down-regulation of
TNFR1-dependent oxidative stress. Am. J. Pathol. 2009, 175, 519–532. [CrossRef] [PubMed]
15. Lee, I.T.; Yang, C.M. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and
pulmonary diseases. Biochem. Pharmacol. 2012, 84, 581–590. [CrossRef] [PubMed]
16. Zuo, L.; Otenbaker, N.P.; Rose, B.A.; Salisbury, K.S. Molecular mechanisms of reactive oxygen species-related
pulmonary inflammation and asthma. Mol. Immunol. 2013, 56, 57–63. [CrossRef] [PubMed]
17. Otterbein, L.E.; Kolls, J.K.; Mantell, L.L.; Cook, J.L.; Alam, J.; Choi, A.M. Exogenous administration of heme
oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J. Clin. Investig.
1999, 103, 1047–1054. [CrossRef] [PubMed]
54
Int. J. Mol. Sci. 2019, 20, 3157
18. Li, F.J.; Duggal, R.N.; Oliva, O.M.; Karki, S.; Surolia, R.; Wang, Z.; Watson, R.D.; Thannickal, V.J.; Powell, M.;
Watts, S.; et al. Heme oxygenase-1 protects corexit 9500A-induced respiratory epithelial injury across species.
PLoS ONE 2015, 10, e0122275. [CrossRef] [PubMed]
19. Srisook, K.; Han, S.S.; Cho, H.S.; Li, M.H.; Ueda, H.; Kim, C.; Cha, Y.N. CO from enhanced HO activity or
from CORM-2 inhibits both O2- and NO production and downregulates HO-1 expression in LPS-stimulated
macrophages. Biochem. Pharmacol. 2006, 71, 307–318. [CrossRef]
20. Cheng, S.E.; Lee, I.T.; Lin, C.C.; Kou, Y.R.; Yang, C.M. Cigarette smoke particle-phase extract induces HO-1
expression in human tracheal smooth muscle cells: Role of the c-Src/NADPH oxidase/MAPK/Nrf2 signaling
pathway. Free Radic. Biol. Med. 2010, 48, 1410–1422. [CrossRef]
21. Choi, Y.K.; Por, E.D.; Kwon, Y.G.; Kim, Y.M. Regulation of ROS production and vascular function by carbon
monoxide. Oxid. Med. Cell. Longev. 2012, 2012, 794237. [CrossRef] [PubMed]
22. Chi, P.L.; Lin, C.C.; Chen, Y.W.; Hsiao, L.D.; Yang, C.M. CO Induces Nrf2-Dependent Heme Oxygenase-1
Transcription by Cooperating with Sp1 and c-Jun in Rat Brain Astrocytes. Mol. Neurobiol. 2015, 52, 277–292.
[CrossRef] [PubMed]
23. Taille, C.; El-Benna, J.; Lanone, S.; Boczkowski, J.; Motterlini, R. Mitochondrial respiratory chain and
NAD(P)H oxidase are targets for the antiproliferative effect of carbon monoxide in human airway smooth
muscle. J. Biol. Chem. 2005, 280, 25350–25360. [CrossRef] [PubMed]
24. Motterlini, R.; Green, C.J.; Foresti, R. Regulation of heme oxygenase-1 by redox signals involving nitric oxide.
Antioxid. Redox Signal. 2002, 4, 615–624. [CrossRef] [PubMed]
25. Lee, I.T.; Yang, C.M. Inflammatory signalings involved in airway and pulmonary diseases. Mediat. Inflamm.
2013, 2013, 791231. [CrossRef] [PubMed]
26. Motterlini, R.; Otterbein, L.E. The therapeutic potential of carbon monoxide. Nat. Rev. Drug Discov. 2010, 9,
728–743. [CrossRef] [PubMed]
27. Yang, C.M.; Lin, C.C.; Lee, I.T.; Hsu, C.K.; Tai, Y.C.; Hsieh, H.L.; Chi, P.L.; Hsiao, L.D. c-Src-dependent
transactivation of EGFR mediates CORM-2-induced HO-1 expression in human tracheal smooth muscle
cells. J. Cell. Physiol. 2015, 230, 2351–2361. [CrossRef]
28. Alam, J.; Cook, J.L. How many transcription factors does it take to turn on the heme oxygenase-1 gene?
Am. J. Respir. Cell Mol. Biol. 2007, 36, 166–174. [CrossRef]
29. Alam, J.; Stewart, D.; Touchard, C.; Boinapally, S.; Choi, A.M.; Cook, J.L. Nrf2, a Cap’n’Collar transcription
factor, regulates induction of the heme oxygenase-1 gene. J. Biol. Chem. 1999, 274, 26071–26078. [CrossRef]
30. Constantin, M.; Choi, A.J.; Cloonan, S.M.; Ryter, S.W. Therapeutic potential of heme oxygenase-1/carbon
monoxide in lung disease. Int. J. Hypertens. 2012, 2012, 859235. [CrossRef]
31. Xue, J.; Habtezion, A. Carbon monoxide-based therapy ameliorates acute pancreatitis via TLR4 inhibition.
J. Clin. Investig. 2014, 124, 437–447. [CrossRef] [PubMed]
32. Qin, W.; Zhang, J.; Lv, W.; Wang, X.; Sun, B. Effect of carbon monoxide-releasing molecules II-liberated
CO on suppressing inflammatory response in sepsis by interfering with nuclear factor kappa B activation.
PLoS ONE 2013, 8, e75840. [CrossRef] [PubMed]
33. Takasuka, H.; Hayashi, S.; Koyama, M.; Yasuda, M.; Aihara, E.; Amagase, K.; Takeuchi, K. Carbon monoxide
involved in modulating HCO3− secretion in rat duodenum. J. Pharmacol. Exp. Ther. 2011, 337, 293–300.
[CrossRef] [PubMed]
34. Wu-Zhang, A.X.; Newton, A.C. Protein kinase C pharmacology: Refining the toolbox. Biochem. J. 2013, 452,
195–209. [CrossRef] [PubMed]
35. Yang, C.C.; Lin, C.C.; Chien, P.T.; Hsiao, L.D.; Yan, C.M. Thrombin/Matrix Metalloproteinase-9-Dependent
SK-N-SH Cell Migration is Mediated Through a PLC/PKC/MAPKs/NF-kappaB Cascade. Mol. Neurobiol.
2016, 53, 5833–5846. [CrossRef] [PubMed]
36. Mills, R.D.; Mita, M.; Nakagawa, J.; Shoji, M.; Sutherland, C.; Walsh, M.P. A role for the tyrosine kinase
Pyk2 in depolarization-induced contraction of vascular smooth muscle. J. Biol. Chem. 2015, 290, 8677–8692.
[CrossRef] [PubMed]
37. Rhee, I.; Davidson, D.; Souza, C.M.; Vacher, J.; Veillette, A. Macrophage fusion is controlled by the cytoplasmic
protein tyrosine phosphatase PTP-PEST/PTPN12. Mol. Cell. Biol. 2013, 33, 2458–2469. [CrossRef]
38. Hsieh, H.L.; Wang, H.H.; Wu, C.Y.; Yang, C.M. Reactive Oxygen Species-Dependent c-Fos/Activator Protein
1 Induction Upregulates Heme Oxygenase-1 Expression by Bradykinin in Brain Astrocytes. Antioxid. Redox
Signal. 2010, 13, 1829–1844. [CrossRef]
55
Int. J. Mol. Sci. 2019, 20, 3157
39. Rochette, L.; Cottin, Y.; Zeller, M.; Vergely, C. Carbon monoxide: Mechanisms of action and potential clinical
implications. Pharmacol. Ther. 2013, 137, 133–152. [CrossRef]
40. Kamata, H.; Hirata, H. Redox regulation of cellular signalling. Cell Signal. 1999, 11, 1–14. [CrossRef]
41. Mulier, B.; Rahman, I.; Watchorn, T.; Donaldson, K.; MacNe, W.; Jeffery, P.K. Hydrogen peroxide-induced
epithelial injury: The protective role of intracellular nonprotein thiols (NPSH). Eur. Respir. J. 1998, 11,
384–391. [CrossRef] [PubMed]
42. Barbieri, S.S.; Cavalca, V.; Eligini, S.; Brambilla, M.; Caian, A.; Tremoli, E.; Colli, S. Apocynin prevents
cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redox-dependent
mechanisms. Free Radic. Biol. Med. 2004, 37, 156–165. [CrossRef] [PubMed]
43. Stanley, A.; Hynes, A.; Brakebusch, C.; Quondamatteo, F. Rho GTPases and Nox dependent ROS production
in skin. Is there a connection? Histol. Histopathol. 2012, 27, 1395–1406. [PubMed]
44. Tavares, A.F.; Teixeira, M.; Romao, C.C.; Seixas, J.D.; Nobre, L.S.; Saraiva, L.M. Reactive oxygen species
mediate bactericidal killing elicited by carbon monoxide-releasing molecules. J. Biol. Chem. 2011, 286,
26708–26717. [CrossRef] [PubMed]
45. Prabhakar, N.R. NO and CO as second messengers in oxygen sensing in the carotid body. Respir. Physiol.
1999, 115, 161–168. [CrossRef]
46. Choi, Y.K.; Maki, T.; Mandeville, E.T.; Koh, S.H.; Hayakawa, K.; Arai, K.; Kim, Y.M.; Whalen, M.J.; Xing, C.;
Wang, X.; et al. Dual effects of carbon monoxide on pericytes and neurogenesis in traumatic brain injury.
Nat. Med. 2016, 22, 1335–1341. [CrossRef]
47. Alam, R.; Gorska, M.M. Mitogen-activated protein kinase signalling and ERK1/2 bistability in asthma.
Clin. Exp. Allergy 2011, 41, 149–159. [CrossRef]
48. Yuan, X.; Xu, C.; Pan, Z.; Keum, Y.S.; Kim, J.H.; Shen, G.; Yu, S.; Oo, K.T.; Ma, J.; Kong, A.N. Butylated
hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling
pathway in HepG2 cells. Mol. Carcinog. 2006, 45, 841–850. [CrossRef]
49. Foresti, R.; Bani-Hani, M.G.; Motterlini, R. Use of carbon monoxide as a therapeutic agent: Promises and
challenges. Intensive Care Med. 2008, 34, 649–658. [CrossRef]
50. Pawate, S.; Shen, Q.; Fan, F.; Bhat, N.R. Redox regulation of glial inflammatory response to lipopolysaccharide
and interferongamma. J. Neurosci. Res. 2004, 77, 540–551. [CrossRef]
51. Cheng, P.Y.; Lee, Y.M.; Shih, N.L.; Chen, Y.C.; Yen, M.H. Heme oxygenase-1 contributes to the cytoprotection
of alpha-lipoic acid via activation of p44/42 mitogen-activated protein kinase in vascular smooth muscle
cells. Free Radic. Biol. Med. 2006, 40, 1313–1322. [CrossRef] [PubMed]
52. Sen, C.K.; Packer, L. Antioxidant and redox regulation of gene transcription. FASEB J. 1996, 10, 709–720.
[CrossRef] [PubMed]
53. Alam, J.; Igarashi, K.; Immenschuh, S.; Shibahara, S.; Tyrrell, R.M. Regulation of heme oxygenase-1 gene
transcription: Recent advances and highlights from the International Conference (Uppsala, 2003) on Heme
Oxygenase. Antioxid. Redox Signal. 2004, 6, 924–933. [PubMed]
54. Urquhart, P.; Rosignoli, G.; Cooper, D.; Motterlini, R.; Perretti, M. Carbon monoxide-releasing molecules
modulate leukocyte-endothelial interactions under flow. J. Pharmacol. Exp. Ther. 2007, 321, 656–662.
[CrossRef] [PubMed]
55. Almolki, A.; Taillé, C.; Martin, G.F.; Jose, P.J.; Zedda, C.; Conti, M.; Megret, J.; Henin, D.; Aubier, M.;
Boczkowski, J. Heme oxygenase attenuates allergen-induced airway inflammation and hyperreactivity in
guinea pigs. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287, L26–L34. [CrossRef] [PubMed]
56. Sun, B.; Sun, H.; Liu, C.; Shen, J.; Chen, Z.; Chen, X. Role of CO-releasing molecules liberated CO in
attenuating leukocytes sequestration and inflammatory responses in the lung of thermally injured mice.
J. Surg. Res. 2007, 139, 128–135. [CrossRef]
57. Kilkenny, C.; Browne, W.; Cuthill, I.C.; Emerson, M.; Altman, D.G.; Group NCRRGW. Animal research:
Reporting in vivo experiments: The ARRIVE guidelines. Br. J. Pharmacol. 2010, 160, 1577–1579. [CrossRef]
[PubMed]
58. McGrath, K.C.; Li, X.H.; McRobb, L.S.; Heather, A.K. Inhibitory Effect of a French Maritime Pine Bark
Extract-Based Nutritional Supplement on TNF-alpha-Induced Inflammation and Oxidative Stress in Human
Coronary Artery Endothelial Cells. Evid. Based Complement. Altern. Med. 2015, 2015, 260530. [CrossRef]
[PubMed]
56
Int. J. Mol. Sci. 2019, 20, 3157
59. Hsu, C.K.; Lee, I.T.; Lin, C.C.; Hsiao, L.D.; Yang, C.M. Nox2/ROS-dependent human antigen R translocation
contributes to TNF-alpha-induced SOCS-3 expression in human tracheal smooth muscle cells. Am. J. Physiol.
Lung Cell. Mol. Physiol. 2014, 306, L521–L533. [CrossRef]
60. Lee, C.W.; Chien, C.S.; Yang, C.M. Lipoteichoic acid-stimulated p42/p44 MAPK activation via Toll-like
receptor 2 in tracheal smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286, L921–L930.
[CrossRef]
61. Hsieh, H.L.; Lin, C.C.; Hsiao, L.D.; Yang, C.M. High glucose induces reactive oxygen species-dependent
matrix metalloproteinase-9 expression and cell migration in brain astrocytes. Mol. Neurobiol. 2013, 48,
601–614. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
57

 International Journal of 
Molecular Sciences
Article
Key Role of Reactive Oxygen Species (ROS) in
Indirubin Derivative-Induced Cell Death in
Cutaneous T-Cell Lymphoma Cells
Marwa Y. Soltan 1,2, Uly Sumarni 1, Chalid Assaf 1,3, Peter Langer 4,5, Ulrich Reidel 1 and
Jürgen Eberle 1,*
1 Skin Cancer Centre Charité, Department of Dermatology and Allergy, Charité—Universitätsmedizin Berlin,
Charitéplatz 1, 10117 Berlin, Germany; Marwayassin@med.asu.edu.eg (M.Y.S.);
uly.sumarni@googlemail.com (U.S.); chalid.assaf@helios-gesundheit.de (C.A.);
ulrich.reidel@charite.de (U.R.)
2 Department of Dermatology and Venereology, Faculty of Medicine, Ain Shams University,
Cairo 11591, Egypt
3 Clinic for Dermatology and Venereology, Helios Klinikum Krefeld, Lutherplatz 40, 47805 Krefeld, Germany
4 Institute of Chemistry, University of Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany;
peter.langer@uni-rostock.de
5 Leibniz Institute of Catalysis at the University of Rostock e.V., Albert-Einstein-Str. 29a,
18059 Rostock, Germany
* Correspondence: juergen.eberle@charite.de; Tel.: +49-30-450-518-383
Received: 8 February 2019; Accepted: 2 March 2019; Published: 7 March 2019
Abstract: Cutaneous T-cell lymphoma (CTCL) may develop a highly malignant phenotype in its
late phase, and patients may profit from innovative therapies. The plant extract indirubin and its
chemical derivatives represent new and promising antitumor strategies. This first report on the
effects of an indirubin derivative in CTCL cells shows a strong decrease of cell proliferation and
cell viability as well as an induction of apoptosis, suggesting indirubin derivatives for therapy of
CTCL. As concerning the mode of activity, the indirubin derivative DKP-071 activated the extrinsic
apoptosis cascade via caspase-8 and caspase-3 through downregulation of the caspase antagonistic
proteins c-FLIP and XIAP. Importantly, a strong increase of reactive oxygen species (ROS) was
observed as an immediate early effect in response to DKP-071 treatment. The use of antioxidative
pre-treatment proved the decisive role of ROS, which turned out upstream of all other proapoptotic
effects monitored. Thus, reactive oxygen species appear as a highly active proapoptotic pathway
in CTCL, which may be promising for therapeutic intervention. This pathway can be efficiently
activated by an indirubin derivative.
Keywords: CTCL; apoptosis; cell viability; c-FLIP; XIAP
1. Introduction
Reactive oxygen species (ROS) play important roles in tissue damage and aging, as also addressed
in this special issue. On the other hand, an increasing number of scientific studies in recent years
indicated a particular role of ROS in apoptosis regulation in cancer cells. The mechanism(s) are still
under discussion. Here, we give an example of cutaneous T-cell lymphoma (CTCL), where ROS is
induced by the drug candidate indirubin.
Non-Hodgkin’s lymphomas (NHL) have shown increasing incidence in the last decades. About
5% of NHL are characterized by primary cutaneous manifestation through clonal proliferation of
skin-homing memory T cells. This group of cutaneous T-cell lymphomas (CTCL) encloses Mycosis
fungoides, Sézary syndrome and CD30(+) lymphoproliferative disorders. Cutaneous T-cell lymphomas
Int. J. Mol. Sci. 2019, 20, 1158; doi:10.3390/ijms20051158 www.mdpi.com/journal/ijms59
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represent a clinically and biologically distinct group of NHL without evidence for systemic disease at
the time of first diagnosis. In clinical appearance and prognosis, they are clearly different from the
histotypically cognate systemic lymphomas and their possible secondary cutaneous manifestations.
Typically, they have the immunophenotype of CD3+ CD4+ CD45RO+ memory T-lymphocytes. While
in its early stage CTCL may show an also indolent clinical course, it frequently transforms to a rapidly
growing, malignant phenotype in later phases [1,2]. New treatments are needed particularly for
these patients.
The elimination of tumor cells through the induction of apoptosis represents a principle goal in
cancer treatment, and therapy resistance can thus be frequently explained by apoptosis deficiency [3].
Also, established therapies for CTCL as UV radiation or extracorporal photopheresis aim at an
induction of apoptosis in tumor cells [4]. Extrinsic proapoptotic pathways are initiated by death
ligands as CD95L/FasL or TRAIL (TNF-related apoptosis-inducing ligand), which also contribute
to self-control of lymphocytes. Their binding to death receptors results in the formation of a
death-inducing signaling complex, where initiator caspase-8 is activated [5]. Caspase-8 activation
can be prevented by the competitive inhibitor protein c-FLIP (cellular FLICE-inhibitory protein) [6].
Initiator caspase-8 may cleave and activate the main effector caspase-3, which itself cleaves a large
number of death substrates with the final result of DNA fragmentation [7]. Caspase-3 is negatively
regulated through the binding of XIAP (chromosome X-linked inhibitor of apoptosis protein) [8].
In CTCL cells, the activation of the extrinsic caspase cascade plays a decisive role in controlling
apoptosis. Thus, apoptosis resistance is correlated with reduced expression of the death receptor
CD95/FAS [9] as well as with high and constitutive expression of c-FLIP [10]. Also, activation of the
pro-survival transcription factors NF-κB [11] and STAT3 [12] were reported. In particular, different
therapeutic strategies as NSAIDs, SAHA (suberoylanilide hydroxamic) and pentoxifylline resulted
in downregulation of c-FLIP and XIAP in CTCL cells [13–15]. Finally, reactive oxygen species (ROS)
may contribute to the regulation of apoptosis [16,17]. This is also suggested by enhanced levels of
singlet oxygen (1O2) in the course of photodynamic therapy (PDT), used for the treatment of actinic
keratosis [18,19] and also considered for CTCL [20]. However, the relation of ROS with described
apoptosis pathways is still largely elusive.
The natural compound indirubin and a number of reported chemical derivatives are considered
as candidates for cancer therapy. Indirubin was identified as an active component in a traditional
Chinese medicine remedy (Danggui Longhui Wan), also applied for chronic myeloid leukemia.
In clinical trials, indirubin has shown significant antitumor activity in chronic myeloid and chronic
granulocytic leukemia [21,22]. Explaining the mode of action, a large number of intracellular targets
have been described for indirubin derivatives, including cyclin-dependent kinases (CDK1, CDK2,
CDK4 and CDK5), pRb, glycogen synthase kinase 3 (GSK-3), STAT3 (Signal transducer and activator
of transcription), EGFR (Epidermal growth factor receptor), c-Jun, and JNK2 [23–26]. The activation
of extrinsic apoptosis pathways by indirubin derivatives was found in melanoma cells [27,28].
To improve the anti-cancer activity of indirubin, we have previously introduced a series of chemical
modifications [29–31]. Here, we investigated the direct effects of the indirubin derivative DKP-071
in CTCL cells. We furthermore unraveled its mode of action, which is based on caspase activation,
downregulation of the caspase antagonists c-FLIP and XIAP and, in particular, on early production
of ROS.
2. Results
2.1. Decreased Cell Proliferation and Viability Along with Induced Apoptosis by DKP-071
Synthesis and structural aspects of the indirubin derivative DKP-071/substance 9d (Figure 1a)
have been reported previously [31]. Here, its effects in three CTCL cell lines MyLa, HuT-78 and
HH were investigated. These cell lines are characterized by the formation of cell clusters, a typical
lymphocyte differentiation step [32,33]. In a first approach, we observed reduced cell cluster size
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in response to DKP-071, likely indicating reduced T-cell activity (Figure 1b). In line with this, cell
proliferation was significantly reduced at 24 h, as determined by WST-1 assay (Figure 1c). Reduced cell
numbers were however not due to direct cytotoxicity, as lactate dehydrogenase (LDH) release assays
at 24 h did not show a significant increase in MyLa or in HH cells (Figure 1d).
Figure 1. Decreased cell proliferation of CTCL cells by DKP-071. (a) Chemical structure of the indirubin
derivative DKP-071 (termed substance 9d in [31]). (b) Cell cluster formation in CTCL cell lines
MyLa, HuT-78 and HH. Control cells (Ctr) are shown vs. cells treated for 48 h with 10 μM DKP-071
(magnification: 1:40). Many independent experiments showed the same result. (c) Cell proliferation of
MyLa, HuT-78 and HH, at 24 h in response to treatment with 5, 10 and 20 μM DKP-071 (DKP). Cell
proliferation data were determined by WST-1 assay, and values are shown in relation (rel) to negative
controls (0), which were set to “1”. Statistical significance is indicated (** p < 0.01). (d) Cytotoxicity was
determined at 24 h in MyLa and in HH cells by LDH release assay. Values are shown in relation (rel) to
H2O2-treated positive controls, which were set to “1”.
Cell viability, as determined by calcein staining, was strongly decreased. A dose dependency
(5–20 μM) was shown for MyLa and HH cells. At 48 h of treatment, 10 μM DKP-071 reduced the
numbers of viable cells to 23% (MyLa), 9% (HuT-78) and 38% (HH), respectively (Figure 2a). Based on
cell viability data, we calculated IC50 values of 7 μM DKP-071 for Myla and 11 μM for HH. For HuT-78,
we used the WST data of Figure 1c, which resulted in an IC50 value of 8 μM for HuT-78. Loss of
cell viability went along with an induction of apoptosis, which was determined by counting sub-G1
cells in cell cycle analyses. Induction of apoptosis showed a comparable dose dependency. At 48 h
of treatment, 10 μM DKP-071 induced apoptosis in 17% (MyLa), 24% (HuT-78) and 22% of HH cells,
respectively (Figure 2b). The concentration of 10 μM was selected for subsequent experiments.
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2.2. Changes of Mitochondrial Membrane Potential and ROS Production
Questioning the mechanisms that mediate the antineoplastic effects of DKP-071 in CTCL cells, we
determined the relative changes in the mitochondrial membrane potential (MMP) as well as relative
levels of reactive oxygen species (ROS) in response to treatment. Loss of MMP, indicative for an
activation of mitochondrial apoptosis pathways, already started in the three cell lines at 5 h (31–49%)
but was much more evident at later time (24 h, 90% cells with low MMP; Figure 3a).
Reactive oxygen species (ROS) may mediate independent cell death pathways in cancer cells
which are not yet completely understood [16]. Earlier than the loss of MMP, ROS levels were already
strongly enhanced after 2 h. Thus, 87%, 83% and 57% of MyLa, HuT-78 and HH cells, respectively,
showed high ROS levels at 2 h of DKP-071 treatment (Figure 3b).
Figure 2. Reduced cell viability and induction of apoptosis. (a) Cell viability and (b) apoptosis were
determined in three cell lines, in response to 48 h treatment with DKP-071 (5, 10 and 20 μM for
MyLa and HH as well as 10 μM for HuT-78). Values were determined by calcein staining (a) and
propidiumiodide staining (b), respectively. Characteristic histograms are shown for each cell line
(10 μM treatment, overlays with controls); fractions of non-viable and viable as well as of apoptotic
cells (sub-G1) are indicated. Mean values of triplicates +/− SDs of a representative experiment are
shown. Statistical significance is indicated (treated cells vs. controls; * p < 0.05; ** p < 0.01).
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Figure 3. Effects on mitochondrial membrane potential and on ROS levels. (a) Relative changes in
mitochondrial membrane potential (MMP) were determined at 5 h and 24 h in three CTCL cell lines in
response to treatment with DKP-071 (10 μM). Mean values of triplicates +/− SD are shown; a second
independent experiment series of MyLa revealed highly comparable results. Representative histograms
(overlays of treated cells vs. controls) are given on the right side. (b) ROS levels were determined at 2 h
of treatment. Mean values of triplicates +/− SD are shown; for MyLa, three independent experiments,
each one with triplicates, revealed highly comparable results. Representative histograms (overlays of
treated cells vs. controls) are given on the right side. Statistical significance is indicated (treated cells vs.
controls; * p < 0.05; ** p < 0.01).
2.3. Critical role of ROS for Proapoptotic Effects of DKP-071
To prove the significance of ROS as well as of caspase activation for the antineoplastic effects,
the antioxidants tocopherol (vitamin E, VE) and N-acetyl cysteine (NAC) as well as the pan-caspase
inhibitor QVD-Oph were applied. ROS production in response to DKP-071 was slightly reduced by
VE and was strongly reduced by NAC, as shown in MyLa at 2 h. Most effective was a combination of
VE and NAC (both at 2 mM, VE/NAC), which completely abolished ROS production after DKP-071
treatment in the three cell lines. QVD-Oph remained without effect on ROS, indicating that ROS was
independent of caspase activity (Figure 4).
ROS scavenging by VE/NAC proved the significant and upstream role of ROS for
DKP-071-mediated effects. Thus, cell proliferation, which was decreased by DKP-071 at 24 h,
was restored in three cell lines by VE/NAC (Figure 5a). Similarly, the effects of DKP-071 on cell
viability were strongly diminished by VE/NAC as shown in MyLa at 48 h (from 4% to 78% viable
cells, Figure 5b). Finally, the induction of apoptosis, induced by DKP-071 in MyLa at 48 h (35%),
was completely prevented by VE/NAC (3%, Figure 5c). Caspase inhibition through QVD-Oph
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also diminished apoptosis and loss of cell viability, which was, however, less effective than the
antioxydative treatment (Figure 4b,c). These findings support the explanation that ROS production
was an upstream step.
Figure 4. ROS suppression by antioxidative treatment. ROS levels are shown in MyLa in response to
DKP-071 (10 μM). In addition, antagonists as vitamin E (VE, 1 mM), N-acetyl cysteine (NAC, 1 mM),
the pancaspase inhibitor QVD-Oph (QVD, 10 μM), as well as combined NAC and VE (each 2 mM) were
applied 1 h before DKP-071 treatment was started. Cells which received only DKP-071 but no antagonist
are indicated by (- - -). The antioxidative effect was also shown in HuT-78 and in HH by the use of
VE/NAC. Mean values of triplicates +/− SD of a representative experiment are shown; for MyLa, three
independent experiments, each one with triplicates, revealed highly comparable results. Examples
of flow cytometry measurement are shown on the right side as overlays versus control. Statistical
significance of the differences of DKP-071/NAC-treated cells as well as DKP-071/VE/NAC-treated
cells is indicated, each compared to the cells that received only DKP-071 (** p < 0.01).
Figure 5. Cont.
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Figure 5. ROS suppression prevents apoptosis and restores cell viability. (a) Cell proliferation was
determined at 24 h in response to DKP-071 as well as in response to the combination of NAC and VitE
(2 mM; VE/NAC). Values were normalized to non-treated controls (100%). (b,c) Effects of agonists
and antagonists on apoptosis induction (b) and cell viability (c), both at 48 h, are shown for MyLa
cells. Examples of flow cytometry measurement are shown on the right side as overlays of treated cells
versus controls. Mean values of triplicates +/− SD of representative experiments are shown; at least
two independent experiments, each one with triplicates, revealed highly comparable results. Statistical
significance of the differences between DKP-071/VE/NAC-treated cells to cells that received only
DKP-071 is indicated (** p < 0.01).
2.4. Role of Caspases and Caspase Antagonistic Proteins
ROS also appeared upstream of MMP loss. Thus, VE/NAC almost completely prevented the loss
of MMP in MyLa at 5 h (24% to 7%) whereas caspase inhibition was less effective here (18%, Figure 6a).
Extrinsic caspase pathways are of major importance for apoptosis regulation in lymphoma cells, also
including CTCL [10]. Thus, we investigated by Western blotting the activation/processing of initiator
caspase-8 and the main effector caspase-3 as well as the expression of the caspase-3 antagonist XIAP
and the caspase-8 antagonist c-FLIP.
In response to 40 h treatment with DKP-071, the proform of caspase-8 (53/55 kD) disappeared,
indicating its complete processing. In parallel, Caspase-3 was processed to its mature, active cleavage
product of 15 kDa. Importantly, VE/NAC strongly reduced the processing both of caspase-8 and
caspase-3. In particular, no active cleavage product of caspase-3 (15 kDa) was detected, but the
processing was stopped at an intermediate product of 19 kDa. In clear contrast, QVD-Oph remained
without effect on caspase-8. It, however, prevented caspase-3 autoprocessing and halted the cascade
at the 19 and 17 kDa intermediate cleavage products (Figure 6b, top). These findings clearly
showed that ROS was upstream of any caspase regulation, while QVD-Oph acts downstream as
a caspase-3 antagonist.
Explaining the activation of caspases, DKP-071 strongly reduced the expression of two most
characteristic caspase antagonists, namely XIAP (51 kDa) and c-FLIP (long isoform, 52 kDa and short
isoform, 25 kDa). Of particular note, this downregulation was completely prevented by antioxidants
(VE/NAC), while caspase-3 inhibition through QVD-Oph remained without effect on c-FLIP and
XIAP (Figure 6b, bottom). Thus, ROS was also upstream of the downregulation of c-FLIP and
XIAP. These findings suggest a cascade in CTCL cells, leading from ROS production in response
to DKP-071 treatment to c-FLIP and XIAP downregulation and further to caspase activation and
apoptosis (Figure 6c).
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Figure 6. Effects on MMP and caspase cascade. (a) Effects of antioxidative treatment (VE/NAC,
2 mM) as well as of QVD-Oph (QVD, 10 μM) on mitochondrial membrane potential (MMP) are
shown for MyLa cells at 5 h of DKP-071 treatment. Cells, which received only DKP-071 but no
antagonist are indicated by (- - -). Mean values of triplicates +/− SD of a representative experiment
are shown; two independent experiments, each one with triplicates, revealed highly comparable
results. Statistical significance of the differences between DKP-071/VE/NAC-treated cells to cells
that received only DKP-071 is indicated (** p < 0.01). Examples of flow cytometry measurement are
shown below as overlays versus control. The cell population with low MMP is indicated. (b) Effects
of DKP-071 and antioxidative pre-treatment on the expression of characteristic regulatory proteins of
the extrinsic apoptosis caspase cascade were investigated by Western blotting. Each 30 μg of protein
was loaded per lane, and blots were probed with antibodies for extrinsic initiator caspase-8 (proform,
53/55 kDa), main effector caspase-3 (proform, 32 kDa; cleavage products, 23, 19, 17, 15 kDa), caspase-3
antagonist XIAP (51 kDa) and caspase-8 antagonist c-FLIP (FLIPL, long, 52 kDa; FLIPS, short, 25 kDa).
The housekeeping protein glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 37 kDa) was used
as loading control. Three independent series of protein extracts and Western blotting experiments
revealed highly comparable results. (c) The pathway suggested for indirubin DKP-071-mediated
apoptosis. Arrows indicate activation; blunt end lines indicate inhibition.
3. Discussion
Many new therapies established in recent decades for most tumors have sometimes dramatically
enhanced patients’ survival. Also for CTCL, present therapeutic options as topical steroids, bexarotene,
phototherapy, interferon or some forms of targeted therapy have strongly improved the clinical
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outcome and often allow long-term survival. Nevertheless, in its late phase, CTCL may transform to a
rapidly growing and ulcerating phenotype, characterized also by pronounced therapy resistance [1,2].
As apoptosis deficiency represents an in principal decisive issue in therapy resistance, the specific
targeting of apoptosis pathways appears as a promising strategy [3].
Indirubin has been identified as the major component of a traditional Chinese medicine remedy,
also applied for leukemia. In clinical trials for chronic myeloid and chronic granulocytic leukemia, it
revealed significant antitumor activity, resulting in partial or complete remissions [21,22]. Chemical
modifications of indirubin may further enhance its activity. Thus, we have recently reported
the synthesis of new indirubin derivatives characterized by N-glycosylated 3-alkylideneoxindol
structures [31]. This first report on the effects of an indirubin derivative in CTCL cells shows a
particular high activity resulting in decreased cell proliferation and cell viability as well as induction of
apoptosis. There is no cutaneous non-tumorigenic T-cell line, which could be used for investigations
in vitro and prove the tumor-specificity of the effects. However, due to the only moderate side
effects reported for indirubin in clinical trials [21,22], the here investigated indirubin derivative may be
suggested as a potential new therapeutic option for CTCL. A proapoptotic strategy, as by DKP-071, may
also apply for early CTCL, characterized by an indolent clinical course and apoptosis susceptibility.
As concerning the pathways, by which indirubins may exert their effects, multiple targets
have been suggested including CDKs, GSK-3β, pRb, c-Src, FGF-R1, VEGFR, STAT3, c-Jun and
JNK2 [23–26]. In melanoma cells, we have previously shown that indurubin derivatives enhance
extrinsic apoptosis pathways as induced by TRAIL (TNF-related apoptosis-inducing ligand [27,28].
Extrinsic apoptosis pathways via caspase-8/caspase-3 are of particular importance for apoptosis
regulation in CTCL cells [10,34]. Also in CTCL, DKP-071 mediated its proapoptotic effects via activation
of the extrinsic caspase cascade, as shown by caspase-8 and caspase-3 processing as well as by the
inhibition of the effects of indirubin through the caspase-3 antagonist QVD-Oph. Caspase activity is
controlled by several antiapoptotic proteins such as the competitive caspase-8 antagonist c-FLIP and
the protein family of cIAPs (cellular inhibitor of apoptosis proteins), e.g., the caspase-3 antagonist XIAP
(chromosome X-linked) [6,8]. These two antagonists appeared as essentially involved in the present
setting, as strongly downregulated by DKP-071 in CTCL cells. Downregulation of these two factors
in CTCL has also been reported by other treatments. Thus, c-FLIP was downregulated in response
to SAHA (suberoylanilide hydroxamic) and NSAIDs, while XIAP was downregulated in response to
SAHA and pentoxifylline [13–15].
Reactive oxygen species (ROS) play important roles in tissue damage and aging, and antioxidative
strategies were established to prevent these negative effects. Besides this, ROS may also be involved
in proapoptotic signaling in cancer cells [16,28,35,36]. As an example from the clinic, photodynamic
therapy (PDT), used for the treatment of actinic keratosis, results in the production of high amounts of
singlet oxygen. However, the role of ROS in PDT is still controversially discussed [18–20]. ROS may
act as a signaling molecule e.g., by affecting the mitochondrial membrane and thus activating intrinsic,
mitochondrial apoptosis pathways, or it may provoke cellular damage e.g., by oxidizing membrane
lipids resulting in necrosis or activation of a damage response.
Here, we show even another alternative. In CTCL, ROS acts in cellular signaling clearly upstream
of the extrinsic apoptosis pathway. It is induced already at 2 h in response to indirubin treatment
and resides upstream of the downregulation of XIAP and c-FLIP as well as upstream of the loss
of MMP, suggesting a signaling cascade as shown in Figure 6c. Also for other treatments in CTCL
cells, relations of ROS and apoptosis induction have been reported, such as for an inhibitor of the
antioxidative protein mucin 1 [37], for silencing of the enhancer of zeste homolog 2 (EZH2) [38] and
for doxycycline [39]. Thus, ROS production appears to be an important cellular signaling step related
to the induction of apoptosis. The new proapoptotic pathways behind this may be useful for targeted
cancer therapy. In CTCL, our data suggest a strong relation between ROS, caspase antagonists and
the activation of the extrinsic apoptosis pathway. This signaling cascade is efficiently triggered by the
indirubin derivative DKP-071, suggesting it as a therapeutic strategy for CTCL.
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4. Materials and Methods
4.1. Cell Culture and Treatments
Three CTCL cell lines have been used here, which derive from patients with Mycosis fungoides
and Sézary syndrome, respectively: Cell line MyLa was kindly supplied by Prof. K. Kaltoft, Århus
University, Århus, DK. It derived from a plaque biopsy of a patient with MF [40]; HuT-78 was kindly
supplied by Prof. R.C. Gallo, University of Maryland, Baltimore, MD, USA. [41] It derived from PBMCs
of a patient with Sézary syndrome; and HH (CRL-2105, ATCC, Manassas, VA, USA) derived from
peripheral blood of a patient with aggressive CTCL [42]. Cells were grown at 37 ◦C, 5% CO2 in RPMI
1640 medium supplemented with L-glutamine, 10% FCS and antibiotics (Biochrom, Berlin, Germany).
Under these applied conditions, the cell lines revealed a similar growth behavior and proliferation
rate; only the formation of cell clusters, typical for T-cells, varied considerably (Figure 1a).
For assays, cells were seeded in 24-well culture plates (100,000 cells and 500 μL per well) or in
96-well pates (40,000 cells and 200 μL per well). For protein extraction, cells were seeded in 6-well
plates (400,000 per well, 2 mL). Treatments started at 24 h after seeding.
The indirubin derivative DKP-071 (termed substance 9d in [31]; Figure 1a) was used in
concentrations of 5–20 μM. For caspase inhibition, cells were pre-incubated for 1 h with the pan-caspase
inhibitor QVD-Oph (Sigma-Aldrich, Taufkirchen, Germany, 10 μM). For ROS scavenging, cells
were pre-treated for 1 h with 1 mM α-tocopherol (vitamin E, Fluka, Steinheim, Germany), with
N-acetylcysteine (NAC; Sigma-Aldrich, Taufkirchen, Germany; 1 mM) or with a combination of
vitamin E and NAC (VE/NAC; each 2 mM).
4.2. Assays for Apoptosis, Cytotoxicity, Cell Viability and Cell Proliferation
Apoptotic cells were quantified as sub-G1 cells (less DNA than G1 cells) in cell cycle analyses.
The assay reveals less DNA in apoptotic cells, because small DNA fragments are washed out from
isolated nuclei [43]. Cells were harvested by centrifugation, lysed and stained for at least 1 h in
hypotonic PI solution (40 μg/mL propidium iodide, Sigma-Aldrich, in 0.1% sodium citrate, 0.1% Triton
X-100). Stained isolated nuclei were analyzed by flow cytometry at FL3A with a FACS Calibur (BD
Bioscience, Bedford, MA, USA). Cells in G1, G2 and S-phase as well as sub-G1 cells were determined.
Cell cytotoxicity was determined by the analysis of cell supernatants for the activity of lactate
dehydrogenase (LDH), which is released from cytotoxic cells in culture. Aliquots of cell supernatants
were collected at 24 h, and LDH activity was quantified with a LDH activity assay (Cytotoxicity
detection assay; Roche Diagnostics, Penzberg, Germany), following the protocol of the supplier.
As positive controls, Triton X-100 (0.7%)-treated cells were used. Relative values were determined in
an ELISA reader. The increased LDH activity in treated wells traces back to damaged, cytotoxic cells.
Cell viability was determined by staining cells with calcein-AM (PromoCell, Heidelberg,
Germany), which is a cell-permeant non-fluorescent substance that is converted to green-fluorescent
calcein in live cells by the activity of intracellular esterases. Cells, grown and treated in 24-well
plates, were harvested after 24 h or 48 h by centrifugation. After washing 1× with PBS, they were
resuspended in 200 μL of 2.5 μg/mL calcein-AM in PBS. Staining was done at 37 ◦C for 1 h. Labeled
cells were washed again with 1 mL of PBS and were resuspended in 200 μL PBS. The percentage
of viable cells was determined by flow cytometry (FL2H). In the calcein assay, the total cell number
does not contribute to the results, only the percentage of active cells in the remaining cell population
is determined.
Cell proliferation was determined by WST-1 assay (Roche Diagnostics). It depends on the cleavage
of the water-soluble tetrazolium salt by mitochondrial dehydrogenases in metabolically active cells.
CTCL cells were seeded in 96-well plates, and treatments were started after 24 h. At the time of analysis
(24–48 h), WST-1 reagent was added for 1–2 h, and the absorbance at 450 nm was determined in an
ELISA reader. Data were reported as the percentage of non-treated controls. The WST-1 assay gives
an overview of all the antiproliferative effects of a given drug, which includes a lack of cells due to
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decreased cell proliferation as well as a lack of cells due to the induction of apoptosis or induction of
cytotoxicity. Furthermore, the cell activity of the remaining cells contributes to the results.
4.3. Mitochondrial Membrane Potential (MMP) and Reactive Oxygen Species (ROS)
Changes to MMP over time or in response to drug treatment can be assessed by staining cells with
the fluorescent dye TMRM+ (Tetramethylrhodamin-methylester, Sigma-Aldrich). Due to its positive
charge, TMRM+ accumulates in negatively charged mitochondria. In the course of depolarisation of
the mitochondria, (e.g., at the beginning of apoptosis), anions are released and TMRM+ concentrations
decrease. This staining may also be used to determine the effectiveness of therapeutic compounds [44].
Cells grown and treated in 24-well plates were harvested and stained for 20 min at 37 ◦C with 1 μM
TMRM+. After two-times washing with PBS, cells were analyzed by flow cytometry (FL2H).
Intracellular ROS levels were determined by the cell-permeable substance H2DCFDA
(2′,7′-dichlorodihydrofluorescein diacetate; Thermo Fisher Scientific, Hennigsdorf, Germany). In cells
with high ROS, the non-fluorescent H2DCFDA is oxidized and thus converted in the strongly
fluorescent DCF (2′,7′-Dichlorfluorescein). Cells grown in 24-well plates were pre-treated for 1 h
with H2DCFDA (10 μM), before starting treatment with effectors. After treatment, cells were harvested
by centrifugation, washed with 1 mL PBS, resuspended in PBS, and analyzed by flow cytometry
(FL1H). As positive controls, cells were treated with H2O2 (1 mM, 1 h).
4.4. Western Blotting
For Western blotting, total protein extracts were obtained by cell lysis in 150 mM NaCl, 1 mM
EDTA, 2 mM PMSF, 1 mM leupeptin, 1 mM pepstatin, 0.5% SDS, 0.5% NP-40 and 10 mM Tris-HCl,
pH 7.5. Western blotting on nitrocellulose membranes was performed as described previously [45].
Primary antibodies: Cleaved caspase-3 (9664, rabbit, 1:1000, Cell Signaling, Danvers, MA, USA); XIAP
(#2042, rabbit, 1:1000, Cell Signaling); caspase-8 (#9746; mouse, 1:1000, Cell Signaling); c-FLIP (G-11,
sc-5276; Santa Cruz, Heidelberg, Germany; 1:50); and GAPDH (sc-32233, mouse, 1:1000, Santa Cruz
Biotech). Secondary antibodies: peroxidase-labelled goat anti-rabbit and goat anti-mouse (Dako,
Hamburg, Germany; 1:5000).
4.5. Statistics
Assays described above were performed in triplicate determinations, and usually at least two
completely independent series were performed for each experiment. For the determination of statistical
significance, the values of all individual experiments were given together, after normalizing according
to the controls. A Student’s t-test (two-tailed, heteroscedastic) was applied, and p-values of <0.05 were
considered as statistically significant, while p-values of <0.01 were considered as highly significant.
When applicable, significance is indicated in the bar charts (* for p < 0.05; ** for p < 0.01). The results of
Western blots were reproduced in three independent series of experiments.
5. Conclusions
In summary, cutaneous T-cell lymphoma cells can be targeted by the induction of ROS. This
results in an activation of the extrinsic apoptosis pathway via downregulation of c-FLIP and XIAP.
This pathway is efficiently activated by an indirubin derivative, which thus represents an interesting
candidate for therapy of cutaneous T-cell lymphoma.
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Abstract: Oxidative stress is believed to be one of the main causes of neurodegenerative diseases
such as Alzheimer’s disease (AD). The pathogenesis of AD is still not elucidated clearly but oxidative
stress is one of the key hypotheses. Here, we found that artemisinin, an anti-malarial Chinese
medicine, possesses neuroprotective effects. However, the antioxidative effects of artemisinin
remain to be explored. In this study, we found that artemisinin rescued SH-SY5Y and hippocampal
neuronal cells from hydrogen peroxide (H2O2)-induced cell death at clinically relevant doses in a
concentration-dependent manner. Further studies showed that artemisinin significantly restored
the nuclear morphology, improved the abnormal changes in intracellular reactive oxygen species
(ROS), reduced the mitochondrial membrane potential, and caspase-3 activation, thereby attenuating
apoptosis. Artemisinin also stimulated the phosphorylation of the adenosine monophosphate
-activated protein kinase (AMPK) pathway in SH-SY5Y cells in a time- and concentration-dependent
manner. Inhibition of the AMPK pathway attenuated the protective effect of artemisinin. These
data put together suggested that artemisinin has the potential to protect neuronal cells. Similar
results were obtained in primary cultured hippocampal neurons. Cumulatively, these results
indicated that artemisinin protected neuronal cells from oxidative damage, at least in part through
the activation of AMPK. Our findings support the role of artemisinin as a potential therapeutic agent
for neurodegenerative diseases.
Keywords: artemisinin; SH-SY5Y cells; hippocampal neurons; H2O2; AMPK pathway
1. Introduction
Neuronal damage caused by oxidative stress (mainly reactive oxygen species) is one of the major
causes of neurodegenerative diseases such as Alzheimer’s disease (AD) [1–3]. Excessive levels of
reactive oxygen species (ROS) enhances cellular oxidative stress, leading to lipid peroxidation, protein
denaturation, and DNA damage, disrupting cell function and integrity, leading to cell apoptosis [4].
Oxidative stress is an imbalance between ROS production and antioxidant defense and has been found
to be associated with aging and aging-related neurodegenerative diseases [5–7]. H2O2 is an important
source of ROS and is widely used as an inducer of oxidative stress in cell models for the study of
various neurodegenerative diseases caused by oxidative stress [8,9].
Artemisinin is extracted from the plant Artemisia annua. It is one of the most effective anti-malarial
drug which has saved the lives of millions of malaria patients worldwide [10,11]. In addition to
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anti-malarial benefits, artemisinin has many other biological and pharmacological properties, including
antioxidant, anti-inflammatory, antiviral and anti-tumor effects [12–14]. In addition, we have recently
shown that artemisinin have neuroprotective potential [15–17]. However, the effect and underlying
action mechanism of artemisinin against oxidative stress in SH-SY5Y neuronal cells and primary
cultured neurons are still unknown. Artemisinin can cross the blood–brain barrier (BBB) and has no
observable toxicity to the central nervous system itself. This support the hypothesis that artemisinin
can have a favorable effect in the treatment of neurological diseases [18].
Decreased mitochondrial membrane potential is a marker of early cell apoptosis and is closely
related to cellular oxidative damage and apoptosis.The production of ROS occurs mainly in
mitochondria and it accumulates during aging ultimately becoming a major cause of cellular damage.
AMP-activated protein kinase (AMPK) is an energy sensor which plays a key role in regulating
complex signaling networks of mitochondrial biogenesis [19]. Emerging evidence have shown that
AMPK not only maintains energy metabolism balance, but also regulates oxidative stress, endoplasmic
reticulum stress, autophagy and inflammation, thereby increasing stress resistance [20]. Moreover,
AMPK activation seems to decline during aging. In addition, activation of the AMPK cascade have
been shown to be associated with improved glucose and lipid metabolism, as well as neuroprotective
and anticancer effects [21,22]. The effects of age associated decline in AMPK activity on mitochondrial
dysfunction and age related oxidative damage have also been verified previously [23].
In the present study, we evaluated whether artemisinin can protect against H2O2-induced
cytotoxicity and the potential mechanisms behind the protective effects of artemisinin in SH-SY5Y cells
and primary hippocampal neurons. Our results showed that artemisinin protected SH-SY5Y cells from
H2O2-induced injury as indicated by3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) assay and mitochondrial membrane potential assay. Furthermore the nuclear morphology
and abnormal changes in intracellular ROS were also restored to normal by artemisinin treatment.
In addition, caspase-3 which is a key performer of apoptosis and was reported to be activated by
H2O2 [24], was shown to be downregulated upon artemisinin treatment in present study. The AMPK
signaling pathway plays an important role in systemic energy balance and metabolism and regulation
of age-related diseases [11,25,26]. Finally, we also delineated the role of the AMPK signaling pathway
in the protective effect of artemisinin. All of these may provide interesting insights into the potential
applications of artemisinin in future AD research.
2. Results
2.1. Artemisinin Attenuated the Cell Viability Induced by H2O2 in SH-SY5Y Cells
SH-SY5Y cells were incubated with different concentrations of artemisinin or H2O2 for 24 h and
the cell viability was determined by MTT assay. No cytotoxic effect was observed upon artemisinin
treatment in SH-SY5Y cells up to 200 μM concentration (Figure 1B). Compared with the control group,
H2O2 caused significant cytotoxicity in SH-SY5Y cells 600 μM onwards (Figure 1C), and therefore
600μM H2O2 concentration was used in further experiments. To test the protective effects of artemisinin,
SH-SY5Y cells were pretreated with artemisinin for 2 h before being exposed to H2O2 for another 24 h.
The result showed that pre-treatment with artemisinin significantly reduced H2O2-induced cell death
(Figure 1D) and 12.5 μM artemisinin was used in further experiments.
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Figure 1. Artemisinin attenuated the decrease in cell viability caused by H2O2 in SH-SY5Y cells.
(A) The structure of artemisinin. (B) The cytotoxicity of artemisinin, cells were treated with artemisinin
(1.65–200 μM) for 24 h and cell viability was measured using the MTT(3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide) assay. (C) The cytotoxicity of H2O2. (D) Cells were pretreated with
artemisinin at indicated concentrations and then induced with or without 600 μM H2O2 for a further
24 h and cell viability was measured using the MTT assay. Data represent means ± SD, * p < 0.05,
** p < 0.01, *** p < 0.001, # p < 0.05, ### p < 0.001.
2.2. Artemisinin Pretreatment Attenuated H2O2-Induced Apoptosis in SH-SY5Y Cells
Both apoptosis and necrosis contribute to the cell viability loss during cell injuries. We tested
if the protective effect of artemisinin against H2O2 insult was mediated by its anti-apoptosis effects.
Nuclei condensation was observed in SH-SY5Y cells after exposure to 600 μM H2O2 in Hoechst 33342
staining assay. However, pre-treatment with 12.5 μM artemisinin significantly improved these changes
(Figure 2A,B). The result was further confirmed using flow cytometry for Annexin V-FITC/PI-positive
cells and data from these experiments indicated that H2O2 exposure markedly increased apoptosis in
SH-SY5Y cells, while 12.5 μM artemisinin pretreatment significantly reduced the apoptosis caused
by H2O2 (Figure 2C,D). Caspase-3 plays an important role in apoptosis and in order to further verify
the anti-apoptosis effect of artemisinin we checked the caspase-3 activity. We found that artemisinin
reversed H2O2-induced increase in the activity of caspase—(Figure 2E).
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Figure 2. Artemisinin suppressed H2O2-induced apoptosis in SH-SY5Y cells. Cells were pre-treated
with 12.5 μM artemisinin for 2 h and then induced with or without 600 μM H2O2 for another 24 h.
The pictures have been taken at a magnification of 40× (100 μm). (A) Photographs of representative
cultures measured by Hoechst staining. Apoptotic cells are marked with white arrows (B) Quantitative
analysis of (A). (C) Photographs of representative cultures measured by flow cytometry. (D) Quantitative
analysis of (C). (E) The activity of caspase-3 was monitored by caspase assay. Data represent means ± SD,
*** p < 0.001, ## p < 0.01, ### p < 0.001.
2.3. Artemisinin Inhibited H2O2-Induced Increase in ROS Level and Restored the Mitochondrial Membrane
Potential in SH-SY5Y Cells
Loss of mitochondrial membrane potential (Δψm) due to mitochondrial inhibition was involved
in the cell apoptosis caused by H2O2. In further study, we elucidated whether artemisinin could
reduce H2O2-induced Δψm loss. The Δψm in SH-SY5Y cells was assessed by analyzing the red/green
fluorescent intensity ratio of JC-1 staining. The results revealed that artemisinin pretreatment
significantly prevented the decline of Δψm induced by H2O2 (Figure 3A,C). The generation of excess
ROS is considered to be among the main causes of cell apoptosis induced by H2O2. Therefore,
we investigated whether artemisinin blocked H2O2-induced oxidative stress in SH-SY5Y cells. Cellular
oxidative stress was determined by the CellROXs Deep Red Reagent. SH-SY5Y cells pretreated with or
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without 12.5 μM artemisinin for 2 h were treated with 600 μM H2O2 for 24 h. As expected (Figure 3B,D),
artemisinin significantly decreased the intracellular ROS production induced by H2O2.
Figure 3. Artemisinin inhibited H2O2-induced increase of reactive oxygen species (ROS) level and
restored the mitochondrial membrane potential in SH-SY5Y cells. (A). After pre-treatment with 12.5 μM
artemisinin or 0.1% DMSO (vehicle control) for 2 h, SH-SY5Y cells were incubated with or without
600 μM H2O2 for another 24 h. The decline in the membrane potential was reflected by the shift of
fluorescence from red to green indicated by JC-1. The pictures have been taken at a magnification of 40×
(100 μm). (B). Intracellular ROS level was measured by the CellROXs Deep Red Reagent. The pictures
has been taken on 40× (100 μm). (C). Quantitative analysis of (A). (D). Quantitative analysis of (B).
The data were represented as the mean ± SD of three independent experiments. *** p < 0.001, ## p < 0.01.
2.4. Artemisinin Stimulated the Phosphorylation of AMPK in SH-SY5Y Cells
AMPK is a highly conserved regulator of cellular energy metabolism that plays an important role
in regulating cell growth, proliferation, survival, and regulation of energy metabolism in the body.
We therefore tested whether AMPK is involved in protective effect of artemisinin in SH-SY5Y cells.
As shown in Figure 4, after treatment with different doses of artemisinin for different time points,
the phosphorylation of AMPK was gradually increased (Figure 4A–D).
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Figure 4. Artemisinin stimulated the phosphorylation of AMP-activated protein kinase (AMPK) in
SH-SY5Y cells. (A,C) The SH-SY5Y cells were collected with artemisinin treatment for different times
(0, 15, 30, 60, 90 and 120 min) at 12.5 μM, and at different concentrations (3.15, 6.25, 12.5, 25 and 50 μM)
for 120 min. The expression of phosphocreatine AMPK, total AMPK and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) were detected by western blot. (B,D) Quantification of representative protein
band from western blotting. The data were represented as the mean ± SD. * p < 0.05, ** p < 0.01, versus
the control group was considered significantly different.
2.5. AMPK Mediated the Protective Effects of Artemisinin in SH-SY5Y Cells
In order to examine whether AMPK is involved in the survival promoting effect of artemisinin
on cell apoptosis induced by H2O2, we knocked down AMPKα by using shRNA plasmid specific for
AMPK in SH-SY5Y cells (Figure 5A). After 24 h of transfection, cells were treated with or without
artemisinin, then incubated with 600 μM H2O2 for 24 h, and the cell viability was determined by
MTT assay. As shown in Figure 5B, knockdown of AMPKα by shRNA significantly attenuated the
protective effect of artemisinin. To further confirm the effect of AMPK, we used the compound C
(a specific inhibitor for the AMPK) to pretreat cells for 30 min. MTT assay showed that pretreatment
with Compound C blocked the protective effects of artemisinin (Figure 5C). We got the similar result
from TUNEL staining assay (Figure 5D,E). Western blot also showed that AMPK pathway played an
important role in the protective effect of artemisinin (Figure 5G,H). At the same time, blocking the
AMPK signaling pathway also restored the activity of caspase-3 (Figure 5G,I).
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Figure 5. AMPK pathway mediated the protective effects of artemisinin in SH-SY5Y cells. (A). Cells
were pretreated with shAMPKα 1–3 plasmid for 24 h, The knockout efficiency was determined by
western blot. (B). Cells were pretreated with shAMPKα1 plasmid for 24 h before 12.5 μM artemisinin
treatment for 2 h, and then incubated with or without 600 μM H2O2 for a further 24 h. Cell viability
was evaluated using the MTT assay. (C). Cells were pre-treated with 5 μM Compound C (AMPK
inhibitor) for 30 min, and treated with 12.5 μM artemisinin for 2 h, then incubated with or without
600 μM H2O2 for another 24 h, and the cell viability was determined by MTT assay. (D,E). TUNEL
staining manifested that artemisinin attenuated H2O2-induced cell apoptosis significantly. The pictures
have been taken at a magnification of 40× (100 μm). (F). The activity of caspase-3 was measured by
caspase assay. (G). The expression of phosphorylated AMPK, total AMPK, cleaved caspase-3 and
GAPDH were detected by western blot. (H,I). Quantitative analysis of (G). The data was represented
as the mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ## p < 0.01, ### p < 0.001, & p < 0.05, &&& p < 0.001.
2.6. Artemisinin Protected Primary Cultured Hippocampal Neurons Against H2O2 Induced Injury via
AMPK Kinase
In order to verify whether the neuroprotective effects of artemisinin against H2O2 are limited
to SH-SY5Y, we also checked its protective effects on primary cultured hippocampal neurons.
In concordance with SH-SY5Y, artemisinin successfully protected hippocampal neurons against
H2O2 insult in a concentration-dependent manner as shown in Figure 6A–C and Figure S1. Similar
results was found in cortex neuron (Figure S2).The primary cultured neurons were more sensitive to
both H2O2 insult and artemisinin treatment and therefore artemisinin achieved its significant protective
effect at a lower concentration. Moreover, the protective effect of artemisinin is also inhibited by AMPK
inhibitor compound C in these primary neuron cells (Figure 6E–H). The protein NeuN is localized in
the nucleus and perinuclear cytoplasm of most neurons in the central nervous system. It is widely
used to assess the functional status of neurons and their pathological states. Our results show that
artemisinin can improve neuronal damage caused by H2O2 (Figure 6D). These results are consistent
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with our results from SH-SY5Y cells and further confirmed that artemisinin was able to protect neuronal
cells from oxidative stress via the activation of AMPK kinase.
 
Figure 6. Artemisinin attenuated the decrease in cell viability caused by H2O2 in neuronal cells.
(A) The cytotoxicity of H2O2 on neuronal cells. (B) Dose of artemisinin. (C) Primary cultured
hippocampal neurons were pretreated with artemisinin at indicated concentrations and then induced
with or without 100 μM H2O2 for another 24 h, and cell viability was measured using the MTT assay.
(D) Primary cultured hippocampal neurons pretreated with 2.5 μM compound C for 30 min were treated
with 25 μM artemisinin for 2 h, and then incubated with or without 100 μM H2O2 for another 24 h.
Immunocytochemistry of NeuN in each group was detected. The pictures were taken at a magnification
of 40× (100 μm). (E) Primary cultured hippocampal neurons pretreated with 2.5 μM compound C for
30 min were treated with 25 μM artemisinin for 2 h, and then incubated with or without 100 μM H2O2
for another 24 h. Cell viability was measured by the MTT assay. (F) The expression of phosphorylated
AMPK, total AMPK, cleaved caspase-3 and GAPDH were detected by western blot. (G,H) Quantitative
analysis of (F). The data were represented as the mean ± SD. ** p < 0.01, *** p < 0.001, ## p < 0.01,
### p < 0.001.
3. Discussion
In this study, we demonstrated that artemisinin blocked H2O2-induced neuronal damage by
activating the AMPK pathway. This study discovered a novel neuroprotective effect of artemisinin,
suggesting that artemisinin may have potential for the treatment of neurodegenerative diseases.
In addition to antimalarial effect, recently, artemisinin has also demonstrated to possess anti-tumor and
anti-inflammatory properties [27]. The hippocampus is one of the most vulnerable parts of the brain
and is susceptible to numerous pathological conditions [28]. In the current study, we used H2O2 injury
cellular model SH-SY5Y and hippocampal neurons to study the effects of artemisinin on oxidative
stress. We found that pretreatment with artemisinin provided protection to SH-SY5Y and hippocampal
neurons from H2O2-induced damage. Consistent with others and our previous reports, we found that
H2O2 is cytotoxic to SH-SY5Y cells in a dose-dependent pattern [29]. In addition, data from Hoechst
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33342 staining assay and flow cytometry showed that H2O2 also induced apoptosis in SH-SY5Y cells.
The cell viability of SH-SY5Y cells incubated with H2O2 was significantly increased when pretreated
with artemisinin. In addition, artemisinin can also attenuate H2O2-induced apoptosis of SH-SY5Y cells,
which further suggests that artemisinin has a protective effect on H2O2-induced SH-SY5Y cells.
Mitochondria are the major site of ROS production [30], and H2O2 increases oxidative stress
damage by increasing ROS production [29]. We concluded that pretreatment with artemisinin reduced
H2O2-induced ROS accumulation. Mitochondrial dysfunction caused by oxidative stress plays a
key role in the pathogenesis of aging-related neurodegenerative diseases [31]. Strategies to block
mitochondrial dysfunction have been declared to be a potential therapy for preventing cell death [32].
The results of the current study have shown that artemisinin pretreatment can inhibit H2O2-induced
Δψm loss.
The AMPK signaling pathway plays a major role in cell survival, apoptosis and senescence
prevention [33]. This pathway has been shown to be a key signaling pathway that induces cellular
antioxidant mechanisms. Our data suggest that artemisinin pretreatment stimulates phosphorylation
of AMPK and activates the AMPK pathway and plays a key role in the neuroprotective effects of H2O2
induced injury, consistent with activation of the AMPK cascade. The protective effect of artemisinin was
attenuated after blocking the AMPK signaling pathway with the specific knockout plasmids of AMPK
and specific pharmacological inhibitor Compound C. Consistently, pretreatment with artemisinin
reversed [34] the increase in caspase-3 activity caused by H2O2. After blocking AMPK, the effect of
artemisinin on caspase-3 activity disappeared. A major mechanism in the cellular defense against
oxidative is activation of the Nrf2-antioxidant response element signaling pathway, but when blocked
AMPK pathway Nrf2 expression was decreased (Figure S3).Taken together, these results provided
mechanistic evidence to support the view that artemisinin-mediated protection against H2O2 induced
injury occurs through AMPK activation. We got consistent results in hippocampal neurons as well
(Figure 6). Our results suggest that the possible regulatory mechanism of artemisinin operates by
protecting neuronal SH-SY5Y cells and hippocampal neurons from H2O2-induced oxidative damage
via activating the AMPK signaling pathway (Figure 7), including inhibition of intracellular ROS
production; restoration of mitochondrial membrane potential (Δψm); activation of AMPK signaling
pathway; and reduction of caspase-3 activity. In addition, we also checked some of the other derivatives
of artemisinin, like dihydroartemisinin (DHA), performed cellular viability assays, and found that
DHA was less effective. The results are attached in the supplementary data (Figure S4). When we
compared both the compound cellular viability assay results we found that the artemisinin was better
than DHA. Owing to its lipid-soluble nature, artemisinin can pass the blood brain barrier and maintain
a higher concentration in the central nervous system [35], giving it advantage over other neurological
drugs. Also as an FDA-approved anti-malarial drug, artemisinin has been clinically used for decades
with no significant adverse effects [36].
Our results found that artemisinin can eliminate ROS and protect the SH-SY5Y and hippocampal
neurons from H2O2-induced oxidative damage. Therefore, artemisinin has the potential to be a novel
drug to prevent and treat neurodegenerative diseases.
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Figure 7. The possible mechanism of artemisinin. Excessive H2O2 leads to excessive ROS production
and abnormal mitochondrial membrane potential, which in turn produces oxidative stress. Oxidative
stress further leads to activation of caspase-3, which ultimately initiates apoptosis. Administration of
artemisinin significantly inhibited H2O2-induced apoptosis and artemisinin ameliorated abnormal
changes in these markers by activating the AMPK pathway. By blocking AMPK, the protective effect
of artemisinin disappears. Therefore, artemisinin can be considered as a promising candidate for the
treatment of neurodegenerative diseases caused by oxidative stress.
4. Materials and Methods
4.1. Materials
Analytical grade artemisinin was purchased from Meilunbio (Dalian China). Dimethyl sulfoxide
(DMSO), Dulbecco’s modified Eagle’s medium (DMEM) and hydrogen peroxide (H2O2) were procured
from Sigma (St. Louis, MO, USA). Poly-D-lysine, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl-benzimidazolyl-carbocyanineiodide (JC-1) and
Hoechst 33258 were purchased from Molecular Probes (Eugene, OR, USA). anti-phospho-AMPK (2525,
1:1000 Rabbit IgG), anti-AMPK (5831, 1:1000 Rabbit IgG), NeuN (24307, 1:100 Rabbit IgG) and GAPDH
antibodies (2683s, 1:1000 Rabbit IgG) were purchased from Cell Signaling Technology (Woburn, MA,
USA). CellROX Deep Red Reagent were ordered from Thermo Fisher Scientific (Rockford, IL, USA).
Annexin V-FITC/PI Apoptosis Detection Kit was obtained from BD Biosciences (San Diego, CA, USA).
Fetal bovine serum (FBS) and 0.25% Trypsin were purchased from Life Technologies (Grand Island, NY,
USA). AMPK-ShRNA was purchased from Shanghai Genechem Co; Ltd. (Shanghai, China). AMPK
inhibitor (Compound C) was ordered from Calbiochem (San Diego, CA, USA).
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4.2. Methods
4.2.1. SH-SY5Y Cell Culture
Human neuroblastoma SH-SY5Y cells were cultured in 75-cm2 flasks in DMEM supplemented
with 10% heat-inactivated FBS and 0.1% penicillin/streptomycin at 37 ◦C with 5% CO2 humidified
atmosphere. The medium was replaced every 2–3 days, and cells were sub-cultured once 80–90%
confluency was reached. After digestion with 0.25% trypsin, cells were collected by centrifugation
at 1000 rpm for 5 min and resuspended in fresh medium. Cells were seeded into 96-well, 12-well or
six-well plates and grown overnight. Adherent cells were used for further experiments.
4.2.2. Hippocampal Neurons Culture
Newborn C57BL/6 mice were procured from the animal facility of University of Macau. The whole
body was disinfected with 75% alcohol and the brain was surgically removed and stored into cold
HBSS (Ca2+, Mg2+ free) balance solution. The whole hippocampus region was dissected using a glass
rod which was bent on both sides. The hippocampus was cleared of the blood and the mixed blood
vessels by washing thrice with HBSS. Then the hippocampus was chopped into 1 mm3 pieces using
scissors and after washing thrice with HBSS the tissue was digested with 0.125% of trypsin at 37 ◦C
for 15 min. The enzymatic digestion was stopped with 10% FBS and 5 mL of Neurobasal A (Gibco,
USA) was added to the digested hippocampus tissue in a 15 mL centrifuge tube. The turbid tissue
supernatant was collected in another 15 mL centrifuge tube and centrifuged at 1000 rpm for 10 min.
The resulting cell pellet was resuspended in Neurobasal A/B27 (Gibco, Carlsbad, CA, USA) and seeded
in poly-D-lysine treated plates at a density of about 1–2 × 105 cells /mL and incubated for growth at
37 ◦C in 5% CO2 humidified atmosphere.
4.2.3. MTT Assay
For the MTT assay, SH-SY5Y cells were seeded at a density of 6–8 × 103 cells/well in 96-well plates
with 1% FBS medium for 24 h. After serum starvation, the cells were incubated with drugs or inhibitors
for appropriate time, and treated with H2O2 for another 24 h. The cells were then incubated with MTT
(0.5 mg/mL) for additional 3–4 h. The medium was aspirated from each well and DMSO (100 μL) was
added to dissolve the dark-blue formazan crystals that were formed in intact cells and absorbance
of each well solution was measured with a microplate reader (SpectraMax 250, Molecular Device,
Sunnyvale, CA, USA). The data were presented as Optical Density (OD) at a wavelength of 570 nm.
4.2.4. Hoechst 33258 Staining
Apoptosis of cells was examined by staining with the DNA binding dye. SH-SY5Y cells were
pretreated with 12.5 μM artemisinin for 2h before being exposed to 600 μM H2O2 for another 24 h,
followed by fixing the cells in 4% formaldehyde in PBS for 10 min at 4 ◦C. The fixed cells were further
incubated for 10 min with 10 μg/mL of Hoechst 33258 in order to stain the nuclei. After rinsing twice
with PBS, the apoptotic cells were visualized under a fluorescent microscope (Olympus, Japan). Cells
exhibiting apoptosis hallmarks such as condensed chromatin or fragmented nuclei were scored as
apoptotic cells. A minimum of 200 cells in five random fields were collected and quantified for each
Hoechst staining experiment. The data was statistically presented as percentage of apoptotic cells.
4.2.5. Annexin V-FITC/PI Staining for Apoptosis Evaluation
Flow cytometry using Annexin V-FITC/PI staining was carried out for apoptosis evaluation. Flow
cytometry was performed as described in the guidelines of assay kit. Briefly, SH-SY5Y cells were
pretreated with 12.5 μM artemisinin for 2 h before being exposed to 600 μM H2O2 for another 24 h,
then the cells were trypsinized and washed twice with ice-cold PBS then centrifuged at 1000 rpm for
5 min and re-suspended in Annexin V-FITC/PI binding buffer (195 μL). Annexin V-FITC (5 μL) was
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supplemented and the cells were incubated in the dark at room temperature for 10 min. The cells
were then centrifuged at 1000 rpm for 5 min and re-suspended in Annexin V-FITC/PI binding buffer
(190 μL); propidium iodide (PI) (10 μL) was further added, followed by incubation in the dark for
5 min. Apoptosis was quantified using Flow cytometry. Cell Quest Pro software (BD AccuriC6, BD,
USA) was used for analyzing apoptosis condition.
4.2.6. Measurement of Intracellular ROS Levels
Intracellular ROS generation was assessed by CellROXs Deep Red Reagent. After pretreatment
with 12.5 μM artemisinin for 2 h before being exposed to 600μM H2O2 for another 24 h, the SH-SY5Y
cells were exposed to CellROXs Deep Red Reagent (5 mM) in DMEM for 1 h in the dark. After rinsing
twice with 1× PBS solution, the Fluorescence was observed and recorded on a fluorescent microscope
at excitation and emission wavelengths of 640 nm and 665 nm respectively. The semi quantification of
ROS level was analyzed using Image-J software (version 1.48; NIH, Bethesda, MD, USA) and all the
values of ROS levels were normalized to the control group.
4.2.7. Measurement of Mitochondrial Membrane Potential (Δψm)
JC-1 dye was utilized to monitor mitochondrial integrity. In brief, SH-SY5Y cells were seeded into
96-well plates (1 × 104 cells/well) in dark. After pretreatment with 12.5 μM artemisinin for 2 h before
being exposed to 600 μM H2O2 for another 24 h, the cells were treated with JC-1 dye (10 μg/mL in
medium) for 15 min at 37 ◦C and rinsed twice with PBS. For quantification of the signal, the intensities
of red (excitation 560 nm, emission 595 nm) and green fluorescence (excitation 485 nm, emission
535 nm) were assessed using an Infinite M200 PRO Multimode Microplate reader. Δψm was calculated
as the ratio of red/green fluorescence intensity and the values were normalized with respect to the
control group. The fluorescent signal in the cells was also recorded with a fluorescent microscope.
4.2.8. Immunocytochemistry (ICC)
ICC is a method of detecting specific antigens in cells using an appropriate antibody labeling
strategy. After drug treatment, cells were washed twice in PBS and then fixed in 4% paraformaldehyde
for 15 min at room temperature to maintain cell morphology. The cells were then rinsed three times
with PBS, and incubated in PBST (0.1% Triton X-100 in 1× PBS) for 20 min at room temperature.
Following this, the cells were blocked with 1% BSA for 1 h at room temperature which can help reduce
non-specific hydrophobic interactions. And then the primary antibody/antibodies were added and kept
at 4 ◦C overnight. The next day after washing cells with PBS three times, the fluorophore-conjugated
secondary antibodies were added for 2 h at room temperature, away from light. A drop of mounting
medium was added to each slide. Then, samples were observed by confocal laser scanning microscopy.
4.2.9. TUNEL Assay
SH-SY5Y cells were pre-treated with 5 μM Compound C (AMPK inhibitor) for 30 min, and treated
with 12.5 μM artemisinin for 2 h, then incubated with or without 600 μM H2O2 for a further 24 h. After
treatment, the cells were fixed with 4% PFA for 30 min and washed with 0.1% Triton-X PBS for 3 times.
Then cells were incubated with TUNEL test solution (C1086, Beyotime, China) at 37 ◦C for 60 min in
the dark following the manufacturer’s instruction. After washing with 1× PBS, images were taken
with a fluorescence microscope.
4.2.10. Caspase-3 Activity Assay
After drug treatment, SH-SY5Y cells were digested with trypsin and harvested by centrifugation at
600 g for 5 min at 4 ◦C. The supernatant was carefully aspirated and washed once with PBS. According
to the manufacturer’s protocol, 100 μL of lysate was added per two million cells, and the pellet was
resuspended. The supernatant was transferred to an ice-cold centrifuge tube and lysed on ice for
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15 min. Then centrifuged at 16,000–20,000× g for 15 min at 4 ◦C. The reaction system was set up
according to the manufacturer’s instructions. The detection buffer was added first followed by the
sample to be tested, and finally 10 μL of Ac-DEVD-pNA (2 mM) was added, mixed well avoiding the
bubbles. The reaction system was then incubated in a working solution for 60–120 min at 37 ◦C. A405
was then determined by Infinite M200 PRO Multimode Microplate. All values of caspase-3 activities
were normalized to the control group.
4.2.11. Western Blotting
Western blotting was performed following the standard procedure [15]. The experimental cells
under different treatments were lysed in ice-cold RIPA lysis buffer and the protein concentration was
assessed using a BCA protein assay kit according to the manufacturer’s instructions. Samples with
the same amount of proteins were separated on 10% polyacrylamide gels, and later transferred to
PVDF membrane. After blocking with 3% BSA for 1 h, the membranes were incubated with selective
primary antibodies overnight. Following day, the primary antibody was washed with 1× TBST thrice,
and incubated with secondary antibody for another 2 h. After exposure with BCL, the intensity of the
bands was quantified using Image J software.
4.2.12. Transfection of ShRNA Plasmid
The shRNA of AMPKα were designed and synthesized by GenPharma Co., Ltd. (Shanghai,
China). One day before the transfection, SH-SY5Y cells were seeded into a 12-well plate at a density of
1 × 105 cells/well, grown overnight, and transfected when the cell density reached 80%. SH-SY5Y cells
were transfected with Lipofectamine 2000 reagent according to the manufacturer’s protocol. Protein
samples were collected after 48 h of transfection. The AMPKα knockdown efficiency was verified by
western blot.
4.2.13. Data Analysis and Statistics
Statistical analysis was performed using GraphPad Prism 5.0 statistical software (GraphPad
software, Inc., San Diego, CA, USA). All experiments were performed in triplicates. Data are expressed
as mean± standard deviation (SD). Statistical analysis was carried out using one-way ANOVA followed
by Tukey’s multiple comparison, with p < 0.05 considered statistically significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/11/
2680/s1.
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Abstract: Compelling evidence supports a tight link between oxidative stress and protein aggregation
processes, which are noticeably involved in the development of proteinopathies, such as Alzheimer’s
disease, Parkinson’s disease, and prion disease. The literature is tremendously rich in studies that
establish a functional link between both processes, revealing that oxidative stress can be either
causative, or consecutive, to protein aggregation. Because oxidative stress monitoring is highly
challenging and may often lead to artefactual results, cutting-edge technical tools have been developed
recently in the redox field, improving the ability to measure oxidative perturbations in biological
systems. This review aims at providing an update of the previously known functional links between
oxidative stress and protein aggregation, thereby revisiting the long-established relationship between
both processes.
Keywords: protein aggregation; redox; oxidative stress; proteinopathy
1. Introduction
Protein aggregation consists of any association of proteins into larger structures with non-native
conformation [1]. Aggregates can have either an amorphous or a highly ordered structure (amyloid).
The presence of aggregates is generally indicative of proteostasis imbalance, either due to insufficient
proteostasis or to disrupted chaperone capacity. Aggregates can also be a response to cellular stress
related to environmental changes [2] (Figure 1).
The intrinsic parameters of protein aggregation are not fully understood, but the ability of certain
proteins to aggregate more readily compared to others has been known for a while. Intrinsic aggregation
capacity can be obvious, as in the case of peptide poly(Q) tracts that form high molecular weight
aggregates in some neurodegenerative diseases (including Huntington’s disease). Such aggregates
exhibit a fibrillar or ribbon-like morphology, reminiscent of prion rods and amyloid-β (Aβ) fibrils in
Alzheimer’s disease (AD) [3]. Aggregation is controlled in vitro, not only by poly(Q) tracts length
(51–122 glutamines causing huntingtin’s aggregation in vitro), but also by protein concentration
and reaction time [4]. In addition, most proteins contain one or more aggregation prone-regions
(APR), which are protected from aggregation by protein interactions or by specific structural features
(e.g., burying into a hydrophobic core) in physiological conditions [5].
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Figure 1. General picture of the protein aggregation process. The unfolded and misfolded monomer
structures are aggregation prone. Folded monomers can also aggregate from native-like conformations
without going through the unfolded step. The association of several monomers gives rise to oligomeric
aggregates with low molecular weight. The addition of oligomers in an ordered manner permits the
growth of oligomers to protofibrils and mature fibrils. Amorphous aggregates can arise from the
precipitation of monomers or oligomers, possibly leading to protein inclusions.
However, the aggregation of proteins without any obvious features is intriguing. An interesting
study used three different stress agents: Arsenite, a toxic metalloid, hydrogen peroxide (H2O2),
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a ubiquitous oxidative stress agent, and azetidine-2-carboxylic acid (AZC), a proline analog whose
incorporation into proteins provokes conformation alterations, misfolding, and aggregation [6,7].
The authors identified that despite distinct stress conditions with distinct mechanisms of action, some
of the proteins that aggregate are of similar types, suggesting that proteins within aggregates are
intrinsically aggregation-prone [7]. Indeed, it appears that aggregation prone proteins like PrPC
(the prion protein) or Shadoo (also a member of the prion protein family) exhibit large intrinsically
disordered domains (IDDs). The resulting conformational plasticity is likely to offer a wide range
of interacting possibilities for these proteins, thereby regulating their localization and aggregation
propensity [8–10]. Several computational approaches have tried to question the intrinsic determinisms
of aggregation. Noticeably, the Waltz algorithm was developed to try to predict amylogenic regions in
protein sequences, based on a scoring matrix deduced from the biophysical and structural analysis of
previously characterized hexapeptides with amyloid properties [11]. Based on the accuracy of their
pWALTZ prion prediction method derived from Waltz, Sabate and co-workers recently suggested a
model for prion formation that depends on the presence of specific short sequence elements, embedded
in intrinsically Q/N-rich regions, with high amyloid propensity [12].
Interestingly, the aggregation of globular proteins into amyloids from a native or native-like
state has also been described. In such cases, aggregation-prone states can be reached from native-like
conformations after small temperature or pH changes, or stress modulations in general, without the
need to cross the energy barrier to unfold [13]. Several examples in the literature illustrate this fact,
such as the aggregation of one of the acylphosphatases from the Drosophila melanogaster (AcPDro2) [13],
the human lysozyme aggregating through a nucleation-dependent growth process [14], the globular
acylphosphatase from Sulfolobus solfataricus (forming aggregates in which the monomers maintain
their native-like topology [15]), and the transthyretin-like domain of human carboxypeptidase D
(h-TTL), a monomeric protein with homology to human transthyretin that aggregates under close
to physiological conditions [16]. Another example is the src tyrosine kinase SH3 domain, whose
aggregation-prone state favors a domain swap that allows amyloid formation [17]. In such cases,
the free energy gap between the native and the aggregation-prone state is an essential determinant of
the aggregation propensity of the proteins [14,17]. Moreover, even though unfolded proteins have a
high capacity to aggregate, the residual aggregation potential of proteins within a folded state may be
physiologically relevant and play a role in several clinical situations [13,14,16].
Protein aggregation is obviously related to several human pathological situations. Amyloidoses,
for example, are a group of diseases originating from the aggregation of oligomers into amyloid fibrils
that deposit in tissues and are, in turn, toxic to the cells. Which of the oligomers or the fibrils are
the most toxic to cells is still a matter of debate. Further, well-known neurodegenerative diseases,
including Alzheimer’s (AD), Parkinson’s (PD), and motor neuron diseases, appear to be a consequence
of protein aggregation in neurons, leading to toxicity and neuronal cell death. Although pathological
protein aggregation may have different causes, the chronic disturbance of cellular homeostasis (due
to exogenous pollutants, or aging for example) is likely to play a major role by modifying the
physico-chemical equilibrium and influencing protein folding and aggregation. Redox perturbations,
in particular, have long been linked to protein aggregation diseases.
Reactive oxygen species (ROS) are normal by-products arising from various cellular reactions,
mostly during electron transport in mitochondria or chloroplasts. Intracellular ROS levels are
maintained low within cells, ensuring redox homeostasis for proper cellular chemical reactions.
Oxidative stress occurs when the ROS concentration is excessive regarding the antioxidant capacities
of the cell, leading to the oxidation of cellular molecules and their alteration [18]. Proteins appear to be
a major target for oxidation due to their elevated quantities compared to other cell components and
also due to their high reactivity with ROS [19]. Proteins are susceptible to ROS modifications of amino
acid side chains that alter their structure.
We provide here a review of recent data on the functional links between oxidative stress and
protein aggregation.
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2. Oxidative Stress Can Produce Aggregation: A Mechanistic View
2.1. Oxidation of Critical Amino Acids Induces Structural Changes within Proteins, Leading to Aggregation
2.1.1. Cysteine Oxidation
Among the amino acids, cysteine (Cys) possesses a thiol group, which is highly nucleophilic. This
structural feature makes cysteine particularly prone to oxidation by ROS. Amorphous aggregation of
γ-cristallins is the cause of cataracts, a widespread disease among seniors. Internal disulfide bond
formation between Cys32 and Cys41 due to oxidation was found necessary and sufficient to provoke
aggregation under physiological conditions, likely by stabilizing an unfolded intermediate prone to
protein–protein interaction between an extruded hairpin and a distal β-sheet in the γD-crystallin [20].
Being essential for serotonin synthesis, Tryptophan hydroxylase 2 (TPH2) is considered a
phenotypic marker for serotonin neurons. Known to be extremely labile to oxidation, TPH2 aggregates
through both intra- and inter-molecular disulfide cross-linking upon oxidation of cysteines [21].
Accordingly, in a systematic cysteine-mutagenesis approach, a single cysteine out of 13 was found
sufficient for aggregation, whereas only cysteine-less mutants were found resistant to aggregation upon
oxidation, thereby indicating that cysteines are necessary for the responses of TPH2 to oxidation. These
results led the authors to hypothesize that redox homeostasis changes occurring during Parkinson’s
disease might be involved in disulfide links in TPH2, causing TPH2 to shift from a soluble compartment
to large inclusion bodies, consequently losing its catalytic function [21].
Alternatively, disulfide bonds can occur in proteins’ native structures in physiological conditions.
Disulfide-rich domains (DRDs) are peptide domains whose native structures are stabilized by covalent
disulfide bonds through an oxidative folding reaction. The authors questioned whether this specific
folding might be associated with an increased aggregation propensity of DRDs. Among the 97 DRDs
analyzed in silico, a majority were intrinsically disordered, but remained more soluble and had fewer
aggregating regions than those of other globular domains [22]. This work suggests that DRDs might
have evolved to avoid aggregation before proteins acquire their covalently linked native structures or
after oxidative stress.
2.1.2. Other Aminoacids Involved
Caseins are very abundant in milk as they represent more than 80% of total milk protein
content [23]. Inter- and intra- covalent di-tyrosine (di-Tyr) and di-tryptophan (di-Trp) cross-links have
been shown to provoke α- and β-casein aggregation, due to the Trp-or Tyr- derived radicals produced
by photo-oxidation mediated by riboflavin, a photosensitizing vitamin [24]. Oxygen was found to
strongly modulate this phenomenon and to increase protein aggregation by decreasing the overall
cross-link formation, but allowing the formation of oxidized Trp, Tyr, Methionine (Met), and Histidine
(His) residues [24].
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is involved in energy production and has
been shown to convert from its native soluble state into a non-native high molecular weight, which
is insoluble, and an aggregated state, during the course of several diseases, including Alzheimer’s
disease [25–27]. Interestingly, methionine, rather than cysteine oxidation, was shown to be a primary
cause of GAPDH aggregation, as mutating methionine 46 to leucine rendered GAPDH highly resistant
to aggregation after exposure to (3E)-4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide (NOR3), a potent
oxidative agent driving GAPDH aggregation [25,28,29]. In this case, the authors propose that
methionine oxidation represents a “linchpin”, a permissive event for subsequent misfolding and
aggregation [28].
It appears that protein residue oxidation, including the resulting disulfide bonds between
cysteines, is not directly responsible for aggregation, per se, but in most cases induces limited or
extensive unfolding of the surrounding environment of the protein. This further favors protein–protein
interactions and aggregation, as summarized in Table 1.
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Table 1. Residue oxidation causing protein aggregation.
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2.2. Role of Metals
Metals’ contributions to Fenton’s or Haber-Weiss’ reactions have been described for a number of
years, as they lead to highly reactive ROS that can be deleterious to cell components. In particular, they
are responsible for amino acid oxidation. The involvement of metals in various pathological situations
has also been recognized [30].
Parkinson’s disease pathology involves misfolding and aggregation of the presynaptic protein
α-synuclein, together with an alteration of the homeostasis of brain metals, including iron. A recent
analysis of iron’s role in the aggregation and secondary structure of N-terminally acetylated α-synuclein
(NAcαS), the pathologically relevant form in PD, revealed the importance of oxidation in the
phenomenon [31]. The sole addition of iron(II) in presence of oxygen was shown to induce an
antiparallel right-twisted conformation of NAcαS, and generate the oligomer-locked NAcαS−FeII/O2
conformation, thus initiating oligomer formation but preventing further processing into fibrils. This
was not observed in the absence of oxygen. In contrast, the addition of iron(III) led to the formation of
fibrils in the presence of oxygen. Thus, the iron oxidation status in the presence of oxygen differentially
controls aggregation. This may have physiological or pathological implications [31].
Particular mutations in the Apolipoprotein A-I (APOA1) gene provoke hereditary amyloidosis.
Interestingly, Fe(II) can reduce the formation of fibrillar APOA1 species, as opposed to Fe(III), which
enhances their formation in vitro [32]. The increased levels in Fe(III) compared to Fe(II) under
particular oxidative physiological conditions, e.g., in older patients or in presence of air pollutants,
might thus contribute to the development of amyloidosis and possibly other diseases involving protein
aggregation [32].
Several studies have demonstrated amyloid-β-mediated ROS production in the presence of Cu
ions, and mechanisms that can generate a superoxide anion (O2• −), hydrogen peroxide (H2O2), and a
hydroxyl radical (HO•) have been proposed [33,34]. The Amyloid-β peptide (Aβ) is produced after
cleavage of the transmembrane Amyloid Precursor Protein (APP) by β- and γ-secretases. Aβ is thus
released in the extracellular space. Its accumulation and aggregation are a hallmark of Alzheimer’s
disease (See Figure 2). A recent work identified that Cu(I) or Cu(II) cations predominantly bind the M1
site located in domain E2 of APP, with a comparablely high affinity (picomolar) being liganded by
four histidine residues. Cu(II) binding to M1 was found to stabilize E2 but also alters its structural
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conformation into a more open state [35]. The authors demonstrated the aerobic catalytic oxidation of
ascorbate, an abundant antioxidant molecule in the central nervous system, by the Cu-E2 complex,
with an experimental set up close to physiological conditions. APPβ might thus play the role of redox
catalyst in vivo and cause protein damage, as observed in brain tissues from Alzheimer’s patients [35].
Figure 2. Amyloid Precursor Protein (APP) processing. (A) Cleavage of APP occurs through two
pathways. The non-amyloidogenic pathway (grey, left) involves two cleavages by α- and γ-secretases
and produces a long APPα fragment, which is secreted. C-Terminal Fragment (CTF)83, 3-kd peptide,
(P3), and APP intracellular domain (AICD) fragments are also released. In parallel, the amyloidogenic
pathway (pink, right) involves two cleavages by β- and γ-secretases, producing a long APPβ, which is
secreted. CTF99, AICD, and Aβ fragments are also produced. In pathological conditions, Aβ peptides
accumulate and can ultimately aggregate and form oligomers and fibrils that are toxic for the cells
(adapted from [36]). (B) Schematic representation of the APPα fragment, produced after cleavage of
the APP by α-secretase. The E2 domain is highlighted (green). (C) Zooming in on the four cysteine
residues involved in the tetra-His M1 site, included in the E2 domain. The Cu cation is pictured as a
red ball (adapted from [37] with permission).
2.3. Carbonylation Leads to Aggregation
Carbonylation is a particular type of oxidation involving the irreversible addition of a carbonyl
group (CO) into proteins. The ROS-mediated carbonylation of proteins mainly affects lysine,
arginine, threonine, and proline residues [38] and was frequently reported in chronic inflammatory
diseases [39,40]. Protein carbonylation is commonly considered a standard marker of oxidative stress.
While carbonylation is reported as having a role in protein quality control, in tagging damaged proteins
for degradation with the 20S proteasome (via an unresolved mechanism), excessive carbonylation
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has been shown to be responsible for protein aggregation, especially when proteasome activity is
impaired [41]. However, few publications provide mechanistic insight into how protein carbonylation
causes aggregation. A recent report indicated that these specific modifications are also associated
with physiological aging and favor the formation of denser and more compact aggregates, including
several proteins previously reported for their aggregation propensity [42]. Inducing carbonyl stress
in young mice increased protein aggregation, similar to the aggregation naturally observed in old
mice, indicating that post-translational oxidative alterations are responsible for increased protein
aggregation [42]. Despite evidence that carbonylation leads to aggregation, to our knowledge, no
direct mechanism has been explicitly reported.
Recent attention has been paid to reactive dicarbonyl species, such as methylglyoxal (MGO)
and glyoxal (GO), considered to be side-products of several metabolic pathways, as they produce
specific oxidative modifications of proteins, mainly reacting with lysine and arginine [43]. These
oxidative modifications, including carbonylation, are subsequently responsible for secondary and
tertiary structure alterations and the formation of high molecular mass protein aggregates and may have
an underestimated role in several proteinopathies, including Alzheimer’s and Parkinson’s diseases.
2.4. Protein Oxidation Influences Aggregation by Modulating Chaperone Protein Activity
Oxidation-induced structural changes in proteins may also prevent specific interactions with
partners. A very interesting case has been described recently, with the nucleotide exchanger and
co-chaperone Mge1 within the mitochondria. Mge1 is actually modified by persistent oxidative stress,
and methionine 155, in particular, can be reversibly oxidized into methionine sulfoxide. As a result,
due to local structural changes in Mge1 binding to its partner, the heat shock protein 70 (Hsp70) is
defective. Hsp70 is a central heat-shock protein involved in controlling protein folding and plays
an important role in ensuring proteostasis. If not reduced by the endogenous methionine sulfoxide
reductase, the oxidized Mge1 aggregates into amyloid-type particles. Interestingly, the authors noticed
that highly oxidized Mge1 actually increased the binding capacity of Hsp70 to a denatured protein,
suggesting that the oxidation-induced defective binding of Meg1 to Hsp70 and MgeI aggregation
may protect the cells from the aggregation of other proteins in an oxidative stress context [44]. It is
interesting to note that some isoforms of Hsp70 are stress-modulated. For instance, oxidants like
methylene blue and hydrogen peroxide inactivate Hsp72, possibly due to the oxidation of two specific
cysteine residues resulting in structural changes within the nucleotide-binding domain. Noticeably,
this oxidation-induced inactivation of Hsp72 is associated with decreased levels of tau in several
Alzheimer’s disease models. The authors suggest that Hsp72 inactivation could clear the cytosol from
misfolded Hsp72 substrates like tau, even though the mechanism remains unclear [45].
Tsa1 is a surprising protein that exhibits a double role, acting as a peroxidase but also as a chaperone
for aggregated proteins—specifically, by chaperoning misassembled ribosomal proteins, thereby
preventing toxicity to arise from aggregation [46]. It is noticeable that the absence of Tsa1 both provokes
an increase in [H2O2] and the accumulation of aggregated proteins in the meantime [47]. This dual
role might argue for a strong functional connection between oxidative stress and protein aggregation.
2.5. Protein Oxidation Influences Aggregation by Perturbing the Translational Process
Yeast Sup35 is a translation termination factor well known for its capacity to form a prion (i.e.,
a self-perpetuating amyloid aggregate), in response to environmental or cellular factors. This prion is
called [PSI+] [48]. When aggregated into [PSI+], Sup35 loses its function in translation termination,
and an elevated read-through of the stop codons occurs, thereby generating C-terminally extended
polypeptides. Following exposure to H2O2, [PSI+] formation was shown to occur with increased
frequency, possibly linked to the oxidation of methionine residues [49]. As a consequence, exposure to
oxidative stress perturbs the translational process through titration of Sup35.
Defective mRNAs are normally handled by mRNA quality control systems within cells, among
which the non-stop decay (NSD) pathway and the no-go decay (NGD) pathways prevent the production
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of abnormal, potentially aggregation-prone proteins. Interestingly, NSD components (e.g., Ski7) and
NGD components (e.g., Dom34/Hbs1) were recently shown to be required during oxidative stress [50].
Moreover, overexpression of Sup35 actually decreases stop codon read-through and improves the
tolerance of yeast cells to oxidative stress, thus providing an unanticipated link between oxidative stress
tolerance and NSD, as NSD substrates noticeably accumulate as a consequence of [PSI+] formation
after oxidative stress [50].
2.6. Oxidative Stress Contributes to Aggregation by Modulating the Proteasome and Autophagy Capacity
Proteasomes are central players of the Ubiquitin–Proteasome System (UPS), which ensures
the quality control of proteins. The 20S proteasome, constituting 28 subunits, is considered the
“core” proteasome and is involved in unfolded, misfolded, or intrinsically disordered or oxidized
protein removal by proteolytic degradation. Ubiquitination is not needed for degradation by the 20S
proteasome, unlike the 26S proteasome. Several other proteasome components regarded as regulators
have been characterized, including the 19S proteasome. Obviously, increasing 20S proteasome
activity in pathogenic conditions due to protein aggregation might be of interest. The small,
imidazoline-derivative molecule TCH-165 was shown to increase 20S proteasome levels to the
detriment of the 26S proteasome, resulting in the enhanced proteolysis of intrinsically disordered
proteins. These include aggregation-prone proteins such as α-synuclein and tau, whose aggregation
are hallmarks of Parkinson’s and Alzheimer’s diseases, respectively, and proto-oncogenes, such as
ornithine decarboxylase and c-Fos. Noticeably, high concentrations of this molecule resulted in the
accumulation of ubiquitinated substrates [51].
Similarly, proteasome impairment has been shown to favor the accumulation and aggregation
of aggregation-prone proteins [52–55]. UPS disturbances have been correlated with the spreading of
diseases involving protein aggregation, including Alzheimer’s, Parkinson’s, and Huntington’s diseases,
as well as amyotrophic lateral sclerosis (ALS). ALS, in particular, is characterized by ubiquitinated
proteic inclusions.
For our current focus, it is worth noticing that the UPS is actually redox regulated, and S-
glutathionylation, specifically, has been involved in the post-translational control of proteasome activity.
For example, 20S glutathionylation was shown to be responsible for increased proteolytic activity [56],
favoring the removal of oxidized or unstructured proteins in stressful situations. After an acute oxidative
event, a coordinated response involving poly[ADP-ribose] polymerase 1 (PARP-1) activation and a
ubiquitination block, followed by the inactivation of the proteolytic capacity, occurs, before massive de
novo synthesis of proteasome players and consequently increased proteolytic activity [57]. In contrast
to 20S, 26S proteolytic activity was reduced in oxidative conditions. Indeed, the S-gluthationylation
of a regulatory subunit of the 19S proteasome, resulting in diminished 26S proteasome activity, was
observed in the presence of chronically increased hydrogen peroxide concentrations both in vitro and
in cellulo [58]. These data might reveal differential redox regulations for the proteasome’s components.
Under normal physiological conditions, the oxidized proteasomes (ubiquitin-dependent proteolytic
20S core and regulatory 19S) are S-glutathionylated, as evidenced in several cellular contexts [56,58–60].
It is also interesting to report here that the anti-malaria drug dihydroartemisinin, an artemisinin
derivative used in clinics, acts by inhibiting the parasite’s proteasome, possibly through oxidative
damage to the proteasome [61].
Thus, chronic oxidative stress favors protein aggregation through by impairing proteasome
capacity (Figure 3). In addition, the slow and gradual accumulation of aggregates during aging
has been observed. These aggregates are composed of oxidized proteins (including carbonylated
aggregates) due to proteins escaping the UPS and are suggested to bind the proteasome and inhibit its
function [62,63], thereby fostering this aggregation loop.
Autophagy is a cellular process that allows the recycling of cellular components, such as proteins
or organelles, through a lysosome-mediated catabolic pathway. Particular types of autophagy are
primarily distinguished (macroautophagy, chaperone-mediated autophagy, microautophagy) by
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how target substrates are recognized and delivered to lysosomes. More specifically, autophagy is
central in eliminating the substrates that will ultimately give rise to amyloids and fibrils in several
neurodegenerative diseases (Aβ peptide and tau protein in AD [64,65], alpha-synuclein in PD [66],
mutated huntingtin in Huntington disease [67], and superoxide dismutase 1 (SOD1) in ALS [68]).
Accordingly, mice deficient in autophagy show neurodegenerative disorders, and defects in autophagy
have been associated with various human neurodegenerative diseases [69–73].
Redox regulation of autophagy has been suggested, as antioxidant treatments actually prevent
autophagy [74]. This type of regulation was proposed by several authors [75–79]. Interestingly,
recent work identified that the absence of the glutathione reductase gsr-1 gene leads to major
redox homeostasis unbalance in the model organism, Caenorhabditis elegans, and is also responsible
for autophagy impairment by preventing the nuclear translocation of a key transcription factor,
HLH-30/TFEB. In addition, the aggregation of both homologous and heterologous proteins (Aβ peptide
(AD), α-synuclein:: YFP (PD), and Q40::YFP (Huntington disease) expressed in C. elegans was increased.
This study reveals a glutathione-dependent regulation of autophagy, allowing the control of protein
aggregation, a process also conserved from lower eukaryotes to mammals [80]. Recently, several drugs
were developed to modulate autophagy in search of therapeutic improvement in neurodegenerative
disorders. Noticeably, Rapamycin targets mTor, a master regulator of cell growth and metabolism.
Rapamycin activates autophagy and lysosomal biogenesis [81] and, furthermore, was shown capable
of reducing Aβ accumulation and improving cognitive impairments in a transgenic mouse model by
increasing autophagy [82,83]. Autophagy activation by rapamycin in neurons was also shown to favor
the clearing of intracellular aggregates of misfolded prion proteins and to reduce neurotoxicity [84].
The rapamycin derivative, Rilmenidine, which is protective against oxidative cytotoxicity [85], was
also shown to increase autophagy, despite failing to decrease the accumulation and aggregation of
SOD1 in a mouse ALS model [86]. Another rapamycin derivative, biolimus, was also shown to be
capable of activating autophagy efficiently in smooth muscle cells [87]. Most of these drugs have been
shown to play on the oxidative balance within cells. Nevertheless, whether the effect of these drugs on
protein aggregation is related to redox modulation has not been consistently characterized.
Figure 3. General diagram showing the regulation of protein aggregation. Arrows indicate the activation
relationship, and blunt-ended arrows indicate the repression relationship. References supporting
this diagram within this review are as follows: 1: [20,21,24,28,31,32,35,41–47,49,50]; 2: [58,61]; 3: [57];
4: [62,63]; 5: [51–55]; 6: [80]; 7: [74–80]; 8: [64–73,82–84]; 9: [47,88–99]; 10: [100–107].
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3. Aggregation Can, in Turn, Produce Oxidative Stress, or Protect Against Oxidative Insults
3.1. Pro-Oxidative Effects
As noticed previously, the yeast peroxiredoxin Tsa1 acts both as a chaperone and an ROS scavenger.
The proline analogue azetidine-2-carboxylic acid (AZC) induces aggregation in yeast cells, and yeast
mutants lacking TSA1 are highly sensitive to AZC-induced misfolding. The toxicity of AZC is actually
related to ROS accumulation, as decreasing ROS levels prevents sensitivity to AZC. Interestingly,
inhibiting nascent protein synthesis with cycloheximide rescues the tsa1 mutant sensitivity to AZC,
confirming that aggregation in this case causes ROS production [47].
ROS production due to mitochondrial dysfunction was often found to be associated with protein
aggregation, as in the case of Huntington’s [88,89] or Alzheimer’s disease [90]. Alpha–synuclein
aggregation is a hallmark of Parkinson’s disease, as previously explained, and is known to influence
mitochondrial morphology, interrupting ER–mitochondria communication [108–110] and modulating
mitochondrial fragmentation [111], even though the molecular determinants of these changes are
not very clear. The preferential binding of pathological alpha–synuclein aggregates to mitochondria
was recently identified in neurons [91], and this process was accompanied by cellular respiration
defects, suggesting mitochondrial dysfunction and leading to the hypothesis of a direct mitochondrial
impairment by alpha-synuclein aggregates, inducing ROS production.
RNA aptamers are synthetic nontoxic and non-immunogenic RNA oligonucleotides able to bind
a specific target and can thus be used as therapeutic weapons. For instance, specific RNA aptamers
can efficiently inhibit aggregation of mutant huntingtin, with a pathogenic polyglutamine stretch, by
stabilizing the monomer both in vitro and in cellulo. Oxidative stress is a hallmark of Huntington’s
disease and has been shown to occur in cells exposed to mutant huntingtin aggregates. Whether it is
a cause or a consequence of the disease is not yet clear. However, it is interesting to note that RNA
aptamers inhibiting mutant huntingtin’s aggregation lead to reduced oxidative stress levels in cellular
models [92]. The authors smartly engineered cells expressing RNA aptamers under the control of an
oxidative stress-inducible promoter. A nine-fold increase in aptamer expression occurred in mutant
huntingtin-expressing cells, which consequently reduced mutant huntingtin aggregation in these cells.
As a consequence, oxidative stress levels were also reduced, so RNA aptamer expression was also,
in turn, reduced [93]. This smart design unambiguously demonstrates that protein aggregation is
responsible for intracellular oxidative stress production in this context. Accordingly, mitochondrial
dysfunction was also reduced using this particular experimental design, indicating that ROS production
is likely related to mitochondrial impairment [93].
Human Amylin (hA) is a 4 kDa pancreatic hormone, synthesized and secreted along with
insulin by islet beta cells. Like other amyloid proteins, it is prone to aggregation and remains a
hallmark of type-2 diabetes mellitus [96]. Previous studies indicated that either exposure of beta
cells to hA or hA-overexpression in cells results in intracellular ROS accumulation, supporting the
hypothesis that hA aggregation might be a cause of oxidative stress [94], possibly through mitochondrial
dysfunction [95]. Recent work identified that a misfolded amylin actually activates an upstream
apoptosis signal regulating kinase-1 (ASK1), with a concomitant decrease in the intracellular levels of
reduced glutathione [96]. Moreover, the pro-oxidative activity and expression of a plasma membrane
bound NADPH oxidase (NOX) and its regulatory subunits were stimulated, suggesting that NOX1
and ASK1 mediate the cytotoxic effect of aggregated hA in pancreatic beta-cells [96]. Interestingly,
NOX had also been previously identified as a main ROS producer in cultured neurons exposed to
amyloid-β peptides [97,98].
Stabilizing α-synuclein monomers also proved to decrease the growth of misfolded cytotoxic
aggregates and consequently reduced oxidative damage to the cells by limiting the binding of aggregates
to the cell membrane [99]. Thus, a membrane’s structure seems to play an important role in oxidative
stress production in response to protein aggregation, possibly involving membrane bound oxidases for
ROS production, as a consequence of aggregates binding to the membrane.
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3.2. Anti-Oxidative Effects
Even though the role of aggregates in ROS production was unambiguously demonstrated
through obvious examples, other findings describe how aggregates can also “buffer” oxidative
effects. Surprisingly, 40-aminoacids, as well as 28-aminoacids amyloid-β peptides (Aβ1–40 or Aβ1–28),
either soluble or aggregated, revealed potent anti-oxidant activity in cell-free systems, despite their
accumulation and aggregation being a hallmark of Alzheimer’s disease, which is also characterized by
chronic oxidative stress [100,101]. The authors suggest that peptides might first chelate metal ions,
including Zn(II), Cu(II), and Fe(II), as previously suggested by other authors [102–104], which would
inhibit Fenton’s reaction, and then scavenge radicals by oxidation of His and Tyr residues [100,101].
Whether a peptide with similar His and Tyr residue content are also capable of “buffering” free radicals
would be worth testing. A more recent study reported similar anti-oxidant activity of amyloid-β
aggregates. Overexpression of 21 variants of the amyloid-β 42 peptide fused with GFP in yeast
(covering a broad range of intrinsic aggregation propensities) led to various levels of intrinsic oxidative
stress production [105]. A striking correlation was observed—the more aggregation-prone the mutated
GFP-Abeta is, the less oxidative stress is produced, suggesting that large insoluble aggregates might
act to limit cellular oxidative stress. An aggregation propensity threshold could be defined, above
which proteins with a high aggregation propensity accumulate into foci. The authors then suggested
that protein foci formation is an active ATP-dependent process, which might serve as a protective
mechanism against oxidative stress damage, despite its high energetic price [106].
Similarly, it is noteable that [PSI+] formation has been reported as protective against oxidative stress,
as antioxidant enzyme-lacking yeasts become more sensitive to H2O2 when [PSI+] is eliminated [107].
Finally, Carija et al. propose that different kinds of aggregates have different effects on ROS levels,
as small particles called “diffuse” aggregates are associated with increased intracellular oxidative
stress, whereas larger protein inclusions are not [105]. Similar conclusions were previously reached,
that hydrogen peroxide is generated during the early stages of protein aggregation in the course of
Alzheimer’s disease pathogenesis, possibly by an early form of protein aggregation, in the absence of a
mature amyloid fibril [112].
4. Aggregation and Oxidation can be Parts of a Vicious Circle
In about 12% of familiar and 1.5% of sporadic cases of ALS, mutations in the superoxide dismutase
1 (SOD1), a major player in ROS detoxification, are found. The misfolding and aggregating of SOD1
are considered a hallmark of the disease [113]. A mutated version of SOD1 named SOD1A4V is
particularly aggregation-prone. Its expression is associated with a profound disturbance of free
ubiquitin distribution within the cells, and with UPS dysfunction. These data suggest that protein
aggregation, per se, might cause UPS disturbance and participate in a vicious circle that eventually
prevents the elimination of aggregates [114]. Because SOD1 is a major player in ROS detoxification,
and its absence is responsible for increased oxidative stress, the latter being suggested to play a key
role in ALS progression [115,116], it is a possibility that oxidative stress plays a role in UPS disturbance
in this particular case. Both would participate a vicious circle involving SOD1 aggregation and
oxidative stress.
In light of the mechanistic insights described previously, multifunctional modulators that are
able to chelate metals and prevent ROS generation and protein aggregation have been designed for
several years, in an attempt to develop new therapeutic tools [117,118]. TGR86 is composed of both the
metal chelating clioquinol and the antioxidant, epigallocatechin gallate [119]. TGR86 was shown to be
capable of both interacting with amyloid-β and efficiently modulating its aggregation and complexing
with Cu(II), as well as preventing ROS generation. Another bifunctional molecule, composed of a
nitroxide spin label linked to an amyloidophilic fluorine (spin-labeled fluorine, SLF), was recently
developed [120]. Using super-resolution confocal microscopy imaging, the authors identified that
assembling those two modules within SLF creates a synergistic effect in cultured neurons, preventing
the intracellular accumulation of amyloid-β on the one hand, together with the reduction and the
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scavenging of amyloid-β-induced ROS on the other. Further studies are now needed to evaluate the
therapeutic potential of these molecules in Alzheimer’s disease.
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Abstract: Sarcopenia is characterized by the progressive loss of skeletal muscle mass and strength. In
older people, malnutrition and physical inactivity are often associated with sarcopenia, and, therefore,
dietary interventions and exercise must be considered to prevent, delay, or treat it. Among the
pathophysiological mechanisms leading to sarcopenia, a key role is played by an increase in reactive
oxygen and nitrogen species (ROS/RNS) levels and a decrease in enzymatic antioxidant protection
leading to oxidative stress. Many studies have evaluated, in addition to the effects of exercise, the
effects of antioxidant dietary supplements in limiting age-related muscle mass and performance, but
the data which have been reported are conflicting. In skeletal muscle, ROS/RNS have a dual function:
at low levels they increase muscle force and adaptation to exercise, while at high levels they lead to a
decline of muscle performance. Controversial results obtained with antioxidant supplementation in
older persons could in part reflect the lack of univocal effects of ROS on muscle mass and function.
The purpose of this review is to examine the molecular mechanisms underlying the dual effects of ROS
in skeletal muscle function and the analysis of literature data on dietary antioxidant supplementation
associated with exercise in normal and sarcopenic subjects.
Keywords: sarcopenia; reactive oxygen species; redox signaling; antioxidant supplementation; exercise
1. Age-Related Sarcopenia
Aging is characterized by a progressive decline in muscle mass and strength. In 1988 Irwin
Rosenberg proposed the term sarcopenia (from the Greek “sarx” = flesh and “penia” = loss) to describe
muscle size decrease that occurs in the elderly [1].
Roubenoff tried to differentiate sarcopenia from other processes leading to muscle mass loss, such
as wasting and cachexia [2]. Wasting was considered an unintentional weight loss, including loss
of both fat and lean body mass, due to inadequate caloric intake. Cachexia, on the other hand, was
defined as “the loss of fat free mass with no significant weight loss“ as a result of hypermetabolism and
hypercatabolism mediated by cytokines. Conversely, sarcopenia was regarded as a process that could
take place even without malnutrition or disease and in this sense could be considered a natural process
in aging. The currently most used definition in clinical practice and diagnostic criteria consensus
for age-related sarcopenia has been developed by the European Working Group on Sarcopenia in
Older People (EWGSOP) [3], which claims that a subject with low muscle strength and low muscle
mass or quality must be diagnosed with sarcopenia. Hence, sarcopenia can occur either acutely or
chronically. Diagnosis of sarcopenia relies on combined measurement of (1) muscle mass, which is
assessed for example by dual energy X-ray absorptiometry (DXA) or bioelectrical impedance analysis
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Int. J. Mol. Sci. 2019, 20, 3815
(BIA); (2) muscle strength, assessed by functional tests like grip strength; and (3) physical performance,
including assessment of mobility, strength, and balance [4].
Sarcopenia can be considered a multifactorial event which is characterized by inflammation,
oxidative stress, motor neuron loss, and changing of endocrine function [5]. Loss of strength and
mobility, together with balance disorders induced by sarcopenia, increase the rate of falls and fractures
in old age, leading to immobilization, which in turn contributes to worsening of sarcopenia. In addition,
old age is often associated with appetite loss, protein-energy malnutrition, and weight loss, which
concur with sarcopenia. Therefore, an adequate nutrient intake is recommended in sarcopenic patients
to preserve muscle mass. Often physical inactivity and malnutrition reinforce each other; indeed,
reduced mobility leads to a decline in nutrition capability, worsening malnutrition and sarcopenia.
However, all these factors contribute to skeletal muscle atrophy and weakness, accompanied by
disability increase, frailty, and life quality impairment [5].
Several studies have focused on the pathophysiology of age-related sarcopenia; nonetheless, the
biological mechanisms underlying decline in muscle strength and mass with age are not completely
understood. Loss in muscle mass and impairment of muscle force has been associated with the
disruption of excitation–contraction coupling. In single human skeletal myocytes obtained by needle
biopsy of the vastus lateralis, a significant reduction of dihydropyridine (DHP)-sensitive Ca2+ currents
have been recorded in fibers from old people compared to those in young people. Moreover, a reduced
peak of Ca2+ transient and a decrease in the voltage-/Ca2+-dependent Ca2+ release ratio has been
registered in old fibers compared to young ones, suggesting that the decrease of Ca2+ available for
mechanical responses in aged skeletal muscle is due to DHP receptor (DHPR)-ryanodine receptor
(RyR) uncoupling [6]. Similar results have been obtained in experiments conducted in mice [7].
Age-associated muscle mass and strength decline may also be explained by motor unit remodeling,
which has been observed in old mice, in which denervated muscle fibers are reinnervated by axonal
sprouting of adjacent motor units [8]. Moreover, fibers from aged rats contract more slowly than those
from young rats; in an in vitro motility assay with isolated soleus muscle fibers an age-related alteration
in myosin with a decrease of the maximum shortening velocity has been evidenced [9]. A replacement
of muscle mass by fat and connective tissue with aging results in a gradual decrease of muscle
size/volume. Moreover, muscle biopsies from old and young subjects have shown that number and size
of muscle fibers, mainly of type II (fast-twitch) are reduced in the elderly [10]. Indeed, a loss of muscle
mass explains only in part muscle decline, and other possible mechanisms are related to alterations
in muscle fiber quality and changes in fiber type [11]. It has been also hypothesized that a reduction
and/or dysregulation of satellite cells involved in skeletal muscle regeneration may contribute to the
loss of skeletal muscle mass observed in aging [12]. Among the mechanisms underlying sarcopenia, an
emerging role is being played by endoplasmic reticulum (ER) stress due to accumulation of unfolded
or misfolded proteins within the ER and its adaptive responses involving reactive oxygen species
(ROS) signaling [13]. Finally, recent studies on the role of gut microbiota in inflammatory diseases
indicate a relevant contribution of gut microbial changes and activity that occur with aging to the types
of inflammatory molecules present in the environment surrounding muscles [14].
The molecular mechanisms leading to sarcopenia are complex and have not been completely
clarified. Redox signaling and oxidative damage are among the most accepted mechanisms underlying
the decline of muscle mass and strength with aging and they will therefore be discussed in more detail
in separate sections of this review.
2. Endogenous Sources of Reactive Oxygen Species and Antioxidant Systems
ROS are generated through various pathways; one of the main sites of ROS production is the
mitochondrial electron transport chain, where the transfer of a single electron to molecular oxygen
gives rise to a monovalent reduction of oxygen, which leads to the formation of superoxide ions.
The superoxide production can also occur enzymatically through NADPH oxidase enzymes or the
xanthine/xanthine oxidase system. NADPH oxidase was discovered first in phagocytes, where it
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generates high levels of superoxide as a microbicidal mechanism in host defense [15]. NADPH oxidase
is an enzymatic complex consisting of various cytosolic units (p40-, p47-, and p67phox), and the
membrane-anchored components p22phox and cytochrome b558 (gp91phox); the latter is the site of the
catalytic activity of the complex. The activation of the complex also requires the involvement of small
GTP binding proteins Rap1A and Rac. In mammalians there are seven genes encoding distinct catalytic
subunits, namely, NOXs 1-5 and DUOX1-2 [16]. Xanthine oxidase enzyme catalyzes the hydroxylation
of hypoxanthine to xanthine and xanthine to uric acid. In both steps, molecular oxygen is reduced,
forming the superoxide anion [17].
Among the antioxidant enzymes, superoxide dismutases are responsible for the dismutation of
O2− in molecular oxygen and hydrogen peroxide [18,19], which is converted into water by catalase or
glutathione-peroxidase. There are three SOD isoenzymes, namely, the cytosolic dimeric Cu,Zn SOD
(SOD1) [20], the mitochondrial manganese-containing SOD (MnSOD or SOD2) [21], and the tetrameric
extracellular CuZn SOD (EcSOD or SOD3) [22].
In the reaction catalyzed by glutathione-peroxidase, glutathione is oxidized to glutathione
disulfate, which can be converted to glutathione by glutathione reductase in a “NADPH-consuming”
process (NADPH→ NADP+) [23]. Catalase is a high molecular weight tetrameric enzyme containing
porphyrin in the active site [24]. In the presence of transition metal ions (e.g., Fe2+\3+, Cu+\2+),
hydrogen peroxide produces the highly reactive oxygen species hydroxyl radical (OH.) and hydroxyl
ion (OH−) according to the Fenton reaction [25].
Endoplasmic reticulum (ER) is involved in the control of the redox state of the cells as well [26].
The accumulation of unfolded or misfolded proteins within the ER leads to ER stress and to the
activation of the signaling pathways of the unfolded protein response (UPR) as adaptive response.
Aiming to re-establish ER proteostasis, the UPR pathway reduces ER protein load and enhances ER
quality control and autophagy. The adaptive response of the UPR pathway induces antioxidant gene
transcription through the activation of nuclear factor E2-related factor 2 (Nrf 2). However, the UPR
pathway can even enhance ROS production; indeed, the increased protein folding during ER stress
causes the peroxide levels to rise through the pancreatic ER kinase (PERK)/C/EBP homologous protein
(CHOP) pathway, thus enhancing the expression of Ero1, encoding for an ER peroxidase. This pathway
leads to oxidative stress, and, eventually, apoptosis [27].
The levels of ROS/reactive nitrogen species (RNS) inside the cells are strictly controlled by the
balance between the rate of synthesis by ROS/RNS generating systems and the rate of removal through
the non-enzymatic and enzymatic antioxidant systems. An accurate control of ROS levels guarantees
the maintenance of physiological levels of ROS necessary for cell functions. Excessive ROS/RNS
production or the impairment of antioxidant status may disturb the cellular redox balance, inducing
oxidative stress in cells or tissues.
3. The Role of Reactive and Nitrogen Species in Muscle Functions
Many studies suggest that high levels of free radicals can damage biological molecules while
low levels play physiological roles such as regulation of cell signaling [28–36]. ROS, including mainly
superoxide anions and hydrogen peroxide and hydroxyl radicals, are continuously produced by muscle
cells in resting condition, and their levels increase during contraction modulating force production [37].
However, while at low levels a ROS increase produces an enhancement in the development of muscle
force up to a maximum peak, a further ROS increase induces a dramatic decline in the force [38].
Moreover, intense and prolonged exercise has often been associated with increase of ROS production
and oxidative damage to cellular constituents.
ROS are produced in muscle cells by various sources in different cell compartments. Mitochondria
are an important site of ROS production, and during exercise, ROS increases due to high oxygen
consumption by increased mitochondrial activity [39,40]. Another source of ROS in skeletal muscle is
NOX enzymes [41]. NOX1, NOX2, and NOX4 are three NOX isoforms expressed in skeletal muscle [42].
NOXs are located in the sarcoplasmic reticulum (SR), transverse tubule, and plasma membrane; in
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particular, the superoxide anion generated by NOX2 in the SR can stimulate the correct release of
calcium from intracellular stores through the oxidation of RyR1 [43]. Thus, this enzyme plays an
important functional role in excitation contraction coupling. Although mitochondria have long been
considered the principal site of muscle ROS production [35], much evidence suggests that NOXs are
the main source of ROS induced by skeletal muscle contractions. Indeed, during contractions, the
increase in cytosolic ROS comes first and is greater than the rise in mitochondrial ROS [44].
ROS-mediated ROS release due to crosstalk between NOXs and mitochondria has been described
for different cells. The uncoupling of electron transfer can result from oxidation of mitochondrial
electron transfer chain complexes [45]. Moreover, NOX-derived ROS can induce mitochondrial ROS
production through the opening of mitochondrial ATP-sensitive K+ channels (mito-KATP) [46] and
consequent potassium influx into the matrix that reduces the mitochondrial membrane potential,
opening permeability transition pores. Another mechanism that can explain the crosstalk between
NOXs and mitochondrial ROS production is the rise of intracellular Ca2+ levels by NOX-derived ROS,
which, increasing mitochondrial Ca2+ load, induce ROS production by these organelles [47]. The
existence of NOX-mitochondria redox crosstalk has also been demonstrated insmooth and cardiac
muscle cells. Although there is no direct evidence of the existence of ROS-mediated ROS release in
skeletal muscle cells, it is plausible that these mechanisms are also active in these cell types.
Another striking example of ROS-mediated ROS release is the crosstalk between ER and
mitochondria. ER oxidative stress can be transmitted to mitochondria through Ca++ influx. Across
mitochondrial-associated ER membranes (MAMs), Ca++ ions and other metabolites are transferred to
mitochondria, leading to the opening of permeability transition pores and increased mitochondrial
ROS levels [26].
RNS as well as ROS may be messenger molecules that activate muscle adaptive responses through
the induction of redox-sensitive signaling to maintain cellular oxidant-antioxidant homeostasis during
exercise. RNS arise from several sources and the levels increase with contractile activity. Nitric oxide
(NO) is formed from L-arginine in a reaction catalyzed by the nitric oxide synthase (NOS) enzyme.
In skeletal muscle there are all the different isoforms of this enzyme: nNOS, eNOS, and iNOS. A
calmodulin (CaM)-binding domain is present in nNOS and eNOS, and, therefore, these Ca2+sensitive
isoforms are responsive to contractile activity [48]. Moreover, NO generated by NOSs readily reacts
with superoxide to form peroxynitrite (NO+ O2−/ONOO−), which decreases the bioavailability of NO
and superoxide, modifying the redox balance in the myocyte [49].
Regular physical exercise modulates ROS in a bell-shaped hormesis curve due to the activation
by ROS of adaptive response resulting in increasing activity of repair enzymes and low degree of
oxidative stress [50]. Overall, it seems that with the exception of high intensity and long duration
exercise, physical activity cannot result in harmful oxidative damage.
4. ROS-Mediated Mechanisms in the Development of Age-Related Sarcopenia
Cumulative damage to skeletal muscle and nerve cells in sarcopenia may result from oxidative
stress. Oxidative stress causes damage in many tissues, including the loss of muscle mass and strength,
which is associated with impairment of neurotransmitter release and neuronal degeneration.
Sarcopenia could be caused by an increase of endogenous ROS formation in skeletal muscle
but the source of ROS in sarcopenic muscle is still relatively unknown; however, an age-associated
increase of ROS levels in muscle mass, as a consequence of an upregulation of NOX2 enzyme, has been
reported [51]. Moreover, a study by Sullivan-Gunn and Lewandowski [52] has highlighted the role
of NOX2 enzyme in a healthy mouse model of aging, suggesting that elevated levels of H2O2 from
NOX2, as well as the lack of antioxidant protection from catalase and glutathione peroxidase (GPx),
carry out a key role in the onset of sarcopenia. The lack of SOD1 also causes a reduction of skeletal
muscle mass, impairment of neurotransmitter release, and neuronal degeneration in mice [53].
O2− radicals induce neuromuscular degeneration and mitochondrial dysfunction in SOD1-deficient
mice [54]; moreover, the reduction of cellular antioxidant capacity by disruption of the SOD1 gene in
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mice (Sod1−/−) causes severe oxidative stress and oxidative damage associated with an acceleration of
age-related loss of skeletal muscle mass accompanied by neuromuscular junction (NMJ) morphologic
changes, increased denervation, and an elevated production of superoxide and hydrogen peroxide by
muscle mitochondria [54]. Elevated ROS have been shown to interfere with synaptic vesicle axonal
transport and formation of new vesicles in the trans-Golgi network [55]. This, in turn, may lead to the
accumulation of fewer synaptic vesicles at NMJs, resulting in reduced neurotransmitter release [56]. In
addition, Sod1 gene ablation in adult mice causes physiological changes at the NMJ, similar to that
occurring in old wild types [57]. Moreover, the increase of cytosolic oxidative stress caused either by
the deletion of SOD1 (Sod1−/− mice) or by introduction of mutations of SOD1, (e.g., the SOD1G93A
amyotrophic lateral sclerosis mutant mouse model) increases ROS levels, causing muscle atrophy and
weakness in mice which are phenotypically similar to muscle changes observed in older animals [54,58].
The use of SOD1G93A and other SOD1 mutant models to decipher the mechanistic aspects of
oxidative stress in muscle atrophy could be confounded by the toxic gain of function that results in
the formation of SOD1 protein aggregates [59]. Indeed, recently, it has been shown that a gain of
function of the mutated SOD1G93A could be associated with an increase of oxidative stress, intracellular
calcium concentration, and proapoptotic effect in both human neuroblastoma SK-N-BE and mouse
motor-neuron-like NSC-34 cells. These effects are carried out through an activation of extracellular
signal regulated kinases (ERK) 1–2, serine threonine kinase (Akt), and intracellular calcium levels
mediated by the activation of muscarinic M1 receptor [28]. Systemic administration of endogenous
nitric oxide donor S-nitrosoglutathione enhances extracellular SOD3 expression and the antioxidant
activity protecting structural and functional integrity of skeletal muscle [60]. However, it is noteworthy
to underline that SOD1 is secreted as well [61], and, therefore, the elevated extracellular oxygen radical,
associated with sarcopenia, could also be scavenged by cytosolic SOD1.
ER stress and UPR response also play an important role in age-related sarcopenia [13]. ER stress
can directly impact muscle mass since sustained ER stress leads to cell death of muscle cells [62], which
is mediated by increased ER ROS. ER stress can also inhibit rapamycin complex 1 (mTORC 1) that
mediates the response to anabolic stimulus of nutrients and contractile activity, thus inducing anabolic
resistance and reduced regenerative potential of skeletal muscle observed during aging. Moreover,
it has been shown that in the chronic kidney disease uremic toxin-accumulated sarcopenia model,
ER stress and UPR pathways account for the inhibition of myoblast differentiation and myotubular
atrophy induction through the activation of a ROS-eIF2α axis [63].
Aging is also characterized by mitochondrial dysfunction in skeletal muscle with accumulation of
mitochondrial damage and oxidative stress [64]. Mitochondrial dynamics are controlled by fusion
and fission proteins. Mitofusin 1 and 2 (Mnf 1 and 2) are involved in the outer mitochondrial
membrane fusion while optic atrophy 1 (OPA1) mediates fusion of the inner mitochondrial membrane.
Aging is associated with a progressive reduction in Mnf2, and Mfn2 deficiency in mouse skeletal
muscle reduces mitophagy, leading to the accumulation of damaged mitochondria [65]. On the
other hand, OPA1, which is also a sensor of physical activity, is downregulated during aging-related
sarcopenia. Interestingly, in adult mice, acute, muscle-specific deletion of OPA1 leads to ER stress,
which through UPR pathways, ROS, and FoxOs induces a catabolic program, muscle loss, and systemic
inflammation [66].
In conclusion, age-related ROS overproduction generates oxidative damage of muscle but
it also plays a role in regulating intracellular signal transduction pathways that are directly or
indirectly involved in skeletal muscle atrophy, motoneuronal degeneration, and impairment of
muscle contractility.
5. Redox Signaling in Exercise Adaptation in Age-Related Sarcopenia
Muscle has meaningful plastic properties. Indeed, regular physical exercise ameliorates skeletal
muscle performance along with other multiple body functions. During exercise the great oxygen flux
required for ATP production leads to ROS generation at different rates and from different sources
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depending on type, intensity, and duration of exercise. ROS generated during exercise regulate signal
transduction pathways responsible for muscle remodeling and for the adaptive response necessary to
limit oxidative stress.
Nuclear factor (NF) κB, mitogen-activated protein kinases (MAPKs), and peroxisome
proliferator-activated receptor γ co-activator 1 α (PGC1α) are among the main redox-sensitive
pathways activated during muscle activity involved in the adaptive response to oxidative stress [67].
NFκB, induced by hydrogen peroxide and pro-inflammatory cytokines, increases the expression
of proteins and enzymes that require consensus binding of κB, including SOD2, glutamyl-cysteine
synthetase (GCS), iNOS, and cyclooxygenase 2 (COX2), among others [68].
MAPK pathways, comprising c-Jun N-terminal kinases (JNK), ERK 1–2, and p38 MAPK, are
activated by a variety of physiological events associated with exercise like ROS, hormones, calcium
influx, and neural or mechanical stimuli [69]. Through p38 MAPK activation/phosphorylation, ROS
increases glucose uptake by muscle cells during exercise [70].
PGC1α plays a pivotal role in the regulation of mitochondria biogenesis, antioxidant enzyme
expression, and regulation of anti-inflammatory cytokine expression [67]. Moreover, PGC1α promotes
mitochondrial oxidative metabolism [71] and plays a role in fiber-type specificity inducing slow
phenotype specification [72]. PGC1α is regulated at transcriptional and post-transcriptional levels
by pathways activated during muscle contraction like AMP-activated protein kinase (AMPK), sirtuin
1 (SIRT1), protein kinase C, changes in intracellular Ca2+ concentration, p38 MAPK, NO, ROS, and
hypoxia-inducible factor-1 (HIF-1) [73]. An important anabolic pathway inducing protein synthesis
involves activation of the phosphatidylinositol 3-kinase (PI3K)/Akt, which stimulates mammalian target
of rapamycin (mTOR), which is essential for muscle growth during development and regeneration;
this pathway has a role also in the regulation of muscle mass which strictly depends on protein
synthesis [74]. In most cases, the effects of ROS on these signaling molecules differ in dependence of
the levels. For example, JNK phosphorylation levels depend on the relative activity of specific kinases
and phosphatases. Low levels of ROS induce JNK phosphorylation without affecting phosphatase,
leading to a transient activation of JNK, while higher ROS levels may activate the JNK pathway and
inactivate phosphatases, resulting in a prolonged activation of JNK [75]. In addition, ROS activate the
PI3K/Akt pathway, either by directly activating PI3K or inactivating phosphatase and tensin homolog
(PTEN) which inhibits the activation of Akt through cysteine residues oxidation [76]. At lower levels,
ROS also oxidize the disulfide bridges in Akt leading to a short-term activation of Akt signaling [77].
Muscle adaptation to different training conditions is associated with the activation of different
pathways. The main muscle adaptive response to non-exhaustive endurance training is mitochondria
biogenesis, which increases muscle oxidative capability [78]. The underlined mechanism relies on the
production of reactive oxygen species like ubisemiquinone, NO, superoxide, and H2O2 [79,80].
A key modulator of mitochondria biogenesis is PGC1α, which guarantees the balance between the
production and scavenging of reactive oxygen species by regulating both mitochondrial biogenesis and
the expression of antioxidant enzymes like SOD1, GPx, and catalase [81]. Unlike endurance training,
resistance training induces skeletal muscle hypertrophy. Indeed, resistance training is associated with
an increase in protein biosynthesis with respect to protein breakdown. ROS produced during resistance
exercise activate multiple pathways, including the insulin/IGF-1-IP3K, MAPKs, and Ca-calmodulin
pathways [82] involved in protein biosynthesis.
Finally, short-term anaerobic exercise, such as sprinting, is associated with high levels of ROS
and oxidative stress. During sprinting exercise, the main ROS sources are NOXs [83] and the
xanthine/xanthine oxidase system [84], while mitochondria play only a minor role. Additionally,
exhaustive endurance and resistance exercise are related to increased levels of skeletal muscle ROS,
oxidative stress, and cortisol, leading to transitory immunosuppression [85]. In the elderly, protein
anabolic pathways are reduced [86] while protein catabolic pathways are activated [87], contributing
to muscle atrophy. In particular, with aging a reduction in the mitochondrial protein synthesis rate in
muscle is correlated with a decrease in mitochondrial enzyme activity and oxidative capability [88]. In
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addition, a significant decline in mitochondria biogenesis, lower levels of testosterone, and a PGC1α,
Akt, and mTOR expression decrease contribute to the loss of muscle mass and strength, which are
hallmarks of sarcopenia [89,90]. Much evidence highlights the role of reactive oxygen species in
age-related neuromuscular deficit [91]. Impaired mitochondrial electron transport chain has been
involved in the increase of ROS levels in aged skeletal muscle [92]; moreover, in aging, skeletal muscles
produce higher levels of ROS during an acute bout of exercise, while chronic exercise has a protective
effect against oxidative damage [93]. In addition, physical inactivity increases the levels of oxidative
stress contributing to the onset of sarcopenia [94].
Much evidence highlights the positive role of exercise in elderly skeletal muscle. Elderly subjects
who regularly exercise show oxidative stress levels comparable to that of younger individuals who do
not perform physical activity [95].
Both redox-sensitive mitochondria biogenesis and PGC1α levels are increased by exercise training
and increased expression of PGC1α in old mice is associated with high mitochondria biogenesis and
lower oxidative stress, inflammation, and apoptosis [89].
Overall, ROS/RNS signaling plays a pivotal role in skeletal muscle contractile function, hypertrophy,
mitochondrial biogenesis, and glucose uptake as an adaptive response to exercise. Increasing knowledge
of redox signaling involved in responses to exercise will lead to the development of new approaches
to regulate muscle metabolism and function to prevent loss of muscle mass and performance in
age-related diseases.
6. Dietary Intervention in Age-Related Sarcopenia
It is well known that old age is often associated with appetite loss, which contributes to decreased
food intake, protein-energy malnutrition, and weight loss. Therefore, it is important to evaluate
different dietary interventions to assure an adequate nutrient intake in sarcopenic patients to preserve
muscle mass.
In the elderly, muscle protein homeostasis is impaired because of a reduced synthesis and increased
rate of degradation. In addition, reduction in muscle mass is facilitated by physical inactivity and
decreased dietary protein intake [96]. Several authors suggest the consumption of good sources of
proteins low in fat, including lean meat, poultry, and fish, and high protein intake (1.2–1.4 g/Kg/die) [97]
for the treatment of sarcopenia. In vitro experiments, performed in cardiomyoblast cell lines, have
shown that serum from vegan subjects induces oxidative stress and cell death compared to vegetarian
and omnivorous sera [98], suggesting a mechanistic link between deficient protein intake, oxidative
stress, and loss of muscle mass.
The list of natural compounds with antioxidant activity is very long. However, we have focused
our attention on the most known nutritional antioxidants, including L-ascorbic acid (vitamin C),
tocopherols (vitamin E), carotenoids, flavonoids, and polyphenols [99–105], whose function on muscle
have been more extensively studied.
Vitamin C is the primary water-soluble and non-enzymatic antioxidant in plasma and tissues.
Humans, unlike most mammals and other animals, do not have the ability to synthesize vitamin C due
to lack of the last enzyme in the biosynthetic process, and it must therefore be obtained by dietary
intake. The principal sources of vitamin C are kiwifruit, strawberries, broccoli, kale, tomatoes, and
sweet red pepper [106]. Important enzymatic reactions requiring vitamin C as an essential cofactor are
the biosynthesis of collagen, carnitine, and neuropeptides, and the regulation of gene expression [107].
Cohort studies also indicate that higher vitamin C status, assessed by measuring circulating vitamin C
levels, is associated with lower risks of hypertension, coronary heart disease, and stroke [108]. This
vitamin is also involved in the regeneration of fat-soluble vitamin E [109], which is particularly able to
inhibit lipid peroxidation.
Naturally occurring vitamin E includes eight fat-soluble isoforms, but in the human body
α-tocopherol is the most common isoform. Plant seeds, especially sunflower seeds, almonds, and
hazelnuts are rich sources of α-tocopherol; moreover, many vegetable oils (e.g., olive oil and canola
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oil) and tomato, avocado, spinach, asparagus, Swiss chard, and broccoli also contain this vitamin.
α-tocopherol is uniquely suited to intercept peroxyl radicals and thus prevent lipid peroxidation and
the detrimental effects of free radicals in membranes and plasma lipoproteins [110]. α-tocopherol is
also likely to be involved in cell-mediated immunity [111,112]. In addition to its direct antioxidant
properties, vitamin E modulates signal transduction and gene expression in a redox-dependent and
redox-independent manner, regulating cellular functions relevant for its action and for preventing
a number of diseases, including cancer, atherosclerosis, inflammation, and neurodegenerative
diseases [113]. Carotenoids are another important type of dietary antioxidant which play a protective
role in many diseases. They are organic pigments present in fruits and vegetables like pumpkins,
carrots, corn, and tomatoes [114]. They have important antioxidant functions such as singlet oxygen
quenching and radical scavenging [115]. Recently, the benefits of carotenoids against oxidative stress
in human have been reviewed [116]. Some carotenoids like beta-carotene are dietary precursors
of the fat-soluble vitamin A, or retinol, with important antioxidant activity and liver protection
functions [117]. In addition, vitamin A is converted in retinoic acid and functions as a ligand, regulating
the expression of genes involved in cell metabolism [118]. Some evidence suggests that carotenoids
beside their antioxidant activity also exert signaling functions. Indeed, carotenoids or their metabolites
may up-regulate the expression of antioxidant or detoxifying enzymes via the activation of the
Nrf2-dependent pathway [119].
Polyphenols are phytochemicals with antioxidant properties which occur in vegetal food [105].
Quercetin, a natural flavonoid found mainly in nuts, grapes, onions, broccoli, apples, and black tea,
has shown important antioxidant activity and protective effects on the intestinal mucosal barrier [120],
as well as the ability to reduce inflammation by suppressing the expression of pro-inflammatory
mediators [121,122].
Resveratrol is a natural polyphenolic compound occurring in several plants and in food, including
in red wine, peanuts, blueberries, raspberries, and mulberries [123]. In preclinical studies, it has been
observed that resveratrol is important in the prevention and/or treatment of cancer, cardiovascular
disease, and neurodegenerative diseases [124]. Another biologically active polyphenolic compound
is curcumin, which is found in turmeric, a spice derived from the rhizomes of the plant Curcuma
longa Linn. Many preclinical studies show that curcumin modulates numerous molecular targets and
exerts antioxidant, anti-inflammatory, anticancer, and neuroprotective activities [125]. Furthermore,
curcumin is important to prevent and treat Type 2 diabetes mellitus disease [126]. The effects of
polyphenols cannot be explained solely on the basis of their antioxidant action; indeed, the health
benefits of these substances may rely on their effects on enzyme, membrane, or nuclear receptors and
intracellular transduction mechanisms [127]. Functions and sources of the main dietary antioxidants
are summarized in Table 1.
In the elderly there is an impairment of the endogenous antioxidant defense system [141] and
a decline of mitochondrial function associated with inadequate antioxidant dietary intake. Great
interest has been devoted to antioxidant supplementation as a potential intervention in sarcopenia [142]
since oxidative damage is considered to be one of the mechanisms leading to the loss of muscle mass
and function.
Studies conducted in animal models in which supplementation of diet with antioxidants and
physical activity have been combined in many cases seem to support the use of antioxidants to
ameliorate exercise performance. Resveratrol, which is able to promote mitochondrial adaptive
response and strength of upper limbs in mice after 12 weeks of treadmill exercise training suggests that
this natural antioxidant could be used as a performance enhancer [138]. Resveratrol also exerts beneficial
effects on muscle performance in animal models of aging. The dietary administration of resveratrol, in
combination with habitual exercise in mice, has been shown to improve mitochondrial function and
aging-related decline in physical performance [139]. In addition, curcumin supplementation ameliorates
exercise performance in rats increasing time of run to exhaustion compared to control animals [137].
On the contrary, vitamin A administration in exercise training rats has been shown to induce lipid
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peroxidation and protein damage, decrease SOD1 levels, and attenuated exercise-dependent increase
of SOD2 in the skeletal muscle [135].
Table 1. Functions and sources of principal nutritional antioxidants.






• Boosts antioxidant defense
• Protects cell membranes
• Enhances immune functions





• Principal hydrophilic antioxidant
• Scavenger of free radicals
• Enhances immune function








• Antioxidant activity and protective
effects on intestinal mucosal barrier
• Reduced exercise-induced
lipid peroxidation
• Reduced oxidative stress and
inflammatory biomarkers
Nuts, grapes, onions,
broccoli, apples, black tea [132–134]
Carotenoids
• Scavenger of free radicals and
singlet oxygen quenching
• Cancer prevention




• Scavenger of reactive oxygen species
(ROS) and reactive nitrogen species
• Neuroprotective activity




• Prevention of cancer and
cardiovascular disease
• Inhibition of neuroinflammation





However, the positive findings obtained in animals have not always been confirmed in human
trials. In young football athletes, antioxidant supplementation has been shown to not counteract muscle
damage or soreness induced by acute exercise and also to not ameliorate physical performance, although
it has been seen to reduce oxidative stress [128]. Moreover, even where a decrease of oxidative stress or
inflammatory markers and reduced onset of age-related pathophysiological disorders has been shown in
human subjects assuming quercetin supplementation accompanied by constant and moderate physical
exercise, an amelioration of muscle performance has not been clearly evidenced [132–134]. A recent
review by Beaudart et al. [143] summarizing the results of 37 randomized clinical trials in which exercise
and nutritional interventions, including the administration of natural antioxidants, were combined,
evidenced a beneficial effect of exercise on muscle mass and strength in subjects over 65 years, while
the effects of dietary antioxidant supplementation were more controversial. Moreover, importantly,
some studies have highlighted that prolonged antioxidant supplementation can lead to undesirable
effects like disruption of endogenous antioxidant levels, thus failing to counteract exercise-induced
oxidative stress, and interfering with muscle adaptation to exercise [144–146]. Moreover, long-term
administration of vitamin C has been observed to prevent mitochondrial biogenesis, decreasing the
expression of endogenous antioxidant enzymes [131].
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However, other literature data have suggested beneficial effects of antioxidant supplementation
in muscle performance in normal young adult and sarcopenic subjects. A study conducted in subjects
aged 65–80 years assuming resveratrol combined with 12 weeks of exercise has indicated a novel
anabolic role of resveratrol in exercise-induced adaptations of older persons, and this suggests that this
compound combined with exercise is likely to better counteract sarcopenia than exercise alone [140].
Moreover, the strongest evidence supporting the beneficial effects of antioxidant supplementation in
physical performance has been obtained with vitamin E alone and in combination with vitamin C.
Recently, He et al. [129] showed a decrease of markers of muscle damage, an amelioration of antioxidant
status, and a delayed onset of muscle soreness after repeated downhill runs in moderately-trained
males assuming vitamin C and E.
Several studies have reported the association between vitamin E and sarcopenia. In particular,
Cesari et al. [130], in their study “Invecchiare in Chianti”, showed that vitamin E daily intake level
positively correlated with knee extension strength and total physical performance. Moreover, it seems
that vitamin C, by regenerating vitamin E, is responsible for muscle protection [147]. Flavonoids have
many health benefits and improve exercise performance in athletes and in subjects not necessarily in
constant training, such as aged people [148]. Finally, sarcopenia has also been associated with low
levels of carotenoids even if further studies are necessary to better ascertain the existence of a direct
link between low carotenoids status and muscle decline [136].
Several reasons could underlie these contradictory results. The lack of beneficial effects of
antioxidants in sarcopenia could be due to the fact that supplemented antioxidants, which are
non-enzymatic antioxidants, may not be able to make up for the enzymatic antioxidant deficiency
that characterizes sarcopenia. It must also be considered that some antioxidant enzymes, such as
SOD1 [149] and SOD2 [150], are up-regulated by ROS and that the scavenging effects of antioxidants
could further down-regulate them, worsening muscle oxidative damage and performance.
Moreover, the dual role of ROS in muscle performance could explain the conflicting data obtained
with different nutritional protocols and exercise settings. Antioxidant treatment associated with
exercise could eliminate the adaptive response, and, therefore, it has been suggested that if antioxidants
are administered before exercise-induced ROS levels reach their peak they can prevent the physiological
function of ROS, while they can exert beneficial effects if administered after the bell-shaped curve of
ROS has reached its summit [50].
The search for the right association of antioxidant supplementation in sarcopenic subjects who
perform physical activity still has a long way to go. In experimental protocols considering the
contemporary administration of antioxidant supplementation and physical training in elderly subjects,
the type, strength, and duration of exercise, as well as the research design and the timing and extent of
favorable effects of ROS in muscle adaptation to exercise [151] must be carefully taken into account in
order to better clarify the issue.
7. Conclusions
Western societies are characterized by a progressive aging population which results in increasing
prevalence of sarcopenia with subsequent increasing healthcare costs. Aging is associated with skeletal
muscle oxidative stress due to increased ROS generation and impairment of antioxidant enzymes
systems. On the other hand, muscle disuse and malnutrition are often associated with aging and also
contribute to increased oxidative damage of skeletal muscle, leading to a decline in muscle mass and
strength (Figure 1). From this complex scenario, it is clear that both physical activity and nutritional
interventions must be contemplated for sarcopenic individuals.
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Figure 1. Aging, physical inactivity, and malnutrition lead to oxidative stress, contributing to sarcopenia.
Due to the central role played by oxidative stress in the onset of sarcopenia, a great effort has
been focused on the understanding of the underlined cellular and molecular mechanisms involving
ROS signaling in the attempt to identify the right strategies based on antioxidant supplementation for
prevention and treatment of this condition.
Unfortunately, despite the fact that redox mechanisms leading to muscle mass and strength loss
in sarcopenia have in part been unraveled, clinical data with antioxidant supplementation are far from
clear and as a result of these conflicting reports, antioxidant supplementation cannot yet be considered
as a nutritional intervention to prevent and treat sarcopenia. A more intense research effort must be
made to clarify the right association between diet and exercise effective to counteract the onset and
extent of age-related sarcopenia.
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Abstract: A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione
(GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism
for increased GSH levels is to counteract damaging ROS to sustain the viability and growth of the
malignancy. Here, we review the current knowledge about the three main RCC subtypes, namely
clear cell RCC (ccRCC), papillary RCC (pRCC), and chromophobe RCC (chRCC), at the genetic,
transcript, protein, and metabolite level and highlight their mutual influence on GSH metabolism.
A further discussion addresses the question of how the manipulation of GSH levels can be exploited
as a potential treatment strategy for RCC.
Keywords: Renal cell carcinoma (RCC); reactive oxygen species (ROS); glutathione (GSH) metabolism;
cancer therapy; clear cell RCC; papillary RCC; chromophobe RCC
1. Introduction
Increased reactive oxygen species (ROS) levels, including the superoxide anion, hydrogen peroxide,
and hydroxyl radical, have been reported in many different cancer types. ROS can be either generated
by genetic alterations and endogenous oxygen metabolism or by exogenous sources, such as UV light
and radiation. ROS were long thought to be only damaging byproducts of the cellular metabolism that
can negatively affect DNA, lipids, and proteins [1]. However, more recent studies have highlighted the
important role of ROS in cell signaling, homeostasis, metabolism, and apoptosis [1]. One common
characteristic of cancer is the ability to balance the increased level of oxidative stress with a high level of
antioxidants. Glutathione (GSH), a tripeptide thiol antioxidant composed of the amino acids glutamic
acid, cysteine, and glycine [2], is the main ROS scavenger in cells. GSH is highly reactive and exists in
both a reduced (GSH) and oxidized disulfide (GSSG) form [3]. The predominant form is in the reduced
state, which is the most abundant low molecular weight thiol in the cell, ranging from 0.5 to 10 mM in
most cell types, whereas extracellular GSH exists in concentrations lower by magnitudes [4]. The de
novo biosynthesis of GSH involves two ATP-dependent enzymatic reactions: The first step is catalyzed
by glutamate cysteine ligase (GCL), which ligates the amino group of cysteine to the γ-carboxylate of
glutamic acid to form the dipeptide γ-glutamyl cysteine. The second reaction involves GSH synthetase
(GSS), which catalyzes a combination of the cysteinyl carboxylate of the dipeptide and the amino group
of glycine to synthesize GSH [5] (outlined in Figure 1).
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Figure 1. Schematic overview of glutathione (GSH) metabolism and the targeting sites of inhibitors.
Color codes are defined as follows: black = enzymes or transporters; red =metabolites; blue = inhibitors.
GGT: γ-glutamyl transferase; xCT: solute carrier family 7 member 11, a cystine-glutamate antiporter;
GLS1: glutaminase 1; GCL: glutamate cysteine ligase; GSS: glutathione synthetase. GSSG: glutathione
oxidized form; ROS: reactive oxygen species.
Besides the classical role of GSH acting as an ROS scavenger by being prey for radicals, GSH
has several additional functions, including but not limited to providing a cysteine reservoir [6], being
involved in the maturation of iron–sulfur proteins [7], detoxifying xenobiotics [8], regulating protein
bioactivity by S-glutathionylation [9,10], and regulating redox signaling [11]. In cancer, GSH plays
the role of a double-edged sword in its initiation and progression. Moderate ROS levels are widely
recognized to trigger cancer initiation and progression by inducing mutations and promoting genome
instability, eventually activating oncogenic signaling pathways that promote cell survival, proliferation,
and stress resistance [12]. On the contrary, massive ROS accumulations can also limit cancer growth
by causing severe oxidative damage of biomolecules, which finally can lead to cell death [13]. As a
consequence, cancer cells are required to deliberately balance the levels of ROS and antioxidants (mainly
GSH) to maintain redox homeostasis, which sustains viability and growth. For many years, one of the
most obvious therapeutic strategies to overcome new balanced redox homeostasis in renal cell carcinoma
(RCC) was to fight elevated ROS levels with the supplementation of antioxidants such as vitamins to
actively force the tumor into apoptosis. Many clinical trials were initiated, and the outcomes showed
mixed results, including worse survival rates upon supplementation with ROS inhibitors [14].
In this review, we will focus on the role of the ROS scavenger GSH in RCC and discuss possible
strategies that can potentially exploit the manipulation of GSH levels for therapeutic strategies in RCC.
2. Renal Cell Carcinoma: An Overview
RCC represents approximately 4% of adult malignancies [15] and was ranked as the sixth deadliest
cancer worldwide in 2018 [16]. The American Cancer Society estimated that about 73,820 new RCC
cases would be diagnosed by the end of 2019 and more than 14,770 deaths would be caused by RCC
this year in the USA alone [15]. RCC can be classified according to distinct morphologic and molecular
genetic features and is composed of different subtypes, such as clear cell RCC (ccRCC), papillary RCC
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(pRCC), and chromophobe RCC (chRCC, Table 1). Many studies have been performed recently to
characterize RCC to better understand its classification and subclassification and to elucidate pathway
remodeling in these cancers [17–19]. A new classification concept based on molecular clustering of
chromosoms, DNA, RNA, miRNA, and protein data was proposed [18,20], where the organ of origin
does not fully determine the tumor type as the only factor [21]. Instead, the cancer classification should
be based on the similarity of molecular features across different tissue types, which was considered to
be more relevant for targeting the same mutations and oncogenic signaling pathways [21].
Here, we review the genetic foundation of the main RCC types and shed light on the sparse data
of transcriptome, proteome, and metabolome profiles performed in these malignancies.
Table 1. Summary of the three renal cell carcinoma (RCC) subtypes, incidences, main mutations, and
GSH regulation.
RCC Subtypes Clear Cell Papillary Chromophobe
Incidence 75% 15% 5%
Main mutations VHL MET, FH TP53, PTEN
Metabolites GSH, GSSG increased GSH, GSSG increased GSH, GSSG increased
GSH regulation
1. GCL protein abundance
increases;
2. Increased serum GGT as a
marker for metastatic ccRCC;
3. GLS1, glutamine importers,
and cysteine antiporter xCT
enhance to favor GSH synthesis;
4. Increased PPP flux to produce
NADPH for GSH conversion.
1. FH mutation causes HIF
stabilization;
2. FH mutation activates
NRF2–ARE pathway, leading
to increased GSH synthesis
and enhanced expression of
antioxidant proteins.
Loss of GGT1 increases
sensitivity to oxidative
stress in chRCC cells.
ccRCC: clear cell RCC; chRCC: chromophobe RCC; pRCC: papillary RCC; VHL: von Hippel-Lindau; MET:
proto-oncogene c-Met; FH: fumarate hydrotase; TP53: tumor antigen p53; PTEN: phosphatase and tensin homolog;
PPP: pentose phosphate pathway; HIF: hypoxia-inducible factor; NRF2: nuclear factor erythroid 2-related factor 2;
ARE: antioxidant response element; GGT1: γ-glutamyl transferase 1.
2.1. Clear Cell Renal Cell Carcinoma
Clear cell RCC is the most prevalent subtype and accounts for about 75% of all RCCs (Table 1) [22].
It is an aggressive cancer that originates from the proximal convoluted tubule, with a recurrence
rate of up to 40% after the initial treatment of a localized tumor [23]. In its metastatic form, it is
associated with a high mortality rate [24]. Clear cell RCC cells have, in general, a clear cytoplasm,
(which helped coin the name “clear cell”) that is circled by an easily distinguishable cell membrane and
uniform round nuclei [25]. About 90% of all ccRCCs carry mutations in the von Hippel-Lindau (VHL)
tumor suppressor gene [17,26], which was originally identified in a hereditary disease called VHL
syndrome [27]. The VHL protein is a target recruitment subunit in an E3 ubiquitin ligase complex and
recruits the hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions for subsequent
proteasomal degradation. Thereby, VHL can repress the transcription of more than 100 target genes
through interaction with HIF1α and HIF1AN, which plays a vital role in forming the phenotype of
ccRCC [28]. HIF1α is a master transcription factor that contributes substantially to the regulation of
gene expression that is dependent on oxygen levels. Under normoxic conditions, VHL interacts with
HIF1α and hydroxylates the proline residues in the oxygen-dependent degradation (ODD) domains of
HIF1α by recruiting members of the Egl-nine homolog (EGLN) family [28–30]. With hypoxia or loss
of function of VHL, these proline residues cannot be hydroxylated, which stabilizes HIF1α. HIF1α
subsequently forms a HIF1α–HIF1β heterodimer, and this dimer translocates into the nucleus to
enhance the transcription of HIF target genes, which are associated with crucial oncogenic pathways,
including glucose uptake, glycolysis (e.g., glucose transporter type 1, GLUT1), cell proliferation
(e.g., epidermal growth factor receptor, EGFR), and angiogenesis (vascular endothelial growth factor,
VEGF) [30–33].
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Furthermore, the gluconeogenic enzyme fructose 1,6-bisphosphatase 1 (FBP1) has been found to
be decreased in over 600 ccRCCs and has been associated with poor disease prognosis. FBP1 has two
distinct functions, antagonizing the glycolytic flux and inhibiting the nuclear function of HIFα [34],
which can explain its ubiquitous loss in ccRCC [34]. Besides FBP1, the whole gluconeogenesis pathway
has been shown to be severely diminished in ccRCC at the transcriptome [34] and proteome level [35].
This stimulates the metabolic switch by increasing glycolytic target genes [34], which is reflected by
the metabolomic analysis of ccRCC, where metabolites in the glycolysis pathway show over two-fold
increases in abundance compared to the normal kidney [36]. Furthermore, GSH metabolism-related
metabolites, including cysteine, γ-glutamyl cysteine, and GSH, have all been shown to increase in
late-stage ccRCC and are associated with worse survival outcomes in ccRCC patients [36].
2.2. Papillary Renal Cell Carcinoma
Papillary RCC represents about 15% of all RCCs (Table 1) and also derives from the proximal
convoluted tubule, similarly to ccRCC [22]. It is a less aggressive subtype compared to ccRCC and
has a high five-year survival rate of 80% to 85% [37]. The term “papillary” describes the papilla-like
protuberances in most of the tumors. It can be further subdivided into type I and type II tumors based
on morphological features. Type I pRCC is more common and shows small fibrovascular papillae
that are covered by a single layer of small cuboidal cells with scant pale cytoplasm and usually grows
slowly [38]. In contrast, type II pRCC consists of papillae, is lined by large columnar pseudostratified
cells with an eosinophilic cytoplasm, and is often more aggressive [38,39]. Type I and type II pRCC
have also been shown to be clinically and biologically distinct, as alterations in the MET pathway
were associated with type I [18,40]. The proto-oncogene c-Met (MET) protein, a transmembrane
receptor tyrosine kinase, can bind to its ligand hepatocyte growth factor (HGF) and activate several
downstream intracellular pathways, including focal adhesion kinase (FAK), RAS/RAF/MEK/ERK,
and PI3K/AKT [41]. The frequently activating mutations and amplification of MET in type I pRCC
enable the activation of MET/HGF signaling and its above-mentioned downstream pathways to
promote cancer cell proliferation, angiogenesis, and malignant transformation [41].
Frequent mutations in type II pRCC include CDKN2A silencing, SETD2 mutations, and TFE3 fusions.
Type II tumors are characterized by increased expression of the nuclear factor erythroid 2-related factor 2
(NRF2)–antioxidant response element (ARE) pathway [18]. The NRF2–ARE pathway is a major regulator
of cellular redox balance, and its activation under oxidative stress favors cell survival. Furthermore,
fumarate hydratase (FH) mutations are also frequently found in type II pRCC [42,43]. The FH gene
encodes a TCA cycle enzyme that catalyzes the hydration of fumarate to malate, and its deficiency causes
fumarate and succinate accumulation [44,45]. Accumulated fumarate and succinate are believed to be
able to suppress the hydroxylation of the proline residues in the ODD domain of HIFα, and thus FH
mutations in type II pRCC also cause the stabilization of HIFα, similarly to ccRCC [44,45]. Some genes
(such as CDKN2A/B and TERT) where mutations can be found in both types [40] play a pivotal role as
tumor suppressors by regulating the cell cycle. Mutations of the above-mentioned genes and activation
of the oncopathways are the main driver mutations in the progression of pRCC.
How do these genetic alterations in pRCC translate to the protein and metabolite level? Proteome
profiles of pRCC versus matching healthy tissues have indicated a tremendous reprogramming of main
metabolic pathways. Oxidative phosphorylation, the TCA cycle, branched-chain amino acids, cytochrome
P450 drug metabolism, peroxisomes, fatty acid metabolism, and several amino acid metabolism pathways
were significantly decreased in pRCC, whereas the spliceosome, the ribosome, and the cell cycle were
significantly increased [46]. A striking anticorrelation between the proteome and the transcriptome
data [18] was identified for oxidative phosphorylation. Transcripts of the respiratory chain were
significantly increased in pRCC, whereas the entire pathway was significantly decreased on the proteome
level. Most likely, the lower protein abundance of the respiratory chain was a consequence of the reduced
mitochondrial DNA (mtDNA) content in pRCC, as a similar association was observed in ρ0 cells [47].
ρ0 cells entirely lacking mtDNA, which encodes for 13 core respiratory chain subunits and consequently
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miss all of the respiratory chain complexes [47]. Furthermore, the discrepancy between the transcripts
and proteins of the respiratory chain in RCC can also originate from the regulation of post-translational
modifications. The metabolome indicated a tremendous increase of reduced and oxidized GSH levels in
pRCC tissues [46], as well as significantly increased rates of GSH de novo synthesis based on glutamine
consumption in the pRCC-derived cell lines Caki-2 and ACHN [46]. All of these alterations can in
principle serve as potential therapeutic targets. Specifically, a dysregulated respiratory chain can cause
electron leakage [48,49]. This, in turn, leads frequently to an increase in ROS stress [50,51], which is
subsequently compensated for by increased GSH levels in RCC and might serve as a main therapeutic
site to eradicate RCC, as discussed later on.
2.3. Chromophobe Renal Cell Carcinoma
Chromophobe RCC accounts for approximately 5% of all RCCs (Table 1) [22], is thought to
originate from the cortical collecting duct, and was first reported in 1985 [52]. Different morphological
and ultrastructural features of the cytoplasm lead to the identification of the classical chromophobe
and the eosinophilic variant. The cells of the classical type usually have abundant clear cytoplasm and
a perinuclear halo caused by cytoplasmic organelles being pushed away from the center to form a rim
along the cell membrane [53]. The eosinophilic type has, in general, smaller cells with an inconstant
level of cytoplasmic organelles in the periphery. Both cell types frequently coexist in chRCC tumors,
usually with one cell type predominating [53]. One of the most characteristic genetic features of chRCC
is the monosomy of chromosomes 1, 2, 6, 10, 13, 17, and often 21 [54–57]. The most commonly mutated
genes in chRCC are TP53 (32%), PTEN (20%), and gene fusions involving the TERT promoter [19,54].
Mutations in these tumor suppressors combined with the deletion of one of their chromosomes leads to
a complete loss of function. Further mutations with a lower frequency were observed in MTOR, NRAS,
TSC1, and TSC2, indicating that the genomic targeting of the mTOR pathway occurred in 23% of all
chRCC [19]. Hence, the anticancer functions of TP53 in apoptosis, genomic stability, and the inhibition
of angiogenesis and the role of PTEN in the intracellular signaling pathway PI3K/AKT/mTOR are both
disrupted and can thus be regarded as major driving events in chRCC tumorigenesis.
Proteome profiling has identified metabolic reprogramming in chRCC, including stalled
gluconeogenesis, downregulated oxidative phosphorylation, and fatty acid and amino acid metabolism [57].
A similar anticorrelation between transcripts and proteins (as in pRCC) was also identified in chRCC.
As chRCC has a significantly lower microvessel density and a lower glucose uptake rate compared
to ccRCC and pRCC [58,59], it seems that chRCC cells prefer a different way to acquire nutrients to
compensate for the nutrient-poor microenvironment. Chromophobe RCC cells can activate the endocytosis
and downstream lysosomal pathways to gain extracellular macromolecules as a nutrition source for cell
survival and proliferation, which is indicated by the abundance increase of proteins involved in these
pathways and their enzymatic activities [57]. Metabolome profiling in chRCC [57,60] and the closely
related but hardly distinguishable benign renal oncocytomas [61,62] has also elucidated a striking increase
of GSH and GSSG levels in kidney tumors, thus a hallmark in all RCCs.
In the next chapters, we will investigate the role of GSH metabolism in RCC progression and how
this adaption to increased ROS levels can be exploited therapeutically.
3. Rewired Glutathione Metabolism in RCC Is a Key Metabolic Alteration Involved in Tumor
Progression
3.1. γ-Glutamyl Cycle and ccRCC Progression
The γ-glutamyl cycle was originally proposed by Meister in 1970 and involves the de novo
biosynthesis and degradation of GSH [63]. Its main functions rely on the two enzymes GCL and GSS
for biosynthesis and γ-glutamyl transferases (GGTs) for degradation (Figure 1).
GCL is involved in the first step of de novo GSH synthesis, which catalyzes the reaction of
γ-glutamyl cysteine production. Other than substrate availability, GCL is the rate-limiting enzyme
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of GSH biosynthesis. It is composed of two different subunits: GCLC, the 73-kD catalytic subunit,
which contains the active site for catalyzing the reaction; and GCLM, the 31-kD modulatory subunit,
which interacts with GCLC to increase catalytic efficiency [64]. Under physiological conditions,
the activity of the GCLC/GCLM heterodimer can be regulated by a negative feedback loop by its
product GSH [5]. GCLC and GCLM were reported to have increased protein abundances, matching the
significantly increased enzymatic activity in the tumor tissues of ccRCC patients [34,65,66]. Validation
by siRNA-mediated silencing of GCLC led to a strong cell number reduction of ccRCC cell lines, which
was accompanied by significantly decreased GSH levels [66]. The direct inhibition of GSH synthesis
caused ferroptosis, a nonapoptotic form of cell death, in ccRCC cells [66]. These data support the
substantial role of GSH metabolism in ccRCC progression.
GGTs are membrane-bound, N-terminal nucleophile hydrolases that catalyze the breakdown of
extracellular GSH and transfer the γ-glutamyl group from GSH to produce the constituents glutamate
and cysteine, which can be further used for intracellular GSH synthesis (Figure 1) [67]. Increased
serum GGT was reported to be a sensitive marker for metastatic ccRCC [68], as GGT levels positively
correlated with advanced stages, higher grades, and the presence of tumor necrosis, and it was further
associated with worse survival rates in ccRCC patients [69].
3.2. Precursor Amino Acid Availability for GSH de novo Synthesis
Apart from the γ-glutamyl cycle, GSH de novo synthesis also relies on the availability of its three
composing amino acids—glutamate, cysteine, and glycine—and the activity of their corresponding
transporters, as summarized in Figure 2.
Figure 2. The availability of the precursor amino acids that influence GSH synthesis. Color codes are
defined as follows: black = enzymes or transporters; red = metabolites. SLC38A1/2: solute carrier
family 38 member 1 and 2, glutamine transporters; GLUD: glutamate dehydrogenase; SAM: S-adenosyl
methionine; SAH: S-adenosyl homocysteine.
One of the metabolic hallmarks of ccRCC is the addiction to glutamine. The malignancies, therefore,
require exogenous glutamine for growth and feature reprogrammed glutamine metabolism [70,71].
The availability of glutamine can directly or indirectly influence GSH de novo synthesis in three
different ways. First, glutamine can be converted to glutamate by two isozymes, glutaminase 1 and
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2 (GLS1 and GLS2). GLS1 is increased in many cancer types and is the main isoform within the
kidney [72]. Second, glutamine-related transporter transcripts are consistently increased in ccRCC
tumors, e.g., the glutamine importers SLC38A1 and SLC38A2 [73], to sustain glutaminolysis in ccRCC.
Interestingly, SLC38A1 expression is also regulated by MYC in K562 and HeLa cells: Considering
that MYC has been shown to be upregulated and that MYC pathway activation cooperates with VHL
loss to induce ccRCC [73–75], SLC38A1 probably plays an important role in the progression of ccRCC.
Third, glutamine can contribute to the de novo synthesis of GSH through the generation of NADPH via
glutamate dehydrogenase (GLUD) or malate regulation [76]. Overall, glutamine is of vital importance
to GSH de novo synthesis to modulate the oxidative stress level in ccRCC.
Cysteine, although a nonessential amino acid, plays an important role in protein synthesis by
forming intraprotein disulfide bonds to stabilize proteins. There are multiple cellular pathways and
transporters, which contribute to the availability of cysteine in cells. Aside from the γ-glutamyl cycle,
the trans-sulfuration pathway serves as an important source for cysteine recruitment, which has
been reported to be dysregulated in ccRCC [34,36]. Thereby, methionine is converted to S-adenosyl
methionine (SAM), is hydrolyzed to homocysteine, and can then enter the trans-sulfuration pathway,
where it gets converted into cystathionine, which forms cysteine in subsequent reactions [77].
Metabolome profiling of ccRCC tumors has identified elevated SAM, S-adenosyl homocysteine
(SAH), and homocysteine in ccRCC compared to healthy kidney tissues [34,36], indicating a high
demand for cysteine, which is synthesized through the trans-sulfuration pathway. Cystine, the oxidized
dimer of cysteine, can also be absorbed from the tumor microenvironment by xCT (SLC7A11), which is
a heterodimeric cystine–glutamate antiporter [78], where overexpression is associated with overall
poor survival in ccRCC [26].
3.3. Increased Flux of the Pentose Phosphate Pathway in ccRCC to Support GSH Synthesis
The pentose phosphate pathway (PPP) is, in part, a metabolic pathway parallel to glycolysis.
It generates NADPH and pentoses, including ribose 5-phosphate (R5P). Its primary role is considered
to be anabolic rather than catabolic, as it provides R5P, a precursor for the synthesis of nucleotides.
NADPH is an important cofactor for the enzyme GSH reductase (GR) to catalyze the reduction of
GSSG to GSH and hence links PPP directly to GSH synthesis. Therefore, high GSH/GSSG ratios in
ccRCC can also be explained by increased flux through PPP, which provides the necessary molecules of
NADPH for GSH conversion [26,34,79]. Indeed, glucose-6-phosphate dehydrogenase (G6PD), which
determines the production of NADPH and R5P within PPP, was found to be increased in ccRCC, and its
elevation was associated with higher levels of NADPH and PPP-derived metabolites [79]. Furthermore,
the inhibition of G6PD in chRCC cells decreased the NADPH level and increased ROS production to
significantly impair cancer cell survival, suggesting that PPP plays a fundamental role in the regulation
of redox homeostasis and progression in ccRCC [79]. Recently, fructose 1,6-bisphosphate (FBP), a
glycolytic intermediate, was found to be accumulated in ccRCC, leading to the suppression of NADPH
oxidase 4 (NOX4), which caused an increase in NADPH and a decrease in ROS, independent of
PPP [80]. These changes were caused by the downregulation of aldolase B (ALDOB), which portended
significantly worse survival in ccRCC patients [80].
3.4. Fumarate Hydratase Mutations and GSH in Type II pRCC
Fumarate hydratase (FH) is frequently mutated in type II pRCC, causing FH deficiency and
affecting the normal flux of the TCA cycle [42,43]. The FH deficiency of this tumor leads to metabolic
reprogramming, including impaired oxidative phosphorylation and aerobic glycolysis, known as
the “Warburg effect”, which is probably caused by the stabilization of HIF through fumarate
accumulation [44,45]. A further study showed that the accumulation of fumarate was fueled by
glutamine rather than glucose in type II pRCC cells [81]. Apart from causing HIF stabilization,
fumarate accumulation has been reported to activate NRF2 and its downstream ARE pathway [82,83].
Moreover, somatic mutations of NRF2 and its regulator Kelch-like ECH-associated protein 1 (KEAP1)
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have been reported to be highly correlated with poor prognosis in type II pRCC and pancreatic
cancer [82,84,85]. NRF2 plays an important role in cellular redox balance as a transcription factor
that regulates the expression of various genes to combat the harmful effects of extrinsic and intrinsic
damage, such as xenobiotics and oxidative stress. NRF2 is primarily regulated by KEAP1, a substrate
adapter protein of Cullin 3 (CUL3), which contains an E3 ubiquitin ligase activity. Under normal
conditions, NRF2 builds a complex with KEAP1 via its Kelch domain for ubiquitination, and NRF2 is
then targeted for subsequent proteasomal degradation [84,86,87]. However, in response to a diverse
array of stimuli, such as oxidative stress, the cysteine residues within KEAP1, Cys151, Cys273, and
Cys288 can be modified, which results in a conformational change along with the dissociation of
NRF2 to avoid KEAP1-mediated degradation [84,87]. Stabilized NRF2 can then translocate to the
nucleus and bind to ARE to activate the downstream effector genes of at least two pathways involved
in cytoprotection [84]. First, NRF2 can activate genes involved in regulating GSH synthesis and
metabolism by activating GCL [85], and second, NRF2 promotes the expression of genes coding for
antioxidant proteins, such as GSH peroxidases (GPXes) and GSH S-transferases (GSTs). GPX is an
enzyme family with peroxidase activity that protects cells from oxidative damage, and GSTs are
comprised of a family of isozymes that catalyze the conjugation of GSH to xenobiotic substrates for
detoxification [78,84]. Additionally, fumarate can directly bind to GPX1 through interaction with the
Thr143 and Asp144 residues, and fumarate accumulation is thus able to activate GPX1 and decrease
the ROS level in cells [88].
Apart from mutations in FH, NRF2, CUL3, or KEAP1 in type II pRCC, several other mechanisms
can also lead to increased NRF2 activity in other cancers, including epigenetic silencing, modifications
of cysteine residues, metabolic alterations, and oncogene-dependent signaling [85].
3.5. Glutathione Salvage Pathway in chRCC
One member of the membrane transpeptidase family GGT is γ-glutamyl transferase 1 (GGT1),
which can remove and transfer the γ-glutamyl moiety from extracellular GSH, GSSG, or even GSH
conjugates to an amino acid acceptor, known as the GSH salvage pathway. This degradation of
extracellular GSH species fuels the cytoplasm of cells to maintain intracellular GSH levels [67]. Recent
metabolomic profiling studies have identified significantly increased amounts of GSH, GSSG, and its
precursor γ-glutamyl cysteine in chRCC compared to normal kidney tissue [57,60]. Unlike in ccRCC,
significantly lower expression of GGT1 has been reported in chRCC [57,60]. The specific loss of GGT1 in
chRCC leads to an increased sensitivity to oxidative stress, mitochondrial damage, and reprogramming
of glutamine and glucose metabolism [60]. Interestingly, renal oncocytomas, which are considered
to be the benign counterpart of chRCC, were found to have a similar increase of GSH moieties and
decreased levels of GGT1 relative to normal kidney tissue [61].
4. Therapeutic Strategies to Exploit Increased GSH Levels in RCC
Nonmetastatic primary RCC can be removed by partial or complete nephrectomy. Metastases
that occur in about one-third of all RCC patients must be treated with various therapeutic agents [89].
One severe problem is that the malignancies gain a fast treatment resistance through the activation
of alternative metabolic pathways, or parts of the cancer cells that are not responsive outgrow
the responsive tumor cells. For example, angiopoietin 2, MET, or Interleukin (IL) can serve as
alternative angiogenesis factors, or the AKT/PI3K/mTOR pathway can stimulate proliferation upon its
activation [90,91]. Depletion of GSH alone has been shown to be insufficient to induce cell death in most
cancer cell lines. The imposed selective pressure during cancer initiation and progression led to a robust
adaption mechanism to tolerate these stress conditions [92]. To overcome these limitations, combinatory
therapies targeting two independent mechanisms are promising. The following subchapters highlight
current strategies that manipulate GSH metabolism and intend to eradicate RCC.
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4.1. The Cystine–Glutamate Shuttle Inhibitor
xCT is a cystine–glutamate antiporter that is essential to the uptake of cystine (Figure 1). After the
conversion of cystine into cysteine, it serves as a building block for the synthesis of intracellular GSH,
as discussed before. xCT is upregulated in a variety of cancers, where the antiporter-assisted production
of GSH reduces oxidative stress levels to protect cancer from apoptosis [93]. Pharmacological inhibition
of xCT decreases cystine uptake and induces ferroptosis in cancer cells [94], which makes xCT inhibitors
potential treatment agents for cancer.
Sorafenib, an FDA-approved kinase inhibitor drug used for almost 15 years for the treatment of RCC,
has multiple kinase inhibition activities, including cell surface tyrosine kinases (e.g., vascular endothelial
growth factor receptor, VEGFR; platelet-derived growth factor receptor, PDGFR; tyrosine-protein kinase
kit, KIT; Fms-like tyrosine kinase 3, FLT3; RET proto-oncogene, RET) and downstream intracellular
serine/threonine kinases (e.g., both wild-type and mutant BRAF and CRAF) [95]. As these kinases play
important roles in cancer cell proliferation, angiogenesis, and apoptosis, sorafenib has been shown to
inhibit the proliferation of cancer cells and induce apoptosis in vitro, as well as reduce angiogenesis and
inhibit tumor growth in vivo [95]. Recently, sorafenib, but not other kinase inhibitors of the same class,
has been reported by several studies to have novel inhibition activity versus xCT, leading to decreased
cysteine uptake, GSH depletion, and ROS accumulation, finally causing endoplasmic reticulum stress
and ferroptosis [94,96,97].
Besides sorafenib, there are two other xCT inhibitors worth discussing in more detail, erastin
and sulfasalazine. Erastin is a small molecule that inhibits xCT activity through the mitochondrial
voltage-dependent anion channel 2 and 3 (VDAC2 and VDAC3), causing abolition of the antioxidant
defenses of the cell, and it furthermore has selectively lethal activity toward oncogenic RAS mutant
cell lines [98,99]. A cystine addiction of VHL-deficient RCC cells was identified, and the deprivation
thereof or treatment with erastin or sulfasalazine in RCC cells induced cell death [100]. Chromophobe
RCC, but not pRCC, was found to have significantly increased abundances of the VDAC1, VDAC2,
and VDAC3 proteins [46,57] and should have a good response to treatment with erastin. Sulfasalazine
has been in use for over 50 years for the treatment of inflammatory conditions such as arthritis. It is a
well-characterized specific inhibitor of xCT and shows anticancer effects on multiple types of cancers,
including RCC [94,98,100]. The safety and side effects of sulfasalazine are well investigated and
understood, and this old drug has the potential to be a novel, effective, and economical treatment
option for RCC patients.
4.2. Glutaminase 1 Inhibitor
Glutaminase 1 (GLS1), a key mitochondrial enzyme that controls glutamine metabolism and
contributes to de novo GSH synthesis (Figure 1), is very important for tumor proliferation and survival.
The glutaminase inhibition of glutamine-addicted cancer cells leads to the disruption of metabolic
pathways, such as macromolecule synthesis, ATP production, and the intracellular redox balance [101].
Thus, targeting glutaminase to disrupt vital metabolic pathways of tumors is considered to be a novel
strategy to treat cancer.
CB-839, a potent, selective, and orally bioavailable GLS1 inhibitor, has been reported to exhibit
significant antiproliferative activity in multiple cancer cell lines and has shown an antitumor effect
in tumor xenografts and cancer patients [102]. CB-839 is currently being investigated in multiple
phase 1 and 2 clinical trials for patients with locally advanced, metastatic, and/or refractory solid
tumors, including ccRCC [102]. Emberley et al. [102] reported a cytotoxic effect of CB-839 in 18 out
of 23 tested RCC cell lines and 0 out of 6 non-RCC cell lines. MacKinnon et al. [103] found that the
abundance of pyruvate carboxylase (PC), which catalyzes the conversion of pyruvate to oxaloacetate
to fuel the TCA cycle, strongly correlated with resistance, and knockdown of PC reduced TCA cycle
activity and sensitized cells to CB-839 treatment, suggesting that PC expression may be a biomarker
of resistance to CB-839. Chromophobe RCC and pRCC have been reported recently to have low
PC expression [46,57]: They may lack this mechanism and therefore would probably be sensitive to
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CB-839. In addition, decreases in mTOR signaling were also observed in RCC cell lines that were
sensitive to CB-839, indicating that CB-839-induced glutamate deprivation has a direct influence on
the mTOR pathway [102]. These observations suggest that receptor tyrosine kinase (RTK) signaling
or mTOR inhibitors would have synergistic effects with CB-839 to increase cytotoxicity in RCC cell
lines. The combined CB-839 and cabozantinib (RTK inhibitor) therapy, which reached phase 2 clinical
evaluation (CANTATA: NCT03428217), showed pronounced reductions in TCA cycle activity and in
signaling via AKT and ERK compared to single-agent treatments. When applying CB-839 in combination
with everolimus (mTOR inhibitor) to RCC cell lines in vitro and to a Caki-1 RCC xenograft model
in vivo, synergistic antitumor activity and inhibition of both glucose and glutamine utilization were
observed [104]. Furthermore, the combined therapy of CB-839 with everolimus in a phase 1 clinical
trial showed a 100% disease control rate (DCR) in ccRCC and 67% in pRCC [104], and it is currently
in a phase 2 investigation in patients with advanced ccRCC (ENTRATA: NCT03163667). Moreover, a
phase 1/2 study of CB-839 in combination with nivolumab (anti-PD-1 antibody) is currently ongoing
(NCT02771626) and has shown a 74% DCR in ccRCC patients. Furthermore, CB-839 was found to
have a synergistic effect in selectively suppressing the growth of ccRCC cells in vitro and in vivo when
combined with poly(ADP-ribose) polymerase (PARP) inhibitors [105]. Currently, a phase 1b/2 clinical
trial of CB-839 in combination with talazoparib (PARP inhibitor) is under investigation (NCT03875313).
At present, CB-839 is the only small-molecule GLS1 inhibitor being studied in a clinical setting,
but there are other GLS1 inhibitors in preclinical investigations, including bis-2-(5-phenylacetamido-
1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), 6-diazo-5-oxo-l-norleucine (DON), and 5-[3-bromo-4-
(dimethylamino)phenyl]-2,3,5,6-tetrahydro-2,2-dimethyl-benzo[a]phenanth-ridin-4(1H)-one (968).
Two of these GLS1 inhibitors have not been further applied and investigated in clinical studies
due to the low solubility and potency of BPTES and the high toxicity and poor binding selectivity of
DON [106]. However, 968 is known to be a noncompetitive inhibitor of GLS1 and is currently still in
the preclinical stage [106].
4.3. The Glutamate–Cysteine Ligase Inhibitor Buthionine Sulfoximine
GCL, the enzyme catalyzing the first reaction in GSH de novo synthesis (Figure 1), plays an
important function in maintaining intracellular GSH levels to combat oxidative stress in RCC [65,66].
Thus, targeting GCL for the treatment of RCC remains a potentially effective strategy to benefit patients.
Buthionine sulfoximine (BSO) is a specific and competitive inhibitor of GCL [107]. Developed in
1979 by Griffith and Meister [108], BSO is able to decrease the intracellular GSH level and sensitize
different types of cancers both in vitro and in vivo to various chemotherapies and other cytotoxic
therapies, e.g., irradiation and hyperthermia [107,109]. BSO has been reported to enhance the activity
of melphalan, doxorubicin, daunorubicin, and other cytotoxic agents in myeloma, breast cancer, and
lung cancer [107,109]. Two clinical trials of BSO in combination with melphalan were conducted for
the treatment of neuroblastoma. In a pilot study and a phase I clinical trial, BSO in combination with
melphalan was well tolerated and had therapeutic activity toward recurrent and refractory high-risk
neuroblastoma (NCT00002730, NCT00005835) [110,111]. Sorafenib, as discussed earlier, has xCT and
multiple kinase inhibition activity. However, it has been reported that some RCC patients were initially
resistant or acquired resistance to sorafenib within a median of 5–9 months [112]. Mechanistic studies
have shown that the resistance to sorafenib in RCC was mediated by enhanced expression of HIF
and numerous HIF-regulated genes, such as VEGF [112,113]. As the redox state could regulate HIF
expression and downstream substrates to cause drug resistance [29,114], BSO, which can regulate the
redox environment through GSH, was shown to be able to decrease the expression of HIF [114–116].
These studies indicate that combination therapies with BSO and sorafenib might overcome the drug
resistance of sorafenib in resistant RCC patients.
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4.4. Inhibition of Deubiquitinating Enzymes Initiates Proteotoxicity
A recent report outlined a combinatory treatment strategy applying the before-mentioned GCL
inhibitor BSO together with deubiquitinating enzyme (DUB) inhibitors [92]. Individual DUB inhibitors,
such as MI-2, PR-619, and EERI, were not effective in inducing cell death alone but led to an
induction of proteotoxic stress and cell death in combination with BSO in many different cancer
cell lines. Though the exact molecular role of how DUBs can protect cells from oxidative stress
is still elusive, a dependency on DUB activity to maintain protein homeostasis by eliminating the
accumulation of damaged and potentially cytotoxic polyubiquitinated proteins and cell viability have
been proposed [92]. This hypothesis was supported by a study profiling the ubiquitination status
between ρ0 cells, which entirely lack mitochondrial DNA, and their parent cell line 143B.TK¯. The
significant decrease in the global ubiquitination pattern in ρ0 cells can be explained by the lack of main
ROS generators localized within the oxidative phosphorylation system, namely complex I and III,
which reduce the oxidative damage of proteins to a minimal level [47].
This combination of DUB and GSH inhibitors has not been applied to RCC cell lines yet but would
present a valuable new strategy to trigger proteotoxic stress as a potential beneficial treatment in RCC
cell lines and animal models.
4.5. The Role of GSH Metabolism in the Immune Microenvironment of the Tumor
Traditional immunotherapies using interleukin-2 or interferon-alfa on metastatic RCC have presented
limited efficacy and highly toxic side effects [117,118]. In recent years, a new generation of immunotherapy
utilizing a novel strategy to block immune checkpoints has shown promising efficacy and manageable
toxicity and has emerged as a new milestone for RCC treatment [119]. Currently, the approved
immune checkpoint inhibitors for RCC are ipilimumab (a cytotoxic T lymphocyte-associated protein 4
[CTLA-4] inhibitor) [120], the programmed cell death 1 (PD-1)-specific antibodies nivolumab [121] and
pembrolizumab, and the programmed death-ligand 1 (PD-L1) antibody avelumab.
A main metabolic feature of RCC is the reprogramming of the main metabolic pathways, which
helps cancer cells adapt to and simultaneously shape the tumor microenvironment. Immune cells utilize
different metabolic programs for their differentiation and effective functions. These immune–metabolic
pathways can be modified or “highjacked” in the tumor microenvironment and thus affect the normal
functions of immune cells, e.g., by infiltrating tumor tissues and presenting tumor-associated antigens
to T-cells [122]. Therefore, a huge effort has been put into the development of immunotherapies to take
advantage of the complex crosstalk between immune cells and the tumor [123].
How does GSH metabolism influence this crosstalk in RCC? Though there is sparse literature
on this topic, it has been shown that GSH metabolism can influence the immune microenvironment
in cancer at least in the following two aspects. First, glutamine is a crucial nutrient for the effector
function of T-cells. Glutamine deprivation or its transporter deficiency blocks the differentiation of
T-helper 1 and 17 cells [124,125]. Similarly, the proliferation and differentiation of B-cells also requires
glutamine [126]. As glutamine addiction is one of the main features of RCC, glutamine may be a
limiting nutrient factor in the tumor microenvironment, and thus a lack of glutamine can induce
immunosuppression. Second, T-cell stimulation activates the cystine–glutamate antiporter xCT and
leads to increased uptake of cystine and subsequent GSH synthesis [122]. Reduced GSH levels in
antigen-presenting cells have been shown to influence antigen processing and presentation as well as
T-cell differentiation into T-helper 1 or 2 phenotypes [127]. Furthermore, GSH can bind to anticancer
drugs, and these conjugates can be effluxed out of the cell via multiple resistance-associated protein
transporters, which are the underlying reasons for therapeutic resistance in some cancers [128]. All the
points discussed above impressively show how tumor cells compete with immune cells for GSH-related
nutrients in the tumor microenvironment, but more research on the immune response in RCC is needed
to exploit these mechanisms for new therapy development.
135
Int. J. Mol. Sci. 2019, 20, 3672
5. Conclusions
Altered GSH metabolism contributes significantly to the development and progression of all renal
malignancies but could, at the same time, be the key to potential therapies. All RCCs have a reduced
oxidative phosphorylation capacity in common. The dysregulated respiratory chain is the main source
of electron leakage, resulting in excessive ROS. Raised oxidative stress levels in RCC are counteracted
by tremendously increased GSH levels and thereby potentially prevent immune reactions, apoptosis,
or other forms of cell death as a strategy to foster the survival of the malignancy. Many applied
chemotherapeutics initiate an additional production of ROS as one potent mechanism to eradicate
RCC, frequently accompanied by the supplementation of antioxidants in the past. Not surprisingly,
targeting ROS by antioxidants and the simultaneous generation of ROS by chemotherapeutics has
led to mixed results in the treatability of RCC [14]. New therapeutic ways exploit sensitivity toward
inhibitors of the GSH metabolism, such as xCT, glutaminase, and GCL. However, the inhibition of just
one altered pathway to cure RCC turned out to be not successful either, as cells are fitted by a very
flexible system to compensate for the impairment of one pathway or mechanism. New studies have
shown that a combinatory therapy targeting two independent pathways and one involved in ROS
metabolism is key to improving the survival rate and eventually curing RCC. Although the main role
of GSH and other antioxidants is to scavenge intracellular ROS to maintain an overall healthy pro-
and antioxidant exposure status in cells, GSH can also function as a signaling molecule or as a donor
of the post-translational modification S-glutathionylation to regulate protein bioactivity, which was
not discussed in this review. These diverse functions of GSH, a molecule that was identified more
than 100 years ago, still need to be further investigated for better understanding of the underlying
disease mechanisms in cancer. This might facilitate the development of GSH-related modulators with
improved therapeutic efficiencies in the future.
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ccRCC Clear cell renal cell carcinoma
CDKN2A Cyclin-dependent kinase inhibitor 2A
CDKN2B Cyclin-dependent kinase inhibitor 2B
chRCC Chromophobe renal cell carcinoma
CRAF Proto-oncogene C-RAF
CTLA-4 Cytotoxic T lymphocyte-associated protein 4
CUL3 Cullin 3
DCR Disease control rate
DON 6-diazo-5-oxo-l-norleucine
DUB Deubiquitinating enzyme
EGFR Epidermal growth factor receptor
EGLN Egl-nine homolog
FAK Focal adhesion kinase
FBP Fructose 1,6-bisphosphate
FBP1 Fructose 1,6-bisphosphatase 1
136
Int. J. Mol. Sci. 2019, 20, 3672
FH Fumarate hydratase
FLT3 Fms-like tyrosine kinase 3
G6PD Glucose-6-phosphate dehydrogenase
GCL Glutamate cysteine ligase
GCLC Glutamate cysteine ligase catalytic subunit
GCLM Glutamate cysteine ligase modulatory subunit
GGT γ-glutamyl transferase




GLUT1 Glucose transporter type 1
GPX Glutathione peroxidase
GR Glutathione reductase
GSH Glutathione reduced form
GSS Glutathione synthetase
GSSG Glutathione oxidized form
GST Glutathione S-transferase
HGF Hepatocyte growth factor
HIF Hypoxia inducible factor
KEAP1 Kelch-like ECH-associated protein 1
KIT Tyrosine-protein kinase kit
MET Proto-oncogene c-Met
MYC MYC proto-oncogene
NADPH Nicotinamide adenine dinucleotide phosphate
NOX4 NADPH oxidase 4
NRAS NRAS proto-oncogene, GTPase
NRF2 Nuclear factor erythroid 2-related factor 2
ODD Oxygen-dependent degradation
PC Pyruvate carboxylase
PD-1 Programmed cell death 1
PD-L1 Programmed cell death-ligand 1
PDGFR Platelet-derived growth factor receptor
PPP Pentose phosphate pathway
pRCC Papillary renal cell carcinoma
R5P Ribose 5-phosphate
RCC Renal cell carcinoma
RET RET proto-oncogene
ROS Reactive oxygen species
RTK Receptor tyrosine kinase
SAH S-adenosyl homocysteine
SAM S-adenosyl methionine
SETD2 Set domain-containing 2, histone lysine methyltransferase
SLC38A1 Solute carrier family 38 member 1
SLC7A11 Solute carrier family 7 member 11
TERT Telomerase reverse transcriptase
TFE3 Transcription factor E3
TSC1 Tuberous sclerosis 1 protein
TSC2 Tuberous sclerosis 2 protein
VDAC1 Voltage-dependent anion channel 1
VDAC2 Voltage-dependent anion channel 2
VDAC3 Voltage-dependent anion channel 3
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
VHL von Hippel-Lindau
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Abstract: Reactive oxygen species (ROS) play a key role in cell physiology and function.
ROS represents a potential source of damage for many macromolecules including DNA. It is
thought that daily changes in oxidative stress levels were an important early factor driving evolution
of the circadian clock which enables organisms to predict changes in ROS levels before they actually
occur and thereby optimally coordinate survival strategies. It is clear that ROS, at relatively low levels,
can serve as an important signaling molecule and also serves as a key regulator of gene expression.
Therefore, the mechanisms that have evolved to survive or harness these effects of ROS are ancient
evolutionary adaptations that are tightly interconnected with most aspects of cellular physiology.
Our understanding of these mechanisms has been mainly based on studies using a relatively small
group of genetic models. However, we know comparatively little about how these mechanisms
are conserved or have adapted during evolution under different environmental conditions. In this
review, we describe recent work that has revealed significant species-specific differences in the gene
expression response to ROS by exploring diverse organisms. This evidence supports the notion that
during evolution, rather than being highly conserved, there is inherent plasticity in the molecular
mechanisms responding to oxidative stress.
Keywords: ROS; light; DNA damage; evolution; D-box; cavefish; Spalax
1. Background
Since the origin of life on earth, oxidative stress has posed a major challenge for living systems.
From the evolution of the first plants and photosynthesis to the development of aerobic oxidative
respiration, living systems have faced the challenge of exposure to elevated oxygen levels and
consequently Reactive Oxygen Species (ROS) (including peroxides (e.g., H2O2), superoxide (O2•−),
hydroxyl radicals (•OH) and singlet oxygen (1O2) [1]). Oxidative stress accompanies exposure to
environmental stressors such as hypoxia, UV radiation, as well as visible light and so frequently
changes across the day-night cycle. In more recent evolutionary time, in relation to the impact of
human activities on the environment, the toxic effects of many man-made compounds also induce
oxidative stress.
ROS levels are modulated by a balance between pro-oxidant and antioxidant elements.
When increased levels of ROS are not countered by increases of antioxidant activity or
reducing equivalents, a cell undergoes an oxidative stress state. Higher concentrations of ROS
represent a potential source of damage for many macromolecules due to the induction of single-
and double-stranded DNA breaks, oxidative decarboxylation of α-ketoacids such as pyruvate,
and irreversible denaturation of proteins through oxidation and carbonylation of arginine, proline,
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lysine, and threonine residues [2]. Many cellular mechanisms have evolved to counteract these effects
which are based on enzymatic as well as non-enzymatic processes. One of the best described is the role
of glutathione in its reduced state (GSH). GSH serves as an antioxidant in plants, animals, fungi and also
in some bacteria. It neutralizes ROS by directly donating a reduced equivalent (H+ + e−). Furthermore,
GSH activates oxidative stress response cascades by promoting transcription and post-translational
modifications of proteins that affect their functionality. Another conserved antioxidant mechanism is
based on the rapid rerouting of carbohydrate flux from glycolysis to the pentose phosphate pathway
(PPP) via inhibiting the activity of glycolytic enzymes such as GAPDH (glyceraldehyde-3-phosphate
dehydrogenase). The PPP pathway then has the role of regulating cellular NADPH levels that serve as
the fuel for antioxidant systems [3–5].
Important antioxidant enzymes used in nearly all cells exposed to oxygen are the superoxide
dismutases (SODs) and the catalases, as well as peroxiredoxins and glutathione peroxidases. SODs are
a group of metalloproteins catalyzing the dismutation of superoxide O2•− radicals into two less
damaging species, O2 and H2O2. There are three major families of superoxide dismutase depending
on the metal cofactor used. The SOD Cu/Zn family which binds copper and zinc is mainly used in
eukaryotes including humans; the SOD families which either bind iron and manganese or nickel are
used by prokaryotic and protozoa. The physiological importance of SODs is illustrated by the severe
pathologies observed in genetically engineered model organisms lacking these enzymes spanning
from mouse and Drosophila to yeast [6,7]. Hydrogen peroxide is subsequently degraded by catalase
activity, usually localized in peroxisomes. This highly active enzyme that catalyzes the decomposition
of millions of H2O2 molecules to water and oxygen each second [8], also plays a central role in aging
and degenerative disorders in humans [9]. Other enzymes involved in scavenging H2O2 outside of the
peroxisomes are the Peroxiredoxins [10] and the Glutathione peroxidases [11] that detoxify a broad
range of peroxides to the corresponding alcohols or water.
Together with strategies aimed at reducing the levels of ROS, a key adaptation for surviving the
harmful effects is the evolution of DNA repair mechanisms such as base excision repair, (BER) [12,13],
which targets ROS-induced covalent modifications of bases. Several regulatory systems, including
cell cycle control and apoptosis, also protect organisms from the negative effects of ROS and are
themselves activated by oxidative stress. Cell fate decisions involving cell cycle arrest and apoptosis
represent key cellular responses to the damaging effects of ROS. Furthermore, it is increasingly clear
that ROS, at relatively low levels, can reversibly oxidize redox-sensitive cysteine and methionine
residues, acting as a second messenger via the targeted inactivation of enzymes bearing active site
cysteines, for example, phosphotyrosine phosphatases [14].
The gene expression control mechanisms that enable organisms to survive elevated ROS levels or
harness their effects are frequently ancient evolutionary adaptations that are tightly interconnected
with most aspects of cellular physiology. These mechanisms have received significant attention in
studies involving a small number of genetically accessible model organisms. However, comparatively
little is known about how these mechanisms are conserved or have adapted during evolution under
different environmental conditions.
Even the simplest unicellular organisms possess mechanisms to counter the damaging effects of
oxidative stress. Plants and animals frequently excrete hydrogen peroxide or superoxide-generating
redox-cycling compounds as a strategy to inhibit microbial growth [15,16] and so bacteria frequently
inhabit oxidizing environments. They protect themselves by activating regulons controlled by the
OxyR, PerR and, SoxR transcription factors [16–18]. In Escherichia coli, the SoxR transcription factor
induces the expression of the SoxS protein that in turn activates the transcription of several other
genes including the antioxidant enzyme superoxide dismutase [19]. In Rhodobacter, the redox signal
is detected by the membrane-bound sensor kinase, RegB via a redox-active cysteine located in its
cytosolic domain that in turn regulates autophosphorylation. The active form of RegB is able to
phosphorylate its regulatory partner RegA, capable of activating or repressing a variety of genes [20].
The conservation of both RegB and RegA homologs in a broad range of bacteria points to a central role
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for the RegB/RegA two component system in the transcriptional regulation of redox-regulated gene
expression [21].
In the yeast Saccharomyces cerevisiae, peroxiredoxins are ubiquitous, thiol-containing antioxidant
proteins that serve to reduce hydroperoxides. They also regulate hydrogen peroxide-mediated
signal transduction via activation of transcription factors such as NF-κB [22,23]. Particularly relevant
for the antioxidant function of the peroxiredoxins is a conserved protein called Sulphiredoxin.
Sulphiredoxin can reduce cysteine-sulphinic acid of the antioxidant peroxiredoxins via activation by
phosphorylation followed by a thiol-mediated reduction step. It has been speculated that Sulphiredoxin
is also involved in the repair of proteins containing cysteine-sulphinic acid modifications [24].
In higher organisms, there is evidence for diversity in the response to oxidative stress.
Particularly in plants, the production of O2 by photosynthesis represents a major potential source
of oxidative stress. Furthermore, the generation of H2O2 in response to various pathogens can
elicit localized cell death to limit pathogen spread [25] and thereby serves as part of a systemic
response involving the induction of defense genes regulating plant immunity [26]. Therefore, in plants,
regulatory systems are required to minimize ROS production without decreasing photosynthetic activity
or inhibiting the light-driven production of ROS that is an important signaling molecule controlling
plant growth and development [27]. The most abundant ROS scavengers in plants, ascorbate (AsA) and
GSH, are typically concentrated in chloroplasts. These metabolites function together in the AsA-GSH
cycle to metabolize H2O2 and thereby to dissipate excess excitation energy in chloroplasts. Moreover,
the AsA-GSH detoxification pathway cross-talks with other detoxification pathways including the
peroxiredoxin (PRX) and glutathione peroxidase (GPX) pathways which are also important for the
detoxification of lipid peroxides. It has been speculated that all these detoxification pathways are
tailored to suit specific stressors and that their relative importance probably varies according to the
prevailing environmental conditions [27].
In animals, there is evidence for species-specific differences in the exploitation of the effects of
ROS. For example, in echinoderms fertilization triggers a burst of extracellular production of H2O2 by
a plasma membrane NADPH oxidase with a simultaneous release of ovoperoxidase. This elevated
H2O2 is the oxidant responsible for the extracellular cross-linking reaction involving in the formation
of a protective envelope around the freshly fertilized oocyte [28].
In insects as in plants, reactive oxygen species can also function as immune effector molecules
which exert microbicidal activity. In Drosophila, a burst of ROS is generated by DUOX (dual oxidase)
upon gut microbe infection and regulates the production of antimicrobial peptides (AMPs) by the
fat body, a major immune organ in the fly [29]. As in mammals, the ROS dependent mechanism
which activates antimicrobial peptide production involves the activation of the Toll and the NF-κB
pathways which both play essential roles in antibacterial and antifungal responses [29,30]. At the
same time, the pathogen-induced ROS levels activate the JAK-STAT (Janus kinase–signal transducers
and activators of transcription) and JNK (c-Jun NH2 terminal kinase) pathways to induce stem cell
proliferation counteracting the cellular damage generated by the burst of ROS [31].
Another mechanism underlying oxidative stress tolerance in Drosophila that influences life-span and
xenobiotic response is the conserved Keap1 (Kelch-like ECH-associated protein (1)/Nrf2 (NF-E2-related
factor (2) signaling pathway [32]. The Keap1/Nrf2 dimer activated by ROS plays a crucial role in
reducing oxidative stress in the germline stem cells from Drosophila testis. This pathway regulates the
expression of antioxidant and detoxification genes [32,33] and has also been shown to play a critical
role in ROS detoxification in mammalian systems.
1.1. ROS Regulation of Gene Expression in Vertebrate Systems
Many studies have focused on the regulation of gene expression by ROS in mammalian systems.
It is well known that a moderate level of ROS synthesis is physiologically normal and acts as a
specific signal in the control of cell proliferation, blood circulation, myoblast differentiation and the
regulation of immune and endocrine processes [34]. However, external factors such as xenobiotics
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and UV-radiation as well as hormones, cytokines, and other physiological stimuli can enhance the
production of cellular ROS up to toxic levels [34–36]. To protect against the potentially damaging
effects of ROS, mammalian cells can enhance the level of endogenous non-enzymatic antioxidant
metabolites such as lipoic acid, glutathione, L-arginine and coenzyme Q10 [37] as well as inducing the
synthesis of several antioxidant enzymes including superoxide dismutase, catalase and glutathione
peroxidase. The mechanism underlying this transcriptional response to ROS involves the activation of
MAP protein kinases and redox-regulated transcription factors such as c-Jun, ATF2, ATF4, NFκB, Nrf2
and p53.
Mitogen-activated protein kinases (MAPKs) have been reported to orchestrate ROS-responsive
signaling pathways by activating redox-responsive transcription factors such as AP-1, NFκB/IκB
and the Nrf2/Keap1 systems. The prevention of ROS accumulation by antioxidants blocks MAPK
activation [38,39]. MAPK activation consists of a kinase cascade initiated by a MAPK kinase kinase
(MAPKKK), that phosphorylates and thereby activates a MAPK kinase (MEK, or MKK), which in turn
phosphorylates and activates one or more MAPKs. In vertebrates, three subtypes of MAPKs have been
described. The extracellular signal-regulated kinases (ERKs), the c-Jun N-terminal kinases (JNKs),
and the p38 MAPKs. MAPKs can be activated by a wide variety of different stimuli, but in general,
ERK-1 and ERK-2 are preferentially activated in response to growth factors, while the JNKs and
p38 MAPKs are more responsive to stress stimuli including elevated levels of ROS. The p38 MAPKs
represent stress-activated protein kinases activated by extracellular stress and cytokines, (e.g., tumor
necrosis factor-a (TNF-α) and interleukin-1b (IL-1β)), and are thereby involved in the inflammation
response [40].
The stress-activated protein kinases JNKs, were originally identified by their ability to activate the
transcription factor c-Jun via phosphorylation of its transactivation domain [41]. However, it is now
clear that they also phosphorylate other target proteins. A key question concerns precisely how ROS
activates the JNK and p38 MAPK pathways. Redox-sensitive proteins, such as Trx and glutaredoxin
(Grx) have been implicated in this regulatory mechanism [42]. For example, the oxidation of Trx by ROS
results in dissociation of the Trx/ASK-1 complex leading to the activation of the two stress-responsive
MAPK pathways [42]. ASK1 has been extensively characterized as a ROS-responsive kinase [43,44].
The protooncoprotein c-Jun, as well as ATF2 (Activating transcription factor 2) belong to the
activating protein-1 (AP1) transcription factor family. These factors regulate gene expression in the
context of homo- or hetero-dimeric complexes with other AP1 members (e.g., CREB, Fos, Maf, Jun-B
and Jun-D) [45–48]. AP1 dimers containing ATF2 and c-Jun have been reported to bind to the promoter
consensus sequence TG/TACNTCA that is encountered in the promoters of many genes involved in
DNA repair and apoptosis [49].
ATF2 was originally identified from a human brain cDNA library screen as a CRE-binding
protein [50]. It is activated by various stimuli including oxidative stress, growth factors, ultraviolet (UV)
radiation, and cytokines. ATF2 can shuttle between the nucleus and cytoplasm under basal conditions
and following stress stimuli via an autoinhibition mechanism. Specifically, in the inactive state, the ATF2
N-terminal transcriptional activation domain (TAD) interacts with its C-terminal basic leucine zipper
(bZIP) DNA-binding domain, inhibiting the ability of ATF2 to activate transcription. Following stress
stimuli, ATF2 undergoes phosphorylation at threonine (T69, T71) mediated by stress-activated protein
kinases (e.g., p38 and JNK) and is able to translocate to the nucleus as homo- or hetero-dimers with other
AP1 transcription factors to modulate the expression of hundreds of genes [47,51]. The proto-oncogene
c-Jun is the cellular homolog of the viral oncoprotein v-jun discovered in the avian sarcoma virus
17 [48,52,53]. The c-Jun protein was originally described as a driver of malignant transformation.
One characteristic of c-Jun is that it can activate its own expression [54] and therefore can drive
a positive autoregulatory loop. It has been shown that in response to oxidative damage, c-Jun is
phosphorylated at N-terminal serine residues (S63, S73) by JNK [41,55,56] and that c-Jun play an
important role in cell cycle re-entry after DNA damage induced by UV exposure since immortalized
fibroblasts lacking c-Jun undergo a prolonged UV-induced growth arrest [57].
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The nuclear factor NF-κB is a widely investigated dimeric transcription factor involved in the
regulation of genes that control various aspects of the immune and inflammatory response and is
responsive to ROS. Redox signaling plays a critical role in NF-κB activation by various stimuli via
thioredoxin peroxidases [23]. In unstimulated cells, NF-κB dimers are sequestered in the cytosol
through noncovalent interactions with inhibitory proteins termed IκBs [58]. The nuclear translocation
and activation of NF-κB as a transcription factor by cytokines, microbial agents, oxidative challenge
(ROS) and irradiation occurs through the signal-induced phosphorylation of IκB and its proteolytic
degradation by thioredoxin peroxidases. IκB degradation exposes the nuclear localization signal on
NF-κB, which allows its nuclear translocation and activation of the transcription of its target genes.
Interestingly, the DNA binding function of NF-κB is also regulated by the intracellular redox status.
Specifically, the p50 subunit is targeted by S-glutathionylation which reversibly inhibits its DNA
binding activity [59].
One of those NF-κB target genes which includes in its promoter the GGGDNWTTCC enhancer
element, is the redox-regulating thioredoxin gene (Trx). Trx is an oxidoreductase that works together
with the glutathione system to establish and maintain a reduced intracellular redox state. Other NF-κB
target genes that play a protective antioxidant role include the peroxiredoxin, heme oxygenase-1,
the cystine transporter xc2 and manganese SOD (mnSOD) genes [60].
The redox stress-sensitive transcription factor Nrf2 (nuclear erythroid-derived 2-like) regulates
the expression of several antioxidant and detoxification genes. In the absence of ROS, Nrf2 is retained
in the cytoplasmic compartment in complex with another protein, KEAP1, ensuring effective Nrf2
repression. Upon oxidative stress increase, NRF2 protein is rapidly released from KEAP1 and thereby
translocated into the nucleus of affected cells. Nuclear Nrf2 heterodimerizes with Maf and binds to
the antioxidant response element ARE sequence (ARE; 5′-A/GTGAC/GNNNGCA/G-3′) located in the
promoter regions of antioxidant and detoxification enzymes and by activating expression of these
target genes, counteracts oxidative stress [61–63]. Specific Nrf2-regulatory targets include elements of
the glutathione and thioredoxin antioxidant systems, as well as enzymes catalyzing the detoxification
of exogenous and endogenous products, NADPH regeneration and heme metabolism. Consistently,
loss of Nrf2 function is associated with increased susceptibility to many environmental stressors.
Recently, it has been demonstrated that Nrf2 can cooperate in a ROS detoxification program with
the cAMP responsive transcription factor ATF4 [64]. Moreover, Nrf2 is involved in other cellular
processes such as autophagy, metabolism, stem cell quiescence and unfolding protein responses [65].
More recently, De Nicola and colleagues [66] have pointed out a potential link between the “reduced”
cellular environment and tumor initiation. They have shown that oncogene-mediated induction
of Nrf2 in mice promotes ROS detoxification required for tumor initiation [66]. Furthermore, Nrf2
mutations have been isolated from patients with lung, gall bladder, head and neck cancers supporting
a pro-tumorigenic role for Nrf2 [62].
The cytokine responsive transcription factor STAT3 has also been shown to be regulated by the
redox sensor peroxiredoxin 2 (Prx2) [67]. Specifically, Prx2 act as a sensitive receptor for H2O2 and
transmits oxidative equivalents to STAT3. This, in turn, induces the formation of STAT3 oligomers
with reduced transcriptional activity. This observation is consistent with reports that ROS plays a key
role in the regulation of tissue regeneration and development [68].
The tumor-suppressor p53 is potently induced by oxidative stress and mediates all the
antiproliferative cellular responses to oxidative signals, including transient cell-cycle arrest, cellular
senescence and apoptosis [69,70]. Specifically, after oxidative stress the p53 transcriptional response is
dependent on the p66Shc protein, the redox enzyme implicated in ROS generation and the translation
of oxidative signals into apoptosis [71,72]. The tumor suppressor p53 is critically involved in oxidative
stress-dependent apoptosis and is upregulated upon treatment with H2O2 and UV [73]. Strikingly,
p53−/− MEFs show resistance to UV and H2O2-induced apoptosis [70]. p53 activation leads to a
significant increase in ROS levels and apoptosome assembly via the release of cytochrome C from
the mitochondria. This release of cytochrome C upon oxidative stress is p66Shc-dependent since
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p66Shc−/− cells fail to increase ROS levels. Therefore, p66Shc serves as a downstream effector of
p53 [72]. However, p66Shc is not involved in p53 functions such as cell cycle arrest but it does regulate
p53-dependent apoptosis pointing to a crucial role for p66Shc and p53 crosstalk in the regulation of
intracellular ROS levels [72].
1.2. Circadian Clocks and Timing of the Response to ROS
Close links exist between oxidative stress and the circadian clock. It has been speculated that
during the origin of life on earth, one of the first driving forces for the evolution of an internal timing
mechanism, was the great oxidation event that occurred following the evolution of green plants
and photosynthesis [74]. Hydrogen peroxide production and scavenging are strongly time-of-day
dependent, therefore, the evolution of an endogenous 24 h clock mechanism was a fundamental step
enabling a temporally coordinated homeostatic response to ROS.
The circadian clock is a highly conserved mechanism, from cyanobacteria to humans, that regulates
rhythms with a period of 24 h in almost every aspect of biology and behavior. The circadian clock is
regularly “reset” or “entrained” by external time cues including light, food and temperature (so-called
zeitgebers, time givers) to remain synchronized with the external environment. However, its timing
function also persists in the absence of zeitgebers with a rhythm of circa 24 h and based on this property
is termed “circadian” (for Latin: circa-diem, around one day). At the molecular level, the vertebrate
circadian timing system can be subdivided into three parts: an input pathway that detects and processes
zeitgeber information; a core oscillator that is entrained by the input pathway and generates endogenous
and self-sustained rhythms; and an output pathway that relays this integrated timing information
to various aspects of behavior and physiology [75]. Genetic screens for circadian clock mutants in
several model organisms (Drosophila, Neurospora, Arabidopsis and mouse) led to the identification
of many genes involved in this mechanism [76–81]. Although, the circadian clock genes identified
were not conserved between the different groups of organisms, they all share a functional property,
namely that they generate circadian rhythmicity by serving as elements of transcriptional-translational
feedback loops (TTFL) [81]. In vertebrates, the BMAL and CLOCK basic helix–loop–helix (bHLH),
Per-Arnt-Single minded (PAS) transcription factors serve as positive elements of the core TTFL clock
mechanism. CLOCK-BMAL hetero-dimers bind to E-box enhancer elements (5′-CACGTG-3′) located
in the promoter regions of the negative elements of the TTFL (the period (Per) and cryptochrome
(Cry) genes) as well as in the promoters of other clock-controlled genes [82,83], and thereby activate
their transcription. The induced PER and CRY proteins in turn form a hetero-dimeric complex and
translocate to the nucleus where they inhibit their own transcription by interfering with CLOCK-BMAL
driven transcriptional activation [81]. The stability of this core regulatory TTFL is enhanced by
additional feedback loops [84]. For their discovery of the first elements of the molecular mechanisms
generating circadian rhythms, Michael Rosbash, Michael W. Young and Jeffrey C. Hall obtained the
Nobel prize in Physiology and Medicine in 2017.
In mammals, cell autonomous clocks located in most cell types and tissues (so-called peripheral
clocks) are light-synchronized via systemic signals provided by a specialized clock located in the
SCN (Suprachiasmatic nucleus) of the hypothalamus, a paired neuronal structure located in the
anteroventral hypothalamus above the optic chiasm that is synchronized by light via light-dependent
input from the retina-hypothalamic tract [85,86]. In lower vertebrates, including fish and insects such
as Drosophila, peripheral clocks are reset directly by light without the presence of a light entrainable
central pacemaker [87].
Many lines of evidence point to extensive links between the circadian clock and the redox state of
the cell. Thus, model organisms with genetically disrupted circadian clocks show many features of
abnormal metabolism, such as obesity and diabetes [88–91]. Furthermore, the early aging phenotype
observed in the clock protein BMAL1 knockout mouse has been attributed to an accumulation of ROS
due to mitochondrial uncoupling [92,93].
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The core clock mechanism has been shown to respond to redox state in a range of model
organisms [94,95]. This enables the circadian clock to respond to changes in metabolic activity [96,97].
In vertebrates, a feedback loop links redox homeostasis and clock function. The circadian clock
controls the NAD pathway via regulation of the enzyme NAMPT, crucial for the synthesis of NAD [98].
This regulation governs the cellular NAD+:NADH ratio [99]. Conversely, a NAD+-dependent
deacetylase, the protein SIRT1, directly regulates the expression of clock and clock-controlled genes
via deacetylation of clock proteins and histones [100,101]. The mechanism of protein deacetylation by
SIRT1 is dependent upon the availability of NAD+. Both NADH and NADPH enhance the binding of
CLOCK:BMAL1 and NPAS2:BMAL1 hetero-dimers to the E-box enhancer element, whereas NAD+
and NADP+ inhibit this activity [102].
It has been shown that circadian clock regulation of the redox stress-sensitive transcription factor
NRF2 occurs via the E-box enhancer element. NRF2 regulates the circadian rhythmic expression of
antioxidant genes, and genes involved in NADPH production [103]. Consistent with a clock control of
ROS homeostasis, time of day dependent differences in the levels of DNA damage, lipid peroxidation
and protein oxidation have been documented [104,105].
The clock also regulates the production of the hormone melatonin, a potent antioxidant
molecule [106]. Melatonin can act as a direct free radical scavenger or as an indirect antioxidant by
stimulating antioxidant enzymes including SOD, GPX, and glutathione reductase [107]. Moreover,
melatonin is able to regulate the mitochondrial electron transport chain, thereby reducing electron
leakage and free radical generation [107]. In addition, it has also been hypothesized that intracellular
melatonin can directly neutralize H2O2 by generating N’-acetyl-5-methoxikynuramine (AFMK) [107].
1.3. Stress Response and Cytoplasmic Granules
Following exposure to environmental stress, cells can undergo two alternative fates, either inducing
apoptosis or cell cycle arrest to repair the stress-induced damage. The activation of one or the other
mechanism is strictly dependent on the extent of cellular damage. These processes minimize cell loss
and prevent the survival of cells with genetic and protein alterations. An additional evolutionary
conserved strategy for dealing with an imbalanced redox state is Stress Granule (SG) formation.
Stress Granules are cytoplasmic non-membrane bound aggregates of RNA and proteins whose
formation is associated with inhibition of translation initiation and the disassembly of polysomes [108].
In mammalian cells, stress granule formation is orchestrated by PI3K and p38MAPK that act in
a hierarchical manner to drive mTORC1 activity thus facilitating stress granule assembly [109]. SGs
are composed of only 10% of bulk mRNA molecules as well as some non-coding RNA (ncRNAs).
Recent transcriptomic analyses reveal that SGs are enriched with long mRNAs that exhibit poor
translation efficiency [110]. In addition to RNAs, SGs contain various proteins, including G3BP1, T-cell
restricted intracellular antigen-related protein (TIAR), PABP1, RACK1, HDAC6 and Y box binding
protein 1 (YB-1). Although the role of each protein in SG assembly is not fully elucidated, each
appears to play an essential role in SG-associated functions. For example, YB-1 directly binds to and
translationally activates the 5′ untranslated region (UTR) of G3BP1mRNAs, thereby controlling the
availability of the G3BP1 nucleator for SG assembly.
In mammals, irradiation and genotoxic drugs are prone to trigger apoptosis. Instead, arsenite,
hydrogen peroxide and heat shock treatment induce stress granule formation, that suppresses ROS
elevation and thereby inhibits apoptosis. This antioxidant property results from the function of two
key SG components, namely the GTPase-activating protein SH3 domain binding protein 1 (G3BP1) and
ubiquitin-specific protease 10 (USP10). Under normal conditions, G3BP1 elevates ROS by inhibiting
the antioxidant activity of USP10. However, under oxidative stress or heat shock, G3BP1 and USP10
trigger SG formation, which then activates the antioxidant activity of USP 10 [111].
Interestingly, it has been shown that upon oxidative insults, SG assembly is associated with
an enhancement of YB-1 protein secretion. Furthermore, an enriched fraction of extracellular YB-1
(exYB-1) caused a G2/M cell cycle arrest in receiving cells thus inhibiting cell proliferation [112].
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These observations suggest that the release of extracellular YB-1 can function as a stress-dependent
paracrine/autocrine signal that controls cell cycle progression. Despite the considerable literature on
SGs in mammals, little is known about how much these membrane-less organelles and their functions
are conserved during evolution. Interestingly, it has been shown that the nuclear localization of the
SG marker YB-1 is robustly regulated in fish by the circadian clock [113]. Specifically, a daily nuclear
entry of YB-1 at the beginning of the light phase appears to be mediated by clock-controlled changes in
YB-1 SUMOylation. Moreover, in zebrafish, the YB-1 nuclear protein is able to downregulate cyclin A2
transcript levels thus providing a direct link between the circadian clock, YB-1 and the control of cell
proliferation. Thus, in response to oxidative stress, YB-1 seems to play distinct roles depending on its
subcellular localization. In the nucleus, YB-1 restrains cell cycle progression while in the cytoplasm it
participates in SG assembly and inhibition of translation. Overall, it appears that YB-1 acts to prevent
and then eventually repair genotoxic damage.
Thus, oxidative stress response pathways have been extensively studied in mammalian systems.
However, given the diversity of antioxidative stress pathways in other species, are these pathways
conserved in all vertebrates or may there be species-specific differences in their function depending on
the ecological niche occupied? In the next section, we will explore recent progress made in studying
the oxidative stress response in fish.
2. Fish as Models for Studying ROS Responses
Recent work has compared the response to oxidative stress in selected species of fish with
mammalian models such as human and mouse. Fish represent the most diverse and largest vertebrate
group which occupy an important ecological position and have great commercial value. Furthermore,
zebrafish and medaka are also powerful genetic models that provide a wealth of molecular and genetic
tools for studying various biological processes at the molecular level. Another unique and attractive
advantage of using fish for studying ROS pathways, is that their peripheral tissues are directly light
responsive [87] and central to these light-driven responses is an increase in intracellular ROS levels [114,
115]. Specifically, most tissues and cell types in fish express photoreceptors, directly light-regulated
clocks, light enhanced DNA repair capacity and importantly the expression of many genes is induced
in fish cells upon direct exposure to visible as well as UV light and ROS. This cell-autonomous
property is even observed in cell lines derived from various fish tissues [116–118]. Therefore, fish
cell lines represent powerful in vitro models for exploring the capacity of light via ROS to regulate
physiological mechanisms in vertebrates. The utility of fish also extends to studying the effects of
evolution in response to a changing environment. Notable examples are species of blind cavefish
that inhabit perpetually dark subterranean environments and exhibit a set of striking anatomical
adaptations including eye loss, enhancement of non-visual senses and loss of body pigment, so called
troglomorphisms. One particular species, the Somalian cavefish Phreatichthys andruzzii, represents one
of the most extreme examples of cavefish since it has been completely isolated from surface water and
surface-dwelling forms for at least 2–3 million years. Interestingly, this species also exhibits complete
loss of light, UV and ROS induced gene expression. Therefore, comparing the responses to ROS in
different fish species subjected to different evolutionary pressures, represents a unique approach to
gain insight into how the ROS response is shaped by the environment during evolution.
2.1. Sunlight, ROS and Regulation of the Circadian Clock in Fish
A remarkable feature of the organization of the circadian timing system in vertebrates is a
fundamental difference in the mechanisms whereby light entrains the multiple peripheral tissue
clocks. Thus, while peripheral clocks are directly light-regulated in lower vertebrates such as fish,
in modern mammals the photic entrainment of peripheral clocks is dependent upon a centralized,
retina-based photoreception system [119]. These observations predict the existence of fundamental
changes in the regulatory networks of peripheral clocks over the course of vertebrate evolution.
In zebrafish, functional genomic analysis has identified more than 40 opsins of which 32 are non-visual
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opsins expressed in peripheral organs [85,120]. It has also been shown that exposure to visible
light can stimulate H2O2 production in zebrafish embryonic cell lines and that this production
is a key signal for mediating light-dependent circadian gene expression [114,115]. It is also well
documented that exposure of cultured mouse, monkey and human cells to violet-blue visible
light, as well as UVA, also stimulates H2O2 production via photoreduction of flavoproteins [121].
Hirayama et al., in 2007 [115], demonstrated that ROS species act as a second messenger coupling
photoreception to circadian clock entrainment and consequentially regulate the circadian expression
and activity of clock genes as well as antioxidant enzymes such as catalase that is responsible for
H2O2 degradation. A more recent study [114], revealed a key role for NADPH-flavin-containing
oxidases (NOXes) in the regulation of light-inducible clock gene expression in zebrafish. Using a
pharmacological approach and by studying zebrafish cell lines, visible light was shown to trigger
increases in ROS levels via NADPH oxidase activity, which in turn activates the expression of the light
regulated clock genes zfcry1a and zfper2. This induction of zfcry1a and zfper2 gene expression is also
dependent on the activation of the JNK and p38MAPK stress pathways. Surprisingly, the promoter
enhancer elements targeted by these ROS pathways was not one of the classical enhancers regulated
by ROS. Instead, exposure to ROS species, as well as visible and UV light, activated the expression of
circadian clock and DNA repair genes via D-box enhancer elements located in their promoters [114,122].
Interestingly, in mammalian cells, neither blue light, UV nor H2O2 exposure activates gene expression
via D-box enhancer elements [114,122].
2.2. The D-Box and the Transcriptional Response to ROS
The D-box element was first described in mouse liver as one of the transcriptional enhancers
present in the albumin gene promoter [123]. In 1990, Uli Schibler’s group cloned the first transcription
factor that binds with high specificity to the D-box element of the rat liver albumin promoter, thereby
called DBP (D-binding protein) [124]. Subsequently, two other transcription factors were shown to bind
to the D-box element and to serve as transcriptional activators, namely the thyrotrophic embryonic
factor (TEF) [125] and the hepatocyte leukemia factor (HLF) [126]. DBP, TEF and HLF belong to
the so-called PAR bZip (proline and acidic amino acid-rich basic leucine zipper) transcription factor
family which share a proline-and acidic amino acid-rich domain positioned proximal to a C-terminal
bZip domain as well as an extended basic region at their N-termini and which are highly conserved
throughout evolution [127,128]. These transcription factors constitute a subfamily of the basic leucine
zipper proteins (bZip), characterized by a C-terminal α-helical region that allows homodimerization
or heterodimerization between other bZip proteins [129]. All PAR bZip family members activate
transcription of downstream genes by binding as homo- or hetero-dimers to D-box elements matching
the consensus sequences RTTAYGTAAY [130]. These transcriptional activators compete for DNA
binding with another bZip protein which shares a similar DNA-binding profile but which lacks the
PAR domain and functions as a repressor, namely E4BP4 (E 4 binding protein 4) [129,131].
A striking observation is that the D-box enhancer element operates in a completely different
fashion in mammalian cells compared with fish cells. In mammalian species, the D-box is not involved
in the light input pathway of the clock. The expression of genes which contain D-boxes in their
promoters do not respond to visible light, UV or ROS exposure (Figure 1). Instead, the mammalian
D-box is clock regulated and thereby plays a role in the activation of genes belonging to the output
pathway of the clock machinery [132]. The expression of both DBP [133] and HLF [134] is strongly clock
regulated in the mammalian liver and the D-box enhancer has been shown to mediate the clock-driven
regulation of genes encoding enzymes such as CAT and SOD [115,135] as well as the production of
low molecular weight antioxidants such as glutathione (GSH) [136–138] with important functions in
the defense against xenobiotic and oxidative stress [139].
In contrast, D-box regulation in fish is tightly linked with coordinating the gene expression
response to oxidative stress as well as sunlight. Furthermore, as a result of genome duplication events
in early teleost ancestors, fish species possess extra D-box binding factors (TEF1, TEF2, HLF1, HLF2,
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DBP1, DBP2 and 6 E4BP4 homologs) [140]. These factors exhibit significant differences in their tissue-
and cell type-specific expression patterns and also can bind to D-boxes as hetero- or homo-dimers.
Therefore, it is clear that in fish, transcriptional regulation at the D-box is inherently complex. A clear
challenge for the future is to identify precisely how elevated ROS levels lead to the regulation of this
complex combination of transcription factors via activated JNK and p38 MAPK activity.
Figure 1. Light, reactive oxygen species (ROS) and the D-box enhancer. Schematic representation
of how D-box enhancer-driven gene expression is differentially influenced by blue light exposure in
mammalian, zebrafish and cavefish cells. In all three cell types light triggers an increase in intracellular
ROS levels that in turn activates the p-38 mitogen-activated protein kinase (MAPK) and c-Jun NH2
terminal kinase (JNK) stress pathways. In zebrafish cells (central panel), this signaling results in
the activation of D-box-driven gene expression, ultimately leading to circadian clock entrainment
(indicated by the green arrow). In mammalian cells (left panel) and in cavefish cells (right panel) this
signaling fails to activate gene expression via the D-box enhancer element and does not entrain the
circadian clock. The white arrow starting from the clock and pointing on the D-box element indicates
the circadian clock regulation of this enhancer in mammals [132]. The red cross over the clock in the
cavefish cells indicates the blind circadian clock observed in these cells [141].
2.3. Adaptation of Mechanisms Responding to Oxidative Stress during Evolution
Insight into how the light-ROS-D-box signaling pathway has adapted during evolution under
extreme environmental conditions has been gained from a set of comparative studies focusing on a
species of blind cavefish (Phreatichthys andruzzii). This species has evolved over 2–3 million years
completely isolated from sunlight, in layers of water locked beneath the Somalian desert [114,122].
Like other species inhabiting perpetually dark cave environments, these cavefish exhibit a set of striking
anatomical adaptations including complete eye loss and absence of body pigmentation, so-called
troglomorphisms. By comparing cavefish- and zebrafish-derived cell lines, it was revealed that light
entrainment of the clock as well as photoreactivation DNA repair has also been lost during evolution of
this cavefish [122,141,142]. Specifically, this originates from a loss of light-, UV- and ROS-induced gene
expression. Similar to the situation in zebrafish, blue or UV light triggers an increase in cellular ROS
levels as well as an activation of the MAP kinase stress pathways in the cavefish cell lines. However,
these events do not result in the transcriptional activation of D-box enhancer-regulated clock genes
such as per2 and cry1a or the CPD, DASH and 6-4 photolyase DNA-repair genes (Figures 1 and 2).
Precisely how the D-box regulatory factors have been modified during cavefish evolution remains
unclear. Furthermore, it will be fascinating to compare these cavefish regulatory mechanisms with
those of mammals which also fail to respond to ROS.
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Interestingly, the cavefish P. andruzzii appears to be only species described to date, apart from
placental mammals, that lacks the highly evolutionary conserved photoreactivation DNA repair
function. It has been speculated that in the DNA repair systems of P. andruzzii, we are witnessing the first
stages of a process that occurred previously in the ancestors of placental mammals during the Mesozoic
era. This speculation is based on the “nocturnal bottleneck” theory [143–145]. This theory predicts that
the ancestors of modern mammals became exclusively nocturnal in order to avoid predation by diurnal
carnivorous dinosaurs. This adaptation to a dark ecological niche may also explain many features of
present-day mammals including a general loss of extraretinal photoreception, as well as adaptations in
the eye and retina to facilitate vision under low-lighting conditions [143,145]. Adaptation to a nocturnal
lifestyle is also predicted to have entailed a general loss of light-dependent repair mechanisms that
target UV-induced DNA damage, namely the photolyase genes and photoreactivation function [143].
It is also interesting to note that similar to cavefish cells, in mammalian cell lines light and UV exposure
all trigger an increase in cellular ROS levels followed by activation of the MAP kinase stress pathways
but this does not result in activation of D-box enhancer-mediated gene expression [114,122].
Figure 2. Loss of D-box function in cavefish. Representative in vivo bioluminescence assays performed
in zebrafish (blue traces) and cavefish (orange traces) of cells transfected with the D-box enhancer
luciferase reporter derived from the zebrafish 6-4 phr promoter [122] (upper part of the figure).
Cells were exposed to three different stressors: light-dark cycles (left panel), a UVC pulse (central panel)
or 300 μM H2O2 (right panel). The grey (right panel) trace indicates luciferase expression of cavefish
cells not exposed to H2O2 (negative controls). Black and white bars below each panel indicate the
lighting conditions.
Another example where changes in the response to ROS are coupled with evolution in an extreme
environment is the naked blind mole rat (Spalax). These are small subterranean rodents common in the
Middle East that are distinguished by their adaptation to life in a hypoxic underground environment.
Specifically, these animals undergo cycles of digging closer to the surface and then burrowing in their
subterranean tunnel systems. As a consequence, at the cellular level, these animals experience cycles
of hypoxia followed by reoxygenation. In a normal animal, these alternating shifts in oxygen levels
can serve as a source of genomic instability, which underlies both aging and cancer. Severe hypoxia
results in S-phase arrest, dNTPs depletion and replication stress as well as a general repression of
DNA repair activity. Then, upon reoxygenation, S-phase restarts during an initial period when DNA
repair has still not recovered to normal levels. Therefore, DNA replication occurs in the presence of
ROS-induced DNA damage, leading to the accumulation of mutations. [146,147]. However, Spalax
exhibits remarkable longevity and a striking resistance to cancer [148]. It is therefore evident that a
key aspect of the adaptations Spalax has made for life in its hypoxic environment are fundamental
changes in the molecular mechanisms responding to cycles of hypoxia and oxidative stress. It has been
speculated that the cancer resistance in Spalax results from an amino acid substitution in the p53 gene
leading to a R174K substitution. p53 serves as a master regulator of the DNA damage response and has
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been termed the “guardian of the genome.” This amino acid substitution in Spalax impairs the ability
of the p53 protein to trigger apoptosis, although the protein is still able to induce cell cycle arrest [149].
3. Conclusions
Our current understanding of the molecular mechanisms responding to oxidative stress reveals
extensive conservation of many of the main regulatory pathways between organisms as diverse as
mammals, yeast and Drosophila. However, there are also examples of fundamental changes in these
mechanisms during evolution. For example, the switch in the function of the D-box enhancer from
a ROS regulatory target in fish, to a clock regulatory target in mammals as well as the loss of ROS
responsiveness of the D-box enhancer during cavefish evolution. Furthermore, fundamental changes
in the functionality of the p53 protein have accompanied the adaptation of the naked blind mole
rat to its life in a hypoxic environment. These findings reveal that the functions of ROS responsive
mechanisms are also potentially plastic and are shaped by the selective pressure of the environment.
By identifying precisely which elements of these regulatory mechanisms are “targeted” during the
process of evolution, we will gain considerable insight into how organisms adapt to oxidative stress
and damage over evolutionary time scales.
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Abstract: Unaccustomed and/or exhaustive exercise generates excessive free radicals and reactive
oxygen and nitrogen species leading to muscle oxidative stress-related damage and impaired
contractility. Conversely, a moderate level of free radicals induces the body’s adaptive responses.
Thus, a low oxidant level in resting muscle is essential for normal force production, and the
production of oxidants during each session of physical training increases the body’s antioxidant
defenses. Mitochondria, NADPH oxidases and xanthine oxidases have been identified as sources
of free radicals during muscle contraction, but the exact mechanisms underlying exercise-induced
harmful or beneficial effects yet remain elusive. However, it is clear that redox signaling influences
numerous transcriptional activators, which regulate the expression of genes involved in changes in
muscle phenotype. The mitogen-activated protein kinase family is one of the main links between
cellular oxidant levels and skeletal muscle adaptation. The family components phosphorylate and
modulate the activities of hundreds of substrates, including transcription factors involved in cell
response to oxidative stress elicited by exercise in skeletal muscle. To elucidate the complex role
of ROS in exercise, here we reviewed the literature dealing on sources of ROS production and
concerning the most important redox signaling pathways, including MAPKs that are involved in the
responses to acute and chronic exercise in the muscle, particularly those involved in the induction of
antioxidant enzymes.
Keywords: insulin resistance; cancer; cardiovascular disease; neurodegenerative disorders; exercise;
mitochondria; oxidative stress; PGC-1; Nrf2; UCPs
1. Introduction
For several years the practice of physical activity has expanded in scope from competitive sports
to disease prevention and health promotion. Therefore, physical activity has been widely recognized
as a means for the primary prevention of chronic diseases as well as for patient treatment and
rehabilitation [1]. Furthermore, regular physical activity (training) has beneficial effects on people’s
health and well-being.
The results of numerous studies have shown that regular physical activity reduces risk of several
diseases including cardiovascular diseases, type 2 diabetes (T2DM), some types of cancer, osteoporosis,
fall-related injuries, depression, and obesity [1–3].
Despite these clear benefits, little is known about the adaptive mechanisms involved in the
protection offered by exercise even though to date accumulating evidence has allowed establishing
that the production of free radicals represents a potential link between exercise and protection
against diseases.
Int. J. Mol. Sci. 2019, 20, 3024; doi:10.3390/ijms20123024 www.mdpi.com/journal/ijms165
Int. J. Mol. Sci. 2019, 20, 3024
Currently, free radicals are recognized to play a crucial role in the regulation of critical physiological
processes at both the cellular and system level, and be involved, as causal factors, in the development
of pathological conditions. The regulatory role of free radicals is a relatively recent discovery, because
for several decades they were thought to cause exclusively damaging effects and were gradually
implicated in various pathologies, including cardiovascular disease, diabetes, rheumatoid arthritis,
cancer, and neurodegenerative disorders [4].
The double role played by oxidants in living systems seems to be dependent on the extent of
their production. Indeed, if produced in a massive extent, oxidants cause oxidative damage and tissue
dysfunction whereas, when moderately produced, they serve as molecular signals activating adaptive
responses that are useful for the organism.
A paradigmatic example is provided just by the exercise. Indeed, a single session of strenuous
or prolonged exercise leads to the production of high amounts of radicals and other reactive oxygen
species (ROS), which cause tissue damage and dysfunction. Conversely, the single sessions of a
training program produce low amounts of ROS, which can induce adaptive responses beneficial for
the organism [5].
Interestingly, the incidence of some ROS associated diseases, among which T2DM, rheumatic
arthritis, heart disfunctions, Alzheimer and Parkinson diseases, is reduced by the execution of regular
physical activity [1,6].
The balance of free radicals inside the skeletal muscle is very important, particularly in the context
of exercise and sport as the main adaptations occur in the trained skeletal muscle, which can differ with
the type of exercise but seem to be nevertheless dependent on ROS production. Thus, aerobic physical
activity induces skeletal muscle adaptive responses [1] able to determine an increased resistance to
conditions, among which prolonged or strenuous exercise, in which ROS production increase [7–9].
Conversely, heavy resistance exercise determines hypertrophy and increased strength production but
does not change biochemical characteristics of muscle cells. On the other hand, metabolism of glucose
and lipids in skeletal muscles during the resting state and insulin action in insulin-resistant individuals
are improved by both aerobic [10] and resistance [11] exercises in skeletal muscle leading to decreased
conversion rates to overt diabetes.
In recent times, much progress has been made in understanding the mechanisms underlying the
adaptations evoked in skeletal muscle. However, other studies are needed to understand what factors
lead ROS to become signal and/or stress agents and the molecular mechanisms through which ROS
directly interact with critical signaling molecules to initiate signaling in skeletal muscle. This review,
after examining the link between physical activity and ROS production, focuses on signaling pathways,
such as MAPKS and transcription factors and cofactors, through which ROS produced in the regular
physical activity elicit the adaptive responses implicated in increased antioxidant defenses effectiveness
and mitochondrial content of skeletal muscle.
2. Reactive Oxygen and Nitrogen Species
Until about the mid-20th century free radicals, whose existence in chemical systems had been
demonstrated by Gomberg’s work [12], were still believed as too reactive species to exist in vivo [13].
Subsequently, when free radical existence in biological systems was recognized, they were thought to
cause exclusively damaging effects and to be involved in the development of pathological conditions.
In particular, ROS were thought to be involved in the general aging process and in many age-associated
diseases [14].
This view was mainly supported by the finding that ROS, reacting with most biological
macromolecules, cause their oxidative modification, which can result in the loss of their function [15].
In fact, ROS include both highly reactive species, such as the hydroxyl radical (•OH), which reacts
soon after its formation, and less reactive species, among which are superoxide (O2•−) and hydrogen
peroxide (H2O2) [16]. Similarly, other reactive species containing nitrogen, named reactive nitrogen
species (RNS), include both species not very reactive, such as nitric oxide (NO•), and species very
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reactive such as the peroxynitrite (ONOO−), which originates from NO• and is a very strong oxidant
for biomolecules and can also undergo decomposition releasing small amounts of •OH [17].
Many studies have reported that in normal conditions potentially toxic ROS and RNS are constantly
produced at a low level in living systems. Aerobic organisms are equipped with an integrated system
of antioxidant defenses to counteract the effects of ROS and RNS [18]. The antioxidant network consists
of free radical scavengers of low molecular weight and a composite enzymatic system, which can
scavenge free radicals, interrupt chain reactions, remove or repair the damaged components in the cells.
Enzymatic antioxidants include a family of metalloenzymes called superoxide dismutases (SODs) [19],
which convert O2•− to H2O2, catalase (CAT) an enzyme catalyzing the decomposition of H2O2 to H2O
and O2 [20], glutathione peroxidases (GPXs) [21], a family of selenoproteins which decomposes H2O2
using as substrate the reduced glutathione (GSH) which is converted to oxidized glutathione (GSSG),
glutathione reductase (GR) which reduces GSSG and restores GSH utilizing NADPH as a source of
reducing equivalents [22] (Figure 1). In the cells the redox homeostasis is maintained other than the
redox couple GSH/GSSG also by the thioredoxin proteins (Trxs), which are involved in the reduction of
protein disulfide [23] and are regenerated by thioredoxin reductase (TrxR) and NADPH [24]. Trxs also
collaborate with peroxiredoxins (Prxs) in the hydroperoxide removal as Prxs reduce both hydrogen
peroxides and lipid hydroperoxides to water and alcohol with the help of the proteins containing thiol
such as Trxs [25]. It is worth noting that Trxs, GPX, and SOD have also been recognized as potential
systems able to remove RNS [26].
Figure 1. Reactions by which reactive oxygen species (ROS) are produced and removed by antioxidant
defense system in skeletal muscle.
Normally, the antioxidant system rapidly removes ROS and RNS before they cause cellular
dysfunction and eventual cell death. However, in the living systems generation slightly overcome the
capacity of the antioxidant defense system to neutralize ROS, therefore a modest level of oxidative
damage is always present. Probably, ROS are not all eliminated because they perform important roles,
so that the challenge for the survival process was to evolve antioxidant defenses that allow such roles
while minimizing damage.
However, when a greater imbalance occurs in favor of the ROS, oxidative stress ensues [27]
characterized by widespread tissue damage, to which cells can adapt sometimes by upregulating the
antioxidant system.
3. Exercise Induced Oxidative Damage
It is long known that physical activity promotes well-being and that in inactive subjects there is an
increased incidence of several chronic diseases including obesity, diabetes, hypertension, osteoporosis
and mood problems.
The observation that exercise, long-lasting in trained and of short term in non-trained subjects,
induces damage seemed at odd with the idea of its beneficial effects. The damage was mainly observed
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in exercise in which the eccentric contractions were prevalent, and it included structural and functional
alterations not only in skeletal muscles but also in other tissues [28–31].
ROS implication in tissue damage induced by acute exercise was reported as early as the late
1970s [32]. Some years later, Davies and collaborators [33], using electron spin resonance (ESR)
spectroscopy method proved first that free radical signals were intensified in rat muscle after a bout of
exhaustive running. These results were subsequently confirmed by Jackson et al. [34]. It was later
observed that contracting muscles also produce NO• and other RNS [35].
Since these early observations, many studies have confirmed that muscular exercise promotes
the production of both ROS and RNS in skeletal muscle fibers. Jenkins et al. [36] found that the
tert-butyl-hydroperoxide induced chemiluminescence, a marker of ROS production, was increased by
an exhaustive run in the hindlimb muscles of rats. Furthermore, it was found that ROS production,
measured using the intracellular probe 2′,7′-dochlorofluorescein, increased in rat diaphragm muscle
during contraction [37], in vastus lateralis after exhaustive exercise [38], and in single mature skeletal
muscle fiber [39].
Important advances have also been made about to identification (principally) and quantification
of reactive species. Indeed, a series of studies demonstrated that contracting skeletal muscle transiently
overproduces parent reactive species, such as O2•− and NO•, and secondary reactive species, such
as H2O2, •OH, ONOO−, and lipid-derived oxygen (O2)-centered alkoxyl radicals [39–43]. However,
the direct mechanisms and sources of ROS and RNS production during exercise remain uncertain and
they are likely to differ depending on the type of activity.
In the cell, O2•− is generated by the addition of a single electron to ground state oxygen in several
sites including plasmalemma, cytosol, peroxisomes, mitochondria and endoplasmic reticulum [5].
It has been found that the mitochondria, the NADPH oxidase (NOX), and the enzyme xanthine
oxidase (XO) are the main endogenous sources of ROS in skeletal muscle [44]. In mitochondria,
superoxide production verifies mainly at complexes I and III of the electron transport chain [45], and it
has often been assumed that it is the primary cell source of ROS in physiological and pathological
conditions [46]. However, there is no convincing evidence that mitochondria are the main cellular
source of ROS in contracting muscle fibers [47]. Conversely, using confocal microscopy with specific
fluorescent probes it was observed that muscle contraction increases O2•− in cytosol and subsequently
in mitochondria. This observation suggests that a ROS generator different from mitochondria could be
the potential primary source of ROS production during muscle contraction [48]. Furthermore, the idea
that mitochondria are the main source of ROS during the muscle contraction is also theoretically
inconsistent. In fact, when muscle contraction begins mitochondrial respiration enters State 3 (active
respiration). Since the reduction degree of the autoxidizable carriers, by which mitochondrial ROS
production depends, decreases in State 3 [49], it is foreseeable that the rate of O2•− production also
decreases during the muscle contraction.
Nevertheless, measurements of ROS release by muscle mitochondria isolated from exercised
animals suggest that the rate of mitochondrial ROS release is increased by aerobic exercise. For example,
ROS release by mitochondria isolated from rat exercised to swim until exhaustion increased during both
State 4 and State 3 respiration [50,51]. This increase was accompanied by alterations in mitochondrial
functionality as evidenced by enhanced State 4 and decreased State 3 respiration [50]. Thus, it is
possible to hypothesize that during exercise a source other than mitochondria initially produces the
ROS, which then damage the mitochondria altering their functionality and increasing their ROS release.
NOX, located within the sarcoplasmic reticulum, transverse tubules and sarcolemma, is considered
a key ROS generator during muscle contractions. Indeed, both at rest and during contractile activity it
appears to contribute more than mitochondria to cytosolic O2•− in skeletal muscle [52].
On the other hand, evidence also indicates that XO produces superoxide in the cytosol of
contracting rat skeletal muscles [53] even if it has also been reported that the muscle cells do not contain
large amounts of the enzyme [54]. However, this enzyme is present in associated endothelial cells and
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might contribute to exercise-induced muscle damage [55]. However, additional research is required to
determine the role played by XO in exercise-induced ROS production in human skeletal muscle.
Long lasting, strenuous exercise also induces oxidative muscle damage via ROS production by
phagocytic white blood cells, particularly neutrophils, which infiltrate the muscular tissue [56]. NO•
is produced from the conversion of L-arginine into L-citrulline by enzymes known as nitric oxide
synthases (NOS) [57] of which three different isoforms have been defined: Type I neuronal (nNOS),
type II inducible (iNOS) and type III endothelial (eNOS). Normally, skeletal muscle expresses nNOS
and eNOS, whereas iNOS, is induced in response to infection, inflammation, or trauma [58]. Thus,
it is well established that isolated skeletal muscle fibers produce low levels of NO• during resting
conditions while heavy muscle contraction results in increase of generation of NO• which has many
signaling functions but may also have some detrimental effect because of the danger linked to the
formation of highly reactive ONOO- [42]. Passive stretching of the muscle has also been shown to
increase NO• release from rat skeletal muscle in vitro and to increase nNOS expression. Moreover,
the use of inhibitors of putative generating pathways [42] and western blotting [43] indicates that
contraction induced NO• release is primarily from neuronal NO• synthase enzyme.
4. Markers of Exercise-Induced Oxidative Damage
In addition to the ROS formation during exercise having been directly measured, other support
exists to the idea that during exercise an increased ROS production verifies. Indeed, it is possible to
determine the changes in tissue content of stable molecules arising from the reaction of free radicals
with certain biomolecules. In fact, the increase in radical production often results in profound oxidative
alterations of various biological substances, including lipids, proteins and nucleic acids, which are
commensurate to the increase in free radical production. Thus, the measurement of the content of
derivatives of these substances oxidatively damaged has been used to obtain information on ROS
production in various physio-pathological conditions. Most commonly measured are the molecules
derived from the oxidatively damaged lipids, proteins or DNA or the changes in the levels of antioxidant
molecules such as GSH (Table 1).
Lipid peroxidation has been frequently considered as a marker of exercise-induced oxidative
stress thanks to the extreme susceptibility of lipids to ROS and to the stability of lipid peroxidation
byproducts. Therefore, different studies exist showing that lipid peroxidation increase in skeletal
muscle after acute running [33,59–61] and swimming exercise [8,9,50].
In contrast to lipid peroxidation, few data are available on the effects of exercise on protein and
DNA oxidation in skeletal muscle.
Protein oxidative damage generates several byproducts that originate from oxidative modifications
of lateral chains of different amino acids. Protein carbonyls represent an irreversible form of protein
modification and have been demonstrated to be relatively stable, so that they are considered an
adequate marker of protein oxidation [62]. The first study on accumulation of protein-bound carbonyls
was published by Reznick et al. [63], who reported that a single bout of exercise caused an increase in
protein-bound carbonyl content in the rat skeletal muscle. Similar results were subsequently obtained
in rat skeletal muscle subjected to exhaustive exercise [64]. Conversely, other researchers found that
protein carbonyl formation in deep vastus lateralis [38] and in both fast and slow muscles [65] was
unaffected by exhaustive exercise. More recently, oxidative damage to proteins in homogenates and
mitochondria from skeletal muscle has been found after swimming exercise [50].
To establish DNA oxidative damage, the accumulation of 8-hydroxy-deoxyguanosine (8-OHdG)
is normally determined. The levels of 8-OHdG in several tissues of dog, including skeletal muscle,
showed no significant changes in tissues, except the colon, soon after exercise [66]. Similarly, no
significant changes were found in the levels of 8-OHdG in the nuclear DNA of fast and slow muscles
of rat because of acute exercise [65].
In contrast, increases in 8-OHdG were found in skeletal muscle from young and old subjects 24 h
after a single bout of exercise [67]. It was suggested that the increase in DNA damage was due to a
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delayed effect of exercise, which results in activation of macrophages and neutrophils and involves
massive ROS production.
Some explanations can be provided for the lack of 8-OHdG increase soon after the end of the
exercise. First, it is likely that most of the ROS generated by various cellular sources during the exercise
are intercepted by cytosolic antioxidants before they reach the nuclear DNA. Second, the DNA in the
nucleus is protected by the histone proteins, which render the nuclear DNA less susceptible to ROS
activity [68]. Finally, a specific enzyme, the 8-oxoguanine DNA glycosylase/lyase [69], is activated and
rapidly repairs oxidatively damaged DNA [70].
GSH, a ubiquitous tripeptide thiol, is one of the most important scavengers of ROS, and its ratio
with GSSG may be used as a marker of oxidative stress, because GSH is oxidized to GSSG, and the
GSH/GSSG ratio decreases under oxidative conditions. Several studies have reported a decrease in
muscle GSH/GSSG ratio in response to exercise. An early study by Lew and coauthors [71] showed that
exhaustive exercise causes significant increases in GSSG and ratio between GSSG and total glutathione
(GSH + GSSG) in rat skeletal muscle. Subsequently it was shown that GSSG was elevated to as high
as 160% of the resting levels, whereas GSH/GSSG ratio fell significantly after an exhaustive bout of
exercise [72]. More recent research has also shown that 6 h of swimming exercise reduces muscle GSH
level and GSH/GSSG ratio [50].
Interestingly, like aerobic exercise, anaerobic exercise of enough intensity and duration increases
oxidative modification of proteins, nucleic acids, and lipids [73]. However, aerobic exercise-induced
ROS release and consequent oxidative damage depends on mitochondrial electron transport chain
and on the enzyme NADPH oxidase, which is localized in the sarcoplasmic reticulum, the transverse
tubules and on the muscle plasma membrane [74]. Conversely, the ROS production found during and
after anaerobic physical activity can be due to other systems, among which xanthine oxidase [75].
In the whole, despite some disagreeing results, there seems to be little doubt that acute exercise
results in both enhanced production of reactive species and oxidative damage to components of
muscular cells.
An important consequence of the involvement of the free radicals in tissue damage caused by
acute exercise is the possibility to reduce the radical effects by supplementation with antioxidants such
as vitamins C and/or E, carotenoids, GSH or its precursor the N-acetylcysteine. It has been shown
that antioxidant supplementation protects against the deleterious effects of intense exercise [76–78].
The involvement of free radical in the exercise-induced oxidative damage and the protective effect of
antioxidants are further demonstrated by observation that low levels of vitamin E are associated with
a high exercise induced lipid peroxidation [33].
5. Muscle Adaptations Induced by Training
Skeletal muscle is particularly responsive to training which induces adaptations such as
potentiation of antioxidant system, increased mitochondrial content, increased sensitivity to insulin,
ameliorating the muscle function and protecting against the onset of metabolic disorders [79].
An important concept developed over the past decade is that the responses to training are likely the
result of the acute but cumulative effects of the responses to single exercise bouts [80]. Thus, each bout
of exercise initiates acute and transient changes in gene transcription which are reinforced by repeated
exercise stimuli, leading to altered, chronic expression of a variety of nuclear and mitochondrial DNA
(mtDNA) gene products, that ultimately form the basis of skeletal muscle training adaptation and
improvements in exercise capacity [81].
However, skeletal muscle responds to exercise in a training specific manner. Classically, training
was distinguished in “endurance training” and “strength training” also referred as “resistance training”.
Endurance exercise (e.g., running, swimming, cycling) is generally characterized by high-frequency,
long duration, and development of a relatively low force. Resistance exercise (e.g., weight lifting) is,
in general, characterized by low frequency, short duration, and development of a relatively high force.
These two training modalities represent the extremes of a continuum of exercise protocols of countless
170
Int. J. Mol. Sci. 2019, 20, 3024
options that differ in terms of intensity, duration, frequency, and mode of contraction as well as any
combination of these.
Endurance training enhances the muscle aerobic metabolism capacities but do not induce increases
in muscle mass or capacity to develop strength. Indeed, training to endurance determines in skeletal
muscles a transformation of fiber-type, increases the mitochondrial mass, the production of new blood
vessels and other adaptations [82]. Muscle blood vessels increase is a necessary adaptation to the
increased mitochondrial oxygen requests [83]. Mitochondrial density increases rapidly in muscle
particularly when subjects are previously untrained. The increase in mitochondrial compartment
is accompanied by enhancement in the content of the enzymes of both Krebs cycle and oxidative
phosphorylation among which succinate dehydrogenase (SDH), citrate synthase (CS), and cytochrome
c oxidase (COX) [84]. Due to these adaptations, and of the increased capillarization, in the endurance
trained muscle oxidative capacities are greatly enhanced. Conversely, endurance exercise does not
change the cross-section area of the fibers unless the muscle was preceded by immobilization or
underuse [85].
The adaptations elicited by the endurance-type exercise increase the resistance to exercises of
intensities that in the untrained state can be performed for shorter period.
Strength training induces muscle cells hypertrophy and increase strength production but does not
affect biochemical composition. Classic strength training protocols predominantly impact on muscle
and muscle fiber cross-sectional area. It is important to realize that, in terms of functional changes,
significant strength gains can be obtained by changes in the nervous control of the muscle mainly at
the onset of training session [86]. At the beginning, the functional adjustment can be obtained with
low level of structural changes. Continuing the training of strength, the cross-sectional area increases,
and this is more evident at the origin and insertion of the muscle [87].
It was initially hypothesized that the increase in the cross-section area was due to the expansion
of the preexisting cells and not to the cell proliferation. Subsequently, it was shown that such a growth,
was dependent on the enhanced content of myofibrils, and that the net increase in cross-section area
was mainly due to the increase in the fast fibers of the type IIa and IIX in man [88]. However, evidence
is now available that, in several animal species, eccentric strength training, during which muscle exerts
force while lengthening, is capable of muscle hyperplasia with neoformation of muscle fibers even
though muscle growth depends largely on fiber hypertrophy [89]. The expression of the heavy chain
of myosin is changed by strength training in an extension and direction that apparently depends on
the characteristics of the protocol of exercise.
In older adults particularly salutary is resistance training thanks to its capacity to reduce the
sarcopenia that verifies with age [90]. Resistance training is advisable for all healthy adults for its
beneficial effects in reducing blood pressure [91] and cardiovascular disease risk [92].
Early works suggested that strength training only marginally changes mitochondria and
capillarization in muscle [93]. Indeed, mitochondrial volumes and capillary densities were
found to be low in strength-trained human muscles; muscle metabolism remained dominantly
carbohydrate-dependent such that the relative content of cytoplasm containing glycogen was
increased [94].
However, more recent works indicate that strength training results in effects like those elicited by
endurance training. Indeed, it can improve insulin action and glucose metabolism [11] and stimulate
mitochondrial biogenesis [95]. Moreover, recent researches have challenged the view that endurance
and strength training are distinct exercise modalities, which increase mitochondrial density [96] and
myofibrillar units [88] of skeletal muscle, respectively. It was found that in lean sedentary adults both
10 weeks resistance training or aerobic training enhanced mitochondrial respiration in the skeletal
muscle, and that the oxidative capacity increase was dependent on qualitative changes in mitochondria
not being the mitochondrial density substantially modified [95]. This suggests that mitochondrial
biogenesis is stimulated by both training modalities, although it is likely the two training modalities
do not achieve the same outcome by identical mechanisms.
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A subsequent study also showed that a long period (nine months) of resistance and endurance
training induce muscle mitochondrial proliferation and that the combination of both training modalities
induces a more marked reduction of oxidative damage to lipids and carbohydrates and a greater
increase in mitochondria content and mitochondrial enzyme activities, suggesting that the two modes
of training together are healthier by protecting against T2DM [97].
Interestingly, study performed on elderly muscle, which showed large energetic, but smaller
structural, adaptations, demonstrated that only resistance training induced a rise in mitochondrial
volume density and muscle size [98].
6. Mechanisms of Muscle Adaptive Responses to Training
Accumulating evidence has induced to think that the dual role of ROS in animal organisms
can be responsible for the contrasting effects of acute and chronic exercise. Indeed, it is now well
established that ROS can damage proteins, nucleic acids and membrane phospholipids leading to
cellular dysfunction, but they also have essential physiological functions in the cells acting as signals
for the regulation of transduction, proliferation and transcription [99]. Therefore, the different roles of
ROS in training as signaling molecules for the induction of tissue adaptation, and in acute exercise as
damaging molecules, can depend on differences in the extent and temporal pattern of ROS generation.
The low levels of ROS produced intermittently for a short period of time during a training protocol
program, activate intracellular signaling ways that promote cellular adaptations leading to increased
capacities against subsequent stresses. Conversely, moderate levels of ROS generation for a long period
of time, or high generation due to high intensity exercise, induces structural and functional damage.
In the past years, evidence has been obtained that during each session of a training program
the low level of ROS regulates signaling cellular pathways that result in the induction of the training
induced adaptations that are healthy for the organism [5].
In the subsequent parts of this review we will examine the literature concerning our current
knowledge about some potential signaling pathways that link ROS to the remodeling that occurs in
skeletal muscle during exercise training.
7. Muscle Performance
It was long accepted that the idea that training to physical exercise led the animals or human to
successfully endure exercise loads of different intensities, types and durations. Training shows to be
able to stem the homeostasis disturbance during an exercise bout, allowing the animals or humans
to bear physical work for longer time before fatigue appears [100], but the factors that condition the
physical performance are controversial.
8. ROS and Muscle Performance
In the past years, evidence was obtained that ROS affect the muscle capacity to generate force,
being that the low levels of ROS in the resting (i.e., unfatigued) state is necessary for normal force
production [101]. Therefore, in the muscle the excessive scavenging of ROS by the antioxidant is linked
to reduced force generation [101–103], whereas a low ROS production increases force generation [104].
On the other hand, the ROS capacity to increase muscle force production is reversed when ROS levels
are higher and force production is reduced with increased time of exposition and dose of ROS [104].
These results led to propose the existence of an ideal redox state in which the conditions for the force
production by the muscle are optimal and that the removal from such an ideal state leads to reduced
force production [104].
Endogenous production of NO• can also modulate skeletal muscle force production. Indeed,
studies using excised bundles of muscle fibers reveal that force production during submaximal tetanic
contractions is depressed by NO• donors and increased by NOS inhibitors and NO• scavengers [74].
Conversely, a consensus of literature does not exist to support the notion that NO• production promotes
muscular fatigue [74]. The evidence that sports performance is impaired by redox imbalance through
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various mechanisms that compromise the structure and function of the muscle cells, suggested that ROS
contribute to muscular fatigue during prolonged exercise. The process involved in exercise-induced
muscle fatigue depends on several factors [105,106] and the specific causes of muscle fatigue vary
depending on the type of exercise that produces it [107]. For example, the main factors contributing
to fatigue during high-intensity contractions that take place during resistance exercises and that
contributing to fatigue during low intensity exercise with continued contraction, are different. However,
there is evidence indicating that free radical production in skeletal muscles contributes to fatigue
during various types of exercise.
Indeed, by studying the contribution of oxidants to muscle fatigue using a variety of animal model
evidence of a relationship between endurance and free radical generation was obtained. Several studies
have demonstrated that antioxidant treatment can delay the fatigue, but other studies have shown
that antioxidants are able to reduce the levels of oxidative stress markers but not the onset of fatigue,
mainly in humans [108]. However, most human studies have been performed on athletes or trained
subjects, in whom the antioxidant supplementation can have harmful effects that hinder the adaptive
processes stimulated by ROS (see below). Indeed, endurance to isokinetic cycle exercise was increased
in healthy untrained volunteers by diet supplementation with a whey-based cysteine donor [109].
Furthermore, the administration of vitamin E, which is known to reduce the exercise-induced oxidative
damage [110], prolonged the endurance to physical exercise in mice [111]. Novelli et al. [112] also
observed that directly administered GSH to mice resulted in an increase in swimming endurance.
The most effective substance in inhibiting fatigue was N-acetylcysteine (NAC) [113], a nonspecific
antioxidant and reduced thiol donor that is a precursor and upregulator of the synthesis of GSH [114].
The evidence that muscle performance is most consistently improved by antioxidants that oppose thiol
oxidation leads to think that such antioxidants delay fatigue by helping to maintain thiol groups of
myofibrillar proteins in a reduced state.
9. Training and Muscle Fatigue
In contrast to acute exercise, training does not increase muscle oxidative damage as demonstrated
by the finding that levels of malondialdehyde (MDA), a product of lipid peroxidation, of white muscle
are not modified whereas those of red muscle are decreased in rats trained to run [60]. Furthermore,
levels of MDA and of lipid hydroperoxides, another product of lipid peroxidation, are not modified in
gastrocnemius of young [8] and adult [9] rats trained to swim.
Training also exerts a protective effect against oxidative damage elicited by acute exercise since it
prevents the appearance of some signs of exercise-induced free radical generation, such as the increases
in muscle lipid oxidation normally elicited by acute run exercise [60]. In contrast, exhaustive swimming
exercise gives rise to tissue damage irrespective of the trained state, as documented by similar levels of
muscle lipid peroxidation and loss of SR and ER integrity found in exhausted trained and untrained
rats [8]. However, exercise endurance capacity is greatly increased in trained rats indicating that lipid
peroxidation and tissue damage are strongly slowed down.
10. Antioxidants Enzymes
An explanation for these training effects was provided by the finding that muscle activities of
the key antioxidant enzymes were modified by chronic exercise protocols [115]. The results obtained
in subsequent studies were somewhat variable, but in general they confirmed the idea that exercise
training promotes an increase in key antioxidant enzymes in skeletal muscle (Table 2). Thus, glutathione
peroxidase (GPX) activity was increased, whereas SOD was unmodified and CAT activity was decreased
in skeletal muscle of rats trained to run [116]. GPX and GR activities were increased by swimming
training in gastrocnemius muscles of young (four months) [8,117] and adult (12 months) rats [9].
Training increased total antioxidant capacity irrespective of age [8,9], but its effects on antioxidant
enzymes were dependent on age. Indeed, training increased GPX and SOD activities in young rats,
decreased GR and CAT activities in adult rats and CAT activity in old rats. Thus, it was suggested
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that exercise training, although increasing selective antioxidant enzymes in young rats, does not offer
protection against oxidative stress in the senescent muscle [118]. This view was confirmed by the
observation that run training increased the activities of CAT, GPX, and MnSOD, and did not modify
CuZnSOD activity in young rats, whereas did not modify the activities of CAT, GPX and CuZnSOD
in the soleus muscle and decreased the activity of MnSOD in aged rats, [119]. Moreover, swimming
training enhanced the activity of GPX and CuZnSOD, but not that of MnSOD, in young mice, while it
did not modify enzyme activities in old mice [120].
The magnitude of adaptation was in part dependent upon exercise intensity, so that higher training
intensities induced greater changes in the antioxidant defense [121]. Moreover, the changes induced
by training in muscle antioxidant enzymes were muscle fiber-specific because GPX and SOD activities
increased in vastus lateralis, whereas GR activity declined and those of GPX and SOD remained
unchanged in soleus [122].
Antioxidant adaptation is also dependent upon exercise duration. Indeed, GPX and GR activities,
which were unchanged after the first six-week training period, increased after the 7th week of training,
whereas SOD activities were unchanged after both training periods [54].
It is worth noting that chronic resistance training may provide a protective effect like aerobic
exercise on redox homeostasis. Indeed, it was reported that resistance training reduces serum lipid
peroxidation providing protection against oxidizing agents in vitro and against oxidative damage
generated by aerobic exercise [123], perhaps mediated by improvements in the thiol portion of the
antioxidant defense. Furthermore, resistance training reduces muscle DNA oxidative damage [124]
and increases antioxidant defense in older adults [125]. Indeed, training results in a significant increase
in CuZnSOD and CAT but not MnSOD activity in vastus lateralis muscle [125].
Table 1. Effect of exercise on markers of oxidative damage in skeletal muscle.
Species Activity Marker Ref.
Rat (6 mo) Exhaustive treadmill running (submaximal workintensity) (gastrocnemious, soleus, plantaris) TBARS↑ [33]
Rat (2 mo Exhaustive swimming (gastrocnemious) HPs↑, MDA↑ [8]
Rat (12 mo) Exhaustive swimming (gastrocnemious) HPs↑, MDA↑ [9]





Rat Moderate and high intensity running (red and white VL) HPs↔, MDA ↑ [59]
Rat Treadmill running (20 min) MDA↑ [60]
Rat Treadmill running (1 h) (20 m/min, O% grade) MDA (mit)↑ [61]
Rat Exhaustive exercise (gastrocnemious) C=O↑ [64]
Rat (8 mo, 24 mo) Exhaustive treadmill running (25 m/min, 15 m/min, 5%grade)
MDA↑, C=O↔,
GSH/GSSG↓ [38]
Rat (2 mo) Exhaustive treadmill running (1.6 Km/h) (fast and slowmuscle)
C=O↔, MDA↔,
8-oxodG↔ [65]
Dog Treadmill running (7 h) (splenius, diaphragm,gastrocnemious) 8-oxodG↔ [66]
Men (~26, ~65 yr) Exhaustive treadmill running (45 min, 75%VO2max and45 min, 90% VO2max)
8-oxodG↑ [67]
Rat Exhaustive treadmill running GSH/GSSG↓ [72]
Men (~68 yr) Whole-body resistance exercise training (14 wk) 8-oxodG↓ [124]
Rat (2 mo) Swim training (10 wk) (gastrocnemious) MDA↔ [8]
Rat (12 mo) Swim training (10 wk) (gastrocnemious) MDA↔ [9]
↔ unchanged; ↓reduced; ↑increased; mo: months; yr: years; wk: weeks; mit: mitochondria; VL: vastus lateralis.
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Table 2. Effect of training on antioxidant enzyme activity in skeletal muscle.
Species Activity Enzymes Ref.
Rat (2 mo) Swim training (1 h, 10 wk) (gastrocnemious) GPX↑, GR↑ [8]
Rat (12 mo) Swim training (1 h, 10 wk) (gastrocnemious) GPX↑, GR↑ [9]
Rat (50 days) Swim training (1 h, 10 wk) (gastrocnemious) GPX↑, GR↑ [117]
Mouse (2 mo) Swim Training (1 h, 6 wk) GPX↑, GR↑, MnSOD↔,CuZnSOD↑ [120]
Mouse (26 mo) Swim training (1 h, 6 wk) MnSOD↔,CuZnSOD↔ [120]
Rat Treadmill training (32 m/min, 8%, 2 h, 12 wk)(soleus, gastrocnemious) CAT↓, GPX↑, SOD↔ [116]










Rat Treadmill training (25 m/min 10%, 2 h, 10 wk) (DVL) SOD↑, GPX↑, GR↓ [122]
Rat Treadmill training (25 m/min 10%, 2 h, 10 wk) (soleus) SOD↔, GPX↔GR↓ [122]
Rat (4 mo) Treadmill training (25 m/min, 10%, 10 wk) (DVL) GPX↑, MnSOD↔,CuZnSOD ↑ [126]





Rat (3 mo) Treadmill training (27 m/min, 12% grade, 2 h, 10 wk) (DVL) GPX↑CAT↑, MnSOD↑,CuZnSOD↔ [127]
Men (~23 yr) Maximal cycling sprint training (6 wk) (VL) GPX↔ GR↔, SOD↔ [54]
Men (~23 yr) Maximal cycling sprint training (7 wk) (VL) GPX↑, GR↑, SOD↔ [54]
Men (~71 yr) Unilateral resistance exercise training (12 wk) (VL) CuZnSOD↑MnSOD↔CAT↑ [125]
↔ unchanged; ↓reduced; ↑increased; mo: months; yr: years; wk: weeks; DVL: deep vastus lateralis; VL:
vastus lateralis.
Several experimental evidences suggest that the training-linked adaptations are induced by
changes in gene expression with upregulation of both mRNA levels and protein expression. It must
be underlined that the available data are few and debatable. For example, CuZnSOD activity and
mRNA abundance were found to be higher in vastus lateralis (VL) muscle of trained compared to
sedentary rats. However, the CuZnSOD protein content was not altered in the muscle, but increased in
its superficial portion (type 2b). Moreover, the MnSOD protein content was higher in trained rats but
its activity and mRNA abundance were not affected, whereas the GPX activity was increased without
changing its mRNA abundance [126].
Training increased mitochondrial MnSOD activity in the deep portion of VL, and the MnSOD
protein content in pooled superficial portion of VL and plantaris muscle [127]. The levels of the mRNA
of MnSOD did not change in any muscle. The mRNA level, protein content and activity of CuZnSOD
were not changed by training except for an increased protein content in pooled SVL. GPX and CAT
activities were increased significantly by training only in the muscle DVL. Therefore, it was suggested
that training induces adaptations of the antioxidant enzyme mainly in fibers of the type IIa, probably
for the increased free radical production and for the low antioxidant capacity. The different training
effects on mRNA, content of the enzyme protein and activity indicate that different cellular signals can
affect the pre and post translational regulation of SOD.
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It is worth noting that even acute bouts of exercise were found to be able to increase the activities
of antioxidant enzymes, including SOD, CAT, and GPX [72,128,129] and GR [128], in skeletal muscle.
The threshold and the greatness of the activation appeared different among enzymes and were
fiber-specific because the enzyme activities increased in deep portion of the vastus lateralis but not in
soleus [128]. The mechanisms by which antioxidant enzymes could be activated within a relatively
short period of time during the exercise were largely unknown even though the fast activation suggested
that enzymatic molecules underwent allosteric or covalent modifications. The rapid activation of
antioxidant enzyme synthesis by oxidative stress through a transcriptional pathway had been shown
in prokaryotes (Salmonella and Escherichia) [130], but there was no evidence that a similar mechanism
existed in mammalian cells [131].
Subsequent studies showed muscle fiber specific upregulation of superoxide dismutase gene
expression in skeletal muscle [132]. Indeed, increases in MnSOD mRNA levels were found in the DVL
0, 1, and 2 h after exercise, whereas MnSOD protein levels were not changed. MnSOD mRNA levels
were not modified by exercise in SVL, whereas MnSOD protein levels were increased 10 and 24 h
after exercise. CuZnSOD mRNA levels were not changed by exercise in DVL and SVL, whereas the
CuZnSOD protein content was increased 48 h after exercise in both muscles. Activities of MnSOD,
CuZnSOD and total SOD were not modified by exercise in either muscle [132]. The increases in the
CuZnSOD protein content seen post-exercise, without increases in mRNA abundance in both DVL and
SVL, suggested a translational mechanism in this SOD isoform [132].
Moreover, more recent studies showed that in monocytes, after individual exercise bouts, target
genes of the nuclear transcription factor, peroxisome proliferator activated receptor-γ (PPARγ),
were upregulated at the mRNA level up to 3 h after each exercise, and this effect persisted for less than
24 h [133,134]. In contrast, after an eight-week training program, increases in gene expression were
observed at the protein level in samples taken 48 h after the previous bout of exercise [134].
Such a view was supported by subsequent studies which showed that increase in PPARγ target
gene expression observed after single bouts of exercise were similar, but less pronounced, to that seen
after eight-week training programs involving at least three exercise bouts per week [135]. Thus, a study
using the mass spectrometry coupled with liquid chromatography (LC-MS/MS) to investigate the effect
of an acute bout of endurance exercise on protein composition of human vastus lateralis (VL) muscle
in endurance trained and untrained individuals, found that training altered the content of 92 structural
and mitochondrial proteins. In contrast, a single bout of exercise (3 h) resulted in an alteration of the
content of 44 proteins in untrained athletes [136].
These results suggest that the effects of each exercise bout can merge so that, after a training
program, a more sustained effect is apparent. It can therefore be concluded that acute exercises, except
for the most intense ones, which cause oxidative damage, result in small transient oxidative stresses
which, in turn, induce redox-sensitive responses on local and systemic level, thus contributing to
training adaptations and systemic health benefits.
11. ROS Production
Although it was apparent that training effects on muscle performance were associated to an
increase in the effectiveness of antioxidant defense system, it was not known whether such an increase
was the only change responsible for the slowdown of the peroxidative processes and the muscle
fatigue. In fact, it was conceivable that a delayed onset of fatigue can also be dependent on adaptations
involving a decrease in rate of production of reactive oxygen derivatives. Venditti et al. [137] first
found that mitochondrial H2O2 release supported by succinate was lower in swimming trained than in
untrained rats both in State 4 and State 3, whereas that supported by pyruvate/malate was lower only
in State 4. The decrease in succinate-linked H2O2 release was such to compensate for the increase in
mitochondrial protein content produced by training in the muscle [137]. Although the ROS produced
by mitochondria are only a part of those produced in the cell, the above finding indicated that training
can reduce their contribution to the intracellular steady state concentration of H2O2.
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A subsequent study showed that eccentric training also leads to positive adaptations, decreasing
mitochondrial H2O2 release when mitochondria are incubated with either pyruvate/malate or
succinate [138]. It has also been shown that training decreases mitochondrial H2O2 release in
healthy and diabetic subjects [139]. A recent research has shown that immobilization increases H2O2
emission, while subsequent aerobic training (supervised bicycle training) reverses these effects in
young and older men [140]. A more recent study has shown that training decreases H2O2 production
measured in freshly permeabilized soleus muscle in the presence of substrates of he ttricarboxylic acid
cycle [141].
Surprisingly, another research has shown that training increases mitochondrial ROS production
in old subjects with both normal and impaired glucose tolerance [142].
It remains unclear whether resistance training affects the mitochondrial ROS production in older
adults, because a recent report [143] indicates that resistance training does not induce significant
changes in mitochondrial ROS production in vastus lateralis muscle from older adults.
Although these in vitro models may not correspond to conditions in vivo, overall, the reported
results seem to indicate a potential training-induced decrease for H2O2 release. However, the causes of
the reduction of the mitochondrial ROS release induced by training in skeletal muscle are not well
understood. One possibility is that the decrease in H2O2 release elicited by training is not due to a
decrease in ROS production, but to a greater capacity of mitochondria to scavenge superoxide radical
or hydrogen peroxide, thus limiting the generation of highly reactive hydroxyl radicals. However,
the observation that regularly performed moderate exercise does not modify the total antioxidant
capacity of mitochondria indicates that the reduction in mitochondrial H2O2 release is not due to
a greater capacity of mitochondria to scavenge reduced oxygen intermediates [137]. This view is
supported by the observation that the activities of mitochondrial antioxidant enzymes (MnSOD,
CuZnSOD, GPX, GR, and CAT) are not affected by training [138].
Another possibility is that the chronic exercise leads to changes in factors, which can influence
mitochondrial free radical production, such as mitochondrial membrane potential. In fact, evidence is
available that training produces a drop in mitochondrial membrane potential, although the causes
of such a drop remain still unknown [137]. In theory, the drop in mitochondrial membrane potential
and, therefore, the decrease in H2O2 production could be due to increased uncoupling of the inner
mitochondrial membrane. Such an uncoupling can be dependent on the levels of members of the
mitochondrial transporters family, mitochondrial uncoupling proteins (UCPs), which contribute to
energy dissipation as heat by uncoupling respiratory chain from ATP synthesis [144,145]. Of the five
mammalian forms of UCPs, UCP4 and UCP5 are principally neuronally expressed [146]. The best
characterized of these proteins, UCP1, is expressed exclusively in brown adipose tissue (BAT) [147],
UCP2 is expressed in a large spectrum of tissues including skeletal and cardiac muscle, and UCP3
is mainly expressed in BAT and skeletal muscle [148] in which it is involved in decreasing ROS
production [149].
Since peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) can regulate the
mRNA expression of Ucp2 and Ucp3 in the muscle cell culture [150], it was suggested that the increased
PGC-1α expression induced by training could increase the uncoupling capacity of skeletal muscle
mitochondria and thus decrease their ROS production by [151]. However, such an idea is not supported
by experimental evidence since increases in UCP3 protein content in rat muscle have been found only
after acute exercise [152] and short-term training (10 days) [153].
Rather, it has been hypothesized that the decreased ROS production observed with eccentric
exercise is due to a mild uncoupling caused by an increase in the ratio between polyunsaturated
and saturated fatty acids, and a decrease in the content in arachidonic acid and plasmalogens in
mitochondrial membrane [138].
It is worth noting that the possibility that exercise training can lead to a decrease in skeletal muscle
ROS production reducing the activity of other cellular sources has not been investigated. Only recently,
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evidence has been obtained that decrease in ROS production induced by aerobic exercise training in
skeletal muscle is associated with reduced muscle NADPH oxidase activity [154].
12. Factors Regulating Protein Expression
Although the effects of aerobic exercise on antioxidant capabilities in skeletal muscle have
been well described, the regulatory mechanisms underlying this adaptation are complex and
incompletely understood.
In the 90s of the last century accumulating data indicated that cells exposed to ROS responded by
inducing or repressing a wide variety of genes [155]. These effects seemed to be due to changes in
the intracellular redox balance that influenced multiple signaling pathways leading to a modulation
of the expression of some genes [156–158]. Several genes that could be differentially regulated by
oxidative stress were characterized and included early response genes, genes for enzymes involved in
antioxidant protection, and genes for specific stress and heat shock proteins (HSPs) [156–158].
At present, a complete answer to the question as to how changes in the redox status of muscle
fibers regulate signaling pathways and gene expression is not yet available. However, it is known
that redox signaling can affect numerous transcriptional activators leading to altered gene expression
and modified muscle phenotype. An important mechanism by which redox signaling controls gene
expression is the modulation of the phosphorylation state of transcriptional activating factors due to
ROS ability to control the activities of many kinases and phosphatases [159,160].
Eukaryotic cells possess many families of kinases, but the family of mitogen-activated
protein kinases (MAPKs) represents the main link between cell ROS levels and skeletal muscle
adaptive responses.
12.1. MAPK
MAPK family is one of the main kinase families that are involved in the conversion of cell signals
into cellular responses. MAPKs contribute to the regulation of life-and-death decisions taken in
response to several stress signals including ROS [161]. The control exercised by MAPKs on a wide
variety of pathways of cellular signaling is obtained through phosphorylation-mediated activation or
deactivation of regulatory proteins [162].
All eukaryotic cells possess multiple MAPK pathways, and at least four major groups of MAPKs
have been characterized in mammalian cells such as the c-Jun N-terminal kinases (JNK), the extracellular
signal-related kinases (ERK1/2), the p38 kinase (p38), and the big MAP kinase 1 (BMK1/ERK5), which
can be stimulated by cytokines, growth factors, and cellular stress even though their relative activation
and the specific cellular response evoked depend on the different stimuli [163].
ERK, JNK, p38, and BMK1 are all proline-directed serine/threonine kinases, and the pathways
in which they are activated also share similar homology. Indeed, all MAPKs are activated through
a cascade of phosphorylation events, often referred to as the MAP kinase module, in which a MAP
kinase kinase kinase (MAPKKK) phosphorylates and activates a MAP kinase kinase (MAPKK), which
in turn phosphorylates and activates a MAPK [162,164].
A well-studied member of the MAPKKK family that is preferentially activated in response to
various types of exogenous and endogenous cellular stress, including oxidative stress, is modulated
by redox mechanisms, and mediates cell apoptosis, is apoptosis signal-regulating kinase-1 (ASK-1),
a serine/threonine protein kinase that activates both p38 and JNK pathways [165]. In unstimulated
conditions, ASK-1 binds to the repressor protein thioredoxin (Trx), a ubiquitously expressed redox
regulatory protein, so that its kinase activity is inhibited. The binding of Trx to ASK-1 requires the
presence of a reduced form of an intramolecular disulfide bridge between two cysteine residues in the
catalytic site of Trx. This protein, after its oxidation by ROS molecules such as H2O2, dissociates from
and liberates ASK-1, which is then activated by formation of an oligomeric complex and threonine
autophosphorylation [165].
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Several studies, which have revealed a direct link between ASK-1 and NOX, have also suggested
that ASK-1 is an important effector of NOX in the redox signaling involved in cellular stress
responses [166].
It has been shown that the three best-characterized MAPK subfamilies, JNK, p38 MAPK, and ERK,
are activated by oxidative stress and could potentially be involved in pathways affecting the breakdown
of muscle proteins or loss of nuclei via myonuclear apoptosis [160,167]. It has also been shown
that H2O2 can elicit the activation of ERK, JNK, and p38 MAPK in skeletal myoblasts in a dose-and
time-dependent manner [168]. On the other hand, it has been shown that exercise, as an intermittent
form of cellular stress, is able to activate ERK1/2, p38, and JNK pathways in rat skeletal muscle [169].
Subsequent studies on the adaptations of muscle cells to exercise-linked oxidative stress have
led to conclude that these distinct signaling pathways are partially dependent on the type, duration,
and intensity of the contractile stimulus, and are critical cellular responses to maintain muscle
homeostasis through upregulation of the expression of antioxidant enzymes and other cytoprotective
proteins [170].
12.2. ERK
ERK is composed of two isoforms, ERK1 and ERK2, collectively referred to as ERK1/2 [162,164].
Several mitogens, including epidermal growth factor, platelet-derived growth factor, and ROS can
activate ERK1/2 [162] The activation of ERK1/2 by oxidative stress is consistent with the idea that low,
but adequate levels of ROS are mitogenic [164]. Once activated, the ERKs can phosphorylate different
substrates, including other kinases and transcription factors, and are involved in mediating different
responses, that depend on which ERK substrates the cell expresses [171].
Activation of ERK1/2 regulates the transcriptional activity of activator protein-1 (AP-1) [172],
avian myelocytomatosis virus oncogene cellular homolog (c-Myc) and the cell survival protein B-cell
lymphoma-2 (Bcl-2) [173]. Although it can be considered an oversimplification, in general, ERK1/2
activation seems to promote cellular adaptations that lead to survival [164].
ERK1/2 is phosphorylated rapidly and transiently in response to mechanical stress. Indeed, it was
demonstrated that ERK1/2 is activated in skeletal muscle of rats running on a motorized treadmill for
10–60 min [169] and in a rat plantaris in situ preparation stimulated to contract for 5 min by electrical
stimulation [174].
Early human studies showed an increase in ERK1/2 phosphorylation after endurance-type
exercises, including acute submaximal cycling [175] and marathon running exercise [176]. Subsequent
works also showed an increase in ERK1/2 phosphorylation in response to resistance exercise [177,178].
The magnitude of ERK1/2 phosphorylation during endurance exercise correlates with the intensity
of the protocol [175]. Conversely, resistance exercise upregulates ERK1/2 signaling in a manner that
does not seem to preferentially depend on exercise intensity [179].
Furthermore, one-legged cycling exercise leads to an increase in ERK1/2 phosphorylation only
in the exercised legs, suggesting that phosphorylation is dependent on local rather than systemic
factors [174,180]. This view is supported by observation that ERK1/2 phosphorylation increases in
isolated rat [181,182] and mouse [183] skeletal muscles stimulated to contract in vitro.
The effect of chronic training has been studied on rats subjected to a program of either low-
or moderate-to-high-intensity treadmill running. ERK1/2 phosphorylation was similar to sedentary
values, whereas ERK1/2 expression was increased three- to fourfold irrespective of the prior training
program in muscle sampled 48 h after the last exercise bout [184].
Contrary to previous studies, chronic endurance training does not greatly influence total MAPK
protein expression and pERK/total-ERK in chronically trained runners [185]. Furthermore, total ERK1/2
content was lower in powerlifting and weightlifting trained subjects compared to their controls [186].
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12.3. p38
p38 is activated in response to various physiological stresses, such as osmotic stress, endotoxins
and ROS [164]. ASK-1 represents the link between oxidative stress and p38 activation, because it is
activated in response to ROS, such as H2O2, and is required for phosphorylation-mediated activation
of both p38 and JNK [161]. Five isoforms of p38 have been identified (p38α, p38β, p38β2, p38γ and
p38δ), whose expression differs in the various tissues, with p38γ predominantly expressed in skeletal
muscle [162].
Among the phosphorylation targets of p38 there are several important transcription factors,
including tumor protein p53, a phosphoprotein crucial in prevention of cancer formation [187], nuclear
factor κ-light-chain-enhancer of activated B cells (NF-κB), involved in the induction of antioxidant
enzymes [188], and activating transcription factor 2 (ATF2), which regulates the transcription of various
genes, including those involved in DNA damage response [189]. Of particular importance to apoptosis
is the fact that activation of p53 results in the expression of the pro-apoptosis protein, bcl-2-like protein
4 (Bax), which can promote caspase-3 activation via a mitochondrion mediated pathway [190].
Although ERKs, JNKs and p38 are all activated by H2O2 treatment, following a time- and
dose-dependent pattern in C2 skeletal myoblasts, the time-course of this activation differs among
the MAPK subfamilies. Indeed, p38 activation is more rapid and displays a biphasic pattern, with
a second peak obtained at 2 h of treatment [168]. This p38 re-activation could be attributed to a
feedback mechanism, mediated by its either upstream activators or downstream targets, a phenomenon
previously reported [163].
Phosphorylation of p38, like that of ERK1/2, increases during contraction of isolated skeletal
muscles, implying a local activating factor [182,191]. Moreover, it is also increased by treadmill exercise
in rodents [139] and cycling ergometry [174] and marathon running [176] in humans.
12.4. JNK
There are three isoforms of JNK (JNK1, JNK2, and JNK3) that are encoded by three different
genes. JNK1 and JNK2 are ubiquitously expressed, while JNK3 is only expressed in brain, heart and
testis [162]. Many of the stimuli that activate p38, including endotoxins, osmotic stress, and ROS,
can also activate JNK. Moreover, like p38 activation, even activation of JNK induced by oxidative
stress occurs via the ASK1 pathway [192]. The transcriptional factors AP-1, p53 and c-Myc and many
other non-transcriptional factors, such as Bcl-2 family members, are among the specific molecular
targets of JNK. About this, evidence has been obtained that JNK plays a major role in ROS-mediated
apoptosis. Indeed, because ROS themselves are not able to activate caspases, JNK is required as another
death-signaling pathway for oxidative stress-mediated apoptosis [161,192].
Signal transduction through the JNK pathway is also stimulated by intense exercise protocols and
by those inducing muscular damage [193]. JNK phosphorylation increases linearly with increasing
levels of muscular contraction force [174]. Therefore, JNK activity appears to be modulated by total
muscle tension rather than duration of the contraction stimulus [194].
Summarizing, all three MAPK signaling pathways appear to be responsive to exercise even
though their activation mechanisms (i.e., energetic/metabolic compared to mechanical) remain distinct.
It is likely that the pattern of MAPK signaling have important implications in the different adaptive
responses elicited by exercise. Indeed, MAPK may play an important role as a cellular intermediary
able to couple perceived alteration in stress with adaptive changes, including the transcriptional
regulation of redox state of the skeletal muscle.
12.5. MAPK and Modulation of Gene Expression
In order to execute their functions, the MAPKs phosphorylate hundreds of substrates, thus
modulating their activities. MAPK substrates were identified in the cytoplasm, mitochondria,
Golgi apparatus, endoplasmic reticulum, and particularly the nucleus where they modulate gene
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expression [195–197]. Indeed, stress responses, as well as other cellular processes, are mediated by
MAPK cascade-dependent induction and regulation of de-novo gene expression [198]. For this to
happen, it is necessary that the signals transmitted via the various cascades enter the nucleus where they
modulate the activity of transcription factors, transcription suppressors, and chromatin remodeling
proteins, in order to ensure the correct cellular responses [199].
In fact, inside the cell nucleus, the DNA is packed into the chromatin, a structure consisting of
protein–DNA complexes [200]. This structure is very compact so that it is not accessible to other
proteins, including transcription factors. Therefore, the transcription requires a “decompaction” and
a change into active open euchromatin. Following various types of stimulations, several distinct
processes become operative to induce chromatin remodeling and allow the access to the target genes.
Such processes include histone acetylation, histone phosphorylation, poly ADP ribosylation, changes
in DNA conformation, and binding of other proteins to the DNA. Some of them are regulated by
the cascades of MAPKs, including in particular ERK1/2 and p38s, and are required for the correct
transcription and the induction of processes dependent on MAPKs [201]. At present, among the
numerous substrates of MAPKs, several transcription factors have been identified.
12.6. ROS Sensitive Transcription Factors
Over the past years, it was reported that MAPKs can regulate a wide range of transcription factors
involved in response to oxidative stress elicited by exercise in skeletal muscle. On the other hand,
based on the growing appreciation of the influence exerted by redox-sensitive signaling pathways on
normal cellular processes, a reasonable hypothesis was that an important regulator of the adaptation
in skeletal muscle in response to aerobic exercise may be ROS generated during the exercise.
ROS play a very important role to regulate several cell functions modulating the activity of
preexisting proteins and inducing the expression of many genes via activation of specific redox-sensitive
transcription factors [202]. Due to ROS involvement in almost all-important biological functions,
it is difficult to define all the pathways and gene targets that redox signaling affects during exercise.
Therefore, our examination will be limited to some of the most relevant factors that play critical roles
in homeostatic regulation of muscle oxidant-antioxidant balance during exercise.
ROS are critical in the regulation of several transcription factors, including the activator
protein-1 (AP-1) and the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) [203–205]
two transcription factors known to play crucial functions in proliferation, differentiation,
and morphogenesis.
AP-1 and NF-kB response elements are located in the promoter regions of genes encoding CAT,
GPX, Mn-SOD and CuZnSOD [204] and have been identified as the main factors that are both activated
by exercise-produced ROS and directly implicated in the induction of the aforementioned antioxidant
enzymes [206]. Moreover, combinations of AP-1 and NF-kB with other redox-sensitive transcription
factors can determine which antioxidant enzyme is about to be induced and to what extent.
12.7. NF-κB
NF-κB, one of the most commonly investigated redox sensitive transcription factors, is a
heterodimer composed of two related subunits, p65 and p50, which share a homologous region
at the N-terminal end, necessary for DNA binding and dimerization.
The NF-κB/Rel transcription factors are normally sequestered in the cytoplasm in an inactive
state, linked to the IκBα inhibitory protein. NF-κB is activated by several stimuli, including H2O2,
proinflammatory cytokines, lipopolysaccharide (LPS), and phorbol esters, by the phosphorylation
of IκBα at Ser-32 and -36 by IκB kinase (IKK). Phosphorylation of IκBα results in its dissociation
from NF-κB and subsequent proteasomal degradation. NF-κB, once free, migrated into the nucleus
where it binds to the corresponding DNA sequence of the target genes, including MnSOD and
γ-glutamylcysteine synthetase (GCS) [207], the rate-limiting enzyme in the biosynthesis of glutathione.
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In muscle cells, ROS such as H2O2 are able to induce degradation of the inhibitory IκB protein
subunits bound to NF-κB subunits (p65, p50 and RelB), leading to the rapid migration of NF-kB to the
nucleus and activation of the transcription of specific genes [203]. Zhou et al. [204] showed that the
use of specific NF-κB inhibitors blocked the upregulation of the expression of Cat and Gpx induced
by oxidative stress, thus confirming the hypothesis that ROS are able to modulate mRNA levels of
antioxidant enzymes by activating redox-sensitive transcription factors, such as NF-κB.
In 1997, Sen et al. [208] were the first to bring NF-κB to the attention of exercise physiologists,
demonstrating that NFκB activation in L6 muscle cells was responsive to H2O2 treatment and was
controlled by intracellular GSH: GSSG status. Subsequently, Hollander et al. [134] reported that NF-κB
(and AP-1) binding was significantly increased in rat skeletal muscle in a fiber-specific manner after
an acute bout of prolonged exercise. Since NFκB binding was associated with an increase in MnSOD
mRNA level and protein content, the authors hypothesized that NF-κB activation by ROS generated
in contracting muscle may be the underlying mechanism for training adaptation and increase in
antioxidant enzyme expression. Ji et al. [209], examining NFκB signaling cascades in response to
exercise in rats, found that acute exercise increased NF-κB binding, IKK activity, IκBα phosphorylation
and degradation, and P50 accumulation in the nucleus in rat DVL muscle. The exercise-induced
activation of NF-κB was partially abolished by treatment with pyrrolidine dithiocarbamate, an inhibitor
of the 26S proteosomes. Furthermore, the treatment with a high of t-butylhydroperoxide had scant
effect on NF-κB, suggesting that the signaling was not induced by general oxidative stress but by
specific chemical agents.
In a subsequent study, Ho et al. [210] found an increase in NF-κB activation accompanied by
IKKα/β phosphorylation in the rat soleus (type 1) and red gastrocnemius (type 2a) muscles during 60
min of treadmill exercise. Peak IKKα/β activation was found early during exercise (15 min), whereas
maximal NF-κB binding was found at 1–3 h. IKKα/β and IκB phosphorylation was also increased by
the contraction of isolated extensor digitorum longus (EDL) muscles in vitro. Moreover, application of
p38 and ERK inhibitors reduced IKKα/β activation, suggesting that MAPKs were upstream of NF-κB
and could partially mediate stimulation of NF-κB activity by contraction.
Gomez-Cabrera et al. [53] found that an acute bout of treadmill running in rats activated ERK1/2
and p38 and the activation coincided with elevated gene expression of MnSOD and iNOS. Moreover,
when an inhibitor a xanthine oxidase (XO), allopurinol, was used to partially block ROS generation,
MnSOD and iNOS mRNA expression induced by exercise was severely hampered, and the activities
of ERK, p38, and NFκB were decreased. Although it was not possible to conclude that attenuation
of MAPK signaling was the reason for the decreased MnSOD and iNOS expression, these results
suggested that MAPK proteins played a role in the signaling of antioxidant enzymes and that an
integrated input from both the NFkB and MAPK signaling pathways was required to stimulate gene
expression of these enzymes in the muscle fibers. These results also suggested that nonmitochondrial
ROS were involved in the improvement of muscle antioxidant defense system.
12.8. AP-1
AP-1 is a heterodimer consisting of activating (c-Fos and c-Jun) and inhibitory (Fos-related antigen
(Fra)-1 and 2) subunits, which can generate different heterodimers, thus modulating expression of
target genes [211]. Depending on the cell type and cellular redox milieu, Fos and Jun can dimerize or
interact with other transcription factors such as activating transcription factor (ATF), CCAAT enhancer
binding protein (C/EBP), and proto-oncogene (Maf) leading to either activation or inhibition of gene
transcription of antioxidant and immunoactive proteins [212,213].
AP-l regulates the gene expression in response to signals generated by a wide variety of
extracellular stimuli, among which growth factors, tumor promoters, neurotransmitters, UV light,
and cytokines [214,215]. AP-1 can also be activated by ROS [216] and oxidative stress induces the
binding of AP-1 complex proteins (c-Jun and c-Fos) to DNA [211]. According to this observation, an
increase in AP-1 binding has also been found after a single bout of exercise [134].
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Activation of various kinases which are involved in the MAPK signaling pathway can lead to
the sequential phosphorylation of a variety of proteins, resulting in increased expression of c-Jun, a
subunit of the transcription factor AP-1, which is an important DNA-binding site on many genes able
to respond to oxidative stress [217].
It has been reported that c-Jun is regulated by JNKs to which it gave the name [218]. c-Jun is
constantly expressed in both unstimulated and stimulated cells. Upon stimulation, c-Jun, to exert
its activity, interacts with other transcription factors such as c-Fos, and ATF forming AP-1 [219].
The activation of c-Jun depends on phosphorylation of its transactivation domain by all JNK isoforms
and to some extent by other MAPKs, which leads to induction of the full transcriptional activity within
the AP-1 complex, independent of DNA binding [220].
12.9. Nrf2
Although the protection provided by NF-κB and AP-1 activation is important for cellular redox
homeostasis, another pathway is the main regulator of cytoprotective responses to endogenous and
exogenous stresses caused by electrophilic compounds and ROS [221]. The key signaling protein
within the pathway is the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) that can
bind, together with small musculoaponeurotic fibrosarcoma (Maf) proteins, to a DNA sequence called
antioxidant response element (ARE) in the regulatory regions of target genes. Nrf2 can also bind to
Kelch ECH associating protein 1 (Keap1), a repressor protein very rich in cysteine residues most of
which can be modified in vitro by different oxidants and electrophiles [222,223].
In unstressed conditions, the cellular concentration of Nrf2 protein is maintained at very low levels
by its inhibitor Keap1, which sequesters Nrf2 in the cytosol and facilitates its ubiquitination through the
Keap1/Cul3 ubiquitin ligase and rapid proteasomal degradation. Under conditions of stress or in the
presence of Nrf2 activating compounds, this degradation is hampered because modification of reactive
cysteine thiols of Keap1 and Nrf2 by inducers presumably alters the structure of the Nrf2/Keap1/Cul3
complex, leading to inhibition of Nrf2 ubiquitination Nrf2 release. Subsequently Nrf2, phosphorylated
by protein kinases, moves into the nucleus where it forms heterodimers with Maf proteins. This,
in turn, facilitates the binding of Nrf2 to the antioxidant response element (ARE), a cis-acting enhancer
sequence (TCAG/CXXXGC) in the promoter region of Nrf2-regulated genes [224,225] (Figure 2).
Genome-wide search for Nrf2 target genes has led to identify an array of ARE-regulated genes,
that lead to the production of phase II xenobiotic metabolizing enzymes, antioxidants, molecular
chaperones, DNA repair enzymes, and anti-inflammatory response proteins [226]. They reduce reactive
compounds such as electrophiles and free radicals to less toxic intermediates and increase cell capacity
to repair any damage ensued.
An alternative model of the Nrf2-Keap1 pathway of gene regulation has also been proposed [227].
According to this model, Nrf2 is constitutively expressed in cells and moves directly into the nucleus to
activate gene transcription. Nrf2 is then targeted for degradation by Keap1, a process that requires the
transient Keap1 displacement in the nucleus. In cells under stress, the stabilization of Nrf2 in response
to activating compounds is caused by mechanisms that prevent Nrf2 from binding to Keap1 and
being degraded in the nucleus. The reduced degradation of Nrf2, together with its de novo synthesis,
results in the accumulation and direct recruitment of Nrf2 to the ARE, so that transcription of its genes
increases. This pathway of regulation of Nrf2 activity should allow it to exert its dual function of
controlling gene expression constitutively and inducibly.
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Figure 2. Schematic model of transcriptional activity of nuclear factor erythroid 2-related factor
2 (Nrf2) mediates by oxidants during exercise and Nrf2 degradation in resting condition. MAF,
musculoaponeurotic fibrosarcoma protein; ARE, antioxidant response element; Keap1, Kelch ECH
associating protein 1; Ub, ubiquitin.
Whatever the pathway of gene regulation may be, the transcription factor Nrf2 is certainly the
master regulator of cellular antioxidant defense, because it regulates more than 200 cytoprotective
genes in response to oxidative stress [228]. Nrf2 can regulate many antioxidative enzymes, including
haem oxygenase-1, SOD, CAT, and NADPH quinone oxidoreductase [229]. Nrf2 also make sure that the
antioxidant enzyme expression is coupled with the cofactor supply. Indeed, it controls the expression
of GPX2 [230], which reduces peroxides producing GSSG, and GR1 [230], which reduces GSSG, thus
allowing intracellular levels of GSH to remain constant. In addition to the GSH-based antioxidant
system, Nrf2 also controls the expression of cytosolic Trx1 [231] TrxR1 [230,232] and sulfiredoxin
(Srx1) (a cysteine sulfinic acid reductase) [233], all of which reduce oxidized protein thiols [234].
Antioxidant enzymes, such as GR1 and TrxR1, require NADPH as a cofactor so that it is notable
that NADPH-generating enzymes such as glucose- 6-phosphate dehydrogenase, 6-phosphogluconate
dehydrogenase, isocitrate dehydrogenase, and malic enzyme are all regulated by Nrf2 [235].
Interestingly, Nrf2 also contributes to the maintenance of metabolic homeostasis since Nrf2
induction in pancreatic β cells markedly suppresses oxidative-stress-mediated dysfunction [236].
Evidence is available that the Nrf2 pathway also plays a key role in how oxidative stress mediates
the exercise beneficial effects. Increases in ROS production induced by bouts of acute exercise stimulate
Nrf2 activation and when they are applied repeatedly, as with regular physical activity, this may lead
to upregulation of endogenous antioxidant defenses and overall greater capacity to counteract the
oxidative damage of biological molecules.
Cell culture study using C2C12 skeletal muscle cells provided evidence that Nrf2 is activated by
ROS and this activation is suppressed when antioxidants, such as N-acetylcysteine, are added to the
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culture medium [237]. Subsequent study showed an increase in Nrf2 protein expression after myotube
treatment of myotubes with H2O2 [238].
A single bout of acute exercise in wild-type mice has been shown to increase Nrf2 gene
expression [238,239], Nrf2 protein abundance in skeletal muscle [239], and Nrf2-dependent phase II
enzymes [238,240]. Conversely, no change in Nrf2 activity was observed in Nrf2–/– mice after acute
bout of exercise [239].
The exercise increased oxidative stress and activated Ref1/Nrf2 signaling in a time-dependent
manner, with a linear correlation between the mitochondrial H2O2 content and Ref1/Nrf2 expressions.
The effect of regular exercise training on the Nrf2 response has been studied extensively and it has
been found that, regardless of duration or training regimen, regular aerobic exercise in rodent models
activates Nrf2 signaling across multiple tissues including skeletal [241] and cardiac muscle [242,243].
Taken together, the studies demonstrate that regular exercise upregulates Nrf2 protein abundance
and phase II and antioxidant enzyme amounts. Furthermore, emerging evidence suggests that an
active lifestyle can conserve skeletal muscle cellular redox status via activation of Nrf2 –Keap1 signaling
in elderly. Indeed, a cross-sectional study comparing Nrf2 and Keap1 protein content from a single
muscle biopsy in sedentary and active older adults has shown the age-associated decline in antioxidant
response is due, at least in part, to dysfunction in Nrf2–Keap1 redox signaling, which is preserved in
the skeletal muscle of older adults thus maintaining cellular redox homeostasis [244]. However, it is
not known whether an exercise program can restore redox balance in individuals who already display
a Nrf2 signaling impairment, even though moderate exercise training has been shown to be able to
restore Nrf2 signaling in cardiac muscle in older age [243].
12.10. PGC-1α
Although the molecular mechanisms of the adaptive response to exercise remain to be fully
elucidated, PGC-1α, a transcriptional coactivator, is currently considered a major regulator of
phenotypic adaptation induced by exercise.
PGC-1α was first identified as a transcriptional coactivator of the peroxisome proliferator-activated
receptor (PPAR)-γ in brown fat cells [245]. Subsequently, it was found in other mitochondria-rich
tissues, including skeletal and cardiac muscle, as well as in kidney, liver, and brain [246] in which
it influences numerous aspects of metabolism [247]. PGC-1α and its homolog PGC-1β are also
co-activators for PPARα and PPARδ (involved in adipocyte differentiation and thermogenesis), and for
a variety of other transcription factors [248,249]. Furthermore, PGC-1α promotes upregulation of itself
by an interaction with myocyte enhancer factor 2 (MEF2) on its own promoter [248].
PGC-1α can interact with nuclear receptors and transcription factors activating transcription of
their target genes, and its activity is responsive to a wide variety of stimuli including calcium ion, ROS,
insulin, thyroid and estrogen hormones, hypoxia, ATP demand, and cytokines [249] (Figure 3).
For a long time PGC-1α has been considered to be exclusively a master regulator of mitochondrial
biogenesis by coactivating numerous transcription factors that, in turn, bind to the promoters of
distinct sets of nuclear-encoded mitochondrial genes [250]. However, more recent studies have shown
that PGC-1α is also able to stimulate the expression of endogenous antioxidant proteins. Reduced
mRNA levels of CuZnSod, MnSod, and/or Gpx1 [251], as well as MnSOD protein content [252,253],
were found in skeletal muscle from PGC-1α knockout mice compared to wild type, while PGC-1α
overexpressing mice showed an increase in MnSOD protein content [254]. PGC-1α KO fibroblasts
exhibited a decrease in MnSod, Cat, and Gpx1 mRNA content relative to wild-type fibroblasts and
PGC-1α KO mice were more vulnerable to oxidative stress [255]. Furthermore, PGC-1α is able to
regulate RNA expression of UCP2 and UCP3 in cell culture [150], suggesting that PGC-1α may increase
the uncoupling capacity of mitochondria, thus reducing their ROS production. PGC-1α also promotes
mSIRT3 gene expression, which is mediated by an ER-α binding element mapped to the SIRT3 promoter
region [256]. SIRT3, in turn, binds to mitochondrial enzymes, including MnSOD, and activates them
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by deacylation [257,258]. Taken together, PGC-1 α appears to play a role in reducing cell oxidative
damage by upregulating antioxidant gene expression and activity.
 
Figure 3. Schematic representation of the signalling pathways that mediate the exercise- induced PGC-1
expression and mitochondrial biogenesis in skeletal muscle. PGC-1, peroxisome proliferator–activated
receptor coactivator 1; NRF-1, nuclear respiratory factor 1; NRF-2, nuclear respiratory factor
2; ATF2, activating transcription factor 2; MEF2, myocyte enhancer factor-2; cAMP, cyclic
adenosine monophosphate; CREB, cAMP response element-binding protein; CRTC, cAMP-regulated
transcriptional co-activators; AMPK, AMP-activated protein kinase; PKA, protein kinase A; NO•,
nitric oxide; eNOS, endothelial nitric oxide synthase; CAMK, Ca2+/calmodulin-dependent protein
kinase; p38, p38 mitogen-activated protein kinases; JNK, c-Jun N-terminal kinase; ASK-1, apoptosis
signal-regulating kinase-1.
Interestingly, recent report has shown that PGC-1 is also necessary for the activation of the signaling
network called unfolded protein responses (UPR) during pharmacologically induced endoplasmic
reticulum stress and exercise training [259].
PGC-1 protein expression increases rapidly in muscle fibers stimulated to contract [260]. Moreover,
Pgc-1 gene expression increases in rat skeletal muscle after a single bout of exercise [261] and in human
skeletal muscle after endurance training [262]. Increased levels of PGC-1α protein expression were
also found in rat skeletal muscle after 10 weeks of training to swimming [263].
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It is worth noting that several initiating stimuli, activated during exercise, can contribute to
induction of the PGC-1 gene response. First, acute exercise leads to rapid activation of p38 [264], which
in turn activates PGC-1α by phosphorylation [265] and produces the increase in its expression [266].
Other stimuli activated by exercise, that are able to induce Pgc-1 gene response include: (i) Increased
concentration of cytosolic calcium, which activates several signaling pathways regulated by the
calcineurin phosphatase and the calmodulin-modulated kinase, (ii) decreased levels of high-energy
phosphates, which lead to AMPK activation of, (iii) stimulation of the adrenergic system, which leads
to cyclic AMP synthesis, and activation of various kinases, including protein kinase A [151] (Figure 3).
However, it is worth noting that the regulation of PGC-1α is not limited to variations in its
expression but is also dependent on covalent modifications including phosphorylation, acetylation,
methylation and ubiquitination [267]. Indeed, in vitro experiments have shown that PGC-1α
phosphorylation by p38 MAPK and AMPK produces a more active protein [151].
Most studies point toward H2O2 as an important molecule for PGC-1α upregulation in skeletal
muscle. ROS involvement in contraction-induced increases in Pgc-1α expression is supported by the
observation that the increase in Pgc-1α mRNA, induced by electrical stimulation in cell culture of rat
skeletal muscle, is prevented by antioxidant incubation [268]. Thus, the idea that the upregulation
of ROS-removing enzymes in response to increases in ROS can be in part mediated by PGC-1α is
supported by the observation that the increase in the Sod, Cat and Gpx mRNA content induced by
H2O2 in Pgc-1α KO fibroblasts is lower than that in wild-type fibroblasts [255].
Furthermore, the observation that treatment of cultured muscle myotubes with exogenous H2O2
activates AMPK and increases Pgc-1α expression [268] suggests that H2O2 can promote Pgc-1α
expression through AMPK. Moreover, the sensitivity of PGC-1α to the redox status is confirmed by the
observation that the antioxidant N-acetylcysteine inhibits Pgc-1α upregulation [269].
Pharmacological inhibition of xanthine oxidase with allopurinol also suppresses the upregulation
of PGC-1α induced by a single bout of anaerobic exercise in parallel to blunted activation
(i.e., phosphorylation) of p38 MAPK in rat vastus lateralis muscle [75]. This finding suggests that ROS
generated in response to in vivo contraction are involved in p38 MAPK activation and subsequent
regulation of PGC-1α expression [75]. Moreover, evidence that allopurinol treatment also reduces the
exercise-induced increases in levels of transcription factors, such as nuclear respiratory factor 1 (NRF-1)
and factor of transcription A (Tfam), which are involved in mitochondrial biogenesis, indicates that ROS
arising from nonmitochondrial sources play a major role in stimulating mitochondrial biogenesis [75].
Although in literature there are conflicting results [270], ROS have also been shown to be
functionally important for PGC-1α expression and adaptive responses induced by endurance exercise
in skeletal muscle. Indeed, several experimental studies have reported that antioxidant supplementation
attenuates the increase in Pgc-1 gene expression [271,272] and PGC-1 protein content [263,273] elicited
by endurance training.
Antioxidant supplementation also prevent health-promoting effects of physical exercise, including
mitochondrial biogenesis [263,271,273], endurance performance (running to exhaustion) [273],
and insulin sensitivity [271]. These results strongly support the view that the ROS generated
during each session of exercise can cause beneficial effects functioning as signals regulating molecular
events critical for muscle adaptive responses to training.
It is worth noting that PGC-1α expression in muscle can be regulated by a variety of stimuli
associated with muscular exercise, which, however, seem to be dependent on ROS production. Thus,
the finding that the human PGC-1α promoter contains a binding site for NF-κB suggests that the
expression of PGC-1αmay also be regulated by NF-κB [274]. Analysis of the human PGC-1α promoter
has revealed a variety of consensus transcription binding sites to the following transcription factors:
Specificity protein 1 (SP1), cAMP response element binding protein (CREB), CREB related family
member, activating transcription factor 2 (ATF2), forkhead transcription factor (FKHR), p53, EBox
binding proteins, GATA and muscle enhancer factor 2 (MEF2) [274]. Many of these transcription
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factors have been shown to be ROS-sensitive, which indicates numerous potential possibilities for
redox control of PGC-1α expression.
Additionally, RNS, particularly NO•, may also be involved in the regulation of PGC-1α. The idea
that NO•mediates the upregulation of PGC-1a, thus modulating mitochondrial function and biogenesis,
is supported by the evidence that low levels of NO• induce mitochondrial biogenesis, PGC-1a
and GLUT4 expression in cultured muscle cells [275] and that a genetic deletion of NOS or their
pharmacological inhibition prevents PGC-1a induction that is triggered by endurance exercise [276].
It has also been observed that administration to humans of inorganic nitrate (which can be
converted into NO• in the body) significantly improves energy metabolism during exercise [277].
Reports showing that NOS activity is involved in mitochondrial biogenesis induced by AMPK and
CaMK and PGC-1α expression in L6 myotubes [278] and that AMPK phosphorylates and activates
both eNOS and nNOS [279], led to propose that there is a positive feedback loop between NO•
production and AMPK activity in skeletal muscle [280]. The evidence that NO• production promotes
PGC-1α expression via NO-mediated activation of AMPK (i.e., AMPKα1 isoform) demonstrated that
the proposed model of synergistic interaction between AMPK and NOS is crucial to maintain metabolic
function in skeletal muscle cells [280]. Moreover, it suggested that both ROS and RNS can contribute
to PGC-1α expression via a common signaling pathway (i.e., AMPK activation).
13. Regulation of Cellular Phosphatases by ROS
It has been previously pointed out that changes in the phosphorylation status of signaling
molecules play an important role in the control of cellular adaptation. In this regard, it is necessary
to note that the phosphorylation status of regulatory proteins and/or transcriptional activators is
regulated not only by kinase activity but also by changes in phosphatase activity.
In general, phosphatases are divided into two major classes (i.e., serine/threonine phosphatases and
phosphotyrosine phosphatases), both of which are known to be redox sensitive in many different cell
types, including skeletal muscle. Serine/threonine phosphatases contain metal ions that are susceptible
to oxidation, which leads to their inactivation. Similarly, the phosphotyrosine phosphatases (PTPs) are
susceptible to oxidation-induced inactivation. The PTPs contain a cysteine residue in their active site,
and oxidation of this cysteine inactivates the enzyme [281]. A subclass of PTPs, called dual-specificity
phosphatases (DUSPs), can remove phosphates from both tyrosine and serine/threonine residues.
The DUSPs contain two cysteines in their active sites, leading to inactivation of the enzyme during
oxidizing conditions. DUSP family include 10 members, which differ in their substrate specificity,
subcellular localization, tissue expression, and inducibility by extracellular stimuli [282].
MAPKs including ERK1/2 are dephosphorylated on both the threonine/serine and tyrosine
residues by MAPK phosphatases (MKPs) belonging to the DUSP family. It has been shown that,
in human skeletal muscle, ERK1/2 phosphorylation is increased in an intensity-dependent manner
by acute contractions, but after exercise this phosphorylation is rapidly reduced, and resting levels
are restored within 60 min [175,283]. Recent study has demonstrated that two ERK1/2-specific MKPs,
dual specificity phosphatase 5 (DUSP5) and DUSP6, are the most regulated MKPs in skeletal muscle
after acute exercise [284]. DUSP5 expression is nine-fold higher immediately after exercise and returns
to pre-exercise level within 2 h, whereas DUSP6 expression is reduced by 43% just after exercise and
remains below pre-exercise level after 2 h recovery. It has also been proposed a hypothetical interplay
between ERK1/2 signaling, DUSP5, and DUSP6 in skeletal muscle before and after exercise. Before
exercise, basal phosphorylation of MEK (the kinase phosphorylating ERK1/2) and ERK1/2 is low and
inactive ERK1/2 is bound to inactive MEK and DUSP6 in cytoplasm. During exercise MEK is activated
leading to increased phosphorylation and translocation into the nucleus of ERK1/2, which enhances
expression of its target genes, including DUSP5, which, in turn, increases dephosphorylation and
trapping of ERK1/2 in the nucleus and reduces ERK1/2 recycling to cytoplasm. A higher proportion
of cytoplasmic ERK1/2 is available for phosphorylation by MEK due to the reduced level of DUSP6.
During recovery, MEK and ERK1/2 activities are reduced to the basal level, normalizing the DUSP5
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level. ERK1/2 is translocated back to the cytoplasm and most of it is bound to MEK, whereas DUSP6
level is still low [284].
14. Conclusions
The idea is now widely shared that the utilization of oxygen by aerobic organisms exposes
them to the attack of reactive oxygen and nitrogen species, which can initiate chain reactions leading
to oxidative damage of important biological molecules. Aerobic organisms are provided with an
efficient antioxidant defense system that allows them to neutralize the oxidative effects of reactive
metabolites of oxygen and nitrogen. However, when reactive species production exceeds the cellular
antioxidant capacity, oxidative stress develops, potentially leading to cell structural and functional
alterations and to the development of many pathological conditions. A single session of strenuous
or prolonged exercise leads to the production of high number of radicals and other reactive oxygen
species (ROS), which cause tissue damage and dysfunction. On the other hand, regular exercise
appears to decrease the incidence of a wide range of ROS-associated diseases because the single
sessions of a training program produce low amounts of ROS, which can induce adaptive responses
beneficial for the organism. Cells may adapt to the stress by upregulation of systems of defense against
and repair of oxidative damage so that they are then resistant to higher levels of oxidative stress
imposed subsequently.
Although the effects of exercise on antioxidant capabilities in skeletal muscle have been well
described, the regulatory mechanisms underlying this adaptation are complex and incompletely
understood. To date it is known that cells exposed to ROS are brought to respond by inducing or
repressing a remarkable variety of target genes [155]. These effects appear to be due to modification
of the intracellular redox balance resulting in the activation of several signaling pathways ultimately
leading to a modulation of gene expression. A comprehensive answer to the question as to how changes
in the redox status of muscle fibers regulate signaling pathways and gene expression is not yet available.
However, it is clear that a major mechanism by which redox signaling is able to alter gene expression
and modify muscle phenotype involves changes in phosphorylation status of transcriptional activators
due to ROS capacity to control the activities of many kinases and phosphatases. Evidence that ROS play
a pivotal role in adaptive response elicited by exercise training is provided by researches indicating
that antioxidant supplementation blunts benefits of regular physical activity on skeletal muscle.
In conclusion, ROS generated during muscle activity, from both mitochondrial and
nonmitochondrial sources, may play a pivotal role in muscle adaptive responses to exercise-induced
oxidative stress by activating redox-sensitive signal transduction. Important signaling pathways
that can be activated in response to ROS stimulation include NFκB, Nrf2, and MAPK. Moreover,
the existence of multiple redox-sensitive binding sites on antioxidant genes suggests that the fidelity
of gene expression requires the synergistic activation and interaction of several transcription factors.
These regulatory mechanisms may control not only the effectiveness of antioxidant defense system
through upregulation of antioxidant enzyme expression but also other biological activities in skeletal
muscle, including mitochondrial biogenesis.
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Abstract: Mitochondria are multifunctional cellular organelles that are major producers of reactive
oxygen species (ROS) in eukaryotes; to maintain the redox balance, they are supplemented with
different ROS scavengers, including mitochondrial peroxiredoxins (Prdxs). Mitochondrial Prdxs have
physiological and pathological significance and are associated with the initiation and progression of
various cancer types. In this review, we have focused on signaling involving ROS and mitochondrial
Prdxs that is associated with cancer development and progression. An upregulated expression of
Prdx3 and Prdx5 has been reported in different cancer types, such as breast, ovarian, endometrial,
and lung cancers, as well as in Hodgkin’s lymphoma and hepatocellular carcinoma. The expression
of Prdx3 and Prdx5 in different types of malignancies involves their association with different factors,
such as transcription factors, micro RNAs, tumor suppressors, response elements, and oncogenic
genes. The microenvironment of mitochondrial Prdxs plays an important role in cancer development,
as cancerous cells are equipped with a high level of antioxidants to overcome excessive ROS
production. However, an increased production of Prdx3 and Prdx5 is associated with the development
of chemoresistance in certain types of cancers and it leads to further complications in cancer treatment.
Understanding the interplay between mitochondrial Prdxs and ROS in carcinogenesis can be useful
in the development of anticancer drugs with better proficiency and decreased resistance. However,
more targeted studies are required for exploring the tumor microenvironment in association with
mitochondrial Prdxs to improve the existing cancer therapies and drug development.
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1. Introduction
Mitochondria, with their multifaceted roles, are recognized as indispensable organelles in
eukaryotic cells and are considered as the energy currency of the cell because of adenosine triphosphate
(ATP) production [1]. In addition to being energy sources, they are involved in heme synthesis,
metabolism of amino acids, and the regulation of the redox state of cells [2,3]. These multiple functions
of mitochondria make them prerequisites for cellular life of eukaryotes [4]. Apart from these functions
that are related to cell survival, a large body of evidence has exhibited that this subcellular organelle also
has crucial functions in the cell death program [5,6]. Mitochondria play significant roles in apoptosis
by regulating the release of pro-apoptotic factors [7]. In addition, they are also critical participants in
necrosis and autophagy [8,9].
Mitochondria continuously communicate with other cells by signal transduction to carry out
this diverse array of functions [10,11]. The generation of reactive oxygen species (ROS) is one of
the way of mitochondrial signal transduction and these generated (ROS) function as secondary
messengers [12,13] and play a significant role in cellular signal transduction [14]. ROS are basically
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short-lived species having unpaired electrons [15,16], and they are endogenously generated as a
byproduct during mitochondrial energy production as well as produced as a consequence of fatty
acid β-oxidation and exposure to radiation, light, metals, and redox drugs [17]. Mitochondria being
the largest contributors of ROS in mammalian cells convert approximately 1% of their consumed
oxygen to superoxide anion (O2−) [18], and they have up to ten sites with ROS generation ability [19].
ROS serve as secondary messengers by interacting with a variety of molecules; they are important for
many biologically significant processes, such as adaptive immunity, cell differentiation, and oxygen
cell sensing [13,15,16,20,21]. Mitochondrial ROS, in addition to their cellular signaling properties,
also have cell damaging roles [22].
Therefore, ROS homeostasis is essential for steady state functions of cells [23,24]. The accumulation
of ROS resulting from any imbalance in ROS production and metabolism induces oxidative stress [25].
In other words, oxidative stress is the result of imbalance between two opposite and opposing forces,
i.e., ROS production and antioxidation, and it can lead to pathological defects in living organisms,
such as cancer, atherosclerosis, neurological diseases, aging, and diabetes, as well as can harm the
cellular components, such as DNA, RNA, lipids, and proteins [26,27]. To protect cells from the
oxidative stress, there are many enzymatic and non-enzymatic defense systems in mitochondria [28,29].
The non-enzymatic defense system includes flavonoids, vitamins (A, C, and E), and glutathione [28].
Superoxide dismutase (SOD), superoxide reductase, catalase, glutathione peroxidase, glutathione
reductase, peroxiredoxins (Prdxs), and thioredoxins (Trx) are important enzymatic antioxidants that
are involved in the regulation of mitochondrial ROS [30,31]. ROS production in mitochondria and
their subsequent fate involve interactions between various molecules in normal and pathological
conditions [32] (Figure 1).
Figure 1. Mitochondrial reactive oxygen species (ROS) scavengers and cancer development. Eukaryotic
cells depend upon the mitochondria for energy production, and reactive oxygen species (ROS)
are produced as byproducts during adenosine triphosphate (ATP) generation by the mitochondria.
The amount of mitochondrial ROS is balanced by ROS scavengers in the mitochondria of normal
eukaryotic cells and these ROS regulate different cellular processes such as cell proliferation and
differentiation by acting as signaling molecules. The loss of this specific balance between ROS and ROS
scavengers leads to an outburst growth of cells, resulting in cancer initiation and development.
The aim of the present review is to focus on the signaling for ROS regulation involving
mitochondrial Prdxs in normal as well as disease conditions. Mitochondrial Prdxs are recently
discovered antioxidants presenting a variety of roles in eukaryotic organisms. Recently, mitochondrial
Prdxs have gathered much interest due to their diversified functions and interactions in living organisms.
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In the present review, we describe the factors that are associated with mitochondrial Prdxs in ROS
scavenging, as well as its signaling pattern in normal and pathological cellular conditions.
2. Mitochondrial Prdxs
Prdxs denote the family of proteins having the ability to efficiently scavenge peroxides in the
form of hydrogen peroxide, alkyl hydro peroxide, and peroxynitrite [33]. Prdxs are classified into six
subfamilies, according to PeroxiRedoxin classification index (PREX) and, in mammals, there are six
Prdxs, among which Prdx 1–4 belongs to Prdx1 subfamily, Prdx5 is a member of Prdx5 subfamily,
and Prdx6 represent Prdx6 subfamily [34,35]. Prdxs are also classified as 1-Cys containing only Prdx6,
while typical 2-Cys comprised of Prdx1–4 and Prdx5 belongs to atypical 2-Cys on the basis of their
cysteine residues and their catalytic mechanism [36]. The catalytic activity of Prdxs is highly dependent
upon the conserved peroxidatic cysteine (Cp) in the amino terminal region of the protein. In addition
to this conserved Cp, there is an additional conserved cysteine residue that is present in the carboxyl
terminal portion of the five out of six mammalian Prdxs, termed as resolving cysteine (Cr). [37]. Prdxs
belonging to typical 2-Cys class are typical homodimers containing two identical active sites that brings
peroxidatic and resolving cysteines (Cp and Cr) into juxtaposition. Peroxidatic cysteine of typical 2-Cys
is oxidized by peroxide, resulting in the formation of sulfenic acid (C-SOH), which in turn condenses
with Cr of opposite subunit, and results in the formation of intermolecular disulfide bond. The oxidized
Prdxs are reduced by appropriate electron donor to complete the catalytic cycle. The oxidized Cp of
atypical 2-Cys condenses with Cr within same polypeptide to form intramolecular disulfide bond and
in turn reduced by the Trx2. In contrast to typical and atypical 2-Cys Prdxs, 1-Cys Prdxs has only one
cysteine residue and depends on glutathione (GSH) to complete the catalytic peroxidatic cycle [38].
Members of typical 2-Cys class have the ability to form decamers and do-decamers in their reduced or
hyperoxidized state. This feature enables them to function as chaperons, enzyme activators, and redox
sensors, in addition to their antioxidative abilities [39]. While, atypical 2-Cys Prdxs can undergo
protein-protein interaction in combination with their antioxidative properties [40]. In contrast, 1-Cys
Prdxs cannot form decamers, and mainly functions as antioxidant rather than molecular chaperons,
although their antioxidation catalytic mechanism is similar to typical 2-Cys [41].
Mammalian Prdxs also differ in their cellular location and are distributed in cytosol, mitochondria,
endoplasmic reticulum, peroxisomes, and nuclei [42]. Based on subcellular distribution, Prdx3 and 5
are categorized as mitochondrial Prdxs [43]. Studies on mitochondrial Prdxs were initiated in 1989 with
the cloning of the mer5 gene [44]. This gene is expressed in murine erythroleukemia [45]. Prdx3 was
thought to play a significant role in erythrocyte differentiation [46]. This gene was further investigated
to have considerable sequence identity with bacterial alkyl hydroperoxide reductase (AhpC) [47].
Meanwhile, substrates of mitochondrial ATP-dependent protease, later identified as Lon protease,
were investigated, leading to the discovery of a 22-kDa substrate named as SP-22 [48]. This SP-22 was
found to be a highly abundant protein in the mitochondrial matrix, sharing a sequence homology of 90%
with Mer5 and having considerable identity with AhpC. It is now recognized as “Prdx3”. Prdx3 was
also termed as an antioxidant protein 1 (AoP1) [48]. Simultaneously, when the mer5 gene was cloned,
a novel gene, PMP20, was identified in Candida boidinii, encoding a peroxisomal membrane-associated
protein [49]. The homologue of PMP20 was discovered 10 years later in humans with thiol-specific
antioxidant properties [50]. In the same year, a novel gene, named “AEB166”, having a sequence
identity of 65% with bacterial Prdx, was identified [51]. This gene was later termed as “Prdx5” [52].
3. Characteristics of mitochondrial Prdxs
Prdx3 is located on chromosome 10 (q25–q26) and it is transcribed from seven exons in humans.
It is a 256-amino acid containing protein with a 61-amino acid long mitochondrial targeting sequence
at the N-terminal. The cleavage of this mitochondrial sequence results in a 21.5-kDa protein that
resides in the mitochondrial matrix [37]. Peroxidatic cysteine (Cp) is located at the residue 47 and it is
a highly conserved region of the protein. Prdx3 belongs to “typical 2-Cys” class of Prdxs, i.e., it is a
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homodimer organized in a head to tail manner and during catalysis, utilizes Cp and resolving cysteine
(Cr) residues on opposite subunits [43] (Figure 2).
Figure 2. Structural comparison of mitochondrial peroxiredoxins (Prdxs). Peroxiredoxin 3 (Prdx3) and
Peroxiredoxin 5 (Prdx5) contain a mitochondrial targeting sequence (MTS) at their amino terminal
(N-terminal) and this enables them to reside in the mitochondria. Prdx5 in addition to MTS also
contains a peroxisomal targeting sequence (PTS) at its carboxyl terminal (C-terminal) that is responsible
for the entry of Prdx5 in the peroxisomes. Both mitochondrial Prdxs comprise peroxidatic cysteine (Cp)
and resolving cysteine (Cr) which play an essential role in their catalytic mechanisms. In Prdx3, Cp is
located at residue 47, whereas, in Prdx5, it is located at residue 48 [35].
In contrast to Prdx3, human Prdx5 is located on chromosome 11 (q13) and it is transcribed from six
exons. It contains a 52-amino acid-long mitochondrial targeting leader sequence at its N-terminal and
it also has a C-terminal SQL sequence that is specific for peroxisomes [52] (Figure 2). This peroxisomal
targeting sequence enables this protein to localize in both peroxisomes and mitochondria [53].
The cleavage of mitochondrial targeting sequence yields a 17-kDa protein having Cp at residue 48 of
the mature protein. The active site of Prdx5 has several sequences in common with other Prdx family
members [54]. The human Prdx5 has a divergent sequence sharing a sequence homology of 28–30%
with Prdx1, Prdx2, and Prdx3. Prdx5 is the only mammalian Prdx that belongs to “atypical 2-Cys”
subfamily of Prdxs [55](Figure 2).
4. ROS and Mitochondrial Prdxs
ROS are extraordinarily active oxygen species involving superoxide anion (O2−), hydroxyl radical
(OH·), and hydrogen peroxide (H2O2) [56]. They are generated by the partial reduction of oxygen,
and comprise radical and non-radical oxygen species [56]. Endogenous sources of ROS include
mitochondrial electron transport linked phosphorylation, P450 metabolism, peroxisome metabolism,
and activation of inflammatory cells [13]. Mitochondrial ROS are produced in mitochondrial electron
transport chain during ATP generation [13,15].
Previously, ROS were considered to be damaging to cells because of their association with oxidative
stress, which leads to the induction of pathological responses [14]. However, in the past few decades,
ROS have been recognized as signaling molecules that regulate different processes of biological and
physiological importance [57]. H2O2 is the ROS that directly serves as a secondary messenger and is
majorly produced by the mitochondria [58,59]. Redox signal transduction involves the oxidation of
Cys residues in the proteins that is mediated by H2O2 [58]. At physiological pH, Cys residues exist in
the form of thiolate anions (Cys-S−) and are more receptive to oxidation as compared to protonated
Cys thiols (Cys-SH) [60]. During the process of redox signaling, Cys-S− is oxidized to its sulfenic form
(Cys-SOH) by H2O2, which leads to allosteric alterations in the protein, and ultimately changes its
function [61,62]. Thioredoxin and glutaredoxins can reduce back this sulfenic form of Cys to thiolate
anion and bring back the protein to its original form [63]. Thus, the oxidation of Cys residues in proteins
involves a reversible signal transduction mechanism that mostly occurs at nanomolar concentrations of
H2O2, whereas at higher H2O2 concentrations, thiolate anions are further oxidized to sulfinic (SO2H)
and sulfonic (SO3H) species [62,63]. Sulfiredoxin (Srx) can slowly reduce back the SO2H form of Prdxs
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to its native enzyme [64]. In contrast to Cys-SOH and SO2H species, the oxidation to sulfonic species
can be irreversible, which results in damage to the protein (oxidative stress) [61,65]. Mitochondria and
cells are equipped with professional enzymes to prevent the accumulation of H2O2, particularly Prdxs
and glutaredoxins [66].
Mitochondrial Prdxs play a significant role in H2O2 scavanging and to maintain a tight balance of
H2O2 [67]. Mitochondrial Prdxs that belong to the typical and atypical 2-Cys subfamilies contain a
redox sensitive cysteine at the active site that is oxidized by H2O2 and then reduced by thioredoxins to
complete the catalytic cycle [68]. The oxidized thioredoxins are reduced by thioredoxin reductase at
expense of NADPH [69]. The discriminative characteristic of Prdxs is their ability to undergo reversible
hyperoxidation by a second molecule of H2O2, which results in the formation of sulfinic acid that
consequently leads to the transient inactivation of the protein [70]. The reduction of the hyperoxidized
form of Prdxs to SO− is catalyzed by sulfredoxins through an ATP-dependent mechanism [70].
5. ROS and Mitochondrial Antioxidants in Oncogenic Signaling
Many vital biological processes, such as cellular signaling, metabolism, and epigenetics,
are significantly regulated by ROS and, consequently, these biologically active oxygen species are
involved in disease initiation and progression [15,30]. Mitochondria being one of the major source of
ROS are associated with the roles of ROS in the living organisms and are significantly involved in the
regulation of ROS to maintain a steady state cellular environment and prevent cells from oxidative
damage [71]. ROS, particularly H2O2, is a byproduct of mitochondrial energy generation and is
regulated by mitochondrial antioxidants [72]. Altered cellular metabolism is associated with the
production of cancerous cells [73]. Cancerous cells are characterized by a high rate of proliferation
and active metabolism [73]. These cancerous cells require higher energy levels for aberrant cellular
proliferation and to maintain the high growth rate, these cells hijack the machinery of normal
cells [74–76]. Growth-related pathways are constitutively activated in cancer cells and, consequently,
these cells take up excess amount of nutrients, endure stress, and multiply rapidly [77,78]. This results
in hyper metabolism, which leads to an excessive generation of ROS by the mitochondria, endoplasmic
reticulum, and the action of NADPH oxidases [79]. Mitochondrial ROS are required for the proliferation
of cancerous cells driven by K-ras oncogenes [80,81]. Mutations in the mitochondria that result in
dysfunctions of TCA cycle/electron transport chain produce excess amount of ROS to trigger tumor
associated signaling pathways, such as PI3K and MAP kinase signaling pathways [82–84]. In addition
to these signaling pathways, ROS also target the transcription factor NF-kB (earliest discovered
transcription factor responsive to ROS) that is associated with the survival of tumor cells [85,86]
(Figure 3).
Studies have shown that the association of ROS with cancer progression and suppression is
dependent on their intracellular levels [87]. At low levels, ROS augment cancer proliferation by working
as signal transducers or by prompting the genomic DNA alteration or damage to DNA [88]. For example,
ROS can stimulate cyclin D1 expression [89,90], lead to the promotion of extracellular-signal-related
kinase (ERK) Jun N–terminal kinase (JNK) phosphorylation [91,92], and trigger mitogen-activated
protein kinase (MAPK) activation [93], all of which are associated with carcinogenesis and the survival
of cancerous cells [94]. In addition to the functions of ROS in the pathways associated with cell
proliferation, ROS have been recognized to inversely debilitate tumor suppressors, such as protein
tyrosine phosphatases (PTPs) and phosphatase and tensin homolog (PTEN), because of the presence of
redox-sensitive cysteine in their catalytic sites [95]. PTPs also function to regulate signaling pathways
by inducing antioxidant enzyme expression and decreasing ROS levels [96,97]. Moreover, ROS act as
regulators of normal stem cell renewal and differentiation. Cancerous stem cells (CSCs) exhibit similar
characteristics; however, there is limited knowledge regarding their association with maintenance of
cellular redox balance [98]. Recent studies have exhibited low ROS levels in liver and breast cancer stem
cells, consequently resulting in the upregulation of ROS-scavenging signaling proteins expression [99].
If growth of CSCs is indispensable for tumor induction, maintenance of low ROS levels might be a
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prerequisite for pre-neoplastic foci tolerance [98]. Chemo and radiotherapies stimulate ROS production
and they are useful for demolishing most cancerous cells [98,99]. Certain patients are unable to cure
by the chemo and radio therapies because of increased endurance of CSCs to conditions of high ROS
levels by augmented antioxidant levels [100]. Some adverse effects of anticancer drugs are debatably
mediated by ROS; thus, CSCs may be appropriately released and vigorously chosen by the factors,
depending on increased ROS levels [101]. Moreover, further oxidative stress that is mediated by
these factors may result in additional mutations and DNA damage, ultimately leading to enlargement
of drug-resistant cancer cells [98,101]. Previously, it was assumed that increased ROS generation
in cancerous cells leads to genomic instability, and consequently promotes tumor formation [102].
However, genomic instability is associated with a loss of p53 and other processes that are related to
aneuploidy [103,104]. ROS-dependent oncogenesis driven by Myc oncogenes in cancer cells exhibits
no chromosomal instability [105,106].
 
Figure 3. Role of antioxidants in cancerous cells. Mutations in mitochondria and mitochondrial
dysfunctions lead to the production of increased amount of ROS by the activation of c-Myc and K-ras
factors. The increased production of ROS leads to an imbalance between ROS and its scavengers.
This imbalance activates a number of signaling pathways such as PI3K and mitogen-activated protein
kinase (MAPK), resulting in tumor initiation and progression. The increased amount of ROS in cancerous
cells requires an upregulated expression of antioxidants to prevent cell death. Thus, the activation of
certain transcription factors (NRF2 and FOXO) and tumor suppressors (p53) induces the upregulation
of mitochondrial Prdxs to compensate the increased production of ROS. Thus, mitochondrial Prdxs
along with other scavengers act to protect the cancerous cells from ROS-mediated cell death.
ROS at high levels mediate cell death and cause adverse damage to the cells [107]. Therefore,
cancerous cells must control increased ROS levels, specifically during the initial stages of cellular
proliferation [108]. In cancerous cells with elevated ROS levels, redox balance is maintained by
equally high amounts of antioxidants [109]. These antioxidants control the ROS levels and prevent
the cells from cell death mediated by oxidative stress [110]. Recently, it has been discovered that
conditions that facilitate oxidative stress also induce particular pressure on pre-neoplastic cells to
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trigger effective antioxidant mechanisms [111]. This characteristic is relevant, particularly during
metastasis, which is characterized by the spread of cancer cells to distant organs [112]. Thus, cancer
cells have extraordinary antioxidant capabilities to circumvent elevated ROS levels and they are
accustomed to the diverse biological functions of cells [113]. The antioxidant capabilities of cancer cells
are quite high when compared with those of normal cells [21,73,114]. The elevated antioxidant level in
cancerous cells is achieved by the activation of transcription factors, such as nuclear factor erythroid 2
related factor 2 (NRF2) [115,116], that interacts with kelch-like ECH-associated proteins (KEAP1) and
targets proteosomal degradation [117]. ROS sensitive Cys residues of KEAP1 are oxidized by elevated
ROS levels, leading to KEAP1 dissociation from NRF2 [118]. The translocation of dissociated NRF2
to nucleus and its heterodimerization occurs with a small MAF protein [119]. Subsequently, it binds
with antioxidant-responsive elements (AREs) of various antioxidative genes [119,120]. Although
NRF2 protects the cells from cancer causing agents, it also stimulates tumor formation and cancer
development by safeguarding cancer cells from ROS and the resulting DNA damage [108,115,121].
In some tumor cells, KEAP1 mutations lead to the constitutive NRF2 activation [122]. The loss of NRF2
induces oxidative stress in cancerous cells, and ultimately inhibits tumor formation [123]. The loss of
NRF2 inhibits multiple antioxidant signaling pathways, resulting in damage to the cancer cells [124]
(Figure 3).
Elevated ROS are associated with tumor formation and progression. The tumor suppressive
genes can serve as antioxidants for scavenging ROS and to maintain them at the levels that do not
promote tumor formation [125]. Tumor suppressor p53 regulates the expression of many antioxidant
genes [126,127]. Moreover, mice that are deficient in p53 have demonstrated a reduction in tumor
formation by dietary supplement NAC, which suggests that, in certain cancers, the primary suppressive
function of p53 is to reduce ROS levels [128]. However, it is also suggested that a major tumor
suppressive function of p53 is to regulate the antioxidative and metabolic genes [129]. One mechanism
by which p53 regulates the metabolism to control antioxidant function is the induction of p53 target
TIGAR expression [130]. TIGAR, also known as 2, 6-fructose bisphosphatase, reduces the levels of
fructose 2, 6-bisphosphate (a positive regulator of phosphofructokinase 1) [131]. Consequently, it leads
to a reduction in glycolytic flux by shunting the glycolytic carbons to the pentose phosphate pathway
to generate NADPH and the generated NADPH is required for the maintenance of the antioxidant
system [132]. Other tumor suppressor genes such as FOXO transcription factors, function by activating
many antioxidant genes, such as Prdx3 and Prdx5 [133,134].
ROS also regulate mitogenic signals to promote cancer cell proliferation and also play a role
in adapting to metabolic stress condition when a highly proliferative tumor tissue outstrips its
blood supply [135,136]. Hypoxia-inducible factors (HIFs) are stabilized in the resulting hypoxic
tissue [137,138]. Prolyl hydroxylases (PHDs) hydroxylate proline residues of HIF1α that are recognized
by E3 ubiquitin ligase von Hippel-Landau (pVHL) protein [139]. This causes HIF1α to proteasome
degradation [140]. Non-hydroxylated HIF1α is not recognized by pVHL and translocates to the
nucleus [139,141]. In the nucleus, it dimerizes with HIF1β and then regulates the metabolic adaption to
hypoxia and the expression of pro-oncogenes, such as vascular endothelial growth factor (VEGF) [142].
HIFs that are induced by ROS promote tumorigenesis in certain cancer cells [143]. Moreover, sirtuin
proteins (SIRT3) upregulate the antioxidant system to prevent HIF activation [144,145].
In summary, two counter signaling mechanisms operate in cancerous cells to maintain tumor
proliferation and tumor survival. One type of signaling is associated with excessive ROS generation
that results from the highly active metabolism of cancerous cells and the other is to counter balance this
excessive ROS and to prevent the cancerous cells from oxidative damage that involves the activation
of the antioxidant defense system. Furthermore, increased ROS levels by endogenous sources are
dangerous for cancerous cells, as well as for cancer development [109]. Thus, these antioxidant
protective mechanisms can be targeted to kill cancer cells along with CSCs while protecting the normal
cells and considered to be a better approach for cancer treatment and therapy [146,147].
209
Int. J. Mol. Sci. 2019, 20, 4407
6. Prdx3 and Carcinogenesis
As mentioned in Section 5, the cancer cells are endowed with extraordinarily high antioxidant
capabilities; thus, it is not surprising that cancer cells contain upregulated levels of mitochondrial
Prdxs [148]. Prdx3 is highly sensitive to oxidative stress, and is regulated by sirtuin1, a class III
histone deacetylase (SIRT1). SIRT1 regulates the expression of Prdx3 by enhancing the formation
of PGC-1α/FoxO3a transcriptional complex [149]. The signaling and regulation of Prdx3 varies,
depending on the type of cancer and its interacting partners [150] (Figure 4). The debatable issue is
whether these Prdxs function as cancer promoters or suppressors. Multiple lines of studies have shown
that Prdx3 is upregulated in different types of cancerous cells [151–153]. The overexpression of Prdx3
is observed in colon cancer stem cells (CSCs) having elevated mitochondrial functions [150]. A positive
correlation for upregulated expression of Prdx3 and CD133 is reported along with FOXM1 regulating
the expression of Prdx3 and CD133 by binding to the promoter regions of both Prdx3 and CD133. Prdx3
knock out mice have shown a reduction in tumor volume and metastasis giving a clue for association
of Prdx3 with FOXM1 associated pathways for cancer development [150]. FOXM1 is associated with
cancer cell proliferation and the FOXM1/Prdx3 pathway plays a role in the survival of cells, so they can
be specifically targeted to develop the efficient drugs. This study is significant in that both in vitro and
in vivo results showed that Prdx3 is regulating the survival and metastasis of cancer stem cells through
mitochondrial stabilization and the depletion of Prdx3 can lead to reduce tumor size and promote
cell death by mitochondrial dysfunctions. The upregulated expression of Prdx3 is also observed in
medulloblastoma (MB), along with the decreased expression of miR-383 [154]. RNA and protein levels
of Prdx3 are both considerably reduced upon miR-383 restoration. This study provides clear evidence
for the interaction of miR-383 with Prdx3 through miR-383 seed region in 3′ UTR of Prdx3 and reported
the inverse relationship between miR-383 and Prdx3 in MB cells. However, this inverse relationship
was not observed in MB samples [154,155]. This difference between Prdx3 and miR-383 relationship in
MB cells and MB samples implies the need for in-vivo studies to further enhance the understanding of
Prdx3 roles in cancer cell survival and metastasis. In addition to miR-383, the association of Prdx3
with miR-23b is also observed in prostate cancer (PCa). The PCa-cell line studies showed that Prdx3 is
regulated by miR-23b in normal as well as in hypoxic conditions. miR-23b itself regulated by c-Myc
in-turn regulates the expression of Prdx3 at both RNA and protein levels [156].
The association of Prdx3 with JunD is also observed in PCa, which indicates that JunD regulates
cellular proliferation in PCa by regulating the expression of its associated genes, including Prdx3 with
Myc family genes, as crucial downstream regulators [157]. These studies show that the involvement
of Prdx3 in cancer is for more complicated as in PCa, the Prdx3 expression is regulated by miR-23b
as well as by JunD. It is clear that Prdx3 is regulated by multiple factors and there is a dire need to
analyze the co-relational regulation of Prdx3 by transcriptional factors and micro RNAs to identify the
associated changes on the tumor microenvironment.
The involvement of Prdx3 with hypoxia is also established and it is interesting to note that
the overexpression of Prdx3 suppressed the hypoxia mediated apoptosis of thymoma cells in vitro,
but with regard to the role of von Hippel-Laundau protein (pVHL) in clear-cell renal cell carcinoma,
the protein level of Prdx3 is downregulated and HIF-1α stabilization is induced by pVHL deficiency in
conditions of normoxia or hypoxia; this leads to decrease in Prdx3 expression and is associated with
cellular proliferation of clear cell renal cell carcinoma (CCRCC) [158]. Taken together, these studies
demonstrate the important role of Prdx3 in hypoxia, which is associated with cancer development and
the response to cancer therapies.
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Figure 4. Microenvironment of mitochondrial Prdxs in cancer. The involvement of mitochondrial Prdxs
in cancer depends on their interaction with different factors including transcription factors, different
response elements, micro RNAs, and cancer-related genes. The microenvironment of Prdx3 involves its
regulation by various transcription factors such as FOXO family transcription factors, Jun-D, and TIMP1
in colon, prostate, and hepatocellular carcinomas. These factors are associated with the upregulation
of Prdx3 in the cancerous cells for the abovementioned cancer types. Prdx3 interacts with miR-383
and miR-23b in medulloblastoma and prostate cancer, further regulated by c-Myc in breast cancer
and hypoxia-inducible factors in renal cell carcinoma. Similarly, the expression of Prdx5 in different
malignancies depends on its regulation by a variety of interacting partners such as c-Myc and GATA1
in breast cancer, Snail in gastric cancer, and Ets1/2 and HMGB1 in prostate cancer. Additionally, Prdx5
interacts with transcription factors AP-1 and NF-κB, insulin and glucocorticoid response elements for
the initiation of tumorigenesis and tumor progression.
The upregulated expression of Prdx3 is associated with an enhanced expression of ATP synthase
and increased ATP production in hepatocellular carcinoma, and it plays a role in tumor growth
and progression. However, at the same time, the downregulation of Prdx3 results in enhanced
invasive properties of HepG2 cells through the downregulation of TIMP metallopeptidase inhibitor 1
(TIMP-1) and causes increased extracellular matrix (ECM) degradation [159–161]. This implies that the
differential response of Prdx3 expression is regulated by diverse signaling pathways that are associated
with cancer progression.
Breast cancer is one of the most common cancer among females with many subtypes and it is
associated with a high mortality rate if not diagnosed at early stages [162]. Proteomic analysis of
invasive ductal carcinoma of the breast with luminal B human epidermal growth factor receptor
2-positive (HER2-positive LB) and HER2-enriched (HE) subtypes have shown that Prdx3 with an
upregulated expression of luminal B HER2 can serve as a promising bio-signature for LB subtype and it
can also serve as potential biomarker for the diagnosis of early- and late-stage disease [163]. Enhanced
expression of Prdx3 is also observed in MCF-7 cells [162,164,165]. In cervical cancer, single nucleotide
polymorphism of Prdx3 leads to significant increased risk of cervical cancer and progression [166].
In addition, gene expression analysis has revealed the increase in the expression of Prdx3 in cervical
cancer [166]. Endometrial cancer is among the common cancers in females that affect the genital tract.
The expression of Prdx3 is upregulated in the endometrium of patients that suffer from this type of
cancer as compared to that in normal endometrium [167]. A high expression of Prdx3 is associated
with endometrial cancer and it has the potential to serve as a prognostic marker for endometrial cancer;
thus, it can be targeted for the development of better therapeutic strategies [151,168]. The upregulated
expression of Prdx3 is also observed in malignant mesothelioma (MM) cells and an overexpression of
Prdx3 in MM cells maintains a redox set point that enables these cells to survive in conditions with
elevated levels of mitochondrial ROS [169]. Any disturbance in this Prdx3 regulated redox set point
impairs cellular proliferation by affecting the cell cycle dynamics operating between energy metabolism
and mitochondrial network [170]. Taken together, the upregulated expression of Prdx3 is observed in
211
Int. J. Mol. Sci. 2019, 20, 4407
different cancerous cell lines but the mechanistic details are lacking in how the upregulated expression
affects the environment in cancerous cells.
Our survey of studies analyzing the expression of Prdx3 in human cancers clearly shows that
Prdx3 is upregulated in many cancers and it is associated with cell proliferation. Hence, Prdx3 can be
considered as pro-cell survival, either in healthy or diseased cells, and it can be targeted for cancer
treatment. The cancerous cells have significantly high levels of ROS, irrespective of the upregulated
expression of Prdxs as compared to the normal cell and these cancerous cells cannot respond to the
increased ROS levels, like normal cells having many compensatory mechanisms to respond to ROS.
Therefore, Prdxs inhibition can lead to a further increase in ROS and consequently can promote cell
death of cancerous cells but not the normal cells having protective mechanisms [171]. However, there
is evidence that downregulation of Prdx3 led to enhancing the tumor malignancies and invasiveness
in certain cancers, so the targeting of Prdx3 for effective drug development requires further research
and it will be beneficial to target the signaling pathway instead of a single factor.
7. Prdx5 and Carcinogenesis
Mitochondrial oxidants are produced in significantly large amounts in cancerous cells due to
oncogenic transformation and metabolic reorganization [172]. Like Prdx3, the up- and downregulation
of Prdx5 is also observed in many types of cancers (Figure 4). The expression of Prdx5 is regulated
by different transcription factors, including AP-1, nuclear factor-κB (NF-κB), antioxidant response
element (ARE), insulin response element (IRE), glucocorticoid response element (GRE), and c-Myc;
further, c-Myc might directly regulate Prdx5 expression by interacting with putative responsive
elements in the 5’-flanking region of the gene [54,173]. Despite these other transcription factors,
such as nuclear respiratory factor 1 (NRF1) and nuclear respiratory factor 2 (NRF2; GABPA), which
are associated with the mammalian cells, response to oxidative stress and mitochondrial biogenesis
are also capable of indirectly regulating Prdx5 expression [53,174]. c-Myc not only directly regulates
Prdx5 transcription, but also participates in the establishment of ROS homeostasis by selectively
inducing the transcription of specific Prdxs when the function of one of the Prdxs is compromised [175].
In microenvironmental stress conditions, such as hypoxia, E-twenty-six transcription factor 1 and 2
(Ets1/2), and high-mobility-group protein B1 (HMGB1), mediate the upregulation Prdx5 in cancer
cells, particularly in human prostate and epidermoid cancer cells exposed to H2O2 or hypoxia [176].
The interaction of Prdx5 with a variety of regulators complicates its functions in cell survival during
normal and pathological conditions.
The expression of Prdx5 is closely related to the tumor size, depth, and lymphatic invasion in
patients suffering from gastric cancer [177]. Moreover, the enhanced expression of Prdx5 leads to
augmented carcinogenicity by increasing the proliferation and invasiveness of gastric cancer cells
through the upregulation of Snail [177]. The treatment of Hodgkin’s lymphomas is based on targeting
ROS, but the increased expression of mitochondrial Prdxs leads to chemoresistance [178]. Increased
levels of Prdx5 have been observed in aggressive Hodgkin’s lymphomas [178]. In breast cancer,
Prdx5 is upregulated in the mammary tissues and it is associated with poor prognosis. GATA1
transcription factor binds to the promoter region of Prdx5 in breast cancer cells and downregulates
the transcription of Prdx5 [179]. The overexpression of Prdx5 protects cancerous cells from oxidative
stress-induced apoptosis in a GATA1-regulated manner [165,179]. This implies that GATA1-regulated
Prdx5 transcription can be targeted to treat breast cancer, but it requires further analysis involving
the overexpression of GATA1 and its effects on tumor production and metastasis. Like Prdx3,
the expression of Prdx5 is upregulated in endometrial cancer and this enhanced expression of Prdx5
in the endometrium of females with endometrial tumor can serve as a prognostic marker [167].
Mitochondrial Prdxs are overexpressed in ovarian cancer cells, and Prdx5 serves as a negative predictor
of survival in patients suffering from ovarian cancer [180–182]. The upregulated expression of Prdx5 is
also observed in malignant mesothelioma cells [169], while a reduction in Prdx5 expression has only
been described in adrenocortical carcinoma [183].
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In summary, the Prdx5 is upregulated in different cancers, except for adrenocortical carcinoma,
but which factors are controlling the upregulation of Prdx5, the pathways associated with Prdx5
upregulation and cancer cell survival are lacking and need further investigation to demonstrate
the exact mechanism of action of Prdx5 in different cancers and to develop strategies for effective
drug designing.
8. Mitochondrial Prdxs and Chemoresistance
Cancerous cells are unique when compared with normal cells, in that they include elevated ROS
levels as well as an increased level of antioxidants to counterbalance the ROS [111]. This distinctive
feature of cancerous cells is attributable to the development of resistance in cancerous cells against
chemo and radiotherapy, as these therapies are highly dependent on ROS-developed cytotoxicity [114].
A plethora of literature has described the association of elevated levels of Prdxs with chemo- or
radioresistance to various drugs [184–188].
In breast cancer, the upregulated expression of Prdx3 is associated with the development of
resistance to the drug doxorubicin [189]. Prdx3 regulates the apoptotic signaling pathway by controlling
the release of cytochrome c from the mitochondria, along with establishing the linkage with leucine
zipper kinase and IKB kinase [165]. Therefore, it will be a good strategy to develop drugs that target
Prdx3 and mitochondrion specific electron suppliers, i.e., thioredoxin2 (Trx2), thioredoxin reductase2
(TrxR2), and sulfiredoxin (Srx), for response improvement of different chemotherapeutic agents, such as
cisplatin, paclitaxel, and etoposide [189,190]. In many other cancers, such as breast cancer, ovarian
cancer, and erythroleukemia, chemoresistance is developed by the upregulated expression of Prdx1,
Prdx3, and Prdx6 [191]. In addition, there is evidence that Prdx5 is also involved in chemoresistance to
adriamycin, bleomycin, vinblastine, and dacarbazine in patients of Hodgkin’s lymphoma and in vitro
lung carcinoma U1810 cell lines [192].
Chemoresistance is a complicated process that involves different factors and numerous modes
of action affected by the tumor microenvironment as well as tumor biology [193,194]. Alterations in
endogenous antioxidants play a determining role in the development of chemoresistance, as well as
can serve as promising targets to design new drugs with better efficacy [195] (Figure 5).
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Figure 5. Mitochondrial Prdxs in development of Chemoresistance. The upregulated expression of
mitochondrial Prdxs is associated with the development of drug resistance in a number of cancer types
leading to complications in cancer treatment. These upregulated Prdxs can be specifically targeted in
cancerous cells to develop new drugs against cancer with better efficacy and without causing any harm
to the normal cells.
9. Concluding Remarks
Mitochondrial Prdxs, the multifunctional proteins of the cells, are well known for their
physiological as well as pathological significance based on their interplay with ROS. The crosstalk
between ROS and mitochondrial Prdxs is critical for the initiation and progression of various types
of cancers. The targeting of mitochondrial Prdxs for developing drugs against cancer is a good
strategy. However, because these Prdxs are associated with chemoresistance in certain cancers, it is
conceivable that, instead of targeting mitochondrial Prdxs, it will be better to diagnose the signaling
pathways and microenvironments of these Prdxs in particular cancer types and then develop a drug
that can target the root, leading to the activation of these Prdxs in response to the elevated ROS levels.
10. Future Directions
Our survey of studies analyzing the involvement of mitochondrial Prdxs in human cancers shows
that most of the conducted studies are based on the expression analysis of Prdx3 and Prdx5. It is
depicted that mitochondrial Prdxs are upregulated in variety of cancer types and directly or indirectly
regulated by transcription factors, microRNAs, and oncogenes. Further, the interaction of Prdx5 with
response elements is also reported, but current studies for analyzing the roles of mitochondrial Prdxs
and ROS in cancer need more in depth analyses, as described below
1. Most of the studies reporting the upregulation of mitochondrial Prdxs in human cancers are
cell-line specific, it will be more advantageous to design in-vivo studies to explore the interaction
of these Prdxs in cellular environment.
2. Mitochondrial Prdxs have the ability to function as molecular chaperons, enzyme activators,
and can be involved in protein-protein interactions beyond their enzymatic peroxidase functions.
Accordingly, the transgenic animal (mouse) models should be used to demonstrate the role
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of mitochondrial Prdxs in oncogenic signaling. It will be beneficial to understand the exact
mechanism of action of these Prdxs in cancer and to design effective drugs targeting a particular
pathway associated with cancer survival and progression.
3. Although a plethora of studies describe the regulation of mitochondrial Prdxs by different
transcription factors, oncogenes, and microRNAs in different types of cancer, but the
exact mechanism of mitochondrial Prdxs in different types of cancers and their upstream
and downstream regulators is lacking. Incorporation of variety of omics techniques i.e.,
transcriptomics, proteomics, and metabolomics into the in vitro and in vivo studies of
mitochondrial Prdxs in cancer development can help to elucidate signaling mechanism in
future studies.
4. More clinical investigations are needed to evaluate the differences in the expression of Prdx3
and Prdx5 between normal and diseased state. In addition, the expression of mitochondrial
Prdxs during the early and late stage of cancer should be analyzed to demonstrate their role as
anti-oncogenic or pro-oncogenic in different cellular context.
5. The upregulated expression of Prdx3 and Prdx5 is associated with the development of
chemoresistance in different cancers and selective targeting of these mitochondrial Prdxs can
lead to sensitization of cancer cells to chemotherapy. This fact should be investigated in detail to
unveil the underlying mechanisms.
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Abbreviations







ERK Extracellular signal related kinase
JNK Jun N-terminal kinase
MAPK Mitogen activated protein kinase
PTP Protein tyrosine phosphatases
PTEN Phosphatase and tensin homologues
CSCs Cancerous stem cells
NRF2 Nuclear factor erythroid 2 related factor
KEAP1 Kelch like ECH associated proteins
AREs Antioxidant responsive elements
HIFs Hypoxia inducible factors
PHDs Prolyl hydroxylases
pVHL von Hippel-Laundau protein
CCRCC Clear cell renal cell carcinoma
FOXM1 Forkhead box protein 1
LNCaP Lymph node carcinoma of prostate
TIMP1 TIMP metallopeptidase inhibitor 1
ECM Extracellular matrix
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HepG2 Human hepatocellular carcinoma/hepatoma cell lines
MCF-7 Mitichigan cancer foundation-7 cancerous cell lines
HER2 Human epithelial growth factor receptor 2
Trx2 Thioredoxin 2
TrxR2 Thioredoxin reductase 2
Srx Sulfiredoxin
MM Malignant mesothelioma
NF-κB Nuclear factor κB
ARE Antioxidant responsive element
IRE Insulin responsive element
GRE Glucocorticoid responsive element
Ets 12 E twenty six transcription factor 1 and 2
HMGB1 High mobility group protein B1
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